<SEC-DOCUMENT>0000914475-21-000058.txt : 20211101
<SEC-HEADER>0000914475-21-000058.hdr.sgml : 20211101
<ACCEPTANCE-DATETIME>20211101160519
ACCESSION NUMBER:		0000914475-21-000058
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211101
DATE AS OF CHANGE:		20211101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		211367147

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nbix-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3,d:232e3d73409b464385a0180f5b5ba6e3--><html xmlns:nbix="http://www.neurocrine.com/20210930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN18yLTEtMS0xLTA_114fb0c7-e55a-42b1-afb8-fae10e18921b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN18zLTEtMS0xLTA_b654bc98-e9e2-411a-bdec-422b1ba79695">2021</ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN180LTEtMS0xLTA_90519677-247a-4755-bab0-12d11f1a0df1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN181LTEtMS0xLTA_09bd0288-6c29-4802-a06e-6071f9486e8f">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN182LTEtMS0xLTA_99cdbd48-842b-4fc4-a7e3-4393365955a1">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" name="nbix:NumberOfConsecutiveBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTgzMA_ef1eef62-b79a-46f3-a25d-922b0620d60a">P5D</ix:nonNumeric><ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" name="nbix:NumberOfConsecutiveBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTg3NQ_a16f9f76-754b-427d-8388-b5aa3c37a979">P5D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181NS9mcmFnOjBiYjIxMmRlYmFmZDQ0YWViYWJkNWIwMWE1MDMzYmEyL3RhYmxlOjYzNzlhYzc2MjNhYTQ0N2M4M2Y1Njk4YjZjZDBhZDNhL3RhYmxlcmFuZ2U6NjM3OWFjNzYyM2FhNDQ3YzgzZjU2OThiNmNkMGFkM2FfMi0xLTEtMS0w_e31437ab-a59c-4889-9efa-298b8ff0b8d0">0.0131711</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib35f220670e34eec87e5afe4a89f609d_I20211027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if1fdb74440ee42898adbdc8492008e0f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc60fd6179844c8db173a8451d9462a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iebf2d8484c7e496bae6f2a07d1b08068_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ee034471ac4db29f78d7b85eb9dc6e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62082aae9f3941b69d20896eba9b0249_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57aa7170627244b08601ddb3bf8c9dff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed90fc09e974862855048eb200b7e28_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9101b3965a264dc9a0dfee26e4674bae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5ccd37651e4b678f8252d2497c8369_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9049c0b86b004f30bf4a1ce3cc512077_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7803f4c249304f20b4bb0eb8494c2e78_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754e2b2ae83143ee834e836dd3561f1d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50142418015f4e47be8aea7229195794_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb552e33928d4ba2b771f17e9907962a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f84bfaa23a48129fc63d149d061b27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c540dc7784a4d6f8d16ff59c05b0b06_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea2954b9ed8422aa402be311593fa3c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90699ef320ca4ebeb28f38adba5ef805_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9279c8400ef148e1866482b1844adf56_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5888ff562cf4ba088c5483009e844d7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b123f12d63242b189e51114c701eaf5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ecddd8f9d5f42dc94c8e2a220f3593a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4aa44ca0d044e0a8ec596fca98e7e9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20178cc9ddf43b4a388c72ac34c2134_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f9ecb01ca24fbbb38c14c687ebaf91_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851ba2fafa2f450990491164330f743d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8c778aad0f4e7f8fa77b3cc9856b9b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302b1afa8146416aab065909274c7758_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a08b99dfb094c0b91dfe34866290261_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bb07b5918e4f64bee6b674512d700e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d7325982b647798c3a49c812ccaa00_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15bb181a93e44b49456802a3f4a8de4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f76fb77b1f542479312b2aff85aaf3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0c38cd3765417695f32be58389944a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046db428318141819987db76bcbb0b60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41785e12188b4d7889ba7b5f21da1623_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9298bbb4994683a1431a64d26acfef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide770c7feabe4bcd8899467eab2993a4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421486e0786f480d81e599f2028fb590_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eeef242bbcc4ec59c2143f1f656c851_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a678a1180e4c3caa98573b5cd8f7a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3497105df4834dc893428a1a5d881960_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552dcda95f844a11b769f02470f057fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4ca114f2d34a558af3a50593c0e518_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206634836d714da8902b9e165f6fd187_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421dcee8358442bfb35f87eaafbdae1b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933021bd48984449911c135ddeafa918_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib684ec080b3a48bb93b07be4df5e2401_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>nbix:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="iffcf257f1217481a8a1fa04d4a631d43_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3315e9d2376463bb766c7fda4822a57_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc897ab39e04a5aaf3979ecf0b1aaf3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce6a674873848c2bf34283197bc4a5f_I20210908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7496225d981e45bd95c16039fcf4c975_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22958d29fbc4450c825ab099cc2474a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3408f9286a74ad69f879196398aa1cf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9430cff5e9084463bd1354a6bbc4c537_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e55bf4fc19f4fdab09c36ac40b354de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if448122914d649afac62b3524714a81a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i189642a059634ad084c64f09713076dc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08986f72f2a14760851809292bbcdfa6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08163ab015c545f98f6b59567476ccf0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b114e2d031e4c17872a49ed97a20e50_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89aa56e595949039d1c9644bf3f36ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0120fe55568d4fc3a5928407baa25b60_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87e020d0a114fa4b7c4e0660e4c28b6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e54f0d818448efa8b57b22dab1f6ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0708e1e4554808a818ec7f02b33d99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfab6fa72f8484d9159ecc553820eb1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i187553e4d84849859e9761bba613da29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa625e3b7b743ae8108fe2498a46588_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe511c7bc1040d8bc7d4c231d784b01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e78a0ca3aae402794034bc5f1c455d0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f340ad37bb64e67aa595f0848a1db28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43744412019486abe9d453fb54846d3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc95789714e54acfb4a0507993443712_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b450fe3b5341978f085deda2bc6161_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="ib1dcd5486d1340bfa8e720e23609396b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf2e3d38fff4af1a6188647ded1558b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica52a652db094241b061229da784c22f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fb858a78824577ab6b7073295d027f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157b928b65e741d6b3db895524a44b01_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d140b31a337457eacc3647d03f3f97f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c5af590cb04d4092677c5129d1e809_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671519a4e4e1485fb15ec6c947a07076_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2998a4df4a4439a8cc2c83d9e8f7db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997255409c3c45f39333fc13018a559c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875a9a2626b44cf18fa53b7b885a6bce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8a511b63824552bf8d257b1884b5f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9119184273346b2b8dbad7d616102ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81504f29583943ba9978871037be715e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37e0266d4814246b83de0b9d9c168bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbdfb0943f24a65a8f6da1e886aa8f9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia262940bd03b4238a69d63782e9387d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463c5678112d48c9bc0abef10ada5150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274f33b722f340dd83f22e59cf90400f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4db6ebba6644f3e9527c7fee2cff544_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice63c8557e304f948f1fafe5ab4e071f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87fa5828e80490fb8b8d1bd0374f894_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192729099dcb4d288cb1d45579633c95_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2778fd50f940aa86c54d9c1324bcee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a4d025226f4fe68766605d098d9d0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e972f1fd84e45db85d8fb910086c0f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1703dbc936474604bfd0656c06657637_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f653c1026734aabb17bcf80cee5821b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cc854c976a48e1bbc3de3b9891bc67_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7dba45ab6a493d93352400235e1210_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927462043ac04752942634b64cea6355_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0d773bdaad4ae2b17b1d0b1b65fea4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec29fedb91804fec99b78fa71bf7c4d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e99b5f202a4eeca47d4e76e0d243c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefce9ebfc0840a2bc5e823a2df50751_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fe8c38d81284f58932debf4c8cb7618_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6fe6eba96941e689ad3a457f7112ec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85eea9c802ea4670afeeaa43139cc8fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7630f29609c149bc8ed65aeacddff04f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d8b3c059e442a49871d8451515ebce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b3269f9d1443bfa965fb2dce758c76_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i147d42e72f9341768d5edb4e870a6497_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if013f2d93404456e9e08b22da1ce31cd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5363925363fe4d49a040c9683212cfcf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie66734cfaa1e439ebc58ca3d6feeadb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4b8082c01e4b57b79756ab536ae7e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b12614a8c724ea3b20972094290e1be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3819533757414a9572e60d4e871a06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cc3330f8b146f39c81072617b752b3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i072cce2288a042b489e120bb3ec32f27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034c6598652d4102850711d648ea0aa8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce42ab70b0940f9a48758422d138380_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac443b5cdc54d92bea87fa506638d36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38c9afdc13440eaae85aaebae77f419_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6f931f878e4baca21f094c9ee764f2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9fcf70e01d7421cba408015441496c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ae0844fb5746d38ea81deefd1b9bef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6c3665c37e4724ae7c9e261e7bbc8f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26221cd897194d5fb2af65836642c604_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195a15919a14436a91e3c65518029bbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5815797b06f4ee6a46cb160090f637b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d8ece4878f459d8c0a6ad585eb5fe8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00a3aa3229f47c9b38aa8b37fe637f5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076a6551196f4eff9d3016f750447fd1_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f2ab910308454c8f7155eed697292f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id661067c1cf345799ba33c3aaeb96515_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a1c92268c9462594c709744c9b9d2b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if731862d3ce642ffae334bf7a6733e28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613b05cc13dc49b4a0c7a305b35ce164_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6646025f6a78471b87f269eb801ee821_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65276afd2e6542f0b217ec8483499b87_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b01bcc9a078432796345ea93821c9a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4af071ef4314dd5b5a613cc233965c6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ea3d3697cc4bbbbab42a49a59bd0ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d69c9551a434c0fb66e7651162ab9ea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c660c5054143d681316ee502a02a1e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ffb61e2639493c9292444fcc81cf0b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c87e3ad24243c1a4e073d2ef7e8134_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056102a1b5034e53811a069c914ac932_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1fca71d61f40dc8fbddba62968770a_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i232e3d73409b464385a0180f5b5ba6e3_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg5_a65ada46-ec08-40ed-b779-0271ebd02871">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ODI2MWZmNDJiYjMwNDVhMGEwYThiMzc5OWU1M2VjZjUvdGFibGVyYW5nZTo4MjYxZmY0MmJiMzA0NWEwYTBhOGIzNzk5ZTUzZWNmNV8wLTAtMS0xLTA_1866f67c-f621-40fe-94b4-ccfbc0a34bd1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8xMzg_7b82e1a8-ac5c-4651-93f2-83a5979d36ff">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6OGVkYmFhMmVjY2Q4NGNhZDk3MTkyN2Q2ZTdkNzZjNzkvdGFibGVyYW5nZTo4ZWRiYWEyZWNjZDg0Y2FkOTcxOTI3ZDZlN2Q3NmM3OV8wLTAtMS0xLTA_317d48f3-699d-455d-96e5-4a38e6d60740">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkx_9682dd15-2cd2-425e-ad05-d634388a4e21">0-22705</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTky_54aaab02-f1bd-4fb3-a0a2-1e776d89511f">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk2_dff34f0e-ff81-487b-a89f-af4efa0bcbd5">Delaware</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg2_398fb387-ef0b-4afb-83df-09c2363b7ebe">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkz_0460b7c6-0d52-479d-bf2e-3a43fe32ae0f">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg3_8751b6cd-0803-48b0-bfd8-21a3c4870201">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk3_e1a47fb1-7bc3-48a4-818c-c044b437b2ea">33-0525145</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk0_75ba624a-ae73-430a-a4e7-bd27936959dc">92130</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg4_5b6313a1-435e-4f85-a122-16918becdb85"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk1_15c9824b-3daa-47f9-877c-974c22e9030d">617-7600</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTAtMS0xLTA_6085f359-c87a-4695-a3cb-50a27107f247">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTItMS0xLTA_12e91bb0-7b4e-4323-8e03-7bd6616f1ff2">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTQtMS0xLTA_56503de7-4493-4436-ab04-367aa2f151c7">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;<ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkw_927e6c00-6e3d-4c11-8112-8228fa677382">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk4_5feb09cf-90ab-474e-8ee0-31ed0a2a1c3d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18wLTAtMS0xLTA_eeed40b1-101b-431d-93fb-8ba211efdf01">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18xLTQtMS0xLTA_647931eb-3ca2-40aa-8f70-447b05c3feb6">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18yLTEtMS0xLTA_84c27fe7-1a9d-4d94-a68a-5696eb50cd9e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk5_e97c6ba4-8fd1-4ecb-adb9-60d64bfb5cb4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="ib35f220670e34eec87e5afe4a89f609d_I20211027" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTcz_d74a83a0-d03a-4f58-9714-a2454e437fcf">94,866,693</ix:nonFraction> as of October&#160;27, 2021.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_10">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_19">Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_22">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_22">ondensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_28">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_64">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_64">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_67">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_67">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_70">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_70">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_73">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_73">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_76">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_76">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_79">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_79">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_82">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_82">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i232e3d73409b464385a0180f5b5ba6e3_85">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i232e3d73409b464385a0180f5b5ba6e3_85">47</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_16"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMy0xLTEtMS0w_9186e7ae-3f34-4da5-81ba-3947b317ec58">311.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMy0zLTEtMS0w_894c6557-fa11-4626-89b0-e608fc1d03f7">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale, at fair value (amortized cost $<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0wLTEtMS0wL3RleHRyZWdpb246Y2VhMTQ0M2EyYjRhNDMwOGI5NjA5YjVjNTdlNTQ0Y2VfNzE_c550122c-6146-4c36-baa1-35fe9309c829">454.6</ix:nonFraction> million at September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0wLTEtMS0wL3RleHRyZWdpb246Y2VhMTQ0M2EyYjRhNDMwOGI5NjA5YjVjNTdlNTQ0Y2VfODQ_0f80231b-05c7-4f51-82a3-7b64a4cca97c">612.4</ix:nonFraction> million at December&#160;31, 2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0xLTEtMS0w_23125f44-ade4-4602-aabc-45ebe5279972">454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0zLTEtMS0w_1f981f34-0bb6-4b80-bd05-80c09744e50d">613.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNS0xLTEtMS0w_56bbfbc7-b634-411a-a203-91d98dfded04">163.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNS0zLTEtMS0w_41b0a90b-1249-4f47-8a2f-cbe6648afe88">157.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNi0xLTEtMS0w_addc1733-3b2d-4f8f-a4d8-b5548a4a2964">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNi0zLTEtMS0w_4791e0eb-8e2f-4ac8-b03d-49def5c32385">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNy0xLTEtMS0w_e2d2a0b8-b760-4019-b4d3-0ce9a3d9f765">50.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNy0zLTEtMS0w_4e174432-cb2a-4265-9287-e452888772e2">30.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOC0xLTEtMS0w_3514be28-1271-49b9-bee6-ba3a2433f918">1,005.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOC0zLTEtMS0w_01bbb2d7-6779-4f33-93cc-847f8c574371">1,016.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOS0xLTEtMS0w_d42083c4-1d7b-4fb7-8341-bfe26bd15180">310.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOS0zLTEtMS0w_5fdd3523-7a15-4333-9ee8-5e7775c7b879">319.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale, at fair value (amortized cost $<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmM3YjcwODMxYjRlNDQ2OWJhZmUwZjI5YjFjNmM1N2FhXzcx_75240047-885d-4fb7-b2af-32961604c0b4">513.8</ix:nonFraction> million at September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmM3YjcwODMxYjRlNDQ2OWJhZmUwZjI5YjFjNmM1N2FhXzg0_3338b524-d7a5-41e6-b287-6ee3f56ec6b5">226.7</ix:nonFraction> million at December&#160;31, 2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMS0xLTEtMA_8f237260-7672-4cc6-80bc-f56c49af917f">513.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMy0xLTEtMA_95f03291-6c8b-4b53-ab04-22cf6c0a4f19">227.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTEtMS0xLTEtMA_73de5d00-86fb-4b11-a649-5245d2545f66">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTEtMy0xLTEtMA_ca9806f5-ae93-4abb-a0a7-35b4d7d25e09">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTItMS0xLTEtMA_8af82af2-164d-4b66-9739-bb8c5c42065c">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTItMy0xLTEtMA_91590e72-6fc3-4cfa-bc0a-8cd701165443">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTMtMS0xLTEtMA_075505e6-6fff-401d-9f07-d2b67ced9930">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTMtMy0xLTEtMA_099a2037-6deb-4e6c-8383-9e2bcf24332c">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTQtMS0xLTEtMA_d5e4172f-a3e2-47cf-afb0-9bb36d862b76">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTQtMy0xLTEtMA_94e65406-c546-44fc-8c48-3c8d0ca33d96">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTUtMS0xLTEtMA_fa6221d6-02cf-4dbc-9425-a20baee0df31">2,017.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTUtMy0xLTEtMA_79b0f64c-9334-4810-a028-b022043bca2b">1,734.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTktMS0xLTEtMA_b911d74d-3267-4162-9c05-29658cb53cd7">205.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTktMy0xLTEtMA_7b6a86f0-9a3b-4717-914e-3029443121a1">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjEtMS0xLTEtMA_86135dde-4088-42f2-b34e-a13e909b223f">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjEtMy0xLTEtMA_d80c9132-9fb9-491f-a1a1-b385a7dbd9ff">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjItMS0xLTEtMA_60719919-793a-4742-9bef-c96ed1d1f764">225.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjItMy0xLTEtMA_e0db1041-ca44-493d-a734-955f239acf81">186.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjMtMS0xLTEtMA_e4070052-93db-45f1-95af-3b24d367a0d6">330.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjMtMy0xLTEtMA_0e342565-1e8c-42a2-9eb3-6b0fa79f3bab">317.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjQtMS0xLTEtMA_3fe941ed-01e9-416a-826b-a3a6d7a7d7c5">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjQtMy0xLTEtMA_f67d69b6-d37a-411d-baaf-6ea70034a622">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjUtMS0xLTEtMA_cc8b476c-4297-4c30-a05a-0db286f6d52d">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjUtMy0xLTEtMA_005e1721-0648-46d5-84e1-0a3d2bce58dd">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjYtMS0xLTEtMA_4aac04c1-db65-4673-a6ad-067e740d8299">671.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjYtMy0xLTEtMA_9277fd2d-beb7-4fec-bda0-7b2096c60812">608.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzIy_6e83b16c-9956-42a4-96ac-b4929d184ae7"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzIy_f57b878b-b275-4415-8015-080b88b98f9d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzM2_058838d3-1af4-4470-b33d-bedad751f5ab"><ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzM2_58885f9c-4988-4fb2-a8b6-403c65daf0e1">5.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_31a54a53-3db4-403f-8ae0-c6a6cfd93c0a"><ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_5d4d1f8d-404d-4253-8e11-4abcff30a2ec"><ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_9fc20640-7e80-4cf1-803d-175b9d862c44"><ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_dced4cda-48f4-4b1e-ba95-5c9cbcad8c83">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMS0xLTEtMA_e1ec04b2-cb7f-445e-871a-f065734ee33b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMy0xLTEtMA_c25169bb-6bdf-46dd-9fdc-44a21fc080ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzE5_18be85dc-85eb-46e2-8387-004530c51090"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzE5_fb2e36f6-4536-4d49-8597-e2edbe235191">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzMz_3d714e08-aaac-4b0d-b913-c9a7bcbfd43b"><ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzMz_84242faf-1a87-4812-9fc7-d9e5ee2009cd">220.0</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding shares were <ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3Xzkw_38f59345-0021-4734-9e04-561b3a1f95e5"><ix:nonFraction unitRef="shares" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3Xzkw_8add3c2a-ef80-4a46-bfe3-41f29f7c94eb">94.8</ix:nonFraction></ix:nonFraction> at September&#160;30, 2021 and <ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzEwMw_157dacda-5a5f-4b29-93a8-5d07bdf27fee"><ix:nonFraction unitRef="shares" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzEwMw_edc0a263-00be-4fed-8dd3-c5d59455c9e9">93.5</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMS0xLTEtMA_a616f799-ef8a-43cc-a91b-f8bb6f55ca87">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMy0xLTEtMA_05b00d8e-1ff3-48d9-bfef-d54fe59ee475">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzEtMS0xLTEtMA_2a0dac89-9614-4f69-a8b1-6a155cb0f5ad">1,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzEtMy0xLTEtMA_cfb19fca-158e-434f-91b0-ab7f94c6c6db">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzItMS0xLTEtMA_4e2b73a1-b820-42e8-85e9-b23a835853a3">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzItMy0xLTEtMA_f1016f4c-01a8-4657-96d6-c989588c7de0">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzMtMS0xLTEtMA_4f5194d4-dfca-4c22-bd1c-db3f51696520">628.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzMtMy0xLTEtMA_2aea6d25-bb9f-4d49-b7bb-194058a295ad">725.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzQtMS0xLTEtMA_19b25aaa-d78b-4ba7-8f0a-bbd6203a70a5">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzQtMy0xLTEtMA_4c810bb7-38f8-45bb-8429-3d36cd7428f8">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzUtMS0xLTEtMA_a71a7c1c-f7be-4ac3-9cd7-fabf1f5969d9">2,017.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzUtMy0xLTEtMA_57ec28b9-e1c1-4596-b5dd-77d54342a600">1,734.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf2d8484c7e496bae6f2a07d1b08068_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy0xLTEtMS0w_dee05417-07ad-4d50-919a-47e27da217d0">288.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ee034471ac4db29f78d7b85eb9dc6e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy0zLTEtMS0w_3509b55f-187f-4bfc-8f55-8afd879cb1a3">254.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62082aae9f3941b69d20896eba9b0249_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy01LTEtMS0w_86f39cbb-eafe-4e9b-90a5-be7de937c7bf">786.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57aa7170627244b08601ddb3bf8c9dff_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy03LTEtMS0w_40b987d6-9044-4f8b-92fb-8bf173606cdc">752.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed90fc09e974862855048eb200b7e28_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC0xLTEtMS0w_229e0e5b-2a36-4dd3-9bc1-72f98061e310">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9101b3965a264dc9a0dfee26e4674bae_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC0zLTEtMS0w_32f51185-2ca6-48b9-849c-b623bfccb2e4">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5ccd37651e4b678f8252d2497c8369_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC01LTEtMS0w_aa69c47f-db1f-4694-9e76-50a525bcd500">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9049c0b86b004f30bf4a1ce3cc512077_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC03LTEtMS0w_71401dc0-bd16-4cc7-9799-e1e078e1b6eb">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS0xLTEtMS0w_369d3c9c-5891-438f-91d2-55e6f956cfec">296.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS0zLTEtMS0w_a4dfc2c7-1d1c-4fa1-ab4e-ad80b17ca2f5">258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS01LTEtMS0w_d3d0e3c9-19fb-4166-ae77-de4c9e38c3ad">821.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS03LTEtMS0w_bfa29823-8b26-4561-9c58-9d88424a28f1">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy0xLTEtMS0w_e0f83a69-7c72-47c5-b9fa-e18b7e9fb4b4">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy0zLTEtMS0w_1d6813ad-435a-4a60-9149-8d79a1cba023">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy01LTEtMS0w_347f8269-e602-420f-81fc-09a389529565">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy03LTEtMS0w_a94d7cba-8a44-4c29-bb4a-f900d2ccc8d1">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC0xLTEtMS0w_b69cb1f7-52f9-4313-8f04-57be0489e200">92.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC0zLTEtMS0w_9b3e8647-58f8-49cf-a365-14be4b1fe2ff">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC01LTEtMS0w_85d40bdb-7f40-41fb-b027-de6c585c2bde">240.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC03LTEtMS0w_2f32b2cc-178a-42cd-832d-f6f44cf3bc9b">208.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS0xLTEtMS0w_b15e6e84-2630-4c51-b4e8-900b8c3f7353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS0zLTEtMS0w_1b93eb76-e6c1-4f4c-ac80-4c6f38051dc7">118.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS01LTEtMS0w_d78e8e27-6543-44e8-9490-e04b954e4621">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS03LTEtMS0w_29df1816-5b87-437d-9d7c-495f8fc3832a">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtMS0xLTEtMA_cad9f7ac-e876-466a-a36e-0da5a06fd7be">154.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtMy0xLTEtMA_8b9920d3-f2e5-4e2f-b02f-686df955151c">112.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtNS0xLTEtMA_f3c7c497-cf42-4c18-947f-598d77146afa">426.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtNy0xLTEtMA_1a541b50-6724-4c2c-a9db-2ca1d5f12561">326.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtMS0xLTEtMA_3c5550df-52ca-42da-8d16-575df416dacc">251.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtMy0xLTEtMA_933a1afc-bf2b-4206-8607-a22134bb84ae">302.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtNS0xLTEtMA_c3477491-aada-4394-a4cd-a2de7717cfce">682.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtNy0xLTEtMA_822c2410-77ec-4fca-b91d-070424a45c83">706.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItMS0xLTEtMA_749a5aea-5fbf-4af1-b96d-1857e2f6d917">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItMy0xLTEtMA_eb5e4d5d-da8a-4f03-bc9a-f03b3ff00b76">44.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItNS0xLTEtMA_03e52251-6b99-4fa7-ac1f-40e3bba817c9">138.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItNy0xLTEtMA_634f6873-39b2-47fd-8e06-673d378b495b">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtMS0xLTEtMA_878774b3-265b-441d-abc2-8bd8bdad5d0a">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtMy0xLTEtMA_84796afa-3a0f-4c80-9ba4-0fdc39bdaada">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtNS0xLTEtMA_a130202f-47c7-4a74-a140-fddcff51d500">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtNy0xLTEtMA_3e187071-c9b8-4acb-9679-7facf06ad6da">25.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtMS0xLTEtMA_df57fa07-cc3b-4147-a789-07e5c76c2c99">8.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtMy0xLTEtMA_dfdb6019-ecbb-4dc6-99e8-40c42399b3f6">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtNS0xLTEtMA_97da89dd-9494-4f41-b250-cdb78da2c8af">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtNy0xLTEtMA_c4e6cd49-88cc-4a12-8315-597dc7f8f1dd">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtMS0xLTEtMA_b5e63128-2312-4f7f-9380-d53e3c97c549">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtMy0xLTEtMA_9c86bff7-c281-422f-8134-04344e416074">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtNS0xLTEtMA_29ce4ec9-bc6c-4ced-a998-f9cff70ae5fc">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtNy0xLTEtMA_58a14277-1b20-47fd-82d1-460e5e86209e">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctMS0xLTEtMA_2a8eb109-c5ea-4f4a-b085-8d0b84a83e2c">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctMy0xLTEtMA_105b94d7-ac92-42b6-9317-98b296a570df">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctNS0xLTEtMA_47ca717c-1ae7-4bfb-a41b-224b39d5abbd">23.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctNy0xLTEtMA_d997f429-ab3d-45bc-bc2c-4c8a397cf373">26.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtMS0xLTEtMA_9be0e96d-a7f8-4dee-b033-192db5cf1fe1">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtMy0xLTEtMA_baf0d21d-1ac7-4e63-83d4-8c1661e56db6">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtNS0xLTEtMA_9082cf3b-99ee-4aba-9f2c-fe73bf140bd1">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtNy0xLTEtMA_b5e1064f-a0cb-4fc1-a79b-bd9a0ad5eb6c">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktMS0xLTEtMA_03f7877c-dcee-4259-8e66-2c5688442021">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktMy0xLTEtMA_ba0170d3-9a30-4cf1-9186-9ddb9344ccba">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktNS0xLTEtMA_dd761d08-b3d7-4d7f-a18b-882af63c3396">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktNy0xLTEtMA_ee560d32-bf62-447e-9750-744ccaca9b76">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtMS0xLTEtMA_5cd9fbaa-f49c-4095-ab96-54259daad0c7">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtMy0xLTEtMA_b1bc2332-1d56-44e0-a1a0-574023a433fd">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtNS0xLTEtMA_2a526523-1830-4b6c-a9d5-c5bd29f44caf">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtNy0xLTEtMA_afc2e7ef-c000-4c5e-9c8e-4e837f97c262">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtMS0xLTEtMA_ffe10985-e2a4-44ce-a968-44df9303f356">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtMy0xLTEtMA_d53ce5e7-43d1-41d7-9fad-4f5d95353ba7">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtNS0xLTEtMA_45788085-a8c9-438f-8326-c4e6e503d89c">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtNy0xLTEtMA_d0965d59-8484-4754-bb3a-08d24e511878">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItMS0xLTEtMA_467824b8-d837-4bfc-abfa-b6a9a141cb7b">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItMy0xLTEtMA_a05a170a-5fa4-49e8-909f-931ad7477427">59.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItNS0xLTEtMA_e5df544d-d349-4134-afdf-723f41534104">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItNy0xLTEtMA_1d30273d-93e8-4667-8bf2-c26e9b3ae304">61.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtMS0xLTEtMA_4df478b8-79b6-486a-a14e-468bef0cb3d0">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtMy0xLTEtMA_62af6937-de29-4127-843f-f58397955244">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtNS0xLTEtMA_781f7f4b-d2aa-4e27-ac80-ea4a793320ee">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtNy0xLTEtMA_101464bf-491d-49cc-9ce2-fd7273293eab">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtMS0xLTEtMA_6ca1ba00-f07e-4d81-8f41-025523c5f97b">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtMy0xLTEtMA_26321a92-dc6a-41be-b9f5-ec8357d8229e">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtNS0xLTEtMA_64e8ef94-16ec-4664-96cd-88d5fa51754c">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtNy0xLTEtMA_a875f182-2272-413a-86d0-7fec4610191c">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtMS0xLTEtMA_5cf5fd54-cca4-4d75-943a-7b6ba18453f5">94.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtMy0xLTEtMA_c746f30a-31df-4793-ba90-052a1bf977fc">93.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtNS0xLTEtMA_b8e9ca30-8352-44b6-9996-4cd3a7913d3c">94.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtNy0xLTEtMA_0432d93a-4422-44f9-937a-0c88292211a6">93.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtMS0xLTEtMA_e015787e-f110-4211-ba4e-ff58943fdcdc">97.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtMy0xLTEtMA_73a06f9a-94ed-462a-a448-ca7544f56789">93.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtNS0xLTEtMA_1bcb6e4d-99fc-4ba9-9db8-b39316df6417">97.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtNy0xLTEtMA_59b4573a-5dcf-4790-ae04-94e447de6a44">98.0</ix:nonFraction></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.469%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0xLTEtMS0w_74a52da3-38dc-4f5a-865e-95907d9cb2ed">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0zLTEtMS0w_7d94b885-8db9-431a-aede-32243952e545">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7803f4c249304f20b4bb0eb8494c2e78_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy01LTEtMS0w_42ca067c-22b4-47f7-851f-585f849a9cc8">1,929.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754e2b2ae83143ee834e836dd3561f1d_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy03LTEtMS0w_3d713e12-7c9c-40f3-9d17-ded880717938">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50142418015f4e47be8aea7229195794_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy05LTEtMS0w_cb7719b5-b99e-4e9e-8d7c-176635eae1d0">651.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb552e33928d4ba2b771f17e9907962a_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0xMS0xLTEtMA_6f811c59-f45a-4351-bd33-9c9bc06d8855">1,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f84bfaa23a48129fc63d149d061b27_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNC05LTEtMS0w_7d556280-dbe7-41d6-996a-5384f8ca56b1">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNC0xMS0xLTEtMA_76828410-56d4-4635-a2dc-b7a8798f9cd9">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c540dc7784a4d6f8d16ff59c05b0b06_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNS03LTEtMS0w_dd893eff-2769-461c-b1fb-1f173e174269">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNS0xMS0xLTEtMA_5627b7fe-5932-4e3d-bb02-41b94d68260e">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNi01LTEtMS0w_9b26d917-447b-4624-9512-47b51560037c">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNi0xMS0xLTEtMA_716ead12-dc62-4a0a-8fe4-53e54d447849">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ea2954b9ed8422aa402be311593fa3c_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy0xLTEtMS0w_46394a7e-8282-4d3a-acee-0ad4a4faad2e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy01LTEtMS0w_ebc59e85-a564-43fd-83ad-9e1fdc47be62">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy0xMS0xLTEtMA_6ff32d39-7469-419e-8017-681f63472d3c">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0xLTEtMS0w_b3dc280d-9618-4c5a-bc01-28d8128eaa01">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0zLTEtMS0w_39b5ee49-7ed1-4437-8029-bff2e06670f7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9279c8400ef148e1866482b1844adf56_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC01LTEtMS0w_c0380da5-1066-4d6f-9cf8-af30ec52f4c4">1,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5888ff562cf4ba088c5483009e844d7_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC03LTEtMS0w_4307f81c-5ce2-4e67-b594-723042b74095">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b123f12d63242b189e51114c701eaf5_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC05LTEtMS0w_e2bbdf99-da35-452b-94cf-c647209fe794">628.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0xMS0xLTEtMA_e7e26dd1-24e5-4d11-bef7-c17d8867223b">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMS0xLTEtMA_175d9ab1-74dc-48f9-9d67-e339dd22e555">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMy0xLTEtMA_26ca78fe-9d0c-4206-83fe-fd63437f2ab7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ecddd8f9d5f42dc94c8e2a220f3593a_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtNS0xLTEtMA_60904448-413f-47ed-a5ab-df35da488cb8">1,842.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4aa44ca0d044e0a8ec596fca98e7e9_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtNy0xLTEtMA_82a8b8d7-3ba6-4539-8de2-ba9e69fd7848">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20178cc9ddf43b4a388c72ac34c2134_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtOS0xLTEtMA_fde1e178-31ac-4c96-a3bb-47594826bb03">1,015.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f9ecb01ca24fbbb38c14c687ebaf91_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMTEtMS0xLTA_6fcbbe8d-7133-4098-bdcb-39f80f171f07">831.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ba2fafa2f450990491164330f743d_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTEtOS0xLTEtMA_25ff7d00-3dcf-43cb-8b26-ec4c7198de65">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTEtMTEtMS0xLTA_1fe224a1-5322-4824-bdd3-5aacb7b78f9c">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8c778aad0f4e7f8fa77b3cc9856b9b_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTItNy0xLTEtMA_9d3cc641-1aac-4e72-b7a5-16e793d0392e">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTItMTEtMS0xLTA_90e42f46-a3fc-46c2-b5c3-c7908103671b">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTMtNS0xLTEtMA_50933216-b20f-437a-bb27-41ea6b472cb7">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTMtMTEtMS0xLTA_0f5ec84c-018d-49fd-b207-826dd84eed60">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i302b1afa8146416aab065909274c7758_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtMS0xLTEtMA_ca91ec62-e21e-4347-9a46-2b850d34cb8a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtNS0xLTEtMA_620d348a-c81e-4998-9a71-00a308c9bcec">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtMTEtMS0xLTA_337fdacf-70e0-4b23-847f-7d7a99f74428">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMS0xLTEtMA_9433254e-44dc-4608-8777-3c76d1167ffb">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMy0xLTEtMA_c0d5192f-0a16-4718-8004-b152c1e538fd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bb07b5918e4f64bee6b674512d700e_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtNS0xLTEtMA_2c96d2b7-e397-4cfa-8b19-a4394264f154">1,874.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7325982b647798c3a49c812ccaa00_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtNy0xLTEtMA_fa2dd6fd-1d68-421f-84a5-b7bb52b62934">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15bb181a93e44b49456802a3f4a8de4_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtOS0xLTEtMA_f341e250-ef15-48fd-be51-6d06447fb93b">1,073.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMTEtMS0xLTA_3df78b8c-8873-41b1-a8ac-c8f76b7a454c">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f76fb77b1f542479312b2aff85aaf3d_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMS0xLTEtMA_07cec1f2-9284-4cb8-83ad-b643caa96f67">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f76fb77b1f542479312b2aff85aaf3d_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMy0xLTEtMA_60ce0cd1-b8b8-46cf-a227-8f3e9d40c014">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0c38cd3765417695f32be58389944a_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctNS0xLTEtMA_dece2b4f-92be-4723-bfe3-dcaea1a2dd82">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046db428318141819987db76bcbb0b60_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctNy0xLTEtMA_82f6c6dc-84ea-41ee-88b2-b76967c796d4">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41785e12188b4d7889ba7b5f21da1623_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctOS0xLTEtMA_bcdbb013-24ae-4f70-9ff6-d5eac8f36cb2">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMTEtMS0xLTA_992d36a7-0c23-436e-af32-552f558228a4">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9298bbb4994683a1431a64d26acfef_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTgtOS0xLTEtMA_d5b72017-615b-449e-a894-fdd4e9847c2a">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTgtMTEtMS0xLTA_c5d128d8-8e2e-4a0d-8d86-250bed2ce038">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide770c7feabe4bcd8899467eab2993a4_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTktNy0xLTEtMA_fe11ab7a-dfce-4d98-b8b1-05381b91be70">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTktMTEtMS0xLTA_c0b08100-4bb6-4813-9769-99b58c392357">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjAtNS0xLTEtMA_345f32ab-d8ae-45a1-8061-19e5539aecd6">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjAtMTEtMS0xLTA_85088551-5a39-4337-8f2b-3d63ae0908d8">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i421486e0786f480d81e599f2028fb590_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtMS0xLTEtMA_e0de3d77-808a-4cef-bc6d-0823758f73fd">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtNS0xLTEtMA_e61cde90-9c19-4393-a5cb-c49d26c6039a">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtMTEtMS0xLTA_f6c99213-f295-419d-9342-00d30bf73587">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMS0xLTEtMA_f088bca3-cfd0-4378-a7c5-32d17af1eb5b">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMy0xLTEtMA_2d30c232-65a9-4b57-ba63-0e420bcef6f9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9279c8400ef148e1866482b1844adf56_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItNS0xLTEtMA_2424812f-ee11-48be-8994-1296ddd95948">1,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5888ff562cf4ba088c5483009e844d7_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItNy0xLTEtMA_8a16a678-b790-463d-a140-7c30c3ad5e11">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b123f12d63242b189e51114c701eaf5_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItOS0xLTEtMA_bbed2698-2409-4a1c-a186-7ee79725422f">628.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMTEtMS0xLTA_0c458d9c-eac6-4a99-9b58-6829440719da">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2eeef242bbcc4ec59c2143f1f656c851_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMS0xLTEtMA_2ce01367-e961-46d3-8642-50c4e9ba0ff0">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eeef242bbcc4ec59c2143f1f656c851_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMy0xLTEtMA_37dfff58-a5c6-44e1-b565-5e5d2e5c4b9b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a678a1180e4c3caa98573b5cd8f7a8_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtNS0xLTEtMA_72819369-8602-4edd-9a6c-8bcbe172ecd2">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3497105df4834dc893428a1a5d881960_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtNy0xLTEtMA_282d0251-bdb6-484d-a192-154cb10e747e">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i552dcda95f844a11b769f02470f057fa_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtOS0xLTEtMA_21faa143-5cf3-40e1-afd6-7d489884355f">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4ca114f2d34a558af3a50593c0e518_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMTEtMS0xLTA_075768e6-c0ac-4e67-b97f-9580cb1104cb">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206634836d714da8902b9e165f6fd187_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjUtOS0xLTEtMA_6bfe4db7-098f-41b0-905b-703bb19e6949">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjUtMTEtMS0xLTA_f486939f-8858-415c-bfa4-c9b86d33a3b4">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421dcee8358442bfb35f87eaafbdae1b_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjYtNy0xLTEtMA_dc7fb220-2df6-4270-8b26-86b50db40f60">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjYtMTEtMS0xLTA_4bfc1bfb-122c-47b2-ab46-0c85a1220571">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933021bd48984449911c135ddeafa918_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjctNS0xLTEtMA_38e19a78-d01e-4897-a7f3-16442b5c860e">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjctMTEtMS0xLTA_a9e6ef04-80d3-48d6-9a6c-70d68523b02a">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib684ec080b3a48bb93b07be4df5e2401_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtMS0xLTEtMA_547c432d-792a-4634-b74e-dd4b1ce7a034">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933021bd48984449911c135ddeafa918_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtNS0xLTEtMA_05f17d5f-8172-49c1-be08-d5c91e4f7b80">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtMTEtMS0xLTA_0a88eec6-bfff-440d-b614-086b8c9d5755">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMS0xLTEtMA_322bd8ce-2d36-4a68-9ee4-1ee60d63330e">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMy0xLTEtMA_a4e55ce8-8e88-4cc7-8816-2183a26f8bfa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bb07b5918e4f64bee6b674512d700e_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktNS0xLTEtMA_af19eae1-1929-4385-94bf-315f83f38e3e">1,874.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7325982b647798c3a49c812ccaa00_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktNy0xLTEtMA_8a29fffb-9867-4e5c-b795-bf9227d640e7">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15bb181a93e44b49456802a3f4a8de4_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktOS0xLTEtMA_52f22552-2b61-48bc-85d2-beef37a0e766">1,073.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMTEtMS0xLTA_0be09a04-60e4-407b-bd4e-e2413af634b2">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMy0xLTEtMS0w_cfc5efbc-4276-46c7-a353-11ce162922b8">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMy0zLTEtMS0w_9d711382-1792-4784-a04d-3cce36ef69ca">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNS0xLTEtMS0w_dac45fc8-5a85-45eb-a10c-2f1a5f1d293d">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNS0zLTEtMS0w_7b3a9ee9-9354-466e-b01e-ee1cdd7bb0ff">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNi0xLTEtMS0w_4ab1589b-11ac-4666-9b6c-c5d6c16081a6">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNi0zLTEtMS0w_53ffe51d-a0bc-45f4-b6b7-fb6a286064c8">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNy0xLTEtMS0w_89564540-21c1-45ba-9e83-43da3b8bf809">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNy0zLTEtMS0w_385f4534-970a-4cc5-8de0-d7c59d8fa834">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOC0xLTEtMS0w_62334cd5-6ef7-436a-abac-78c2ece6167d">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOC0zLTEtMS0w_b785f2f7-a35a-468d-b58c-e91d5762f861">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity security investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOS0xLTEtMS0w_46b629a4-e5ed-4b53-8056-1bac06c2b5a0">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOS0zLTEtMS0w_b6588f73-03d9-4dc7-8782-896d206b8f11">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTAtMS0xLTEtMA_c0764e23-7d4d-4fd4-86e4-7bd608079827">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTAtMy0xLTEtMA_82acdbd8-f02e-4e4c-a5ea-049f222af8fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTEtMS0xLTEtMA_3e26dd91-db23-4023-9e16-2fc680b46974">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTEtMy0xLTEtMA_8cc732fe-e13c-48b8-8aee-b150a314e492">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTMtMS0xLTEtMA_9f9fb2b1-ef68-4861-991e-019e243f6e6b">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTMtMy0xLTEtMA_29c7d1bb-14f8-4b8c-a069-961ea9661564">30.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTQtMS0xLTEtMA_a1cb386a-bdbb-43e6-af26-0afb786d7f31">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTQtMy0xLTEtMA_3d9bf1fe-6e52-4484-bdbf-a004d48d5f7a">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTUtMS0xLTEtMA_a7d52dc4-6144-4a7d-802f-4ad6dfb7df67">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTUtMy0xLTEtMA_00e4c4bd-8de0-46c2-8ff7-9fc32a6080c5">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTYtMS0xLTEtMA_feec54ff-a953-4ca7-b89a-dd2a7f8cf25a">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTYtMy0xLTEtMA_b0b615b1-c55d-4d84-a93e-0849c9b6d7f8">35.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTctMS0xLTEtMA_91dc1c60-a86c-4d4b-98fb-984003db3d2d">252.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTctMy0xLTEtMA_12039b2b-64bb-4242-a992-ffb4e9012bad">134.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjAtMS0xLTEtMA_f493323e-0475-4af5-8e68-67642d62a7f9">658.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjAtMy0xLTEtMA_0de98611-82ba-40ed-96a5-267c770faa55">399.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjEtMS0xLTEtMA_6d2d8878-2285-4a67-a748-55bee9dd69c7">523.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjEtMy0xLTEtMA_17899f39-dd4c-4d96-b3f7-da3f306bc549">557.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjItMS0xLTEtMA_ef62adc7-bc78-4650-b54d-8c199aee3f99">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjItMy0xLTEtMA_16e61457-bcd7-4cdb-934a-7d81094a9b40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjMtMS0xLTEtMA_fa2b585b-b81b-462a-89c2-e798c5a04bed">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjMtMy0xLTEtMA_30d789d8-f956-45a0-b364-5c019c10b40a">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjQtMS0xLTEtMA_d9f6f157-1554-49a5-beb4-58407f4a7246">153.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjQtMy0xLTEtMA_dbb0da06-c1e0-46be-9e0b-9d834c3428a9">151.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjctMS0xLTEtMA_5c7d6691-92ac-4190-9821-2b9616e9952a">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjctMy0xLTEtMA_a2ce5889-d8e9-4f9b-8684-a3cca51c8fab">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partial repurchase of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjgtMS0xLTEtMA_4cd1649c-3f02-48a0-8d22-5c64fc2bb2c2">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjgtMy0xLTEtMA_5842c78b-ffa2-42a8-9708-a9674bec90e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjktMS0xLTEtMA_3a8c12a6-0083-4a82-abda-44bf481097e0">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjktMy0xLTEtMA_82f2e845-75e7-4f66-ac18-69a6b9436018">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzAtMS0xLTEtMA_7e2c8d6c-7162-4afa-9f23-7d2ff8ec0964">124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzAtMy0xLTEtMA_421d2f63-5028-425d-8ec4-68b89f61f875">313.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzEtMS0xLTEtMA_85b47180-4d0c-489b-95ec-a8aa932e5202">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4ca114f2d34a558af3a50593c0e518_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzEtMy0xLTEtMA_93e641ea-c774-4a76-bb6e-ceb3f9275d90">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzItMS0xLTEtMA_ba876074-1ba0-42dd-80ce-07a09a4615b5">314.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzItMy0xLTEtMA_564635d9-844f-418b-9c75-2d8f7c290e6e">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzUtMS0xLTEtMA_440f428c-8cc4-4100-a9e6-7919d32d617c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzUtMy0xLTEtMA_2267cb51-8261-45ca-ae4e-3b73a300c3d5">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets acquired through operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzYtMS0xLTEtMA_ddcd0c6c-49a1-4dfb-b10e-96c713e2b96d">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzYtMy0xLTEtMA_28b39ace-7765-4650-b80d-d057a764b243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzctMS0xLTEtMA_f96d9f3f-6779-4e68-816a-1169fca720aa">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzctMy0xLTEtMA_a7c7f5d1-3702-428d-a417-095ffadba020">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzgtMS0xLTEtMA_1ca72620-fdc3-4c3b-ad2e-80103ab3d8c5">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzgtMy0xLTEtMA_c7a0ffdb-0ac5-472b-a48e-eed2f097b3bc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_31"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzNg_8f6034db-20bf-48b2-8a3a-0a9620a0fe05" continuedAt="i684c1b51c2ef4f4b9d72238c1c118d3b" escape="true">Organization and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i684c1b51c2ef4f4b9d72238c1c118d3b" continuedAt="iffcd00e9f14a4f8c89a2010ec10415df"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="nbix:BusinessDescriptionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzOA_f0c6bc14-5c7a-48aa-99cf-0f2464f19725" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have <ix:nonFraction unitRef="subsidiary" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="nbix:NumberOfIrishSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfMzcy_5fee5ef9-47fa-4137-9020-db94caddb496">two</ix:nonFraction> wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzOQ_79643ce5-1878-4939-a15f-2c882a4d9adc" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, or the 2020 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2020, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2020 Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzNw_e42da4f5-2342-494a-980b-d972168ff772" continuedAt="id3da2ed4122a43538f4039658e7d7ca7" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted Accounting Standards Update, or ASU, 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective transition method. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. The adoption of ASU 2019-12 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods. The impact of the adoption is expected to be immaterial to our financial position, results of operations, and cash flows on an ongoing basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities will account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of ASU 2020-06 is expected to prospectively reduce reported interest expense and increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iffcd00e9f14a4f8c89a2010ec10415df"><ix:continuation id="id3da2ed4122a43538f4039658e7d7ca7">share, or EPS, which is expected to result in more dilutive EPS results. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 using the modified retrospective transition method.</ix:continuation></ix:continuation></span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfNzI2OQ_14138727-f01a-49ac-8a7c-33a6884b481d" continuedAt="ie949a4a0969146f1bd953a13a3a9c6c5" escape="true">Significant Collaboration and Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="ie949a4a0969146f1bd953a13a3a9c6c5" continuedAt="i046590eeff4c432694b877f27fddca02"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to (i) luvadaxistat (NBI-1065844/TAK-831) which we are studying in cognitive impairment associated with schizophrenia, (ii) NBI-1065845 (TAK-653) which we are studying in inadequate response to treatment in major depressive disorder, (iii) NBI-1065846 (TAK-041) which we are studying in anhedonia in depression and (iv) four non-clinical stage assets. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="iffcf257f1217481a8a1fa04d4a631d43_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1ODk3OA_7ed15ce6-9423-4906-b63b-c3d88eca5f0f">1.9</ix:nonFraction>&#160;billion upon the achievement of certain milestones associated with luvadaxistat and the four non-clinical stage assets, as well as receive royalties on the future net sales of such assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to luvadaxistat, Takeda declined to opt-in to a profit-sharing arrangement and instead will be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, Takeda will retain the rights to opt-out of the profit-sharing arrangements pursuant to which Takeda would be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out rights immediately following the completion of the associated second Phase II clinical study or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical study for such asset. We and Takeda will equally share in the operating profits and losses associated with NBI-1065845 and NBI-1065846.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ie3315e9d2376463bb766c7fda4822a57_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMjQxOA_b9b71c8d-2513-45c8-a063-c3b5da2d0984">1.7</ix:nonFraction>&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates. Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i3cc897ab39e04a5aaf3979ecf0b1aaf3_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1OTQ5Nw_24a15cd2-61c9-4a26-b7c3-8b7e58b7e53f">1.7</ix:nonFraction>&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we received approval of a clinical trial application, or CTA, submitted in the European Union for NBI-921352 for the treatment of focal-onset seizures in adults. In connection with the approval of the CTA for NBI-921352, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908" decimals="-5" format="ixt:num-dot-decimal" name="nbix:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc4Mg_90c38cdd-b470-4f84-90ea-877a65ac5512">10.0</ix:nonFraction>&#160;million, of which we expensed $<ix:nonFraction unitRef="usd" contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NjI5NQ_651aea50-457d-4d5d-b114-975343f4238e">4.5</ix:nonFraction>&#160;million as research and development in the third quarter of 2021, and purchased <ix:nonFraction unitRef="shares" contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDcxNw_3d127a37-a822-4cab-9f29-73aeda151538">0.3</ix:nonFraction>&#160;million shares of Xenon&#8217;s common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908" decimals="4" name="nbix:PaymentsToAcquireRestrictedInvestmentsSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc3MA_6e8b2f6f-49e9-43cd-b4eb-99557436aa70">19.9755</ix:nonFraction> per share) for $<ix:nonFraction unitRef="usd" contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908" decimals="-5" format="ixt:num-dot-decimal" name="nbix:MilestoneEquityPurchasePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc0NQ_a4f0d2a7-554b-4b8d-ad44-6b6d6d1815b6">5.5</ix:nonFraction>&#160;million. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDY4OQ_0f4ef79b-e79e-4a04-b881-d81624377ee0">4.6</ix:nonFraction>&#160;million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. Further, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908" decimals="-5" format="ixt:num-dot-decimal" name="nbix:PremiumPaidForEquityPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc5Ng_c16f1036-bbda-4549-846b-b023bf5ee43b">0.9</ix:nonFraction>&#160;million to research and development to reflect the premium paid on our purchase of the shares on the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) for Parkinson&#8217;s disease program, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i7496225d981e45bd95c16039fcf4c975_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2MTE0OQ_49957c41-630e-49e4-bdc5-644e43c65cd8">1.3</ix:nonFraction>&#160;billion upon the achievement of certain milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2017, we entered into an exclusive license agreement with BIAL to acquire the United States, or US, and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone). Under the terms of the agreement, BIAL may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i22958d29fbc4450c825ab099cc2474a7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzNzIzNg_2d3718be-839e-4251-b511-42391160f34a">75.0</ix:nonFraction>&#160;million upon the achievement of certain milestones.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i046590eeff4c432694b877f27fddca02"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched ONGENTYS in the US in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2015, we entered into a collaboration and license agreement with MTPC for the development and commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product in select territories in Asia and may also be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ia3408f9286a74ad69f879196398aa1cf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzNzkyMQ_dd8c50ad-b26a-4fc5-b9c8-b69848113de6">55.0</ix:nonFraction>&#160;million upon the achievement of certain milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, MTPC submitted a marketing authorization application, or MAA, with the Ministry of Health and Welfare in Japan for valbenazine for the treatment of tardive dyskinesia. The MTPC submission of the MAA for valbenazine triggered a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i9430cff5e9084463bd1354a6bbc4c537_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY0NTU4NQ_3e42ccd6-658e-4b2e-9b9d-0f3306d0cbc7">15.0</ix:nonFraction>&#160;million, which we recognized as milestone revenue in the second quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting the KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington disease patients with chorea. In connection with our performance of the study, we recognized non-cash collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="i5e55bf4fc19f4fdab09c36ac40b354de_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg1Mw_085d2dd1-917a-441d-989e-a8fc658fc34f">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if448122914d649afac62b3524714a81a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg2Nw_7711b35f-3db5-477c-9e32-956b0bd98b09">3.3</ix:nonFraction>&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $<ix:nonFraction unitRef="usd" contextRef="i189642a059634ad084c64f09713076dc_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg5Ng_c7b65357-9342-4306-bdfd-3517fb4a34db">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i08986f72f2a14760851809292bbcdfa6_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTkxMA_61fb0bdc-c74d-4c33-a6e3-462575371df3">1.8</ix:nonFraction>&#160;million, respectively, in the three and nine months ended September&#160;30, 2020. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="ia3408f9286a74ad69f879196398aa1cf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY0NjMwMA_ad00a60f-dccf-4ad7-a973-e185fd3d69c9">3.5</ix:nonFraction>&#160;million of revenue is being deferred in connection with our continuing performance obligations under the collaboration and will be recognized as non-cash collaboration revenue over the remaining study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#8217;s and men&#8217;s health. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product and may also be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i08163ab015c545f98f6b59567476ccf0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzODQzMA_88801a79-3be8-4f95-bb2b-57564951ef86">366.0</ix:nonFraction>&#160;million upon the achievement of certain milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the US and Canada in August and November 2018, respectively. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the US. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix. We recognized elagolix royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i1b114e2d031e4c17872a49ed97a20e50_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ3OA_7a5d517d-91fa-45f4-b79c-677dc76f0ba6">5.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic89aa56e595949039d1c9644bf3f36ab_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ5MA_9e8d47a9-3a6a-4574-885a-09a7fba3f2c2">16.3</ix:nonFraction>&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $<ix:nonFraction unitRef="usd" contextRef="i0120fe55568d4fc3a5928407baa25b60_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ0MQ_675cfac3-7089-46ac-9e66-57c35154e4f0">3.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie87e020d0a114fa4b7c4e0660e4c28b6_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ1NQ_c9b07973-7be8-4499-855b-56fb3f05ef0a">13.4</ix:nonFraction>&#160;million, respectively, in the three and nine months ended September&#160;30, 2020.</span></div></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1MA_f4e94fc9-10f9-4490-b039-7e121d486322" continuedAt="i61a30a039a5148efb9a166a92fce5fb4" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="i61a30a039a5148efb9a166a92fce5fb4" continuedAt="i0392d585f2a044d6bf61772081065e18"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1MQ_dad10468-5fca-46c0-ab11-a472cf824c2b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0zLTEtMS04MDc3_b0369866-59e5-4ee8-a60a-90c87a381a48">208.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi01LTEtMS04MDg0_990ed46c-572a-480c-9f34-d5fd27e772f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi03LTEtMS04MDg0_b734678d-2fc0-4c7a-8862-0ce7b747e025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi05LTEtMS04MDkw_176d2459-6217-4dd8-8979-a4b61f7feef5">208.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xMS0xLTEtODA5Ng_98964ce3-7aca-4f1f-8eca-9959204f7502">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xMy0xLTEtODA5Ng_2265194c-270e-47eb-80de-63cd1ed2740c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xNS0xLTEtODA5Ng_00ddc01a-a3dd-46db-9f2c-ebb74ef70186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xNy0xLTEtODEwMg_e95e4dd5-f64a-4f15-81f6-fa02b136a9a0">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0zLTEtMS04MDc3_49d34223-dc54-4ee1-bbe6-ca1f5fe34fe9">170.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy01LTEtMS04MDg0_5c7bcb16-a537-4074-8a2d-c24d6dfedbed">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy03LTEtMS04MDg0_2de4227f-106c-4d62-875f-8708e2bcb624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy05LTEtMS04MDkw_22ce9fa3-bfe1-4ecc-a4f0-450635498bba">170.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xMS0xLTEtODA5Ng_9bf76ffa-6590-4015-9e5e-92ea1b1c2b37">299.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xMy0xLTEtODA5Ng_f0a49047-0dfe-4de4-adc6-c02ac12e5055">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xNS0xLTEtODA5Ng_2dd71c37-32e9-4313-9d64-83406cebd175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xNy0xLTEtODEwMg_66fae6bb-2c50-41c3-a9f4-b77f0d4ee54a">300.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0zLTEtMS04MDc3_f35b2bf0-9eb9-47e0-8e23-bb50d4cd077e">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC01LTEtMS04MDg0_187aa4ff-27fe-47c1-91c9-28748664031d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC03LTEtMS04MDg0_3d07acf2-273e-4464-baf6-683b0b45c8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC05LTEtMS04MDkw_640ebcd3-41b4-4cba-9246-2a576a2611c9">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187553e4d84849859e9761bba613da29_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xMS0xLTEtODA5Ng_bf5e5fa2-c1f4-46c2-aa1a-1499b4c45004">230.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187553e4d84849859e9761bba613da29_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xMy0xLTEtODA5Ng_299577fa-8c44-4e72-8fb0-7c2f6297fe0c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187553e4d84849859e9761bba613da29_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xNS0xLTEtODA5Ng_68fe0a5c-9986-4b97-b348-20e829a2b732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187553e4d84849859e9761bba613da29_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xNy0xLTEtODEwMg_7ee316d3-cce3-4abe-b0dd-29dafc38ddb3">231.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0zLTEtMS04MDc3_7777764b-5150-47f7-9167-8b327239f2a9">454.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS01LTEtMS04MDg0_c6739522-ab28-441a-a2e8-83cabf232fe4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS03LTEtMS04MDg0_fd1fe876-f2fb-44dc-8616-a8a09af9d009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS05LTEtMS04MDkw_488c26d5-0141-45be-b907-a7b96745b617">454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xMS0xLTEtODA5Ng_79464065-2645-4922-9fed-c9a3a0a7cad8">612.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xMy0xLTEtODA5Ng_e056197e-eb61-4ed5-9c68-98d1d44bc2b0">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xNS0xLTEtODA5Ng_9f8153f0-7620-494d-843c-3c2ed007b711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xNy0xLTEtODEwMg_be5be8fe-faa6-4c22-8c2f-d19e88ccf2c6">613.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0zLTEtMS04MDc3_66181558-1410-4330-b0c4-966726a95128">328.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy01LTEtMS04MDg0_43bf5d70-2219-429c-a6a9-24b1bbb3bbd6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy03LTEtMS04MDg0_36baaa8a-a5ff-46f0-a2df-a0a04ed639d6">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy05LTEtMS04MDkw_0dbf5c99-cabe-42b6-a1df-f9d5165f0dab">328.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xMS0xLTEtODA5Ng_8ccf6371-61ee-49cb-b2df-d33f76f2932d">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xMy0xLTEtODA5Ng_b4b75730-05b5-4867-b079-b229851739d4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xNS0xLTEtODA5Ng_31d0a2a8-8f6a-47f4-95ea-57b603437571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xNy0xLTEtODEwMg_87a27649-2214-448c-b1e2-044ddf4cfa82">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43744412019486abe9d453fb54846d3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0zLTEtMS04MDc3_4f3f7622-f264-42ab-b720-9f635126de29">185.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43744412019486abe9d453fb54846d3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC01LTEtMS04MDg0_5d483850-241d-41b0-b394-07e59ee3fad1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if43744412019486abe9d453fb54846d3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC03LTEtMS04MDg0_6701a96a-98da-4c8c-9726-2ddf55ef2366">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43744412019486abe9d453fb54846d3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC05LTEtMS04MDkw_4228f00b-9f01-45f0-bdc6-8d04d38ddd8b">185.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc95789714e54acfb4a0507993443712_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xMS0xLTEtODA5Ng_e16e5667-34ee-4f40-9465-48d23f82de87">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc95789714e54acfb4a0507993443712_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xMy0xLTEtODA5Ng_ed98c6ad-4692-4d5e-9955-31c19721b302">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc95789714e54acfb4a0507993443712_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xNS0xLTEtODA5Ng_59cabcca-0455-4aae-a496-c02e16fa7c21">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc95789714e54acfb4a0507993443712_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xNy0xLTEtODEwMg_53a93238-e292-4f21-a319-7b999858ba6e">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0zLTEtMS04MDc3_6d89ad93-8ea0-46c5-a663-71cff50439c8">513.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS01LTEtMS04MDg0_9fdb5fe8-cc83-4a97-a9b2-fc93304aa139">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS03LTEtMS04MDg0_ef31cfd3-13b3-402f-82b8-cdc47765e241">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS05LTEtMS04MDkw_c68aabd0-69f1-4b6c-8bcd-16e063e6f6da">513.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xMS0xLTEtODA5Ng_4eb0f2e0-fcad-4741-ad19-f5db4a5d5b31">226.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xMy0xLTEtODA5Ng_a21e4043-0bdf-475c-b1dc-e652a14b3d6f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xNS0xLTEtODA5Ng_ba55bd32-835b-4ccd-b2e3-d10df7bba4b1">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xNy0xLTEtODEwMg_1d3e4092-52be-4c5a-8c6c-3babebbe12a1">227.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTA5OTUxMTYzNDE1OA_c7518f73-2c5c-4899-b160-67dacd5065b9">160</ix:nonFraction> securities related to investments in debt securities available-for-sale, of which <ix:nonFraction unitRef="security" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTA5OTUxMTYzNDI0NA_6cdbebe7-c7b8-48b5-9316-51351bf752df">82</ix:nonFraction> securities were in an unrealized loss position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position as of September&#160;30, 2021 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0392d585f2a044d6bf61772081065e18"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their amortized cost basis. We did not recognize an allowance for credit losses as of September&#160;30, 2021 or December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1Mg_50170103-056c-40c6-9919-4eaaededd5d7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for less than 12 months, aggregated by major security type. There were no debt securities available-for-sale in an unrealized loss position for longer than 12 months as of September&#160;30, 2021 or December&#160;31, 2020.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMy0xLTEtMS0w_27a78913-32aa-4800-a26d-9f7c229da3ff">298.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMy0zLTEtMS0w_f5c3ff23-5990-4050-83d2-2ce1bc094bb2">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMi0xMi0xLTEtMTA1NzE_7b74d561-80cc-4673-ae77-dcf519adc1e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMi0xNC0xLTEtMTA1NzE_354e36fe-fee0-46aa-a194-963fc6c51aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica52a652db094241b061229da784c22f_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNC0xLTEtMS0w_4df4ba47-47a6-4f72-b283-d4c446a06854">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica52a652db094241b061229da784c22f_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNC0zLTEtMS0w_c14b5b61-aa7d-4e55-b87f-587eb29b1304">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fb858a78824577ab6b7073295d027f_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xMi0xLTEtODY1Ng_a1e8d804-dd4b-4f98-9c93-65d4c5c07cd9">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94fb858a78824577ab6b7073295d027f_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xNC0xLTEtODY1Ng_42f373cf-1062-4ccc-b381-9c73bc949077">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xLTEtMS0w_c0c2c0d9-fe56-49b1-b7ac-c69618a35887">405.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0zLTEtMS0w_b0abc96e-9eb9-4971-81bd-15b0f7749fcc">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xMi0xLTEtODcyMA_e5ae5b4f-97fa-49bb-b6d8-a0e62dffcbd3">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xNC0xLTEtODcyMA_e3f78688-0569-4ebc-ab4b-3d9b95a76222">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTUxOQ_b6c4fe29-a64c-464e-a8a7-42dd837f7ef5">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTUyNg_427378db-c624-406e-a354-d2558357fad1">3.7</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTk2Mw_127eb11a-2b0b-4119-9f2f-9dc8c9598975"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTk2Mw_a4f6f049-4d8d-4e25-955e-279372504015">No</ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during the nine months ended September&#160;30, 2021 or 2020.</span></div></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1Mw_d3a6784d-89e1-40c6-bf74-7427cb698cd6" continuedAt="i5df0578901ee4037835d4301096245ac" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i5df0578901ee4037835d4301096245ac" continuedAt="i52b2f7250bb241f287af75b503460e63"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1NA_81aa08ae-041f-476e-8d8d-7f47b4310ab7" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to certain holding period restrictions are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i52b2f7250bb241f287af75b503460e63"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1NQ_af90768f-f272-4300-ba5c-2a01f2ab0f4a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157b928b65e741d6b3db895524a44b01_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xLTEtMS0w_26421546-8f70-4396-a2d6-6742291eb5fa">311.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d140b31a337457eacc3647d03f3f97f_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0zLTEtMS0w_8d61ac1c-f98b-4c90-844e-b8b89b6a3821">311.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c5af590cb04d4092677c5129d1e809_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy01LTEtMS0w_6de0aab3-2b61-4536-b560-3273c6f07d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671519a4e4e1485fb15ec6c947a07076_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy03LTEtMS0w_3591555d-3a69-40be-85f4-650d7d498332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2998a4df4a4439a8cc2c83d9e8f7db_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy05LTEtMS00MDY1_91f7f8a3-ecdf-4a0e-9086-f6081dcf3a06">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997255409c3c45f39333fc13018a559c_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xMS0xLTEtNDA2NQ_0b86549a-1029-466a-8ddd-8e69c1725f92">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875a9a2626b44cf18fa53b7b885a6bce_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xMy0xLTEtNDA2NQ_0fb4173e-26c5-480a-b82b-8a15c7126dd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8a511b63824552bf8d257b1884b5f8_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xNS0xLTEtNDA2NQ_efd7d665-80fd-4c7e-8931-413cf5e385aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9119184273346b2b8dbad7d616102ee_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xLTEtMS0w_7d7f8c3b-9490-4328-bc32-161156e4432c">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81504f29583943ba9978871037be715e_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0zLTEtMS0w_5a6bd9a0-53be-4121-8a90-a3748303daaf">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37e0266d4814246b83de0b9d9c168bb_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi01LTEtMS0w_068c86b5-2e86-4eb6-a96d-74c4d4ea78ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbdfb0943f24a65a8f6da1e886aa8f9_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi03LTEtMS0w_7631cdc3-777f-4bf9-93eb-669764b4a398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia262940bd03b4238a69d63782e9387d8_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi05LTEtMS00MDY1_b4158d5c-c87d-47d6-84fe-0f403f1d239e">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463c5678112d48c9bc0abef10ada5150_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xMS0xLTEtNDA2NQ_62aac1a8-4493-4916-bb49-fc7eb7137665">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274f33b722f340dd83f22e59cf90400f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xMy0xLTEtNDA2NQ_3929c3e4-192b-43f6-9e86-b00518edd3b0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4db6ebba6644f3e9527c7fee2cff544_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xNS0xLTEtNDA2NQ_7f78bfb6-61fc-4626-9729-65ead30ba4d7">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice63c8557e304f948f1fafe5ab4e071f_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xLTEtMS0w_ef4752ad-5e5e-4d1c-9d3b-14d2ff0ce12a">208.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87fa5828e80490fb8b8d1bd0374f894_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0zLTEtMS0w_eb2a7536-5f75-4a05-bbae-079497a0e9ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192729099dcb4d288cb1d45579633c95_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS01LTEtMS0w_2b53b0c3-00fb-41c5-9bac-605096a3a681">208.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2778fd50f940aa86c54d9c1324bcee_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS03LTEtMS0w_87be1555-903d-4f5b-b59c-933ccf1ca5c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a4d025226f4fe68766605d098d9d0f_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS05LTEtMS00MDY1_ab2c8f1c-c1ec-4ac3-94ec-927e43fd6ab3">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e972f1fd84e45db85d8fb910086c0f5_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xMS0xLTEtNDA2NQ_539708e1-ce0f-4c0f-96b5-52a60a6811fc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1703dbc936474604bfd0656c06657637_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xMy0xLTEtNDA2NQ_d438ed91-8980-437b-9c9e-1fd8d6c1cc10">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f653c1026734aabb17bcf80cee5821b_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xNS0xLTEtNDA2NQ_6b51d5c2-affb-4a00-a18c-640f7eaecb20">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMS0xLTEtMA_003abb91-47d3-433f-aedd-5ebd2d518be9">499.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98cc854c976a48e1bbc3de3b9891bc67_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMy0xLTEtMA_73746160-5e25-4ef0-afd6-70ddbe2e92d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7dba45ab6a493d93352400235e1210_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtNS0xLTEtMA_0a8eea26-a909-43c5-a447-7cc4c2e79e57">499.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927462043ac04752942634b64cea6355_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtNy0xLTEtMA_b58cbc0e-b959-43f8-9f72-c6fae388de5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtOS0xLTEtNDA2NQ_54094236-51ae-4734-9885-768b582889d6">445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0d773bdaad4ae2b17b1d0b1b65fea4_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTEtMS0xLTQwNjU_5e2ffd51-49f9-4e35-ba89-5087f3acbc12">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec29fedb91804fec99b78fa71bf7c4d8_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTMtMS0xLTQwNjU_ecda4c33-c1b2-4d33-9e8e-0d0906de184f">445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e99b5f202a4eeca47d4e76e0d243c5_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTUtMS0xLTQwNjU_0ed55109-665f-47df-96a7-3b8e1ea55118">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica52a652db094241b061229da784c22f_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMS0xLTEtMA_bfb244af-3c12-46a3-946f-9c288f4a548d">260.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefce9ebfc0840a2bc5e823a2df50751_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMy0xLTEtMA_d6762a34-599e-4eef-b359-9c7a409ef54b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe8c38d81284f58932debf4c8cb7618_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtNS0xLTEtMA_426c97b4-bd0e-4662-8bfa-8ae982e996bf">260.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6fe6eba96941e689ad3a457f7112ec_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtNy0xLTEtMA_79d29672-6f07-4568-806c-05d1fbac4c01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fb858a78824577ab6b7073295d027f_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtOS0xLTEtNDA2NQ_81dc4942-4636-46d7-b3d3-b051b8d65a22">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85eea9c802ea4670afeeaa43139cc8fc_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTEtMS0xLTQwNjU_58a937b9-0e09-470e-bc3d-72d7af31f1df">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7630f29609c149bc8ed65aeacddff04f_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTMtMS0xLTQwNjU_b8ca782e-a996-40d2-9262-51c9286a6838">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d8b3c059e442a49871d8451515ebce_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTUtMS0xLTQwNjU_6f045acb-9435-4ecc-8b3f-be0e409138f7">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b3269f9d1443bfa965fb2dce758c76_I20210930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMS0xLTEtMA_0403def5-5cc6-44f8-be88-9f9cccea9e79">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147d42e72f9341768d5edb4e870a6497_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMy0xLTEtMA_6a2bd4f7-0bd0-445d-b290-3d6ab792a2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if013f2d93404456e9e08b22da1ce31cd_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtNS0xLTEtMA_466bcee6-0c70-4a2d-ac51-00031846e5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5363925363fe4d49a040c9683212cfcf_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtNy0xLTEtMA_122d698a-252f-4703-9be3-b3afec67865e">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66734cfaa1e439ebc58ca3d6feeadb8_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtOS0xLTEtNDA2NQ_5aa17a06-7efe-458d-b027-a8fef0d564e3">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4b8082c01e4b57b79756ab536ae7e5_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTEtMS0xLTQwNjU_cc4061f2-5e05-40dd-b22c-458bd7e94860">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b12614a8c724ea3b20972094290e1be_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTMtMS0xLTQwNjU_b15f4878-e39c-476d-969b-062d5faeacf6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3819533757414a9572e60d4e871a06_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTUtMS0xLTQwNjU_035d85a3-ba64-4240-b1c4-ac4beac5e256">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMS0xLTEtMA_8db833cf-4527-4f31-a7e3-a6181a11e2ad">1,318.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cc3330f8b146f39c81072617b752b3_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMy0xLTEtMA_eb887ec1-0708-48d9-a269-defebfbb88b6">314.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072cce2288a042b489e120bb3ec32f27_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtNS0xLTEtMA_4626be1d-f21b-4e1a-9652-7e3e787858ab">968.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034c6598652d4102850711d648ea0aa8_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtNy0xLTEtMA_bcc0da4b-6caa-4ea4-8809-c727e8a8f7d4">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtOS0xLTEtNDA2NQ_30ed4f9e-5910-423e-95bf-cb94918cbb13">1,069.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce42ab70b0940f9a48758422d138380_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTEtMS0xLTQwNjU_fa1d5a15-c168-4d8b-ac8a-f2e86eaa529b">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac443b5cdc54d92bea87fa506638d36_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTMtMS0xLTQwNjU_76d75ede-9a1a-4676-a4f9-1b0da743bc35">841.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c9afdc13440eaae85aaebae77f419_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTUtMS0xLTQwNjU_9a110c34-f1e9-496d-b3b8-54838b24151f">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1Ng_ffd1e858-9c5c-450e-9fa2-a47fa91ceb31" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6f931f878e4baca21f094c9ee764f2_I20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi0xLTEtMS0w_37d99ac7-5508-4cc1-9022-e64eeff57aa7">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fcf70e01d7421cba408015441496c1_I20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi0zLTEtMS0w_0e1209a8-3640-4dd3-b744-926b2b9e4eed">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ae0844fb5746d38ea81deefd1b9bef_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi01LTEtMS0w_cd9778af-b3a0-49fd-80ec-357f84bf65c5">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6c3665c37e4724ae7c9e261e7bbc8f_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi03LTEtMS0w_0760f435-67bb-44d0-a365-ac8214dbfa00">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy0xLTEtMS0w_2a9cbd6f-1abb-4af9-86c3-005a410c986b">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26221cd897194d5fb2af65836642c604_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy0zLTEtMS0w_466f0fd9-66e8-4708-a3cd-31fb81f55599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy01LTEtMS0w_e49af870-1eaa-49ae-94fc-58185a1347ac">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195a15919a14436a91e3c65518029bbe_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy03LTEtMS0w_77e1c7cc-b0cd-4993-850f-ca54481c9464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC0xLTEtMS0w_c28834cf-1d32-491e-9ed3-acdf4e4c9743">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26221cd897194d5fb2af65836642c604_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC0zLTEtMS0w_d2921aca-c49b-4fe0-9155-c22e4c960831">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC01LTEtMS0w_93fa91e2-d72c-4c32-8fd7-576ca66c6857">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i195a15919a14436a91e3c65518029bbe_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC03LTEtMS0w_b41f6514-f810-4210-a050-cad1c30a4cf2">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5815797b06f4ee6a46cb160090f637b_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS0xLTEtMS0w_dbbff840-5fa0-479b-9e57-f8d15affa74b">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS0zLTEtMS0w_2031e5ac-d646-4f14-83c7-0236ea4e4a65">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5815797b06f4ee6a46cb160090f637b_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS01LTEtMS0w_9693fd57-e7f4-423f-886f-6c5de14e13db">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS03LTEtMS0w_d08f8f85-f054-44cb-a999-1ecee877bf1b">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2021, we purchased <ix:nonFraction unitRef="shares" contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfNDk0NzgwMjMzNDIzOA_cc99d8fb-afb0-4a59-afa2-7cd4d94f78f8">0.3</ix:nonFraction>&#160;million shares of Xenon's common stock, valued at $<ix:nonFraction unitRef="usd" contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfNDk0NzgwMjMzNDI1MQ_5fdb616f-450f-431f-a8fd-90fc9a8b15d1">4.6</ix:nonFraction>&#160;million on the date of purchase, in connection with the approval of the CTA for NBI-921352.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the discount for lack of marketability used in the valuation analysis of equity security investments ranged from <ix:nonFraction unitRef="number" contextRef="i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk1Ng_68789312-f513-48ad-a714-63127e833a4a">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia7d8ece4878f459d8c0a6ad585eb5fe8_I20210930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk2Mg_e8bfbbf6-a49f-4f86-968c-d1a4dc615000">7.5</ix:nonFraction>% (weighted average of <ix:nonFraction unitRef="number" contextRef="if00a3aa3229f47c9b38aa8b37fe637f5_I20210930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk4Ng_945d2c6b-3b44-406e-9539-33d960dec6d2">3.9</ix:nonFraction>%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity security investments are included in other income (expense), net.</span></div></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RleHRyZWdpb246NzAxMTM1MjA3ZDI0NDNlN2JkYzEyZTc5ODc0YmQ4MGJfNjE_208752c8-f65d-4ebb-91d6-08e52b3f3568" continuedAt="ie6dad3d5bb7741888c64d0a78db39b9c" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ie6dad3d5bb7741888c64d0a78db39b9c"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RleHRyZWdpb246NzAxMTM1MjA3ZDI0NDNlN2JkYzEyZTc5ODc0YmQ4MGJfNjI_d8b98962-ba6e-4794-8a88-044453fb975f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMS0xLTEtMS0w_6c1c9dba-27ab-4f90-9f0a-41e61d8abd8e">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMS0zLTEtMS0w_ecbb1e3a-8e81-455e-bd17-ba3871602c49">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMi0xLTEtMS0w_27bb6805-d1e7-4ca5-83f5-a43ba370a388">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMi0zLTEtMS0w_78022b63-808e-4f3d-9e08-9dcea567e799">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMy0xLTEtMS0w_eca6d57a-15dd-4df2-b75a-496d4579512e">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMy0zLTEtMS0w_65ee443a-0fd3-4477-b5b2-fdd39484db18">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfNC0xLTEtMS0w_73e9294b-098e-4775-967a-d07a157288b4">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfNC0zLTEtMS0w_d3e86ffd-0b66-43ee-98dc-13b1e1abfc37">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="nbix:RestrictedCashTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RleHRyZWdpb246ODg3MDlhYmEwYTBiNDcyYjgyZjcxMTZjNDRlZTQxYjlfMjE3_25e217a9-8eae-44d6-b980-9104bb5c0d88" continuedAt="i82630ec47b27497aae7dac2447c91a15" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i82630ec47b27497aae7dac2447c91a15"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RleHRyZWdpb246ODg3MDlhYmEwYTBiNDcyYjgyZjcxMTZjNDRlZTQxYjlfMjE4_87d1e347-6877-45fc-ab59-2ed97fcd51c2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMS0xLTEtMS0w_3155f481-5424-43a0-8b9a-3a15a330c92b">311.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMS0zLTEtMS0w_6e9752b7-063a-4a09-a70f-570e4dff4a15">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMi0xLTEtMS0w_eb2d9821-8503-4931-8f7f-596fd0e4984e">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMi0zLTEtMS0w_1d5b37ae-4a91-4d99-8e6b-409ef91c8efe">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMy0xLTEtMS0w_ad7b06cf-2136-45b0-b8de-f0614019dc43">314.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMy0zLTEtMS0w_f14b7675-248e-41b9-ba1c-5363197c9e4e">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODM5_98718752-a687-4d24-af41-4c93d7d8a057" continuedAt="i849e43934db544f1ad3659afa953e105" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i849e43934db544f1ad3659afa953e105"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2024 through 2031. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities. In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfNjYy_a2b0355c-b128-4ee5-871e-4f7c6f4e0caa">3.2</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODQw_fd8a20a7-0b80-410c-aea2-19370bfba76f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMi0xLTEtMS0w_994657f2-9ea1-4df4-b168-09467469de6c">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMi0zLTEtMS0w_8f040711-afb1-4e02-8d83-af83996448d2">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMy0xLTEtMS0w_ead51421-0cf5-4a33-8c21-17b7ba566461">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMy0zLTEtMS0w_e13a392b-3867-47eb-bca8-c593f61e43e0">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNi0xLTEtMS0w_0c7808d5-7095-4ac3-84a3-dc542ee53ebe">9.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNi0zLTEtMS0w_29668ee0-aae3-48ed-a903-68718a35d22c">10.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNy0xLTEtMS0w_b48ee369-a550-4287-9760-02813f4d4bcb">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNy0zLTEtMS0w_91b87072-29c9-4e18-90a2-ed6495d87910">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODM1_ad28531a-c0a1-402a-b1f5-5095e2beef36" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future minimum lease payments under operating leases.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMS0xLTEtMS0w_bca96969-dd2f-4da1-9ffd-72fa9695bb33">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMi0xLTEtMS0w_50eb7a8f-f9ce-422e-aea1-66577cea2fde">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMy0xLTEtMS0w_bf35187f-81bf-4353-b60d-42eb1ab416d5">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNC0xLTEtMS0w_777c2385-e8e5-4365-85cd-1e4c18dc47bd">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNS0xLTEtMS0w_4d060b5e-33dc-4006-bd33-8d6ca7d45301">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNi0xLTEtMS0w_d669407c-29e6-4e92-9e0f-9a1e6ccb6753">85.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNy0xLTEtMS0w_c210440e-b2b2-4527-a13a-a1d70d82c7ef">155.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfOC0xLTEtMS0w_de1c7381-0370-4004-8bda-529560eb0ff8">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfOS0xLTEtMS0w_20493900-552d-44ec-a791-712da136ec98">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMTAtMS0xLTEtMA_ae391964-b8bd-4d80-ab5b-ab04ad47c73a">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMTEtMS0xLTEtMA_d1987468-2284-4c54-8023-1b681f649e7a">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyNg_2de469b8-0fb5-4f1f-bcea-8072e52cb19c" continuedAt="ibbe7ddc9a9c74c73832f89464d248abe" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="ibbe7ddc9a9c74c73832f89464d248abe" continuedAt="i105f1514cff04bbfabd3e0036f872c5e"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODU_bc746105-15a3-47b6-a027-e27fca766c4d">517.5</ix:nonFraction> million&#160;in aggregate principal amount of&#160;the 2024 Notes and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="ia4f2ab910308454c8f7155eed697292f_I20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDAz_1d3e7b77-6d49-43c4-aa48-ef2a057bcb8e">136.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="id661067c1cf345799ba33c3aaeb96515_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDg4_f5793e92-7d75-48bd-80c0-bba83a2de415">186.9</ix:nonFraction>&#160;million in cash. At September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTA3_23e47215-0a50-4513-a212-d80c8b29e556">381.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes remained outstanding. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2024 notes, we could not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTQ4_74332fb4-8fb3-49f0-9ce1-8130877bef98">130</ix:nonFraction>% of the conversion price then in effect (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTAwMA_a06bb8d3-65d3-4bff-8fa0-3edfbac3ca77">98.70</ix:nonFraction> as of September&#160;30, 2021) for at least&#160;<ix:nonFraction unitRef="d" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTAyNg_6496bae9-6ab8-4875-84ec-4d081451593f">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during any&#160;<ix:nonFraction unitRef="d" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTA4Mg_0d19ffd9-7756-403f-a11d-ba2bcfc84e9d">30</ix:nonFraction>&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTU1Mg_70b88d79-2618-462b-9237-86221299a114">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTYxNg_28aa31b4-1fc3-42a0-a63c-bef40296a5ef">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTczNw_d40ec339-123f-40ed-b8f6-ba47114f7a27">130</ix:nonFraction>%&#160;of the conversion price (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTc3NA_a06bb8d3-65d3-4bff-8fa0-3edfbac3ca77">98.70</ix:nonFraction> as of September&#160;30, 2021) on each applicable trading day;</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i105f1514cff04bbfabd3e0036f872c5e" continuedAt="idba6221b584548f18e3a8947f08b5bd7"><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTgzMA_ef1eef62-b79a-46f3-a25d-922b0620d60a">five</span> business-day period immediately after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTg3NQ_a16f9f76-754b-427d-8388-b5aa3c37a979">five</span>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjAwMA_d10e92cb-aae5-49d4-a348-93c27b567b55">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjA5OQ_b4c2a2ab-3b7c-4aa8-939e-f6927bc27c01">98</ix:nonFraction>%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;<ix:nonFraction unitRef="d" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjg0Mw_55fa3c2a-2c65-41bf-910f-7db2241f0457">30</ix:nonFraction>&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzQyNg_fe334ab1-bdfe-4364-9490-329ee154406f">1,000</ix:nonFraction> in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzUxOQ_1790db08-7cd1-4510-98a9-3ed1805320ad">1,000</ix:nonFraction>, and the conversion value during the <ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" format="ixt-sec:durday" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzU1OQ_d8e67b38-6704-408b-a52b-7c5b6c34be03">25</ix:nonNumeric>-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by <ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" format="ixt-sec:durday" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzc0OA_9c9147dc-b5f4-4b19-a41e-0985e5d11fb1">25</ix:nonNumeric> days and the daily volume weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDA1OA_5ee55015-ffa8-425f-9811-8cb2e81ad475">1,000</ix:nonFraction>. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" format="ixt:num-dot-decimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDE0OA_bb90f719-63c9-4165-b8a2-1214411a959c">1,000</ix:nonFraction>&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDIzNw_84242f5b-e954-4eab-81c0-4fda020cbd55">75.92</ix:nonFraction>&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate <ix:nonFraction unitRef="shares" contextRef="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDM4MQ_66fe987d-3d05-4b5c-91be-49e43cd32da0">5.0</ix:nonFraction> million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;<ix:nonFraction unitRef="number" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDYwNQ_dd564e3a-a087-4de6-b078-17cbacf344a8">42.5</ix:nonFraction>%&#160;to the closing sale price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDYzNw_0108f464-05c8-4375-9762-0d26156821f9">53.28</ix:nonFraction>&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$<ix:nonFraction unitRef="usd" contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTE3Mg_e68190f1-49dc-45dc-b7b6-d66180e66d94">381.2</ix:nonFraction>&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTUyMw_675c501c-7f8a-4f16-8586-f500297cfd1c">100</ix:nonFraction>%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the 2024 Notes are currently classified as a long-term liability, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would then be considered a current obligation and classified as such.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idba6221b584548f18e3a8947f08b5bd7"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of issuance. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="-5" format="ixt:num-dot-decimal" name="nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzIzNA_368b8b6c-9c8b-49d2-8063-9bc5e9437318">368.3</ix:nonFraction> million&#160;was calculated using a&#160;<ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzI2MA_0c322a3e-1b31-4edb-a682-d1eba2632c19">7.5</ix:nonFraction>%&#160;assumed borrowing rate. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzMxMQ_cd0137fd-1dfa-4a77-8014-80e792abad88">149.2</ix:nonFraction> million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the <ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyOA_67e5e267-28cb-4d3c-9e30-2a8711baf812">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2021, the remaining period over which the discount on the liability component will be amortized was approximately <ix:nonNumeric contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzk4NA_508fd2e0-7607-48f6-a494-296fd327bf13">2.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODA0Ng_ec8f45fd-6590-4508-bf8e-815e0bbbaa36">14.7</ix:nonFraction> million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;<ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyOQ_62619082-487c-4e52-8a85-2bcb797af306">seven-year</ix:nonNumeric> term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;<ix:nonFraction unitRef="number" contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" decimals="INF" name="nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODc3MQ_5875e29c-6c09-4621-a0b8-7be9e661d81f">100</ix:nonFraction>%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMzMA_26321428-f419-4782-9138-8a731d2144ec" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMS0xLTEtMS0w_a967ceec-9982-4efb-bc97-c369a5640ea0">381.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMS0zLTEtMS0w_cbfba291-622d-4955-9d35-296223e4e04d">381.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMi0xLTEtMS0w_d4931d06-cdd1-452b-8f72-9b6295af7040">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMi0zLTEtMS0w_8cb2c14f-b817-4b0c-b429-3caf50d157c5">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMy0xLTEtMS0w_e958b788-3ae5-4984-a99e-8ba74b28ac2a">47.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMy0zLTEtMS0w_14596c8e-7b52-44c9-8ae0-26b9c3532628">59.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfNC0xLTEtMS0w_5f9a1334-283e-466f-87bd-600814d98777">330.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfNC0zLTEtMS0w_cc87b16c-f13a-4338-9c78-19ecd0af6d03">317.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their <ix:nonNumeric contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMzMQ_5165b0f7-7f3b-4d3b-8adc-b28c52bfc4e0">seven-year</ix:nonNumeric> term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $<ix:nonFraction unitRef="usd" contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMwNA_0f445d72-fc41-4b9c-8489-e2e588a8d1ba">497.7</ix:nonFraction> million at September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if731862d3ce642ffae334bf7a6733e28_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMxNw_7ce692e4-60d3-441f-96b9-425755f352e5">514.3</ix:nonFraction> million at December&#160;31, 2020.</span></div></ix:continuation><div id="i232e3d73409b464385a0180f5b5ba6e3_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNzc2_492e8593-87b2-483f-9561-2ffe69097d74" continuedAt="i9d49b9e33d6f41a49dc6ad771ce06a7b" escape="true">Net Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="i9d49b9e33d6f41a49dc6ad771ce06a7b" continuedAt="i79e4545278b44d9aa6aa1efedf77b984"><ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNzc3_25275e92-b1e0-4b42-af1b-2bb166ff10de" continuedAt="ic7d546e9829c48c1ad021042c4abfb74" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi0xLTEtMS0w_e70400ae-f8d0-4f31-9bd0-7543f8f35959">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi0zLTEtMS0w_7763776b-e918-4821-a181-abf18e439710">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi01LTEtMS0w_661b6a6d-67d6-4629-9f84-246b4b8a14de">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi03LTEtMS0w_dd35df30-94c1-41f6-8179-1c7b2af1e342">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC0xLTEtMS0w_49f15db5-a855-43ec-b5c3-c777b07cbc56">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC0zLTEtMS0w_f41a48a9-aa32-4d91-ae4b-4b783895c3b5">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC01LTEtMS0w_704204b3-b6c4-4756-82fd-35165375ed52">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC03LTEtMS0w_10c8eefc-b90b-4ecd-abcb-3b98f5a2b507">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i613b05cc13dc49b4a0c7a305b35ce164_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi0xLTEtMS0w_8421ee9d-2901-4436-90ca-c7e08b2182e5">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6646025f6a78471b87f269eb801ee821_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi0zLTEtMS0w_dda383b9-78b9-4c9d-afd3-92b6913f8749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65276afd2e6542f0b217ec8483499b87_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi01LTEtMS0w_5017831a-9cec-4e03-a931-ba4d7dd404ae">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b01bcc9a078432796345ea93821c9a0_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi03LTEtMS0w_e066d239-0808-44e5-9de7-cc5b9bda33a7">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4af071ef4314dd5b5a613cc233965c6_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy0xLTEtMS0w_690b0c43-55f1-4a19-b687-610d39aafce8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3ea3d3697cc4bbbbab42a49a59bd0ee_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy0zLTEtMS0w_a7be6479-d4ff-497f-95b8-a154c6484d14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d69c9551a434c0fb66e7651162ab9ea_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy01LTEtMS0w_9c4d2d61-deb4-4bdf-85aa-4281f14022e5">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c660c5054143d681316ee502a02a1e_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy03LTEtMS0w_b59297dc-0ef8-47e7-b380-a7ce0f57e59a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC0xLTEtMS0w_9e30a29b-cc1a-415c-b83c-85a3adcdef9a">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ffb61e2639493c9292444fcc81cf0b_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC0zLTEtMS0w_6936f7c8-4698-4326-9aca-e9f075c45a2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC01LTEtMS0w_087a177a-89c7-414b-bc36-439d5e7642a2">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c87e3ad24243c1a4e073d2ef7e8134_D20200101-20200930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC03LTEtMS0w_f0815825-7a55-4a98-b1d2-42e7f609c8d1">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS0xLTEtMS0w_3c8be11f-9576-4dde-84cd-7e52f9a02f8b">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS0zLTEtMS0w_96f0ed5f-e2ed-44f7-9b42-b1e00dc311cb">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS01LTEtMS0w_641a3d98-faf8-4895-8110-1596b8d8036b">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS03LTEtMS0w_5a67c1b3-e1bb-43bb-9149-e35ec61fa9fd">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtMS0xLTEtMA_0943ccd0-510d-461c-8f05-ef0359524050">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtMy0xLTEtMA_de2ebad8-3768-4e23-a3d4-569d8276a8de">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtNS0xLTEtMA_a4e53a36-e18d-433d-834c-f9d9e1c43414">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtNy0xLTEtMA_9a8a6d0b-6d32-4ff0-b712-cc69a762e26f">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItMS0xLTEtMA_63f63da6-1435-4eb9-83d8-00db0958fe2f">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItMy0xLTEtMA_462a5b41-f3b5-4063-b117-e48764f2136e">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItNS0xLTEtMA_85b2b477-8000-4c81-a83d-fedf5279c576">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItNy0xLTEtMA_38421654-42db-4840-9445-225239a60678">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtMS0xLTEtMA_fd37bf43-b685-494a-a714-fb41de5d8d9b">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtMy0xLTEtMA_d827d210-81c1-490e-a725-8d4ae11c0b5c">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtNS0xLTEtMA_5c6ab879-9618-418e-9c72-b5cb74fe2e84">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtNy0xLTEtMA_1237101c-37e5-4397-958d-c9625aa5ec0b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2021, our board of directors approved an equity grant in the form of restricted stock units, or RSUs, to our full-time employees other than our executive officers, consisting of approximately <ix:nonFraction unitRef="shares" contextRef="i056102a1b5034e53811a069c914ac932_I20210831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfMTA5OTUxMTYzMTcxMw_7f00b533-7f71-46e7-bc49-0639775fe0f3">0.5</ix:nonFraction>&#160;million RSUs, which will vest over a period of <ix:nonNumeric contextRef="i0a1fca71d61f40dc8fbddba62968770a_D20210801-20210831" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfMTA5OTUxMTYzMTMwNA_7f70aa49-503b-4ae0-98c7-904e820f7730">two years</ix:nonNumeric>.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><ix:continuation id="i79e4545278b44d9aa6aa1efedf77b984"><ix:continuation id="ic7d546e9829c48c1ad021042c4abfb74"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately <ix:nonFraction unitRef="shares" contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNjIx_2f5e6f7e-f5ad-4750-9d63-729d365ade49">5.0</ix:nonFraction> million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.</span></ix:continuation></ix:continuation></div><div id="i232e3d73409b464385a0180f5b5ba6e3_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM182MS9mcmFnOmE5ZTQzOTI3OWI5MDQ0MmRhNDI5ZDMyMjcxNDg1YjkyL3RleHRyZWdpb246YTllNDM5Mjc5YjkwNDQyZGE0MjlkMzIyNzE0ODViOTJfMjA0Mg_bc0691d7-bdba-444a-9c84-7b6c4af8edba" continuedAt="i6848ccc035cf424f9e096bdea1908f29" escape="true">Legal Proceedings</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6848ccc035cf424f9e096bdea1908f29">In the second quarter of 2021, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. (each an &#8220;ANDA Filer&#8221;) that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. The ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer&#8217;s manufacture, use or sale of the medicine for which the ANDA was submitted. We filed suit in the U.S. District Court for the District of Delaware in July 2021 against (i) Teva Pharmaceuticals, Inc. and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., (ii) Lupin Limited and its affiliates Lupin Pharmaceuticals, Inc., and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., and its affiliate Crystal Pharmatech Co., Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC. We also filed suit in the U.S. District Court for the District of New Jersey in July 2021 against Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC seeking to prevent any ANDA Filer from selling a generic version of INGREZZA.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item&#160;1A under the caption &#8220;Risk Factors.&#8221; The interim financial statements and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 and our Quarterly Report on Form 10-Q for the nine months ended September 30, 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States, or US, in May 2017 as the first FDA-approved drug for the treatment of tardive dyskinesia. In September 2020, we launched ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) for Parkinson's disease in the US, leveraging our existing INGREZZA commercial infrastructure. INGREZZA net product sales represent the significant majority of our total net product sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie Inc., or AbbVie, launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the US and Canada in August and November 2018, respectively. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the US. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Updates:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NBI-921352 (XEN901)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we received approval of a clinical trial application, or CTA, submitted in the European Union for NBI-921352 for the treatment of focal-onset seizures in adults. In connection with the approval of the CTA for NBI-921352, we paid Xenon a regulatory milestone of $10.0&#160;million, of which we expensed $4.5&#160;million as research and development in the third quarter of 2021, and purchased 0.3&#160;million shares of Xenon&#8217;s common stock (at $19.9755 per share) for $5.5&#160;million. The purchased shares were recorded at a fair value of $4.6&#160;million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. Further, we recorded a charge of $0.9&#160;million to research and development to reflect the premium paid on our purchase of the shares on the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has dramatically changed the ways in which we live and interact with one another. While we adapt to this new shared reality, our mission remains unchanged: to discover and develop life-changing treatments for people with serious, challenging and under-addressed disorders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the initial impact of the COVID-19 pandemic has subsided, we are uncertain how more transmissible variants may impact our business. We remain committed to (1) prioritizing the safety, health and well-being of patients and their caregivers, healthcare providers and our employees; (2) ensuring patients with tardive dyskinesia are well supported and have continued uninterrupted access to INGREZZA, for which we have not experienced and currently do not expect any supply disruption; and (3) advancing ongoing clinical studies. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our field-based employees have resumed in-person interactions, and certain of our office-based employees began to return to the office, in each case on a voluntary basis and in accordance with location-specific guidance. We are planning for a larger-scale return of our workforce to our offices before the end of 2021 and have developed flexible work arrangement guidelines to help balance business needs, employee health, well-being and safety and the evolving work environment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most hospitals, community mental health facilities, physicians&#8217; offices, pharmacies, and other healthcare facilities have relaxed their policies that limited access of patients and our employees to such facilities and limited the ability of patients, pharmacies, and prescribers to interact with each other. However, we anticipate these policies may change from time to time as communities grapple with local or regional outbreaks. The ultimate impact of the COVID-19 pandemic, including any </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lasting effects on our revenue and the way we conduct our business, is highly uncertain and subject to continued change. We recognize that this pandemic will continue to present unique challenges for us throughout 2021, and potentially into 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales by Sales Product. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INGREZZA net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONGENTYS net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compared with the comparable period last year, the increase in INGREZZA net product sales for the three months ended September&#160;30, 2021 was primarily driven by record total prescriptions reflecting higher customer demand and increased commercial activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues by Category. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elagolix royalty revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other collaboration revenues</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Collaboration revenues for the nine months ended September&#160;30, 2021 primarily reflect the achievement of a $15.0 million milestone associated with MTPC's MAA submission for valbenazine for the treatment of tardive dyskinesia in Japan.</span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Collaboration revenues for the nine months ended September&#160;30, 2020 primarily reflect the achievement of a $30.0 million milestone associated with AbbVie&#8217;s receipt of FDA approval for ORIAHNN for uterine fibroids in May 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development, or R&amp;D. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, R&amp;D programs and business development opportunities. Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the R&amp;D activities are part of our collaborative and other relationships.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense categories consist of the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of costs incurred for product candidates in Phase II registrational studies and all subsequent activities. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Early Stage. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consist of costs incurred for product candidates after the approval of an investigational new drug application by the applicable regulatory agency through Phase II non-registrational studies. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Research and Discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of costs incurred prior to the approval of an investigational new drug application by the applicable regulatory agency. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of costs incurred for development and/or regulatory milestones in connection with our collaborative arrangements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ayroll and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of costs incurred for salaries and wages, payroll taxes, benefits and share-based compensation associated with employees involved in R&amp;D activities. Share-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. </span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Facilities and Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of indirect costs incurred for the benefit of multiple programs, including depreciation, information technology, and facility-based expenses, such as rent expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents R&amp;D expense by category.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Late stage</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early stage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compared with the comparable periods last year, late-stage R&amp;D expense for the three and nine months ended September&#160;30, 2021 primarily reflects decreased investment associated with our termination of the NBIb-1817 program for Parkinson&#8217;s disease in February 2021, offset by continued investment in our Phase III programs in congenital adrenal hyperplasia for adults and pediatric patients and our Phase III Huntington Disease trial. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Early Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compared with the comparable periods last year, early-stage R&amp;D expense for the three and nine months ended September&#160;30, 2021 primarily reflects continued enrollment of our Phase II programs in epileptic encephalopathy with continuous spike and wave during sleep, or CSWS, and essential tremor and our initiation of Phase II programs in focal-onset seizure in adults and SCN8A developmental epileptic encephalopathy, or SCN8A-DEE.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expense for the three and nine months ended September 30, 2021 reflects $5.4 million associated with our receipt of approval for the NBI-921352 CTA in September 2021. For the nine months ended September 30, 2020, R&amp;D expense reflects $20.0 million associated with our receipt of FDA approval for ONGENTYS for Parkinson&#8217;s disease in April 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Payroll and benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compared with the comparable periods last year, payroll and benefits R&amp;D expense for the three and nine months ended September&#160;30, 2021 reflects higher personnel expenses primarily driven by increased headcount. Payroll and benefits R&amp;D expense for the nine months ended September&#160;30, 2021 also reflects a non-cash share-based compensation charge of $6.4 million related to the modification of certain share-based awards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development, or IPR&amp;D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">IPR&amp;D expense for the three and nine months ended September&#160;30, 2020 reflects $118.5 million of upfront fees paid pursuant to our exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda. IPR&amp;D expense for the nine months ended September&#160;30, 2020 also reflects $46.0 million of upfront fees paid pursuant to our collaboration and license agreement with Idorsia.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative, or SG&amp;A. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compared with the comparable periods last year, SG&amp;A expense for the three and nine months ended September&#160;30, 2021 primarily reflects increased investment to support our commercial initiatives, including the May 2021 launch of our INGREZZA direct-to-consumer advertising campaign, "TD Spotlight".</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compared to the comparable periods last year, other expense, net, for the three and nine months ended September 30, 2021 reflects periodic fluctuations in unrealized losses recognized to adjust our equity investments in Voyager and Xenon to fair value and decreased interest expense resulting from the November 2020 repurchase of $136.2 million aggregate principal amount of the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes, for an aggregate repurchase price of $186.9 million in cash.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The effective tax rate for the three and nine months ended September&#160;30, 2021 was lower than federal and state statutory rates primarily due to excess tax benefits related to share-based compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On December 31, 2020, we released substantially all of our valuation allowance against our net operating losses and other deferred tax assets. Beginning in the first quarter of 2021, we began recording a provision for income taxes using an effective tax rate approximating federal and state statutory rates. Due to the ability to offset any pre-tax income against previously benefited federal net operating losses, no federal cash tax is expected in 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) and Diluted Earnings (Loss) per Share.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compared with the comparable periods last year, net income and diluted earnings per share for the three and nine months ended September&#160;30, 2021 primarily reflect increased investment to support our commercial initiatives, including the May 2021 launch of our INGREZZA direct-to-consumer advertising campaign, "TD Spotlight", increased investment in our expanded clinical portfolio offset by prior year IPR&amp;D costs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information Regarding Our Cash Flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compared with the comparable period last year, net cash provided by operating activities for the nine months ended September&#160;30, 2021 primarily reflects increased INGREZZA net product sales and lower upfront payments associated with our collaborations with Idorsia and Takeda, partially offset by increased investment to support our commercial initiatives and advancing our expanded clinical portfolio.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Periodic fluctuations in net cash (used in) provided by investing activities primarily reflect timing differences related to purchases, sales, and maturities of debt security investments and changes in our portfolio-mix. Net cash used in investment </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities for the nine months ended September&#160;30, 2021 also reflects a $5.5 million equity investment in Xenon associated with our receipt of approval for the NBI-921352 CTA in September 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Net cash provided by financing activities primarily reflects proceeds from issuances of our common stock for all periods presented.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we completed a private placement of $517.5 million in aggregate principal amount of the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. As of September&#160;30, 2021, $381.2 million aggregate principal amount of the 2024 Notes remained outstanding. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least&#160;130% of the conversion price then in effect (equal to $98.70 as of September&#160;30, 2021) for at least&#160;20&#160;trading days (whether or not consecutive) during any&#160;30&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceed twelve months. If a 1% change in interest rates were to have occurred on September&#160;30, 2021, it would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of new accounting pronouncements which may be applicable to us, see Note 1 to the condensed consolidated financial statements included in this report.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;proforma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part II titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of our exposure to, and management of, market risk appears in Part I, Item&#160;2 of this Quarterly Report on Form&#160;10-Q&#160;under the heading &#8220;Interest Rate Risk.&#8221;</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_70"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports required by the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes to our internal control over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended September&#160;30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. (each an &#8220;ANDA Filer&#8221;) that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. The ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer&#8217;s manufacture, use or sale of the medicine for which the ANDA was submitted. We filed suit in the U.S. District Court for the District of Delaware in July 2021 against (i) Teva Pharmaceuticals, Inc. and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., (ii) Lupin Limited and its affiliates Lupin Pharmaceuticals, Inc., and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., and its affiliate Crystal Pharmatech Co., Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC. We also filed suit in the U.S. District Court for the District of New Jersey in July 2021 against Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC seeking to prevent any ANDA Filer from selling a generic version of INGREZZA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><div id="i232e3d73409b464385a0180f5b5ba6e3_79"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form 10-Q and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations. The risk factors set forth below with an asterisk (*) contain changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical studies may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including our announced sales force expansion in late 2021 and early 2022. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA, or to successfully commercialize ONGENTYS or any product candidate approved by the FDA in the future. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. In parts of the country where the pandemic is having a greater impact, some hospitals, community mental health facilities, and other healthcare facilities continue to have policies that limit access of our sales representatives, medical affairs personnel, and patients to such facilities. These policies are likely to change from time to time as communities or regions grapple with local or regional outbreaks. In addition, many health care practitioners have adopted telehealth for patient interactions, which may impact the ability of the health care practitioner to diagnose tardive dyskinesia. Further, during the COVID-19 pandemic, the use of physician telehealth services increased, fueled in part by an expansion of coverage and reimbursement from government and other payors. The limitations that telehealth places on the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading potentially fewer patients to be diagnosed and referred for treatment. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA or ONGENTYS could be affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for additional indications;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community, patients and payors do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or to successfully commercialize ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care and the price of prescription drugs through various means may impact our revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use. Coverage decisions by payors for our competitors' products may also impact coverage for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the US. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs or indications, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Further, during the COVID-19 pandemic, the use of physician telehealth services has rapidly increased, fueled by an unprecedented expansion of coverage and reimbursement across insurers. The limitations that telehealth places on the ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading potentially fewer patients to be diagnosed and/or treated.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have customers and/or patients, clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, the COVID-19 pandemic has resulted in travel restrictions and the shutdown or delay of business activities in various regions. In response to the COVID-19 pandemic, we implemented a remote work model for all employees except certain key essential members involved in business-critical activities.&#160;Most of our field-based employees have resumed in-person interactions, and certain of our office-based employees began to return to the office, in each case on a voluntary basis and in accordance with location-specific guidance. We are planning for a larger-scale return of our workforce to our offices before the end of 2021 and have developed flexible work arrangement guidelines to help balance business needs, employee health, well-being and safety and the evolving work environment. The effects of our remote and flexible work model may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Although the immediate impact of the COVID-19 pandemic has subsided, the effects of the pandemic continue to rapidly evolve and we may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders, travel restrictions, and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient travel or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff may be hindered, which would adversely impact our clinical trial operations. Increases in COVID-19 cases or hospitalizations on a regional basis in the future could cause us or any of our clinical sites to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease, Friedreich&#8217;s ataxia, and other neurological and endocrine-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful, (including the development of generic equivalents) the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to INGREZZA for tardive dyskinesia, we compete with Teva Pharmaceutical Industries, which received FDA approval for AUSTEDO to treat tardive dyskinesia in August 2017, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as Xenazine (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In endometriosis, ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to ONGENTYS for Parkinson&#8217;s disease, there are currently two other FDA-approved COMT inhibitors. ONGENTYS competes directly with these two drugs and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As for CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the US alone, there are more than two dozen companies manufacturing steroid-based products. Additionally, there are several clinical development-stage programs targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications, or ASMs, and development-stage programs being pursued by several other companies. Commonly used ASMs, among others, include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different ASMs are currently used in these patient populations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">The investigational treatment luvadaxistat for the cognitive impairment associated with schizophrenia, or CIAS, may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA approved treatments specifically indicated for CIAS.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in endocrinology, neurology, and psychiatry, as well as our investigational gene therapies, may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small number of research and development programs ultimately result in commercially successful drugs. In addition, to date the FDA has granted regulatory approval for only a very limited number of gene therapy products and the clinical development of a gene therapy product may result in unforeseen adverse events. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND application or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may not replicate the results of previous trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical site initiation or patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. In addition, due to the impact of the COVID-19 pandemic, clinical site initiation and new patient enrollment has been negatively impacted. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix. We collaborate with MTPC for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. We also rely on BIAL for the commercial supply of ONGENTYS. In addition, we collaborate with Xenon for the development of NBI-921352, Idorsia for the development of NBI-827104 and Takeda for the development of luvadaxistat, NBI-1065845, and NBI-1065846.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may sell, transfer or divest assets or programs related to our partnered product or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing commercial infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had approximately 917 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially with the planned increase in the size of our sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on our organization, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our employees on adequate terms in an increasingly competitive, inflationary market; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management, commercial and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. In addition, the manufacture of gene therapy products, which will be necessary under our collaboration and license agreement with Voyager, is technically complex and necessitates substantial expertise and capital investment. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the US Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, the finished drug product, and packaging in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced US, state, and non-US regulations, and disruptions or delays caused by man-made or natural disasters, pandemics or epidemics, or other business interruptions, including, for example, the COVID-19 pandemic. We depend on a limited number of suppliers for the production and packaging of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or if a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and contract research organizations, or CROs, to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our regulatory applications and our introduction of new treatments. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Clinical Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our expected revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The conditional conversion feature of the 2024 Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the 2024 Notes is triggered, holders of 2024 Notes will be entitled to convert their 2024 Notes at any time during specified periods at their option. If one or more of the holders of the 2024 Notes elects to convert their notes, unless we satisfy our conversion obligation by delivering only shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would then be considered a current obligation and classified as such. We are not aware of any events or market conditions that would allow us to redeem the 2024 Notes or the holders of the 2024 Notes to convert the 2024 Notes for the quarterly period ended September&#160;30, 2021, or as of the date of this report.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. As of September&#160;30, 2021, $381.2 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. As of September&#160;30, 2021, we had an accumulated deficit of 0.6 billion as a result of historical operating losses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson&#8217;s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or for additional indications for our current products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations, in-licensing or acquisition opportunities, and capital expenditures. While we were profitable for the year ended December 31, 2020, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has limited experience in the review and approval of gene therapy products. The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. As a result, the regulatory review process may take longer or cost more than we anticipate, including requirements for additional preclinical studies or clinical trials, and delay or prevent approval and commercialization of our gene therapy product candidates we are developing through our collaboration with Voyager. While the FDA has issued draft guidance for the development of gene therapies and proposed rules that would streamline certain requirements to which gene therapies are currently subject, it remains to be seen as to whether such initiatives will ultimately increase the speed of drug development in gene therapies such as the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. If our gene therapy products are approved but fail to achieve market acceptance among physicians, patients, hospitals, third-party payors or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may adversely affect our ability to initiate or continue clinical development or obtain regulatory approvals for gene therapy product candidates or the commercialization of gene therapy products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy remains a novel technology, with few gene therapy products approved to date in the US. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. Even if we are able to successfully complete clinical development of a gene therapy product and obtain commercial approval, the success of our collaboration with Voyager will depend upon physicians who specialize in the treatment of genetic diseases targeted by gene therapy product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations, negative public opinion related to gene therapy products, or safety issues identified in our clinical trials may delay or impair the development and commercialization of our gene therapy product candidates or demand for any gene therapy products we develop.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. A high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus, small declines in revenue could disproportionately affect financial results in a quarter. While we were profitable for the quarter ended September&#160;30, 2021, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the US tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future US tax expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years beginning on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable US tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2017, will be subject to a percentage limitation to the extent utilized in tax years beginning after December 31, 2020 and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California passed legislation imposing limits on the usability of California state NOLs and certain tax credits in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we commenced recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which could result in a significant reduction in our net income and net income per share.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The price of our common stock is volatile.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $85 per share to approximately $120 per share. The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, or ORIAHNN;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA and foreign regulatory agencies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters and developments in existing litigation matters, such as the ANDA litigation matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a member of the S&amp;P MidCap 400 index. If we cease to be represented in the S&amp;P MidCap 400 index, or other indexes or indexed products, as a result of our market capitalization falling below the threshold for inclusion in the index, certain institutional shareholders may, due to their internal policies and investment guidelines, be required to sell their shareholdings. Such sales may result in further negative pressure on our stock price and, when combined with reduced trading volume and liquidity, could adversely affect the value of your investment and your ability to sell your shares.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors, and all of our product sales of INGREZZA are to these customers. Two of these customers represented approximately 85% of our total product revenue for the nine months ended September&#160;30, 2021 and a significant majority of our accounts receivable balance as of September&#160;30, 2021. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources, together with investment income, and future payments due under our strategic alliances, will be sufficient to satisfy our current and projected funding requirements for at least the next twelve months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to curtail significantly our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the 2024 Notes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any strategic alliances, collaborations, product in-licensing or acquisitions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. As of September&#160;30, 2021, $381.2 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed, and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the US and internationally.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. In addition, potential competitors have in the past and may in the future file an ANDA with the FDA seeking approval to market a generic version of our products before the expiration of the patents covering our products. To prevent infringement or unauthorized use, we have in the past and may in the future need to file infringement claims, which are expensive and time-consuming. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. For a more detailed description of these matters, see Part II, Item 1 of this Form 10-Q. In addition, in an infringement proceeding a court may decide that a patent of ours or a patent of a competitor of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Interference proceedings declared by the US Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the US.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the US, comprehensive health care reform legislation was enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the US will continue to put pressure on the rate of adoption and pricing of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers are required to provide certain information regarding the drug product provided to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding distribution of the drug product. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, notification and purchaser license verification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2010, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our drug products and potential drug candidates are:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive legal and political challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began February 15, 2021 and will remain open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the US Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administered drugs to the lowest price paid in other economically advanced countries. The Most Favored Nation regulations mandate participation by identified Medicare Part B providers and will apply in all US states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. As a result of litigation challenging the Most Favored Nation model, on August 10, 2021, CMS published a proposed rule that seeks to rescind the Most Favored Nation interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. In particular, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and Civil Monetary Penalties Laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements, such as our contributions to patient assistance programs, have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the US will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the US or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. If the FDA or any </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects, and reputation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber security breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect and store confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personally identifiable information of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal information. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors. A security breach or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or other protected information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. Although to our knowledge we have not experienced any material incident or disruption to date, we and our vendors have been the target of cybersecurity incidents of this nature and expect them to continue. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the US and the EU for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. We may </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be successful obtaining orphan drug designations for any indications and, even if we succeed, such orphan drug designations may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. For a more detailed description of these matters, see Note 10 to the condensed consolidated financial statements included in this report.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal, and administrative penalties, fines, and imprisonment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with evolving US and global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the EU&#8217;s General Data Protection Regulation, or GDPR, imposes strict obligations on the processing of personal data, including personal health data, and the free movement of such data. The GDPR applies to any company established in the EU as well as any company outside the EU that processes personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the EU, including the US. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million euros, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, created new individual privacy rights for California consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. For example, the CCPA requires covered companies to provide additional disclosures to California consumers, and provides such consumers with new rights, such as the ability to opt out of certain disclosures of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the US, which could increase our potential liability and adversely affect our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit3_2.htm">Bylaws, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20210930exhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20210930exhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20210930exhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i232e3d73409b464385a0180f5b5ba6e3_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November&#160;1, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nbix-20210930exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iadaaa545686a4ac9bca4c29fd1124b98_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;1, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nbix-20210930exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7b981ab7514049a1b5e70183a0611ce7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;1, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>nbix-20210930exhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if7a8e61ce3354116b80baf244014a405_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nbix-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationandLicensingAgreements" roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements">
        <link:definition>2104102 - Disclosure - Significant Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>2106103 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail">
        <link:definition>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Debt Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail">
        <link:definition>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>2111104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>2312302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.neurocrine.com/role/Inventories">
        <link:definition>2116105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.neurocrine.com/role/InventoriesTables">
        <link:definition>2317303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetail" roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail">
        <link:definition>2418409 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>2122107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>2323305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeInformationDetail" roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetail">
        <link:definition>2424411 - Disclosure - Leases - Narrative Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationDetail" roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetail">
        <link:definition>2425412 - Disclosure - Leases - Supplemental Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetail" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail">
        <link:definition>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetail_1" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1">
        <link:definition>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>2127108 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2328306 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail">
        <link:definition>2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail">
        <link:definition>2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShare">
        <link:definition>2131109 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareTables">
        <link:definition>2332307 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail">
        <link:definition>2433416 - Disclosure - Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail">
        <link:definition>2434417 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.neurocrine.com/role/LegalProceedings">
        <link:definition>2135110 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_NumberOfIrishSubsidiaries" abstract="false" name="NumberOfIrishSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_NumberOfConsecutiveBusinessDays" abstract="false" name="NumberOfConsecutiveBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_RestrictedCashTextBlock" abstract="false" name="RestrictedCashTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_BusinessDescriptionPolicyTextBlock" abstract="false" name="BusinessDescriptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_DebtConversionObservationPeriod" abstract="false" name="DebtConversionObservationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" abstract="false" name="DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsIncMember" abstract="true" name="VoyagerTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PremiumPaidForEquityPurchase" abstract="false" name="PremiumPaidForEquityPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_BIALPortelaCaSAMember" abstract="true" name="BIALPortelaCaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_A225ConvertibleSeniorNotesMember" abstract="true" name="A225ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" abstract="false" name="DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbVieIncMember" abstract="true" name="AbbVieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" abstract="false" name="PaymentsToAcquireRestrictedInvestmentsSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_MilestoneEquityPurchasePayment" abstract="false" name="MilestoneEquityPurchasePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nbix-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adb6a03-0fb4-4a14-a30c-c7d9ee31f283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bfc7f490-65b8-4743-a0a0-2c2bd28dc86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adb6a03-0fb4-4a14-a30c-c7d9ee31f283" xlink:to="loc_us-gaap_Liabilities_bfc7f490-65b8-4743-a0a0-2c2bd28dc86c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02438a62-1ead-4ed6-9c9d-447edcbc9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adb6a03-0fb4-4a14-a30c-c7d9ee31f283" xlink:to="loc_us-gaap_StockholdersEquity_02438a62-1ead-4ed6-9c9d-447edcbc9c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_705c5810-4c91-4793-b8b4-f0d8564924c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_705c5810-4c91-4793-b8b4-f0d8564924c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1196958-8dce-4b8c-ac11-f049be55eacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1196958-8dce-4b8c-ac11-f049be55eacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_88b00951-ed20-437d-8fd9-7d084662590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_88b00951-ed20-437d-8fd9-7d084662590f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4c696735-4215-4bf0-8bb2-605a664d78a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:to="loc_us-gaap_InventoryNet_4c696735-4215-4bf0-8bb2-605a664d78a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1edffb1d-3a74-4de0-8ac1-923afea200ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95618f9b-6eca-4a58-a8fb-15733258eddd" xlink:to="loc_us-gaap_OtherAssetsCurrent_1edffb1d-3a74-4de0-8ac1-923afea200ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8af7d982-5b0d-4b4f-aaf5-833b8a03967d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6db30c0a-ca90-4b95-be24-5ce9b46d2377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8af7d982-5b0d-4b4f-aaf5-833b8a03967d" xlink:to="loc_us-gaap_LiabilitiesCurrent_6db30c0a-ca90-4b95-be24-5ce9b46d2377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_e1c757f9-f363-4111-be66-95f215a040d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8af7d982-5b0d-4b4f-aaf5-833b8a03967d" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_e1c757f9-f363-4111-be66-95f215a040d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c3cc6cc-556d-4a02-ac82-0c9a75a82407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8af7d982-5b0d-4b4f-aaf5-833b8a03967d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c3cc6cc-556d-4a02-ac82-0c9a75a82407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cb49df59-6573-464b-a598-b1415d89a3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8af7d982-5b0d-4b4f-aaf5-833b8a03967d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cb49df59-6573-464b-a598-b1415d89a3ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_beea6612-4f55-46c4-ac14-7bb525ebc997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f33ae137-5919-49e1-b39c-708deff4b2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_beea6612-4f55-46c4-ac14-7bb525ebc997" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f33ae137-5919-49e1-b39c-708deff4b2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_aab02b47-93c5-4c0f-a3cc-d40a84734ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_beea6612-4f55-46c4-ac14-7bb525ebc997" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_aab02b47-93c5-4c0f-a3cc-d40a84734ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_088976d2-fec6-462e-93d5-361e6eed3453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_AssetsCurrent_088976d2-fec6-462e-93d5-361e6eed3453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_0bb12350-3eb3-4d65-a8ba-3567fba487a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_0bb12350-3eb3-4d65-a8ba-3567fba487a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9612a942-61f4-47d5-a716-b54578b236d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9612a942-61f4-47d5-a716-b54578b236d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12f25a51-1899-4f9c-b58a-809e8a7cd711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12f25a51-1899-4f9c-b58a-809e8a7cd711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_0beb8df2-c1f8-4da1-9df0-ca0492c986e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_0beb8df2-c1f8-4da1-9df0-ca0492c986e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_460b79ae-7269-4636-bed9-6116a8c6a6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_460b79ae-7269-4636-bed9-6116a8c6a6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e3495d2f-5e95-4cad-bbd8-71b9b9993516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80cacde1-fa9a-4f13-ad1d-d6fa05e1a901" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e3495d2f-5e95-4cad-bbd8-71b9b9993516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a382595f-f154-4be5-bf87-59088d653a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:to="loc_us-gaap_PreferredStockValue_a382595f-f154-4be5-bf87-59088d653a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_363d002f-f821-4ba4-8eb1-ff7ef8500525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:to="loc_us-gaap_CommonStockValue_363d002f-f821-4ba4-8eb1-ff7ef8500525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a7fc7288-dcdb-4724-bf14-c0ca6cc4b733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a7fc7288-dcdb-4724-bf14-c0ca6cc4b733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_76a4ff8f-70f3-4758-8070-d23baca7e860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_76a4ff8f-70f3-4758-8070-d23baca7e860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb16a4fb-0348-41be-affc-3dfef0dec54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d20b4d0-c830-40fe-b1d4-58d38872febf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb16a4fb-0348-41be-affc-3dfef0dec54c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eaa3f460-5288-41c8-95b4-f6f7aa2413e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_244b5bd7-46c3-4299-8846-fbd5600bc06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eaa3f460-5288-41c8-95b4-f6f7aa2413e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_244b5bd7-46c3-4299-8846-fbd5600bc06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f2287b13-6141-4c78-8779-6faccb4f0f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eaa3f460-5288-41c8-95b4-f6f7aa2413e0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f2287b13-6141-4c78-8779-6faccb4f0f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dc69eca6-62b5-40ee-a2d9-44ade1e4bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6ade2c71-b33b-4b7c-ace1-0b5e7e7362bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc69eca6-62b5-40ee-a2d9-44ade1e4bca2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6ade2c71-b33b-4b7c-ace1-0b5e7e7362bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5d6eefc0-8e30-420f-b1b7-38a3809780c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc69eca6-62b5-40ee-a2d9-44ade1e4bca2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5d6eefc0-8e30-420f-b1b7-38a3809780c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_62109059-fb0e-486b-bf97-132def629fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc69eca6-62b5-40ee-a2d9-44ade1e4bca2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_62109059-fb0e-486b-bf97-132def629fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40ae9cb4-bcd2-460e-9f1d-dc1879b40039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc69eca6-62b5-40ee-a2d9-44ade1e4bca2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40ae9cb4-bcd2-460e-9f1d-dc1879b40039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f477e63e-3fca-4dd9-99ab-7cd27a4120c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83a1b338-7d79-4a1b-b53f-28425b5a3eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f477e63e-3fca-4dd9-99ab-7cd27a4120c3" xlink:to="loc_us-gaap_NetIncomeLoss_83a1b338-7d79-4a1b-b53f-28425b5a3eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_021b38c7-c25a-4a48-aa6d-4a962bfdb02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f477e63e-3fca-4dd9-99ab-7cd27a4120c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_021b38c7-c25a-4a48-aa6d-4a962bfdb02d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_599fe166-6f8e-41e4-a400-bf7459bb66a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce8b83a6-9a4a-4f86-af1f-15db19770e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_599fe166-6f8e-41e4-a400-bf7459bb66a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce8b83a6-9a4a-4f86-af1f-15db19770e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_95b6d510-6bca-49ca-b925-5f4ba53f0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_599fe166-6f8e-41e4-a400-bf7459bb66a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_95b6d510-6bca-49ca-b925-5f4ba53f0ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_52475e77-e0d0-421e-af75-9e0188882e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9bf0fe36-1d61-450e-9463-4c7b65dce2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_52475e77-e0d0-421e-af75-9e0188882e4c" xlink:to="loc_us-gaap_InterestExpense_9bf0fe36-1d61-450e-9463-4c7b65dce2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f19b808e-b846-467b-b16f-b5d1d4b8587b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_52475e77-e0d0-421e-af75-9e0188882e4c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f19b808e-b846-467b-b16f-b5d1d4b8587b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_e772f922-91c8-4003-838a-edf3de44e359" xlink:href="nbix-20210930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_52475e77-e0d0-421e-af75-9e0188882e4c" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_e772f922-91c8-4003-838a-edf3de44e359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc0c6e9d-a82c-4a05-a7e5-9aed1bf9cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e29f93d6-702f-4e36-a2c5-21b5c360e13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cc0c6e9d-a82c-4a05-a7e5-9aed1bf9cbda" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e29f93d6-702f-4e36-a2c5-21b5c360e13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ec45f5b-074a-4b24-88ec-95d0acf266bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cc0c6e9d-a82c-4a05-a7e5-9aed1bf9cbda" xlink:to="loc_us-gaap_CostsAndExpenses_1ec45f5b-074a-4b24-88ec-95d0acf266bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2df9dff-29d8-4dc8-86eb-d80352a2e727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c890b9ed-baf9-4907-865a-970458aad028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2df9dff-29d8-4dc8-86eb-d80352a2e727" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c890b9ed-baf9-4907-865a-970458aad028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_805fba28-e394-4fe5-9795-54f4b4280be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2df9dff-29d8-4dc8-86eb-d80352a2e727" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_805fba28-e394-4fe5-9795-54f4b4280be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3982648e-d62c-40d3-80c0-25a9876601ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21c97b80-3d05-4c19-afd4-13784ebbed66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3982648e-d62c-40d3-80c0-25a9876601ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21c97b80-3d05-4c19-afd4-13784ebbed66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69aa86d0-7a2f-4aa4-bb14-612dba719a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3982648e-d62c-40d3-80c0-25a9876601ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69aa86d0-7a2f-4aa4-bb14-612dba719a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bdcda89a-7d46-4f45-b197-ce76ad7c60a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3982648e-d62c-40d3-80c0-25a9876601ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bdcda89a-7d46-4f45-b197-ce76ad7c60a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04a334c6-4105-4570-a2ba-d3050fab0516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_NetIncomeLoss_04a334c6-4105-4570-a2ba-d3050fab0516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_37c3c0b8-07a0-47c6-923a-f33a2872c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_ShareBasedCompensation_37c3c0b8-07a0-47c6-923a-f33a2872c1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e530af9f-c48d-4edf-a6ae-375e0e8691f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_Depreciation_e530af9f-c48d-4edf-a6ae-375e0e8691f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_fca6753e-083f-41a1-9128-1474727e88db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_fca6753e-083f-41a1-9128-1474727e88db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_844fdd43-a781-4a12-a2ff-721f69185a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_844fdd43-a781-4a12-a2ff-721f69185a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3eff3838-cb86-4632-bce6-50cb5927a9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3eff3838-cb86-4632-bce6-50cb5927a9d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4f1964eb-44e3-499a-94a9-f2257acc6864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4f1964eb-44e3-499a-94a9-f2257acc6864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_38264a70-573a-4bc9-8c68-f89957c0b24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_38264a70-573a-4bc9-8c68-f89957c0b24b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f62bdfb0-0294-4cb0-b035-97241b844f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f62bdfb0-0294-4cb0-b035-97241b844f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b44c5c0a-c847-4f95-b92a-590ae26408b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b44c5c0a-c847-4f95-b92a-590ae26408b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2f4a613b-baee-459b-a131-01fb57ce3e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2f4a613b-baee-459b-a131-01fb57ce3e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_cd8a7052-1bc2-441b-aae0-a68939ed4163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31c786b2-6d4d-4a73-8f21-3fbe31798089" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_cd8a7052-1bc2-441b-aae0-a68939ed4163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e759e403-e5df-47db-b3a9-2a23e7a1e7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fb3fe489-53bd-4557-bab2-17d5dd5f896c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e759e403-e5df-47db-b3a9-2a23e7a1e7d8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fb3fe489-53bd-4557-bab2-17d5dd5f896c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7d4268b4-e9cb-43af-8785-af7304eeb2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e759e403-e5df-47db-b3a9-2a23e7a1e7d8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7d4268b4-e9cb-43af-8785-af7304eeb2b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_74514136-31c6-4299-b0e7-d0e737710bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e759e403-e5df-47db-b3a9-2a23e7a1e7d8" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_74514136-31c6-4299-b0e7-d0e737710bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d0256f65-41e3-4466-a706-8ab2073b4693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e759e403-e5df-47db-b3a9-2a23e7a1e7d8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d0256f65-41e3-4466-a706-8ab2073b4693" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65c3d7b9-0da4-43db-b4fc-dbce37c6e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_694113af-a745-43e0-be10-c4eaa302b03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65c3d7b9-0da4-43db-b4fc-dbce37c6e1c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_694113af-a745-43e0-be10-c4eaa302b03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_904245fb-cfa2-4a00-b18b-3f635341bfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65c3d7b9-0da4-43db-b4fc-dbce37c6e1c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_904245fb-cfa2-4a00-b18b-3f635341bfb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_694fb7f6-ce50-4d36-84e4-5bc22cbda39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65c3d7b9-0da4-43db-b4fc-dbce37c6e1c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_694fb7f6-ce50-4d36-84e4-5bc22cbda39b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#InventoriesSummaryofInventoriesDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_00578286-eb79-4e79-af9e-0fd753cffb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e9701ce1-537d-45a9-8aae-00acbfb1ce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00578286-eb79-4e79-af9e-0fd753cffb00" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e9701ce1-537d-45a9-8aae-00acbfb1ce5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_47740503-5ac1-4c99-9626-4a86d4015c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00578286-eb79-4e79-af9e-0fd753cffb00" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_47740503-5ac1-4c99-9626-4a86d4015c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7dc1abd4-2e5e-4804-84c6-4e65a417ae19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00578286-eb79-4e79-af9e-0fd753cffb00" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7dc1abd4-2e5e-4804-84c6-4e65a417ae19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3c16ec5f-4452-497c-807b-b8962d8e9aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d2a79a9-dee1-429f-9fea-f9bfd5b99e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_3c16ec5f-4452-497c-807b-b8962d8e9aca" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d2a79a9-dee1-429f-9fea-f9bfd5b99e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ecfd20ac-00d8-4edc-8eaf-4715842a4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_3c16ec5f-4452-497c-807b-b8962d8e9aca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ecfd20ac-00d8-4edc-8eaf-4715842a4ace" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesLiabilityPaymentDueDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1a32017b-4528-437f-be2b-f91eb4fa1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_774cd713-7d0c-4cf5-9dce-1af83b29779e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1a32017b-4528-437f-be2b-f91eb4fa1c91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_774cd713-7d0c-4cf5-9dce-1af83b29779e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b1e191b-30e5-49a5-8230-340b091975cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1a32017b-4528-437f-be2b-f91eb4fa1c91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b1e191b-30e5-49a5-8230-340b091975cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20345c45-815e-4a9a-9917-9b92afefad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_343b393a-fc67-48b4-a5ef-dad52cfe240f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20345c45-815e-4a9a-9917-9b92afefad3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_343b393a-fc67-48b4-a5ef-dad52cfe240f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7d4b58c4-0325-409e-951e-c002eccefd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20345c45-815e-4a9a-9917-9b92afefad3c" xlink:to="loc_us-gaap_OperatingLeaseLiability_7d4b58c4-0325-409e-951e-c002eccefd94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesLiabilityPaymentDueDetail_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8fed32fb-28ae-406a-b1e6-86b6723d6461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8fed32fb-28ae-406a-b1e6-86b6723d6461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5b35dd40-4f75-4a57-bf72-37cb8be37f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5b35dd40-4f75-4a57-bf72-37cb8be37f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40d05672-0d29-48bf-b4a5-7c00301c3478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40d05672-0d29-48bf-b4a5-7c00301c3478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_01ef9447-408d-48fc-b2d9-cfb62248d21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_01ef9447-408d-48fc-b2d9-cfb62248d21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_21f09ce1-c773-4957-bb17-333eae9e58a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_21f09ce1-c773-4957-bb17-333eae9e58a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_9aaa5847-68ff-47c8-a33f-ef91a871cf7d" xlink:href="nbix-20210930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b5f777-80dc-4cdd-89b4-015caf6bea2b" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_9aaa5847-68ff-47c8-a33f-ef91a871cf7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_fa75de8a-e672-4aee-97cd-8d5f08dfb0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_56d45520-14c0-44b4-a35e-c36973db6613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_fa75de8a-e672-4aee-97cd-8d5f08dfb0fc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_56d45520-14c0-44b4-a35e-c36973db6613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_de15b10a-5ae0-4ead-a6c5-c54c2893cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_fa75de8a-e672-4aee-97cd-8d5f08dfb0fc" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_de15b10a-5ae0-4ead-a6c5-c54c2893cc30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_def1b6f4-6f0c-4ca9-aa8c-28562883f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_fa75de8a-e672-4aee-97cd-8d5f08dfb0fc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_def1b6f4-6f0c-4ca9-aa8c-28562883f0a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa59fe54-a2e8-46ba-bc49-c2d69f99b8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84581d3e-745b-459c-a07e-442e7ad25602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa59fe54-a2e8-46ba-bc49-c2d69f99b8b9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84581d3e-745b-459c-a07e-442e7ad25602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5b2150a3-7906-4e23-9105-ec5cbc198b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa59fe54-a2e8-46ba-bc49-c2d69f99b8b9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5b2150a3-7906-4e23-9105-ec5cbc198b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_b62959dd-b54a-416a-9cc3-2b5a2e0840c7" xlink:href="nbix-20210930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa59fe54-a2e8-46ba-bc49-c2d69f99b8b9" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_b62959dd-b54a-416a-9cc3-2b5a2e0840c7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nbix-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended" id="i072b9cb9eca340589d097bc36c21970c_CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b937df-0148-415e-b90f-7a0754ec71b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b937df-0148-415e-b90f-7a0754ec71b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f911614f-8c1b-4011-9db0-be5c3ba8e266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f911614f-8c1b-4011-9db0-be5c3ba8e266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9d69cb3-eaf6-4731-82d7-19258a353936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9d69cb3-eaf6-4731-82d7-19258a353936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_776e8774-503c-4e7c-bf8b-ca2eaca1c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_776e8774-503c-4e7c-bf8b-ca2eaca1c22d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3f27ca4a-791b-480c-a8eb-0f6c13aff12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3f27ca4a-791b-480c-a8eb-0f6c13aff12e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f0f7581-8cca-4447-b57f-b11b6f4df6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_CostsAndExpenses_0f0f7581-8cca-4447-b57f-b11b6f4df6b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2bf77f3-ef8d-470b-b697-3da5d041aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2bf77f3-ef8d-470b-b697-3da5d041aea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f38a035e-8d62-4ccb-9ac5-f4dae0d9d284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_InterestExpense_f38a035e-8d62-4ccb-9ac5-f4dae0d9d284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_63231281-ce02-4b0b-9c87-c1f8409602b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_63231281-ce02-4b0b-9c87-c1f8409602b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_93fa432e-a2ce-4208-bc90-e43738ccf6ad" xlink:href="nbix-20210930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_93fa432e-a2ce-4208-bc90-e43738ccf6ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_23c7a193-4440-483c-9aa4-9dc686c9f5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_23c7a193-4440-483c-9aa4-9dc686c9f5b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59e5913b-3555-4da3-81d2-3492458c1c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59e5913b-3555-4da3-81d2-3492458c1c87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_112efa7e-05fd-4fde-a62d-1a87fb73a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_112efa7e-05fd-4fde-a62d-1a87fb73a39c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00d93305-4482-41c7-95f4-d389ae0f54db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_NetIncomeLoss_00d93305-4482-41c7-95f4-d389ae0f54db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a258274-5987-4ec7-a5fd-3e9ed6cbc323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a258274-5987-4ec7-a5fd-3e9ed6cbc323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_be7b1eac-0610-499a-88b2-8f97bc3b98bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_be7b1eac-0610-499a-88b2-8f97bc3b98bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_68679036-c21d-41d6-8d48-b2a746c4b998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_EarningsPerShareBasic_68679036-c21d-41d6-8d48-b2a746c4b998" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4c05b5cb-4f45-461f-97ad-53f9aec4b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4c05b5cb-4f45-461f-97ad-53f9aec4b1a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf58bd04-9fbb-499f-9efd-6edc49342db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf58bd04-9fbb-499f-9efd-6edc49342db7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd29147c-2829-4fac-aac4-82a2299cec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd29147c-2829-4fac-aac4-82a2299cec5d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:to="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cb6363e1-e25d-4e54-b0b8-ae34748c26a6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:to="loc_srt_ProductsAndServicesDomain_cb6363e1-e25d-4e54-b0b8-ae34748c26a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:to="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_34ab89cf-c43a-44b8-bfc2-c392a457a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:to="loc_us-gaap_ProductMember_34ab89cf-c43a-44b8-bfc2-c392a457a21a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_ba07721d-e2bc-4609-87a1-eaf1ed915742" xlink:href="nbix-20210930.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:to="loc_nbix_CollaborationRevenueMember_ba07721d-e2bc-4609-87a1-eaf1ed915742" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="iab84b10a98d4481a9f8db296358c77d8_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_adabe024-11dd-406b-a620-056212b25e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_SharesOutstanding_adabe024-11dd-406b-a620-056212b25e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_434e5a61-d8c4-4d41-8457-10d84a95a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockholdersEquity_434e5a61-d8c4-4d41-8457-10d84a95a33c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f25c920-a0eb-4612-b3ac-2826627818db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_NetIncomeLoss_2f25c920-a0eb-4612-b3ac-2826627818db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4926149c-82a6-4ee5-bf04-924daa6fc796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4926149c-82a6-4ee5-bf04-924daa6fc796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcab1a68-b164-4e48-a524-2c313cb26e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcab1a68-b164-4e48-a524-2c313cb26e7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dae7651b-37e9-4d53-8455-26ce16e06042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dae7651b-37e9-4d53-8455-26ce16e06042" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a5a64b3-1227-4f51-97b7-d3440f834314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a5a64b3-1227-4f51-97b7-d3440f834314" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c74fc17a-de0a-47a8-befe-25debba87fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0a7209f-e0b9-4dfe-8d80-11fc4934fb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:to="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4a97666-58f8-4a8d-a747-f5cebb742b04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:to="loc_us-gaap_EquityComponentDomain_f4a97666-58f8-4a8d-a747-f5cebb742b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:to="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b1bbd156-63fc-4f93-a4f7-a853f15054a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_CommonStockMember_b1bbd156-63fc-4f93-a4f7-a853f15054a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_71a9f006-aefb-4393-84f8-e199f1f196a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_71a9f006-aefb-4393-84f8-e199f1f196a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a869bf41-07ee-42b6-921c-58383fe8f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a869bf41-07ee-42b6-921c-58383fe8f723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f1361666-c5c6-4491-89ab-d089a5968ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_RetainedEarningsMember_f1361666-c5c6-4491-89ab-d089a5968ccb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="extended" id="i0f102706e6fb461696f6199b58500de7_SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_f1dce5d0-c063-4e6d-bd9f-7e6bd8a69187" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PotentialMilestonePayments_f1dce5d0-c063-4e6d-bd9f-7e6bd8a69187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_7142b4f0-7b3c-4296-b447-3e303536fc8a" xlink:href="nbix-20210930.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_MilestonePayment_7142b4f0-7b3c-4296-b447-3e303536fc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8c8733a0-dedf-4f1b-94c0-f4d60e76790d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8c8733a0-dedf-4f1b-94c0-f4d60e76790d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_a9f6f1d9-2016-41e9-bca0-63cb33494cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_a9f6f1d9-2016-41e9-bca0-63cb33494cd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_1bfdd391-4063-482c-b165-9d3aae863455" xlink:href="nbix-20210930.xsd#nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_1bfdd391-4063-482c-b165-9d3aae863455" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestoneEquityPurchasePayment_70c8d76b-4767-4013-86a9-38b21142b519" xlink:href="nbix-20210930.xsd#nbix_MilestoneEquityPurchasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_MilestoneEquityPurchasePayment_70c8d76b-4767-4013-86a9-38b21142b519" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_5915af01-981c-45ce-a0f2-8c943c80e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_5915af01-981c-45ce-a0f2-8c943c80e2ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PremiumPaidForEquityPurchase_804ea488-1d1d-4024-938f-588ceace871d" xlink:href="nbix-20210930.xsd#nbix_PremiumPaidForEquityPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PremiumPaidForEquityPurchase_804ea488-1d1d-4024-938f-588ceace871d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_e82c11cd-8465-439b-b454-903c9e94d1ae" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_e82c11cd-8465-439b-b454-903c9e94d1ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b94f02d0-ac37-48f6-8eef-2782997ae2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b94f02d0-ac37-48f6-8eef-2782997ae2c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7050bcb2-72b2-49c0-9ca2-894abb724525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7050bcb2-72b2-49c0-9ca2-894abb724525" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e1c35bfa-07a3-41fa-8c8f-c3cd3747091c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e1c35bfa-07a3-41fa-8c8f-c3cd3747091c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8022eac4-a8b5-4a79-932c-ba51e9fd1776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8022eac4-a8b5-4a79-932c-ba51e9fd1776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8843c75b-e885-44f1-968a-12ff4943d309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8843c75b-e885-44f1-968a-12ff4943d309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad4345a7-6c9e-4e61-81c6-0022603fbda9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:to="loc_srt_ProductsAndServicesDomain_ad4345a7-6c9e-4e61-81c6-0022603fbda9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:to="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_586e7bdf-51c8-46aa-b66a-14956116b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:to="loc_us-gaap_LicenseMember_586e7bdf-51c8-46aa-b66a-14956116b4ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_49e232f8-e01e-4689-9058-612ea5ae6c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:to="loc_us-gaap_RoyaltyMember_49e232f8-e01e-4689-9058-612ea5ae6c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caa6dc93-ac86-445b-a0b5-ca765e200bb1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caa6dc93-ac86-445b-a0b5-ca765e200bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d788f857-6024-459f-84e5-1bba77c1144a" xlink:href="nbix-20210930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d788f857-6024-459f-84e5-1bba77c1144a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_93d48d5f-e82a-42ae-be5e-cc845a2bce82" xlink:href="nbix-20210930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_93d48d5f-e82a-42ae-be5e-cc845a2bce82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_5ae9f172-1987-4a4f-9be7-d345113dda3a" xlink:href="nbix-20210930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_5ae9f172-1987-4a4f-9be7-d345113dda3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsIncMember_6979a830-9d76-413b-9946-90596739dee7" xlink:href="nbix-20210930.xsd#nbix_VoyagerTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_VoyagerTherapeuticsIncMember_6979a830-9d76-413b-9946-90596739dee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_1ad82741-4671-4143-b329-437474f3c719" xlink:href="nbix-20210930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_BIALPortelaCaSAMember_1ad82741-4671-4143-b329-437474f3c719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_1e82615f-ca62-4c85-8de7-d697fc7d6fa2" xlink:href="nbix-20210930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_1e82615f-ca62-4c85-8de7-d697fc7d6fa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_88f6bf8e-fc30-4137-80d5-5d12e0598b93" xlink:href="nbix-20210930.xsd#nbix_AbbVieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_AbbVieIncMember_88f6bf8e-fc30-4137-80d5-5d12e0598b93" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended" id="ib154f31f4f4a43d1a7dff355ac8d482e_DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55787fa3-3400-4157-bf56-0298c5d18897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55787fa3-3400-4157-bf56-0298c5d18897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c2808da-a9ce-4868-837b-5a5c9b06b645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c2808da-a9ce-4868-837b-5a5c9b06b645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e282dfc1-3d9d-4f81-8f76-c1e3641ae1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e282dfc1-3d9d-4f81-8f76-c1e3641ae1db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08a7ae0f-e8e7-425c-ad31-b9f82f63eb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08a7ae0f-e8e7-425c-ad31-b9f82f63eb54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_04a126cb-3ff9-45b4-84b3-166819398c8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_04a126cb-3ff9-45b4-84b3-166819398c8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_b6dc999c-b64b-488b-b80c-a7460aee9338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_b6dc999c-b64b-488b-b80c-a7460aee9338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_af663e8d-6b42-4598-8da5-7bf90a1832f9" xlink:href="nbix-20210930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:to="loc_nbix_LongTermInvestmentsMember_af663e8d-6b42-4598-8da5-7bf90a1832f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8de27b7f-a098-43d1-8ed6-9ffb5729b329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8de27b7f-a098-43d1-8ed6-9ffb5729b329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_04a645f9-562c-402c-a48b-153e8e9af47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:to="loc_us-gaap_CommercialPaperMember_04a645f9-562c-402c-a48b-153e8e9af47c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c3fda4c-62d2-4c15-9f16-f67dd261274f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c3fda4c-62d2-4c15-9f16-f67dd261274f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_30065f46-c42d-4891-b428-f18a0b0be3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_30065f46-c42d-4891-b428-f18a0b0be3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b43c8ed7-614c-4abb-88bf-70d8776a8c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b43c8ed7-614c-4abb-88bf-70d8776a8c7b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="extended" id="if837f4cf6eff4494920a4a866c7924af_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bb9710bb-c228-4d37-936a-61b4d5c45a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bb9710bb-c228-4d37-936a-61b4d5c45a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_bece1e2f-3b9d-4a43-a837-b2e0b987c410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_bece1e2f-3b9d-4a43-a837-b2e0b987c410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4e031b6-f9b6-4484-be3e-64132dbaa67f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4e031b6-f9b6-4484-be3e-64132dbaa67f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d7ccc22-6d47-4139-86b3-5f2049a6d603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d7ccc22-6d47-4139-86b3-5f2049a6d603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c9cc22a5-ade9-478d-99bb-f043a283aa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c9cc22a5-ade9-478d-99bb-f043a283aa79" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i1e568acc027247bca41b080910934915_FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_b5fc2b18-db1e-4de2-bdb9-073e2d015ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:to="loc_us-gaap_Investments_b5fc2b18-db1e-4de2-bdb9-073e2d015ed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47e2cb00-f09f-49bf-9df8-19edccf1f061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47e2cb00-f09f-49bf-9df8-19edccf1f061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_8fd1f120-17a1-4162-8f02-b95cab9f17e2" xlink:href="nbix-20210930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_8fd1f120-17a1-4162-8f02-b95cab9f17e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f1363f4a-9b0c-4a7b-8a8f-aa5d16dd7d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f1363f4a-9b0c-4a7b-8a8f-aa5d16dd7d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_52f07a93-506e-40f4-ada6-da01112d27db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_us-gaap_CommercialPaperMember_52f07a93-506e-40f4-ada6-da01112d27db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_933f8ac5-edbe-4701-b1b8-8f2c21199ff7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_933f8ac5-edbe-4701-b1b8-8f2c21199ff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ddb30ac6-6243-4097-8217-259953982339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ddb30ac6-6243-4097-8217-259953982339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8758fc8e-b308-4d93-96bc-77a86e374b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8758fc8e-b308-4d93-96bc-77a86e374b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d5508094-9b71-43ee-bf27-68a79156ab52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_EquitySecuritiesMember_d5508094-9b71-43ee-bf27-68a79156ab52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a711955d-4e7f-4999-ba78-6c6ea13de698_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a711955d-4e7f-4999-ba78-6c6ea13de698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9fe458e7-a178-4477-9ad0-4beede446d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9fe458e7-a178-4477-9ad0-4beede446d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_40feeb51-0962-480f-99f0-1a5e0c8f3306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_40feeb51-0962-480f-99f0-1a5e0c8f3306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b2e717b-490a-4904-990d-47ada594ac38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b2e717b-490a-4904-990d-47ada594ac38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e57b2415-a095-4641-bbc9-c909ddc03523_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e57b2415-a095-4641-bbc9-c909ddc03523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6795402f-f453-4402-af11-58a48e24a2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6795402f-f453-4402-af11-58a48e24a2fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended" id="i56fc10c13de045e0aa228c008d3eaac8_FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_912c8cc3-80fb-47b5-86af-e7dde6cff14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_912c8cc3-80fb-47b5-86af-e7dde6cff14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_b5353cb7-36cc-4f3a-82f1-c912f0ab14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_b5353cb7-36cc-4f3a-82f1-c912f0ab14d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e277ed7-dbda-411e-941c-e4235582ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e277ed7-dbda-411e-941c-e4235582ed86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_c9e530dd-8934-4429-a0e4-7460782cc702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_7702db19-47cf-461b-971a-88aea146b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_7702db19-47cf-461b-971a-88aea146b5a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_52ebb45a-3fae-4945-903d-b7fa931142d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:to="loc_us-gaap_CollateralDomain_52ebb45a-3fae-4945-903d-b7fa931142d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:to="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a46d7bd4-b1f1-454f-80d5-ccafca9222da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:to="loc_us-gaap_EquitySecuritiesMember_a46d7bd4-b1f1-454f-80d5-ccafca9222da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d268cac-838c-4fa8-b55c-10784d0c34a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d268cac-838c-4fa8-b55c-10784d0c34a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4657aa55-37a6-45df-bad3-adec1a29704e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4657aa55-37a6-45df-bad3-adec1a29704e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f0bdb330-4f9a-4e63-926a-24f3b35a1058_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f0bdb330-4f9a-4e63-926a-24f3b35a1058_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f2d97bbe-712c-48bf-8fb5-7455bcc7f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f2d97bbe-712c-48bf-8fb5-7455bcc7f60b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a9972b0-5a75-4512-86e2-df0736a34660_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a9972b0-5a75-4512-86e2-df0736a34660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_aa9a26fd-d307-47bc-aaf3-f98c17bf0378" xlink:href="nbix-20210930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_aa9a26fd-d307-47bc-aaf3-f98c17bf0378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e9c9e24-9dff-4578-87c3-887dcc6b4812_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e9c9e24-9dff-4578-87c3-887dcc6b4812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_bbdd889a-59ac-44f2-801d-bd11ebf9b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:to="loc_us-gaap_CollaborativeArrangementMember_bbdd889a-59ac-44f2-801d-bd11ebf9b7d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="ibb3c5bec0481430a944c4d6e3d22c703_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_76b2e0c8-22e1-48fd-8b90-0648f6ec04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_76b2e0c8-22e1-48fd-8b90-0648f6ec04b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b564f092-795c-40fb-a6be-af28c2d839ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b564f092-795c-40fb-a6be-af28c2d839ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_25f855b8-4279-4cfc-bb11-ded68cac246b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_25f855b8-4279-4cfc-bb11-ded68cac246b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:to="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51f13832-7303-4fda-b9c2-417324b821e8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:to="loc_srt_RangeMember_51f13832-7303-4fda-b9c2-417324b821e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:to="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb642c20-9053-4fde-bcf2-7886beb5c0aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_MinimumMember_bb642c20-9053-4fde-bcf2-7886beb5c0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7106f09c-743b-44b2-9c66-0e0f597e58b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_MaximumMember_7106f09c-743b-44b2-9c66-0e0f597e58b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cb036dea-151f-48a8-a929-ef02cb7eaf3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_WeightedAverageMember_cb036dea-151f-48a8-a929-ef02cb7eaf3d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="extended" id="i87b12f3bc74142acac79d643f307c022_ConvertibleSeniorNotesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b544cba8-1f79-441e-a888-b093c5b55632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b544cba8-1f79-441e-a888-b093c5b55632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_089b54c0-9595-46b7-a6b0-40c2587710c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_089b54c0-9595-46b7-a6b0-40c2587710c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_47c115a2-1f59-452a-8d87-192f4319de78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_RepaymentsOfDebt_47c115a2-1f59-452a-8d87-192f4319de78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f09845d3-d3dd-40d8-bd13-7fc3d2dd6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f09845d3-d3dd-40d8-bd13-7fc3d2dd6c10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_5e9892a4-d9bc-476d-aacc-ac91af6d7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_5e9892a4-d9bc-476d-aacc-ac91af6d7de9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_073c3692-16f3-4b3d-965e-ac97abfdb2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_073c3692-16f3-4b3d-965e-ac97abfdb2f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_320740c9-c7b5-49e1-bb14-07dd51960fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_320740c9-c7b5-49e1-bb14-07dd51960fbd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays_1ac8f0be-e211-468b-9111-24645a1acbb9" xlink:href="nbix-20210930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_NumberOfConsecutiveBusinessDays_1ac8f0be-e211-468b-9111-24645a1acbb9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_6d65841c-4d06-4cd5-84d5-32f5cde75a59" xlink:href="nbix-20210930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_6d65841c-4d06-4cd5-84d5-32f5cde75a59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_a7475d91-529b-4d7b-8853-12b5979dfae9" xlink:href="nbix-20210930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_a7475d91-529b-4d7b-8853-12b5979dfae9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_6b32758d-a7bf-447d-9403-c485fa700fb7" xlink:href="nbix-20210930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtConversionObservationPeriod_6b32758d-a7bf-447d-9403-c485fa700fb7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fac06e2c-c9d2-4733-bada-6a6d055ea88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fac06e2c-c9d2-4733-bada-6a6d055ea88c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_04d12f16-0867-4752-8630-26e17e843cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_04d12f16-0867-4752-8630-26e17e843cf1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc8af418-2fbb-4a7d-89c6-481609498350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc8af418-2fbb-4a7d-89c6-481609498350" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_32186271-ac71-46b3-a63e-4b034332ca96" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_32186271-ac71-46b3-a63e-4b034332ca96" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84d405b3-a216-4b26-a8ab-2b73f51f8940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_SharePrice_84d405b3-a216-4b26-a8ab-2b73f51f8940" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4975484a-aec7-4664-bac0-89e9c2bee288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4975484a-aec7-4664-bac0-89e9c2bee288" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_a0bc4721-5879-46f4-811c-531f80bd00e1" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_a0bc4721-5879-46f4-811c-531f80bd00e1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_2230b408-ad48-42df-8c03-31c345c4f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_2230b408-ad48-42df-8c03-31c345c4f3c1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0b7c1b0d-3650-4442-900a-09f87a226e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0b7c1b0d-3650-4442-900a-09f87a226e27" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_30872b2e-3ec9-4469-a347-6e77ea2ccd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentTerm_30872b2e-3ec9-4469-a347-6e77ea2ccd64" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_dd9db0c4-6eac-46d1-8ce2-060a1a58fc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_dd9db0c4-6eac-46d1-8ce2-060a1a58fc1c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f4bb2b28-7492-4b43-a7c4-64b3ec448226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f4bb2b28-7492-4b43-a7c4-64b3ec448226" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_742001b1-f169-440d-8b9a-17edcfc06011" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_742001b1-f169-440d-8b9a-17edcfc06011" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f80f7303-6d91-46d1-9cca-e24d3673a241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f80f7303-6d91-46d1-9cca-e24d3673a241" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e7d5561-5791-46e8-ad3d-a2462df1d261_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e7d5561-5791-46e8-ad3d-a2462df1d261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_ec2a1776-35b2-420a-ae91-f1d296ec46a2" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_ec2a1776-35b2-420a-ae91-f1d296ec46a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="extended" id="i23bb2880518c4bc2b2c3f15131ddcdbf_NetIncomeLossPerShareScheduleofNetIncomePerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ae7aafa-e32d-4b06-9a56-41ff7846ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_NetIncomeLoss_1ae7aafa-e32d-4b06-9a56-41ff7846ff5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f582db46-6af6-4b7c-8486-3f40b33abd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f582db46-6af6-4b7c-8486-3f40b33abd56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86b0cbea-9246-4356-a0a4-9bba8cbc06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86b0cbea-9246-4356-a0a4-9bba8cbc06d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_d580a2fa-271a-4cab-b29f-baed74a19da2" xlink:href="nbix-20210930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_d580a2fa-271a-4cab-b29f-baed74a19da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5445054-8d3b-413b-94af-ca18d89c0c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5445054-8d3b-413b-94af-ca18d89c0c4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_80c5704a-2edc-4243-a309-a94f2c6b601e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:to="loc_us-gaap_EarningsPerShareBasic_80c5704a-2edc-4243-a309-a94f2c6b601e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_460cde6a-b6ae-4fab-9248-fd93b2d880c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_460cde6a-b6ae-4fab-9248-fd93b2d880c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0985c33-3ef4-4b30-9200-3ddca4a274f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0985c33-3ef4-4b30-9200-3ddca4a274f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dd6c61e-8519-447f-a4e5-2b0c4e327035_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dd6c61e-8519-447f-a4e5-2b0c4e327035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fba2af2c-d3df-43c3-a903-b3cfcd39334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fba2af2c-d3df-43c3-a903-b3cfcd39334f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0fea2688-31e4-489c-9e9f-d888b717c361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:to="loc_us-gaap_RestrictedStockMember_0fea2688-31e4-489c-9e9f-d888b717c361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:to="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_d3d5d088-21bd-405d-8645-2ab03105cb92" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_d3d5d088-21bd-405d-8645-2ab03105cb92" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="extended" id="ifb95579ffa0742a6b084e98aef867894_NetIncomeLossPerShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2c253654-67d1-4b30-9be3-d8269ec16555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2c253654-67d1-4b30-9be3-d8269ec16555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe93e64a-aba0-4c8c-97c9-c6f45b72a352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe93e64a-aba0-4c8c-97c9-c6f45b72a352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019050f7-4beb-4f24-a1fc-750b50878e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019050f7-4beb-4f24-a1fc-750b50878e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:to="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f92f6bf-470f-4ecc-968f-5297ee44f609_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f92f6bf-470f-4ecc-968f-5297ee44f609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_3cfffc1e-1013-4dd2-ac52-30406526f248" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_3cfffc1e-1013-4dd2-ac52-30406526f248" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_537ab516-068e-4c76-a537-fd6b84b42a6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_537ab516-068e-4c76-a537-fd6b84b42a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3c0b1571-31a8-4094-8c10-09c4a1e2f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:to="loc_us-gaap_RestrictedStockMember_3c0b1571-31a8-4094-8c10-09c4a1e2f6df" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nbix-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ca728570-9d33-41e2-a91c-a88398d87812_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6dd7edbb-76fc-40ed-9781-399b7c81259f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_af645e22-ee32-4268-b48c-8634f2b3e390_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_711129c7-c401-4259-a196-1b6cbb8a5f2b_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20210930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_31170e6e-88dc-4294-a6ad-6176152fdd9b_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4084496b-8e50-4a42-9df4-dcf07c69391b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_dbe40ec0-394b-46e6-9804-f271cd487622_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7175999b-0015-4d33-8a11-e910627e8a5c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c0f9efc7-8c7a-4a75-ae6f-6b15edfa8752_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcc1f04-a110-47b0-9c56-8c5740365c94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d3675f84-4b54-481c-8796-6742fbd0e628_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c6a406e-3e46-42a0-af9e-23fe040f5b29_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_43d541a5-710e-473a-83fb-21a0b18a52b6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aa34f1cf-8cfd-4b84-887e-19a082c03ae1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2b8b18ae-6c52-4a52-8493-021db1b4e8e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_67f58902-5da8-43ad-8438-72cc51ff9dc6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale, at fair value (amortized cost $454.6 million at September&#160;30, 2021 and $612.4 million at December&#160;31, 2020)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e6547c0c-880c-4198-beec-85979d23f42e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_965fc3b7-a8d8-4bc4-a76d-a49dc03e658f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f76d1997-0d40-4d3d-9a2f-8926bb21988d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f122047d-8d93-4c53-b6d4-4339345631b0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fe35cd93-7917-4971-b053-c206a055af99_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_46eb5689-2813-4d00-8772-d11eb876b741_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_fb8da7fc-cc39-4fc7-ab2f-c51f2cf0b1e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_869a2541-f801-4024-8b3e-2b9658cd4190_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_068dabbd-2c02-4f0c-8012-c576ec09920f_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20210930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2bb8a0f3-39f0-4c0a-a83d-8db89f2511b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e6aefc39-eb4a-4b69-a4d6-fa817b048912_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fcf1c866-6a94-4da3-b0b7-74ef538846fe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9e7c8b71-2863-4d8a-b589-fcfa9be20cee_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9f1197ad-f1a0-400d-a1d8-a050b9bab37f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_473af9ca-cb97-412e-a42b-e942bcf6506d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_de7e8bf4-7dbf-4cb8-8347-f9d649bea443_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_f95c1a15-467d-4fd8-9814-2951f337d0e2_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20210930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_44c90368-53d3-4565-b626-b3e899f862d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_fc8b97e3-a7ba-4b26-a9cc-0d3944d25eaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on liability component, remaining amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9e1e2944-0007-4b32-ad13-6e2692d75706_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8afa5678-c746-4673-b31a-8dbb4606542a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10d71ed8-14fb-46d8-b74d-917d62ca9f85_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c3916251-0ba6-4324-a7d0-3bb65cf2b972_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_04c39f37-18c7-46f9-aaeb-daa93b3c0051_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0a62a1d6-dad4-47c2-8ad2-4de381028566_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_645a80f7-29e9-4e37-a4b9-3ae076f8d24c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_d92aae18-8115-4937-98bc-a1ef575026f7_terseLabel_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes (in shares)</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_label_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_documentation_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:href="nbix-20210930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:to="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0e7e0eb4-cd30-4258-a177-0ec8bef84fc3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_f15279dc-0548-48f6-977a-f0dba77aa48a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8bc34237-996e-4f93-9877-7573379f969b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e54172c0-e76a-41fa-bd73-fcd95634dc14_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f333b4eb-3a59-419a-b82f-0fc8c61a08e8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5dd4d446-6907-4456-8ad1-2059f1490335_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4ea3c0b7-8c8e-4e42-b32f-51a652f915f7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_46b4457b-aca4-40ef-8a5f-c103cc994997_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20210930.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_57562f20-a73c-4420-b030-d4fd98af0dba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2996dc4a-1d03-42b5-9e94-fd16c86d4017_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d98f1834-ee1b-43e9-8d79-e9e17a9152ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_738de9ef-ac01-453e-85bd-1164140d07b7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c9718fa-11ed-41b3-91e5-2ba8bfd66e97_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_36a60f21-78e3-4fd5-917b-ea077851279a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3c24754e-684a-40fa-9f0d-e7d177debe4a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a8d094fb-239b-4152-a289-8957a5b330a8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f6ce38ff-377e-4313-901d-dc91affec3fc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a6c9e200-1b3b-48e3-9a71-c887c42b4ca7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_630aeed6-f079-459a-adfc-2802449c7d3e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1624d8f3-b61a-4040-a777-b06167fdd236_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_5db06766-b84f-44ec-9b9f-82db4facdc06_terseLabel_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_label_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description [Policy Text Block]</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_documentation_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyTextBlock" xlink:href="nbix-20210930.xsd#nbix_BusinessDescriptionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessDescriptionPolicyTextBlock" xlink:to="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ae228504-9a9f-47da-a3f2-cf668415a0ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_15270f96-a116-431b-97fc-ce54685708fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_62932281-04a1-4e9f-96e3-f21fa13d4aba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to settle notes at initial conversion rate (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_235c9118-8dae-4070-aff5-83ecb4310d2b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_24f30ef2-2e62-4f05-9915-00bf4c139570_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_a166707f-e0ff-41c3-a1bc-c4e3898460fc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases to acquire equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_a62ef7f9-4f5a-4d41-b51f-a88b6de2f9e1_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20210930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5a7ee115-dc1c-4584-a9c8-6a72ca7612b2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e5471a47-475a-44c6-921e-52f4b94d49c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_dacde676-073b-45e0-a876-bf4bc0714a04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_b85141dc-a54f-40f8-95ac-029501237c5e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_b867feb1-688e-4c08-b12a-86f7fbf3e68e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_45c7a54c-df8d-4b99-bf8a-f5f54a6861ff_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6f286e65-1f06-451c-8c12-bfd0582b2fd7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_b7a01f6e-9194-47bf-9240-934c6c419022_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trigger (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_17d40c3d-edfa-4f44-bee1-42bc700ee531_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20210930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fad65bbf-53cf-4a95-8b29-335c5affb527_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_44ef7c94-a2c0-41ee-adfd-52ce18cb2394_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_eedc17bd-099a-41bb-9a13-e51c13f3d7b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_bd3cf85b-c768-48e9-8020-f37f4affa14a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale, at fair value (amortized cost $513.8 million at September&#160;30, 2021 and $226.7 million at December&#160;31, 2020)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1fc2eac0-02ff-4d91-a5be-338b20c5407e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_995d8a3f-7b8a-48fc-aa26-49328d237a1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c0c68a17-9cf0-42e6-bf9a-cd544f628d24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ac2aefc-c03e-4cfd-97bd-41010d54a0db_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PremiumPaidForEquityPurchase_529f4751-d43b-4c2f-8e18-0cd49a847915_terseLabel_en-US" xlink:label="lab_nbix_PremiumPaidForEquityPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium paid for equity purchase</link:label>
    <link:label id="lab_nbix_PremiumPaidForEquityPurchase_label_en-US" xlink:label="lab_nbix_PremiumPaidForEquityPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium paid for equity purchase</link:label>
    <link:label id="lab_nbix_PremiumPaidForEquityPurchase_documentation_en-US" xlink:label="lab_nbix_PremiumPaidForEquityPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium paid for equity purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PremiumPaidForEquityPurchase" xlink:href="nbix-20210930.xsd#nbix_PremiumPaidForEquityPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PremiumPaidForEquityPurchase" xlink:to="lab_nbix_PremiumPaidForEquityPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_888f946b-8158-4463-80d3-06c9c80d6af7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_2482338c-86ff-4cc7-9797-21f517cf387e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d3536047-4c24-4526-936f-fec987e91f1c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b4279725-25d2-4b7f-bd01-ede17805ff35_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_27e68fbf-1548-4a14-8642-6c09af63676b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c37e6b27-a2ac-4b78-b956-27e2fe2677af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9e0c0f47-adc1-4142-92f3-9f0825f00016_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_dfb276f1-ec05-402e-b676-ca4133834cea_terseLabel_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_label_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A. [Member]</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_documentation_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember" xlink:href="nbix-20210930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALPortelaCaSAMember" xlink:to="lab_nbix_BIALPortelaCaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_d4b5c060-f6e8-4d77-b9cd-e7311fc03358_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_18426409-4c64-45e1-a161-2149e3d48db5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6852abd4-78c0-4563-9df5-3ac6fdb61e5d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ccd32d96-b892-454c-8b74-4253362c7779_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72a10564-d8dd-460b-bf81-dc199cdcc5a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_4eb48af6-1c04-40cb-9539-248f9228ca09_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_15ae1d35-6a8e-4e12-b4f6-122b3784a6b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_367c638f-523a-4090-9061-371f519fd869_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_351d23a9-ff31-4932-b9f9-24b552f51f84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_fc405e3a-c9eb-4b0c-b5d7-b79190cd6054_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default</link:label>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_label_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default</link:label>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:to="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_da70d4c2-7d85-4839-99f1-0d371d1cdc6d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2ff4ae8f-4c80-4391-a860-4d019ba3a750_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_9cf2060e-6239-40ec-84e2-937b048a6403_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_499e7f89-71c4-4165-8375-0a364dcb7386_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a70b59bc-cf10-4988-8b88-b350954d8571_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b041e44f-c510-47f3-a1f6-7abc8ed26312_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fba3d23c-5db4-4300-abe6-b48f01c761da_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fc873cd9-40e5-485e-9284-840554312dad_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestoneEquityPurchasePayment_75dbf10c-dfeb-434a-ba33-af05b52f61c8_terseLabel_en-US" xlink:label="lab_nbix_MilestoneEquityPurchasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone purchase payment</link:label>
    <link:label id="lab_nbix_MilestoneEquityPurchasePayment_label_en-US" xlink:label="lab_nbix_MilestoneEquityPurchasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Equity Purchase Payment</link:label>
    <link:label id="lab_nbix_MilestoneEquityPurchasePayment_documentation_en-US" xlink:label="lab_nbix_MilestoneEquityPurchasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Equity Purchase Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestoneEquityPurchasePayment" xlink:href="nbix-20210930.xsd#nbix_MilestoneEquityPurchasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestoneEquityPurchasePayment" xlink:to="lab_nbix_MilestoneEquityPurchasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5b31ea4a-febc-4ea3-bd7a-1b7c58edfd35_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_155abfa9-d1b5-4993-ac21-060f303c8b50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6496369b-becb-4633-983a-4a795ec6b2bf_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_bd24a82f-ccb8-4b94-b303-98f0d3bced45_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2c264560-cd23-4971-b97a-c5e70b0b0ed2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_200399ca-5251-46f2-b548-1ee77c0acc4e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_00deab16-42f2-420a-9f6a-b40dc7eda0ae_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_7dfd07ea-fb87-408d-8018-73a327343f34_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_dd7d071e-b96b-4ac4-a997-96f44dd6ec74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d56bcac8-faf7-4208-8848-3fb1ff83449a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_cfd3f774-5b5e-4621-9d4e-38c600acb36b_terseLabel_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned Irish subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_label_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_documentation_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries" xlink:href="nbix-20210930.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfIrishSubsidiaries" xlink:to="lab_nbix_NumberOfIrishSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_c9c4761b-e36e-4387-a48e-b35710625cec_terseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_cd9307d3-4eba-4438-9bb4-9a85aac3eb9a_verboseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:to="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0aaebc2a-7953-4df4-9855-24affbf80d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9efba1ce-cfb7-4eb0-8620-11a5fdf947ef_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_901b3903-18d1-42f0-8bf0-9dfd96f85512_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for Lack of Marketability</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d28f232c-c405-42a7-a6a4-8bc620705cb1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2382908f-4e5b-4c87-83b0-a0aec2c68a8e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_248dc1cf-6d58-447b-8e43-79147dd8939f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ae7b49a-a4db-4562-abfd-007ea0370fda_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_b4fffdfd-7b48-486a-90be-644b15061328_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20210930.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_e8c7777a-d48a-40d0-9621-79642b19e67b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial repurchase of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0cb7304-918f-4908-8aef-25a07f2908ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_19908baa-056d-47bf-90fb-802564e17111_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_bba5cb81-6df6-4657-97f6-1b80ec2880da_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Description of Operating Lease</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7b5d0d57-c1a4-4f75-a116-5197af975afc_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e4e71bad-9741-4577-ba88-35b7b093ddb1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6d1f57b9-de18-4681-9180-13b1535bb059_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7690e6d8-da41-4a39-95db-fa784e66ad5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_f950ae0b-6e8d-4d9b-857d-901fdc6fa5fd_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38197878-3b9e-4d43-b927-87256832f812_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fdf6eed3-96af-4d97-9dad-8d9df05d571d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_47cc99a9-8162-4e4a-973c-79ac488a8d12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_40980524-11ee-432a-b7f4-e5bf50c7e7b7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c5b1bfcf-af43-4256-a0cf-3ff629de2ead_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_03fa9425-721b-4dab-b064-41182385d807_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_eb7c3ca5-9aca-4c32-8db6-ff86b10b1df2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_be215d94-1686-44d3-b2cf-e04c7f425c59_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20210930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_37b3e848-7f68-4fe6-8963-071c66688d96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_0483666f-f396-4e95-aeee-ab672a81f58f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities measurement input</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f31621e5-2b0f-4d49-90b7-325841360b8a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_aca2559c-4dfd-4c73-a388-dd9c7047b7bf_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9aa18c14-9dff-49b2-bc1d-b47e2e5f29e8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_240508d7-4155-44e3-9ac8-5233bcce6053_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_3c01343b-7aad-45ff-9a82-fc22eece7226_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_e4d52d0e-8972-4a87-ab14-c7634f724ad6_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d2dd6ac8-5e91-4dcb-8186-87a93f8d5d70_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e62b3aad-401f-49e0-9283-e834fe425f09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ff20eb25-cc14-4af6-bf6d-2b2269704465_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_6280505c-0dcf-4a43-86ee-07735f689447_terseLabel_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive business days</link:label>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_label_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business Days</link:label>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays" xlink:href="nbix-20210930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfConsecutiveBusinessDays" xlink:to="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e826927c-902b-4535-a50a-625b4282e34e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_bdba00f6-b799-4fce-90d6-5560139ab855_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e9a3b7cd-78d1-4b53-b5b2-bf1add6d4ac5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6e5fa437-2e99-494c-b416-ffcb67763c6b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb326e46-e537-4c85-a038-4fb1ebc09e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_9c941d3c-1fc1-4d83-8a05-20edd49b4000_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20210930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_d889a356-9167-4513-aa8b-28ad4922d6f7_terseLabel_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion observation period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_label_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Observation Period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_documentation_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod" xlink:href="nbix-20210930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtConversionObservationPeriod" xlink:to="lab_nbix_DebtConversionObservationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8f657fc2-266a-4aed-aa6a-fc217e6f8516_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f469fb2c-c731-4673-81b4-6ffc8b81445b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5040087e-578e-4ecd-82e9-d617ee69389d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7241c1c9-1bf3-4a12-b3de-c35bfac3830f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_50c29e6a-7961-460c-8e5c-7b54305ed8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_2a5edf39-48c2-46d7-9d42-ed58cec3452f_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_88d5535a-e1aa-4533-8e1d-073562eed636_terseLabel_en-US" xlink:label="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock per share (in USD per share)</link:label>
    <link:label id="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_label_en-US" xlink:label="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Restricted Investments, Share Price</link:label>
    <link:label id="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_documentation_en-US" xlink:label="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Restricted Investments, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:href="nbix-20210930.xsd#nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:to="lab_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0de4792b-a1a5-4efc-9280-58ad0db76083_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6c0fb0aa-e4df-4c88-8d13-ffecb879d146_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fef60361-3e99-4a57-ad1a-534241105c28_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2b2a7afa-25f6-4221-85f5-ecbcf68df5fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b58bd724-e8d3-4553-b67f-7762a4779783_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a4af784d-d58b-490b-919e-e73991145ba4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d57882c9-f83a-4f09-9f86-23333603987b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eddfc764-3062-4bd1-91a2-8bbf7438c31c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3cfac950-8f72-4c01-9628-dbc66e402fe3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b3998885-9a8f-4f43-a729-be49ffa8e012_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3a6b571a-6bd2-460b-aa9d-1ea1d3d01a5b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_3ef88579-7453-4acf-a93d-b417e67fe1ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2d499ec6-b5a5-4cc7-8f59-406da75d7b89_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsIncMember_e8e041cf-5c3d-4e61-b432-2162388f96b7_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsIncMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsIncMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsIncMember" xlink:href="nbix-20210930.xsd#nbix_VoyagerTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsIncMember" xlink:to="lab_nbix_VoyagerTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_56b3b598-cb1f-4181-8574-92ba9b80c337_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_a5aa915c-b79d-4433-8bdf-e31455c8dd99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_60f81eaa-0e14-4290-b7c8-8e3e955fe7f9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b86e796f-0a5f-4660-9ca3-508f8fd53fb4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e04199f4-d79b-4ef4-8eae-e07610fe572c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c9c0b55-0906-4ef2-ae33-80cf0a088094_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LongTermInvestmentsMember_f9a4860f-ee39-4d35-a452-f5cf0218ccba_terseLabel_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_label_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember" xlink:href="nbix-20210930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LongTermInvestmentsMember" xlink:to="lab_nbix_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_a1b41864-6a91-417a-bd8c-173fb1a8e788_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes convertible in to shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5f4ea811-ab5f-4e6c-a8d3-f40edf29755c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_1f5bcef2-05b3-4b76-a90f-41e8830367bf_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3de17371-25eb-4137-8dc2-4960b5e9bca9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_dbd414f4-25ef-46c8-ac92-ef5664c59893_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b54eee5-9a39-4e09-a741-e46f65dcedfe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3120e0e8-ce57-4c31-9ec8-f51d15945482_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e6ab8446-c20b-4bde-9f03-48a2b1a39f06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_43d488b7-eb04-46b9-a8a9-60a2546f746d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_233b5c6d-50b4-4a91-aec2-6937efbef0ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_946b0710-381d-40ff-9345-a2d7b85ffdd9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcea6831-0fcf-48ca-90c7-da73b4ed32c1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0e71c8c9-9f9c-47c8-8135-b17516472a28_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_165cd224-0f53-41bd-8fe3-76fd2ea79ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Notes Net of Discount and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_707afd67-1333-4633-850c-bf9e1b2c5602_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b2d742a7-ae7a-4cb5-b337-a833d9a4aa90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_26e77342-faf4-4752-b51e-0fb7e829e986_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_9ac016d7-c7eb-4d63-9892-a021ced04e48_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2e9ab110-4fe4-4c11-b86f-d14353e06507_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashTextBlock_669370d9-5a06-40a4-a988-a75619eb3f8b_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_RestrictedCashTextBlock_label_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock" xlink:href="nbix-20210930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashTextBlock" xlink:to="lab_nbix_RestrictedCashTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_341cfa3b-d268-4864-bb70-7c61aef0bed5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8425c55c-c6d1-49e6-ab68-477cd5ced4c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1b4d2665-aae4-4208-9d6f-97339adfb0e9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_94c73a17-495a-449e-b778-f759b03ab061_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c5c8b236-8874-42d1-bef6-7eb770fbf74c_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity security investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_39042a88-57dc-4f2c-9938-cbf6c9eb52dc_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss included in earnings</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_ac07d50f-b6b7-4a67-bad1-87867125944a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_cd4ca8c6-1638-436a-bd65-b3ec607c5996_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4b15ed1d-a5a0-4856-b7fc-862de9c9c732_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d5727d4d-20ab-45d0-a8ea-40e8764bd686_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b4706c61-6f4c-41ae-8fd3-3884dbda80af_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1097cad1-30e6-43af-abe2-832c8e7108e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 94.8 at September&#160;30, 2021 and 93.5 at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6526d939-2f95-4b0e-b24d-3a5bb93fdb1e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0959b6de-2459-4a4f-8867-67ba97fb84cc_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9bd895be-10ff-45ed-bb54-96f4b401e6c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f96278e4-6bbb-40cd-a16a-7d42273bd75f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_922c07f6-f21a-49c0-9527-735cb038ab43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe2ba1f8-0fe2-45fa-b261-5371bdd60974_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5781fffe-d796-4480-a17f-d5e6c650f59a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d8dd1eb3-06fd-4180-8bc1-061bd48d2a92_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021 (3 months remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3672d1d6-829c-48ee-8504-68e3ed94dbd1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_6763a1d3-8743-4763-8422-ae46e00e4398_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_77b63c83-cd4a-4f9a-bc56-ed3d9fc4a8de_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_57b2a312-3fe8-4859-984b-87299fe05cae_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_88f74e0f-120b-40ad-a7a2-fc382c067e7b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_604872de-aab5-4b4f-8b2b-ab7a7676778c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d3dfc5c4-4689-4f45-baff-f83402c4a515_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_710466a8-0e8d-4ea2-9b3f-9fa0e0b6ea17_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_80dcf27f-82e6-438c-b7c4-45da169ffc6a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_1dd71187-a271-40ab-841b-2e98e205b78b_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20210930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6070a588-5605-4f9f-862d-0d95b16936cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6cadd99-e363-4649-beb3-8923ebe88d4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cabe013b-c703-4a73-96f7-27c5c5d85c30_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6c833f1f-19a7-4932-87f3-cead3c859b51_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_9fb65913-1729-4f86-b2e5-a9154f7d5516_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ed39baed-6703-4810-9303-d6c6f0b7412d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4f0fe916-76a9-47f4-b310-0a6f629afb60_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_e540bcd1-13ea-4cd6-a098-d435af17cd7f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_54f47907-35ca-459d-b468-6dff0e30940e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1d24b56f-37e4-40b4-8f71-97511d15eb2c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2764a92d-05ae-41d9-ba9e-9daa89e8b13f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e6c2da57-b69b-4ecd-ba7b-ce1d54780e08_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_38715fbc-54ac-4f0b-b5ba-659353aac127_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6ea7a065-24e1-41fd-a6ad-903c42fcf64f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4102c15e-aa0f-4924-9fd0-e689b487fdcc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e8181ab0-bf45-4a6b-8647-87a9d9b21227_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_dcfc5f84-e2ec-4982-8a1a-7d2cfa2de1e3_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="nbix-20210930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_191796ea-434e-4948-9086-a25181981171_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4954576-a3f3-4ab5-9ce1-d93eabbd36f7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_017697b8-10d9-46d3-9933-0060dff87864_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_de459c05-e75e-4bc5-b684-5db3db6704de_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1a815f35-4506-472d-a928-4ab4b1ad8b76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_863c52f0-b227-4e58-8e48-2b3f8ecdbd3a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_77fb5601-4752-4515-8488-f585a0c036e0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_b4f05e84-c86e-4fc9-8ead-6b2d4e2c277a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_71e8eaab-0efd-4879-8865-770695f76c64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_966c64fc-7e14-42de-b147-dca585e9a4fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_297688f0-6b79-4dff-8ee4-07296db1286d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5bc7f9be-8afc-488d-8514-a0918e5b00f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_13672a6f-63e2-48e3-9dda-ee7362215b71_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_b6f52b43-13f0-4ae5-842c-f72792760f59_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a2c85023-2839-49ae-9338-6a75d0682bed_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_6188fca5-4c4c-4dce-8dd4-c2e0c532c728_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_775c2ca0-e62a-4f8a-93bb-373cc234adbd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_2e4428ad-fdbb-41ca-93de-65acb74e203d_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a3153e84-fe00-4308-b48d-aebbc44ca97d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6fbbaa7-d074-4487-a411-b7c3716f3f23_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_151055e6-6588-4d70-8ac4-6414984d16c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_080610f1-f578-4006-8ae8-cd2ffac5b9bc_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the liability component</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Initial Carrying Amount Of Liability Component</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component of a convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:to="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0812f8df-9002-47b0-81d0-ee0490cf098b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ad57e2c-89ba-4dc6-b227-fae5c7e09be0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_34299410-45e2-439f-b67e-95f5abdd28fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_8a97a9e3-e5fe-40b8-b551-c1710778d99f_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd. [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20210930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4f7fd2cf-34f3-459a-b844-7ad36bcad886_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc768a1e-a47d-49bf-8637-1fd03a519d71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61001611-e810-4740-906e-4eabe6ad4581_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_b76eb5af-dd4a-45c3-a9ca-4df2b7d278ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d5ed0070-2116-4c0a-874a-c6470b2521f5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d4d2d5bb-bc0d-4c4b-9bfb-3c7f42969292_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5486065f-450b-43e0-818a-90537a7c4669_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d551c49e-6d6a-48fa-a037-46c28f11ab90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_22c0caad-310f-4f92-966b-b23a035cb2ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ee74ab0-14f5-4cb5-bf84-a769d6354e5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_491595c6-99c3-4e58-9b4d-51942fcfa68b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_cd8e9514-c670-4fbe-a063-028be2b13abc_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_60cc18a1-706a-4804-b297-f07e02769937_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_db529920-f305-446f-aeee-7ae072f71b30_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_75b815c5-3c25-49bc-bf66-d03926d10095_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e82c91cb-7272-4d04-b99e-2eb017282708_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_aa90a736-4900-4b2a-ae53-7f4708b2d6c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_39d2da14-c737-4197-bb9e-c0bf495f06f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_a37bf1c6-b6d4-4772-869d-be5fe05c2d66_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payment receipts under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a074695c-cb9f-4f99-9301-5732c8d506cb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_509d8e44-7a5d-4b79-bd3a-f40ee535d870_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c95da197-1bf6-40ba-8eb1-619c6836133f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86bd6512-d92d-42bd-9d97-cd27521bb1cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5bb9cf31-9da5-4314-9bfe-cab9ace46fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_24ee2ab3-f5e1-4137-b30e-d40a9768bfcb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_36ffacdc-5cca-4c97-a8b8-65a43b4f4db7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a83730e-a924-40d3-bf96-5ea9ae63d0fa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_b425c845-33ee-4dd7-8d60-93ffff5160e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2b65464d-e3cd-4e42-82f9-681eee83f42c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_8738be86-f22a-4990-ac19-dfac205f7a49_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20210930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_e7cb9b74-aef6-4b30-b45b-c06f33ffdd5b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b4e0f28f-802d-42c0-91d4-2f218185cab9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d23ff1ee-ab1c-4fd2-80f9-7aa4ffd0ae02_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_56b79df8-a358-4386-96f5-c2bdb91bd84e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_89677a73-2fed-46f4-abeb-0cbf9d0d9a3c_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e9d4d95f-5c4b-4335-b859-c45c392b7668_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a8d1c810-dff6-4580-a397-0a72ca589fca_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66465430-35a1-4cdd-9284-b886e77c276c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_85285bc1-dba3-49be-9978-8ed5480a25a8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_741e6940-2276-4ae0-a78c-0c733b912be6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1f3942f9-7c8a-42cc-977a-361de2f663c2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0e8d81fd-7016-452b-93dd-6fd428a11178_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d7f7102c-d9df-4fa8-bd19-a736034e87b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbVieIncMember_c9b78ae7-9490-46cf-9257-c9733d5e05cb_terseLabel_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_label_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc. [Member]</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember" xlink:href="nbix-20210930.xsd#nbix_AbbVieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbVieIncMember" xlink:to="lab_nbix_AbbVieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_642f651c-9aa7-482e-a5b4-cca6e57bf208_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0881e293-55ef-4d3b-b912-2e649b8e568c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_daf53803-649f-43bf-811c-7b3fb985f99e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_55559cc3-2d33-4d9d-b410-a7c21fdeab76_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_de26a815-ba77-48e7-a299-1615b0ae3644_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_47572d9f-56cf-415d-b28c-2fee86f4a7b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ad0b0a8-83f3-49f1-8b39-d0bee93aa4a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d673f712-0c53-4de7-b444-2e3dd357bf6c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_92301c83-ba58-4c2b-b47e-e2cf796e5470_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_27c281ad-e9e2-4a93-9705-511e4426197b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f3053eb6-9e70-4359-ac74-e0fc61726929_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nbix-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a9123f86-20cd-4ff6-b244-7acbbb7c07ba,g:f9098265-5c66-4941-a2c0-e459b461ecf3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec4a975d-d4d0-4ea6-9b87-7b8afe235763" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentType_ec4a975d-d4d0-4ea6-9b87-7b8afe235763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_842c33fd-4819-4dcd-b080-30a3f3a04454" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentQuarterlyReport_842c33fd-4819-4dcd-b080-30a3f3a04454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d19b62b4-f998-4483-bb39-a12c8d518aed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentPeriodEndDate_d19b62b4-f998-4483-bb39-a12c8d518aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_99fbda82-806a-41bb-9c1e-498458149b9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentTransitionReport_99fbda82-806a-41bb-9c1e-498458149b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b8155999-f988-4b59-9377-eea9becbf252" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityFileNumber_b8155999-f988-4b59-9377-eea9becbf252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b29c34b8-003d-4160-a321-d97c485e733b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityRegistrantName_b29c34b8-003d-4160-a321-d97c485e733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3c2661ff-423c-462b-98e8-e95289f53e45" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3c2661ff-423c-462b-98e8-e95289f53e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_76f1d185-491c-4464-879c-0a8d83a061a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityTaxIdentificationNumber_76f1d185-491c-4464-879c-0a8d83a061a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1fdf33c0-3e6c-473f-a052-7147361811b6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityAddressAddressLine1_1fdf33c0-3e6c-473f-a052-7147361811b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_22325cc4-c2f3-4f0d-954b-ec110f474ddc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityAddressCityOrTown_22325cc4-c2f3-4f0d-954b-ec110f474ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_503bef9e-a183-4def-914f-afdb0cde8c37" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityAddressStateOrProvince_503bef9e-a183-4def-914f-afdb0cde8c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_480f5abf-7a10-4bec-a613-55bf86d79fe7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityAddressPostalZipCode_480f5abf-7a10-4bec-a613-55bf86d79fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4569dc7b-f9bc-4721-ac4a-b00073f61b25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_CityAreaCode_4569dc7b-f9bc-4721-ac4a-b00073f61b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_20ff8e5d-c805-47a6-8ced-4b313715cd7c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_LocalPhoneNumber_20ff8e5d-c805-47a6-8ced-4b313715cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e9ed8fce-89a0-4630-abd2-62e6eb1bc76e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_Security12bTitle_e9ed8fce-89a0-4630-abd2-62e6eb1bc76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_668595f3-d0f4-496f-abd9-0338c30429ab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_TradingSymbol_668595f3-d0f4-496f-abd9-0338c30429ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d74a2477-c2f2-4249-b8fc-a3c69e1d6f4f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_SecurityExchangeName_d74a2477-c2f2-4249-b8fc-a3c69e1d6f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1418480b-503d-4954-91c7-94c1aef57dac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityCurrentReportingStatus_1418480b-503d-4954-91c7-94c1aef57dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a9137527-82d3-434f-95eb-24366af65960" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityInteractiveDataCurrent_a9137527-82d3-434f-95eb-24366af65960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ed607697-1b88-4152-98c7-945e467c6fc4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityFilerCategory_ed607697-1b88-4152-98c7-945e467c6fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ca4c04dc-ee56-4076-9eb0-0002fd7e368b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntitySmallBusiness_ca4c04dc-ee56-4076-9eb0-0002fd7e368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6a469f5d-22a8-401c-8178-ceb1f6c8f41d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityEmergingGrowthCompany_6a469f5d-22a8-401c-8178-ceb1f6c8f41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d5ed7216-33d5-421a-a25f-890bb1d10e76" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityShellCompany_d5ed7216-33d5-421a-a25f-890bb1d10e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_34542067-cae2-4dd5-823b-432abc52f60a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_34542067-cae2-4dd5-823b-432abc52f60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e9a926a1-80b5-44b9-9dd4-110c87f85255" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_AmendmentFlag_e9a926a1-80b5-44b9-9dd4-110c87f85255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de6e16a6-fc47-44fa-ad20-288534291709" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentFiscalYearFocus_de6e16a6-fc47-44fa-ad20-288534291709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c9826e04-b447-4126-8309-c148947e28d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c9826e04-b447-4126-8309-c148947e28d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2540d060-6e72-4698-9e7c-c2702381dc8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_EntityCentralIndexKey_2540d060-6e72-4698-9e7c-c2702381dc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a865dd2f-e865-4e0d-9c40-0ad6ca1e2d9b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d1b2f2d9-1caa-45bd-aae5-5bc625d1100d" xlink:to="loc_dei_CurrentFiscalYearEndDate_a865dd2f-e865-4e0d-9c40-0ad6ca1e2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9fd107d8-0fe2-4aa1-9ba8-3d9ea1060f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9fd107d8-0fe2-4aa1-9ba8-3d9ea1060f2b" xlink:to="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f931d057-9406-421d-906e-0211f572836d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f931d057-9406-421d-906e-0211f572836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0ed2af0a-2668-49ec-9a28-0c909ebb2f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0ed2af0a-2668-49ec-9a28-0c909ebb2f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c681a4ab-d36b-4752-a969-45d55ae129aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c681a4ab-d36b-4752-a969-45d55ae129aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ede08d1d-760a-4867-b5f4-c647d2e3c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_InventoryNet_ede08d1d-760a-4867-b5f4-c647d2e3c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ef9db25a-994d-4566-89c1-995253664e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_OtherAssetsCurrent_ef9db25a-994d-4566-89c1-995253664e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7fa6cc7f-995d-4f35-94fb-a8edf95f439a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e9dc083d-e0a7-415e-9382-bf3dcdcb1ecf" xlink:to="loc_us-gaap_AssetsCurrent_7fa6cc7f-995d-4f35-94fb-a8edf95f439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_08452aae-dc0d-4323-8cae-7674cb62813e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_08452aae-dc0d-4323-8cae-7674cb62813e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ddd75af4-59e8-4d61-b7f5-98b6262aadc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ddd75af4-59e8-4d61-b7f5-98b6262aadc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9b02ad72-d80e-4be0-a206-5307bd9587bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9b02ad72-d80e-4be0-a206-5307bd9587bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_cc207f14-e2df-4476-8d85-be0553d9d21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_cc207f14-e2df-4476-8d85-be0553d9d21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_177d0128-a53c-477a-a0d4-f7a9b643ef46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_177d0128-a53c-477a-a0d4-f7a9b643ef46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7e2b638a-50f1-4709-ad60-f8f197818d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7e2b638a-50f1-4709-ad60-f8f197818d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b14a6afe-f2dc-47d7-9604-46a9b067bf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3e71357f-b0c3-49a2-88cb-1cf11bb3ab7c" xlink:to="loc_us-gaap_Assets_b14a6afe-f2dc-47d7-9604-46a9b067bf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9fd107d8-0fe2-4aa1-9ba8-3d9ea1060f2b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b58a461a-1a5a-44b2-bf9a-80477555aa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b58a461a-1a5a-44b2-bf9a-80477555aa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c005801b-8c0b-4551-8fd8-fab674ded6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b58a461a-1a5a-44b2-bf9a-80477555aa8b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c005801b-8c0b-4551-8fd8-fab674ded6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c35f982c-b060-42c6-8f51-c77bd116ebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b58a461a-1a5a-44b2-bf9a-80477555aa8b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c35f982c-b060-42c6-8f51-c77bd116ebd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_429f214b-74de-43b3-bc78-e395aa373504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b58a461a-1a5a-44b2-bf9a-80477555aa8b" xlink:to="loc_us-gaap_LiabilitiesCurrent_429f214b-74de-43b3-bc78-e395aa373504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_126d974f-91e2-45e2-9e78-9d44746e7635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_126d974f-91e2-45e2-9e78-9d44746e7635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99b26181-1cb1-4beb-a4fb-9fb079403c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99b26181-1cb1-4beb-a4fb-9fb079403c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0c1cc32a-bfe4-4b43-b670-d023ee8f5e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0c1cc32a-bfe4-4b43-b670-d023ee8f5e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_35fe7f64-8848-4c9c-ad24-ef04231d22fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_Liabilities_35fe7f64-8848-4c9c-ad24-ef04231d22fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c2111a2e-cbf8-4def-aaf7-ad08239cbddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_PreferredStockValue_c2111a2e-cbf8-4def-aaf7-ad08239cbddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_08574b6e-2367-423d-89c6-f01fbc07d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_CommonStockValue_08574b6e-2367-423d-89c6-f01fbc07d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bfd53655-7eaf-4b42-8804-abaeb2eca2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bfd53655-7eaf-4b42-8804-abaeb2eca2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29a010d2-e3f3-46ad-ab21-9bae812716e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29a010d2-e3f3-46ad-ab21-9bae812716e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ebd98a7a-0f91-43aa-bd8d-fdcbbcb0870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ebd98a7a-0f91-43aa-bd8d-fdcbbcb0870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef1c3e2c-e9f7-44ea-8264-c17effd191be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96da3da2-c5c4-48c3-95fc-3a9d78bb6723" xlink:to="loc_us-gaap_StockholdersEquity_ef1c3e2c-e9f7-44ea-8264-c17effd191be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9716fa56-9f90-4421-ac9b-22826a8c2043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdc63385-a18c-4861-9698-44fe2e727197" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9716fa56-9f90-4421-ac9b-22826a8c2043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_0c441318-5942-4650-8f81-013c364b4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_0c441318-5942-4650-8f81-013c364b4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b9481b68-6f58-40af-beaa-58d1b9537c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b9481b68-6f58-40af-beaa-58d1b9537c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0606a0e-cacc-4224-8fc1-3953f803c15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0606a0e-cacc-4224-8fc1-3953f803c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_509568d6-9370-4d67-9893-9d47c35edc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_509568d6-9370-4d67-9893-9d47c35edc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fde13eb7-2c63-4db1-b1e5-2fba83b7e555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fde13eb7-2c63-4db1-b1e5-2fba83b7e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2c963baa-3acd-4ea2-b2b9-00dd4e18e4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2c963baa-3acd-4ea2-b2b9-00dd4e18e4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ed9c104-cfa2-4366-b9bf-1930273df647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ed9c104-cfa2-4366-b9bf-1930273df647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_304cd0d3-b341-4b6d-95bf-382dd9d89c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_304cd0d3-b341-4b6d-95bf-382dd9d89c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50d90c4c-f94e-4b5c-a596-0b259156c267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_CommonStockSharesIssued_50d90c4c-f94e-4b5c-a596-0b259156c267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c92947cb-5059-40d8-b447-4c1699145655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee52f1e8-04f4-4b8d-8c76-0f2bff930de2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c92947cb-5059-40d8-b447-4c1699145655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_09d1a40e-b4f1-4bcc-9cad-dc030504b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09d1a40e-b4f1-4bcc-9cad-dc030504b61a" xlink:to="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:to="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cb6363e1-e25d-4e54-b0b8-ae34748c26a6" xlink:to="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_34ab89cf-c43a-44b8-bfc2-c392a457a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:to="loc_us-gaap_ProductMember_34ab89cf-c43a-44b8-bfc2-c392a457a21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_ba07721d-e2bc-4609-87a1-eaf1ed915742" xlink:href="nbix-20210930.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27dda0fd-189e-409a-a01c-00960a900e0c" xlink:to="loc_nbix_CollaborationRevenueMember_ba07721d-e2bc-4609-87a1-eaf1ed915742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b9444a80-a30d-4d3f-90ef-5cf407741707" xlink:to="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b937df-0148-415e-b90f-7a0754ec71b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7986a091-6c56-496e-b118-b929350b698e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b937df-0148-415e-b90f-7a0754ec71b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f911614f-8c1b-4011-9db0-be5c3ba8e266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f911614f-8c1b-4011-9db0-be5c3ba8e266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9d69cb3-eaf6-4731-82d7-19258a353936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9d69cb3-eaf6-4731-82d7-19258a353936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_776e8774-503c-4e7c-bf8b-ca2eaca1c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_776e8774-503c-4e7c-bf8b-ca2eaca1c22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3f27ca4a-791b-480c-a8eb-0f6c13aff12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3f27ca4a-791b-480c-a8eb-0f6c13aff12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f0f7581-8cca-4447-b57f-b11b6f4df6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b86690b6-16da-4b99-b60a-ae35c8474bf2" xlink:to="loc_us-gaap_CostsAndExpenses_0f0f7581-8cca-4447-b57f-b11b6f4df6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2bf77f3-ef8d-470b-b697-3da5d041aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2bf77f3-ef8d-470b-b697-3da5d041aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f38a035e-8d62-4ccb-9ac5-f4dae0d9d284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_InterestExpense_f38a035e-8d62-4ccb-9ac5-f4dae0d9d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_63231281-ce02-4b0b-9c87-c1f8409602b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_63231281-ce02-4b0b-9c87-c1f8409602b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_93fa432e-a2ce-4208-bc90-e43738ccf6ad" xlink:href="nbix-20210930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_93fa432e-a2ce-4208-bc90-e43738ccf6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_23c7a193-4440-483c-9aa4-9dc686c9f5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4386898a-b2b5-41dc-9d73-514d5276f4a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_23c7a193-4440-483c-9aa4-9dc686c9f5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59e5913b-3555-4da3-81d2-3492458c1c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59e5913b-3555-4da3-81d2-3492458c1c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_112efa7e-05fd-4fde-a62d-1a87fb73a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_112efa7e-05fd-4fde-a62d-1a87fb73a39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00d93305-4482-41c7-95f4-d389ae0f54db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_NetIncomeLoss_00d93305-4482-41c7-95f4-d389ae0f54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a258274-5987-4ec7-a5fd-3e9ed6cbc323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a258274-5987-4ec7-a5fd-3e9ed6cbc323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_be7b1eac-0610-499a-88b2-8f97bc3b98bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_be7b1eac-0610-499a-88b2-8f97bc3b98bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_68679036-c21d-41d6-8d48-b2a746c4b998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_EarningsPerShareBasic_68679036-c21d-41d6-8d48-b2a746c4b998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4c05b5cb-4f45-461f-97ad-53f9aec4b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4c05b5cb-4f45-461f-97ad-53f9aec4b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf58bd04-9fbb-499f-9efd-6edc49342db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf58bd04-9fbb-499f-9efd-6edc49342db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd29147c-2829-4fac-aac4-82a2299cec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6822ea1-85f1-4161-9f76-277cdc960377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd29147c-2829-4fac-aac4-82a2299cec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6dfd140-70a5-437b-ac4d-31a2ffee3a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6dfd140-70a5-437b-ac4d-31a2ffee3a40" xlink:to="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4a97666-58f8-4a8d-a747-f5cebb742b04" xlink:to="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b1bbd156-63fc-4f93-a4f7-a853f15054a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_CommonStockMember_b1bbd156-63fc-4f93-a4f7-a853f15054a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_71a9f006-aefb-4393-84f8-e199f1f196a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_71a9f006-aefb-4393-84f8-e199f1f196a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a869bf41-07ee-42b6-921c-58383fe8f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a869bf41-07ee-42b6-921c-58383fe8f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f1361666-c5c6-4491-89ab-d089a5968ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db66c1f2-30e6-4ed8-818f-41fa34e9b476" xlink:to="loc_us-gaap_RetainedEarningsMember_f1361666-c5c6-4491-89ab-d089a5968ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b396bad5-1005-417c-a17d-d9f884a5750a" xlink:to="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0f5a328c-60c5-4a36-b673-ae6fd0261583" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_adabe024-11dd-406b-a620-056212b25e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_SharesOutstanding_adabe024-11dd-406b-a620-056212b25e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_434e5a61-d8c4-4d41-8457-10d84a95a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockholdersEquity_434e5a61-d8c4-4d41-8457-10d84a95a33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f25c920-a0eb-4612-b3ac-2826627818db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_NetIncomeLoss_2f25c920-a0eb-4612-b3ac-2826627818db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4926149c-82a6-4ee5-bf04-924daa6fc796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4926149c-82a6-4ee5-bf04-924daa6fc796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcab1a68-b164-4e48-a524-2c313cb26e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcab1a68-b164-4e48-a524-2c313cb26e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dae7651b-37e9-4d53-8455-26ce16e06042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dae7651b-37e9-4d53-8455-26ce16e06042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a5a64b3-1227-4f51-97b7-d3440f834314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a5a64b3-1227-4f51-97b7-d3440f834314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c74fc17a-de0a-47a8-befe-25debba87fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_SharesOutstanding_c74fc17a-de0a-47a8-befe-25debba87fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0a7209f-e0b9-4dfe-8d80-11fc4934fb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890ec497-1b9a-4b2a-a9ff-0101730e10cf" xlink:to="loc_us-gaap_StockholdersEquity_c0a7209f-e0b9-4dfe-8d80-11fc4934fb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2bc5eb94-1766-4e19-92a7-bb531efac798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2bc5eb94-1766-4e19-92a7-bb531efac798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6c76a62d-0658-4dab-b869-809922f5f481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2bc5eb94-1766-4e19-92a7-bb531efac798" xlink:to="loc_us-gaap_NetIncomeLoss_6c76a62d-0658-4dab-b869-809922f5f481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2bc5eb94-1766-4e19-92a7-bb531efac798" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4d786887-4767-445d-90ee-95cb7c68da66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_ShareBasedCompensation_4d786887-4767-445d-90ee-95cb7c68da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a56cbf22-36d2-401a-b2c0-c12b125036bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_Depreciation_a56cbf22-36d2-401a-b2c0-c12b125036bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5300705e-c43e-45ed-8daa-e974782ebd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5300705e-c43e-45ed-8daa-e974782ebd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1741f6ed-a421-4cd1-8598-9dcd37c86164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1741f6ed-a421-4cd1-8598-9dcd37c86164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8d34adcc-4275-4e8e-976b-c3e517c24e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8d34adcc-4275-4e8e-976b-c3e517c24e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_af1d5291-94d6-4a16-a9a4-4ce2899b4de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_af1d5291-94d6-4a16-a9a4-4ce2899b4de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_044b010e-453b-4471-8f6f-0c4ffb9d1915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_044b010e-453b-4471-8f6f-0c4ffb9d1915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3033ee76-0eb6-4aff-aef1-cef56a5592fd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d617f07f-b03e-4050-a0b4-66260b3408ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d617f07f-b03e-4050-a0b4-66260b3408ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_225fb3db-a531-4ea2-a7e6-abcd7ba423ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_225fb3db-a531-4ea2-a7e6-abcd7ba423ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_66b692b7-be0a-4fad-aae2-b9bbd8bff70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_66b692b7-be0a-4fad-aae2-b9bbd8bff70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4745a499-bdef-4522-8765-a14db0595be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edf91a64-4ee9-4189-b139-38d17e32722c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4745a499-bdef-4522-8765-a14db0595be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53bd4bcf-3673-4e6f-8e23-512593c51de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2bc5eb94-1766-4e19-92a7-bb531efac798" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53bd4bcf-3673-4e6f-8e23-512593c51de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fe253df1-ae4d-4f04-9ca0-793def160573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fe253df1-ae4d-4f04-9ca0-793def160573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_52ff42d6-96af-4012-9db3-2790b0ca9946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_52ff42d6-96af-4012-9db3-2790b0ca9946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_86f0c284-ec14-4d9c-ab0f-34d684fe1017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_86f0c284-ec14-4d9c-ab0f-34d684fe1017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e35475cc-60c0-4138-8d07-e95e749d8f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e35475cc-60c0-4138-8d07-e95e749d8f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_426e8681-7e3c-4f3d-b089-35c2ea471e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a73b5a22-cb93-43be-a601-3960ac4e2be6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_426e8681-7e3c-4f3d-b089-35c2ea471e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36405d1a-eac1-4ce1-b4cb-afa5968fd07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36405d1a-eac1-4ce1-b4cb-afa5968fd07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4e621c95-f85f-4db6-802f-2cffeff9ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36405d1a-eac1-4ce1-b4cb-afa5968fd07b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4e621c95-f85f-4db6-802f-2cffeff9ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_a27092c8-f3fa-464c-bd70-011cade54bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36405d1a-eac1-4ce1-b4cb-afa5968fd07b" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_a27092c8-f3fa-464c-bd70-011cade54bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_256649c5-8e45-4068-8aa6-ad421fab284e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36405d1a-eac1-4ce1-b4cb-afa5968fd07b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_256649c5-8e45-4068-8aa6-ad421fab284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebc71a1c-9fcb-41e7-bfb8-7d792b3778aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebc71a1c-9fcb-41e7-bfb8-7d792b3778aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_641b7501-a397-4445-93a4-2f6a11924c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_641b7501-a397-4445-93a4-2f6a11924c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c260afe-5970-49d4-b4a5-d0f76dbb6627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c260afe-5970-49d4-b4a5-d0f76dbb6627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eb051b4-66eb-4494-be0b-b45ce57fa14c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ee2d54f9-f6f6-48b7-ac76-143303a7f3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ee2d54f9-f6f6-48b7-ac76-143303a7f3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5fdd6e00-c813-4146-8ace-3292e1a006f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5fdd6e00-c813-4146-8ace-3292e1a006f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b89f37b2-6a11-4f48-852b-26f8d404a16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:to="loc_us-gaap_InterestPaidNet_b89f37b2-6a11-4f48-852b-26f8d404a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a2a62762-141d-46b5-9ab7-9198fd49448e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b776511c-18cc-46fe-9e61-dc0809af845d" xlink:to="loc_us-gaap_IncomeTaxesPaid_a2a62762-141d-46b5-9ab7-9198fd49448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20210930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6f94554d-acd6-4b51-a2e8-dcf897494576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_139cf4ef-d33f-4c34-a24a-316394653dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f94554d-acd6-4b51-a2e8-dcf897494576" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_139cf4ef-d33f-4c34-a24a-316394653dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20210930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00da87d7-2aa4-4a75-a71d-3c5c3724194b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyTextBlock_4749c052-75f9-4a96-a74c-2815902126b4" xlink:href="nbix-20210930.xsd#nbix_BusinessDescriptionPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00da87d7-2aa4-4a75-a71d-3c5c3724194b" xlink:to="loc_nbix_BusinessDescriptionPolicyTextBlock_4749c052-75f9-4a96-a74c-2815902126b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_868b8f9b-0bc3-4af1-9b3b-c2600dc193e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00da87d7-2aa4-4a75-a71d-3c5c3724194b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_868b8f9b-0bc3-4af1-9b3b-c2600dc193e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1ac053f8-8add-4ca2-b251-d798b39b470c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00da87d7-2aa4-4a75-a71d-3c5c3724194b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1ac053f8-8add-4ca2-b251-d798b39b470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0e696c57-5eac-4ae7-93ef-6e1cfaf1b0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00da87d7-2aa4-4a75-a71d-3c5c3724194b" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0e696c57-5eac-4ae7-93ef-6e1cfaf1b0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f7ac310-6006-456d-a2eb-61669d888272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries_8ee51298-5792-425b-aa8f-fa7eb3141a9f" xlink:href="nbix-20210930.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f7ac310-6006-456d-a2eb-61669d888272" xlink:to="loc_nbix_NumberOfIrishSubsidiaries_8ee51298-5792-425b-aa8f-fa7eb3141a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="simple" xlink:href="nbix-20210930.xsd#SignificantCollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ed6fb0f4-1a1e-4d2f-9081-ffa8b974801c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_398bf663-ca26-4e77-9408-302d3037f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ed6fb0f4-1a1e-4d2f-9081-ffa8b974801c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_398bf663-ca26-4e77-9408-302d3037f4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a68ff845-d669-469d-ada3-f5ad0b8bda24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a68ff845-d669-469d-ada3-f5ad0b8bda24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8022eac4-a8b5-4a79-932c-ba51e9fd1776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8843c75b-e885-44f1-968a-12ff4943d309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3825f347-e670-496c-8f05-0509e1f46749" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8843c75b-e885-44f1-968a-12ff4943d309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad4345a7-6c9e-4e61-81c6-0022603fbda9" xlink:to="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_586e7bdf-51c8-46aa-b66a-14956116b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:to="loc_us-gaap_LicenseMember_586e7bdf-51c8-46aa-b66a-14956116b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_49e232f8-e01e-4689-9058-612ea5ae6c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bf19452-5707-4c6f-a002-ad5a58a609c9" xlink:to="loc_us-gaap_RoyaltyMember_49e232f8-e01e-4689-9058-612ea5ae6c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_caa6dc93-ac86-445b-a0b5-ca765e200bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d788f857-6024-459f-84e5-1bba77c1144a" xlink:href="nbix-20210930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d788f857-6024-459f-84e5-1bba77c1144a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_93d48d5f-e82a-42ae-be5e-cc845a2bce82" xlink:href="nbix-20210930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_93d48d5f-e82a-42ae-be5e-cc845a2bce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_5ae9f172-1987-4a4f-9be7-d345113dda3a" xlink:href="nbix-20210930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_5ae9f172-1987-4a4f-9be7-d345113dda3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsIncMember_6979a830-9d76-413b-9946-90596739dee7" xlink:href="nbix-20210930.xsd#nbix_VoyagerTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_VoyagerTherapeuticsIncMember_6979a830-9d76-413b-9946-90596739dee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_1ad82741-4671-4143-b329-437474f3c719" xlink:href="nbix-20210930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_BIALPortelaCaSAMember_1ad82741-4671-4143-b329-437474f3c719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_1e82615f-ca62-4c85-8de7-d697fc7d6fa2" xlink:href="nbix-20210930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_1e82615f-ca62-4c85-8de7-d697fc7d6fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_88f6bf8e-fc30-4137-80d5-5d12e0598b93" xlink:href="nbix-20210930.xsd#nbix_AbbVieIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bc85638-6f8c-47b5-884d-6801cd22a0ef" xlink:to="loc_nbix_AbbVieIncMember_88f6bf8e-fc30-4137-80d5-5d12e0598b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8f27734-e9dc-4f4f-9670-0058a5265fa2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_f1dce5d0-c063-4e6d-bd9f-7e6bd8a69187" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PotentialMilestonePayments_f1dce5d0-c063-4e6d-bd9f-7e6bd8a69187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_7142b4f0-7b3c-4296-b447-3e303536fc8a" xlink:href="nbix-20210930.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_MilestonePayment_7142b4f0-7b3c-4296-b447-3e303536fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8c8733a0-dedf-4f1b-94c0-f4d60e76790d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8c8733a0-dedf-4f1b-94c0-f4d60e76790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_a9f6f1d9-2016-41e9-bca0-63cb33494cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_a9f6f1d9-2016-41e9-bca0-63cb33494cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_1bfdd391-4063-482c-b165-9d3aae863455" xlink:href="nbix-20210930.xsd#nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice_1bfdd391-4063-482c-b165-9d3aae863455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestoneEquityPurchasePayment_70c8d76b-4767-4013-86a9-38b21142b519" xlink:href="nbix-20210930.xsd#nbix_MilestoneEquityPurchasePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_MilestoneEquityPurchasePayment_70c8d76b-4767-4013-86a9-38b21142b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_5915af01-981c-45ce-a0f2-8c943c80e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_5915af01-981c-45ce-a0f2-8c943c80e2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PremiumPaidForEquityPurchase_804ea488-1d1d-4024-938f-588ceace871d" xlink:href="nbix-20210930.xsd#nbix_PremiumPaidForEquityPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PremiumPaidForEquityPurchase_804ea488-1d1d-4024-938f-588ceace871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_e82c11cd-8465-439b-b454-903c9e94d1ae" xlink:href="nbix-20210930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_e82c11cd-8465-439b-b454-903c9e94d1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b94f02d0-ac37-48f6-8eef-2782997ae2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b94f02d0-ac37-48f6-8eef-2782997ae2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7050bcb2-72b2-49c0-9ca2-894abb724525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7050bcb2-72b2-49c0-9ca2-894abb724525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e1c35bfa-07a3-41fa-8c8f-c3cd3747091c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69978ec2-717a-4ef9-8f50-9fc20376a633" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e1c35bfa-07a3-41fa-8c8f-c3cd3747091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ca3c1ad-eeb1-42e8-92aa-6f6f823e1134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0735612b-fa5f-4dac-be16-3f59277d8d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ca3c1ad-eeb1-42e8-92aa-6f6f823e1134" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0735612b-fa5f-4dac-be16-3f59277d8d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68fdb16d-fb48-4954-b5d6-9df644bba948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8ce02d1d-d699-454b-b0e5-4c3519d6687d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68fdb16d-fb48-4954-b5d6-9df644bba948" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8ce02d1d-d699-454b-b0e5-4c3519d6687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_adcb140d-b448-4ac0-83e5-5d15aa58fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68fdb16d-fb48-4954-b5d6-9df644bba948" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_adcb140d-b448-4ac0-83e5-5d15aa58fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eb5e42ee-9857-4557-9151-3d9ac945eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eb5e42ee-9857-4557-9151-3d9ac945eef8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_04a126cb-3ff9-45b4-84b3-166819398c8a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_b6dc999c-b64b-488b-b80c-a7460aee9338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_b6dc999c-b64b-488b-b80c-a7460aee9338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_af663e8d-6b42-4598-8da5-7bf90a1832f9" xlink:href="nbix-20210930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4ff6c05-6c82-4dbf-aff3-000c1236158c" xlink:to="loc_nbix_LongTermInvestmentsMember_af663e8d-6b42-4598-8da5-7bf90a1832f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8de27b7f-a098-43d1-8ed6-9ffb5729b329" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_04a645f9-562c-402c-a48b-153e8e9af47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8adaa350-fac0-4cac-8692-359a5f0e9e15" xlink:to="loc_us-gaap_CommercialPaperMember_04a645f9-562c-402c-a48b-153e8e9af47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c3fda4c-62d2-4c15-9f16-f67dd261274f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_30065f46-c42d-4891-b428-f18a0b0be3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_30065f46-c42d-4891-b428-f18a0b0be3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b43c8ed7-614c-4abb-88bf-70d8776a8c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b751de4d-a4b4-4ecf-a5d2-8c743180665a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b43c8ed7-614c-4abb-88bf-70d8776a8c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a070e10-2926-4de2-8a0c-c8bb600c03df" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55787fa3-3400-4157-bf56-0298c5d18897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55787fa3-3400-4157-bf56-0298c5d18897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c2808da-a9ce-4868-837b-5a5c9b06b645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c2808da-a9ce-4868-837b-5a5c9b06b645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e282dfc1-3d9d-4f81-8f76-c1e3641ae1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e282dfc1-3d9d-4f81-8f76-c1e3641ae1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08a7ae0f-e8e7-425c-ad31-b9f82f63eb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_596a9cb2-c942-43b8-bf3c-9a7a1d706434" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08a7ae0f-e8e7-425c-ad31-b9f82f63eb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824bef29-762f-49a0-8c82-47caf73c6282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_49d0e9e2-085c-47dc-8b46-dbcfc417df20" xlink:href="nbix-20210930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824bef29-762f-49a0-8c82-47caf73c6282" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_49d0e9e2-085c-47dc-8b46-dbcfc417df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_47ab34f5-14cc-4844-ae6b-fe8a82580590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824bef29-762f-49a0-8c82-47caf73c6282" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_47ab34f5-14cc-4844-ae6b-fe8a82580590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_eb5d045d-49d3-41b8-b0b0-57d293987370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824bef29-762f-49a0-8c82-47caf73c6282" xlink:to="loc_us-gaap_InterestReceivableCurrent_eb5d045d-49d3-41b8-b0b0-57d293987370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_1a7f2bad-0dba-459c-bd04-070abeada623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824bef29-762f-49a0-8c82-47caf73c6282" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_1a7f2bad-0dba-459c-bd04-070abeada623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_04cc7ede-e45f-4db1-a086-6a2180e4e729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_04cc7ede-e45f-4db1-a086-6a2180e4e729" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4e031b6-f9b6-4484-be3e-64132dbaa67f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d7ccc22-6d47-4139-86b3-5f2049a6d603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d7ccc22-6d47-4139-86b3-5f2049a6d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c9cc22a5-ade9-478d-99bb-f043a283aa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71c6c10f-9a53-4dd3-b02f-e2db1915326e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c9cc22a5-ade9-478d-99bb-f043a283aa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_13a3a480-9837-4650-afc5-f5e8e2aa6267" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bb9710bb-c228-4d37-936a-61b4d5c45a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bb9710bb-c228-4d37-936a-61b4d5c45a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_bece1e2f-3b9d-4a43-a837-b2e0b987c410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25178388-481e-4325-9c81-f1be6789bc60" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_bece1e2f-3b9d-4a43-a837-b2e0b987c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5879ee22-d169-4eab-beb0-656ba5533623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bd221b73-b168-4d4f-a936-dbb702f84d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5879ee22-d169-4eab-beb0-656ba5533623" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bd221b73-b168-4d4f-a936-dbb702f84d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_015cba21-2fa5-467d-b215-327a7c3870b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7da81558-d33e-4ec4-b527-95e25a1726d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_015cba21-2fa5-467d-b215-327a7c3870b2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7da81558-d33e-4ec4-b527-95e25a1726d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff777e4f-b1c4-441d-ad85-5abfd0b9cf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_015cba21-2fa5-467d-b215-327a7c3870b2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff777e4f-b1c4-441d-ad85-5abfd0b9cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_98c38e97-713f-4bba-8e9a-6f3cdbd5ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_98c38e97-713f-4bba-8e9a-6f3cdbd5ab50" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb040ba8-2dda-45a0-8ed5-226d47cbfc8c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_8fd1f120-17a1-4162-8f02-b95cab9f17e2" xlink:href="nbix-20210930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_8fd1f120-17a1-4162-8f02-b95cab9f17e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f1363f4a-9b0c-4a7b-8a8f-aa5d16dd7d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f1363f4a-9b0c-4a7b-8a8f-aa5d16dd7d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_52f07a93-506e-40f4-ada6-da01112d27db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe788162-aba1-46e8-ad99-befb70c81a9f" xlink:to="loc_us-gaap_CommercialPaperMember_52f07a93-506e-40f4-ada6-da01112d27db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_933f8ac5-edbe-4701-b1b8-8f2c21199ff7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ddb30ac6-6243-4097-8217-259953982339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ddb30ac6-6243-4097-8217-259953982339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8758fc8e-b308-4d93-96bc-77a86e374b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8758fc8e-b308-4d93-96bc-77a86e374b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d5508094-9b71-43ee-bf27-68a79156ab52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1f8b01-6d74-4cd6-ba8d-778c5d1e3f66" xlink:to="loc_us-gaap_EquitySecuritiesMember_d5508094-9b71-43ee-bf27-68a79156ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a711955d-4e7f-4999-ba78-6c6ea13de698" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9fe458e7-a178-4477-9ad0-4beede446d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9fe458e7-a178-4477-9ad0-4beede446d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_40feeb51-0962-480f-99f0-1a5e0c8f3306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_40feeb51-0962-480f-99f0-1a5e0c8f3306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b2e717b-490a-4904-990d-47ada594ac38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d04e99-456e-4c0c-b425-313f6bb46a6d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b2e717b-490a-4904-990d-47ada594ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e57b2415-a095-4641-bbc9-c909ddc03523" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6795402f-f453-4402-af11-58a48e24a2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7e6574c-6505-4030-8ddc-6874f5dc8654" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6795402f-f453-4402-af11-58a48e24a2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0741000f-f3fa-4527-bb44-c216679ceb30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_b5fc2b18-db1e-4de2-bdb9-073e2d015ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:to="loc_us-gaap_Investments_b5fc2b18-db1e-4de2-bdb9-073e2d015ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47e2cb00-f09f-49bf-9df8-19edccf1f061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0cf740d-08cf-4949-bd92-017a4cd6229c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47e2cb00-f09f-49bf-9df8-19edccf1f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6d9dd90-6692-48f7-a051-ceaaffca09c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6d9dd90-6692-48f7-a051-ceaaffca09c9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_52ebb45a-3fae-4945-903d-b7fa931142d6" xlink:to="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a46d7bd4-b1f1-454f-80d5-ccafca9222da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_8ede2c7f-6c74-4826-b563-26100768de7b" xlink:to="loc_us-gaap_EquitySecuritiesMember_a46d7bd4-b1f1-454f-80d5-ccafca9222da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d268cac-838c-4fa8-b55c-10784d0c34a0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4657aa55-37a6-45df-bad3-adec1a29704e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2615c09c-75a6-4f8a-92cb-f34cdc17f55b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4657aa55-37a6-45df-bad3-adec1a29704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0bdb330-4f9a-4e63-926a-24f3b35a1058" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f2d97bbe-712c-48bf-8fb5-7455bcc7f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a28b4e9-e6e7-49a3-bf74-fa38f2804d3e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f2d97bbe-712c-48bf-8fb5-7455bcc7f60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0a9972b0-5a75-4512-86e2-df0736a34660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_aa9a26fd-d307-47bc-aaf3-f98c17bf0378" xlink:href="nbix-20210930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ca69bf-adc7-41ec-88e0-7c85e72837e8" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_aa9a26fd-d307-47bc-aaf3-f98c17bf0378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9c9e24-9dff-4578-87c3-887dcc6b4812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_bbdd889a-59ac-44f2-801d-bd11ebf9b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55df33ec-1ed1-43ef-b2da-45bb45d8f8e6" xlink:to="loc_us-gaap_CollaborativeArrangementMember_bbdd889a-59ac-44f2-801d-bd11ebf9b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71a93659-ff6e-49cf-b398-e52afe8d63a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40723c56-855a-4d4e-b852-da7059c76424" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_912c8cc3-80fb-47b5-86af-e7dde6cff14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_912c8cc3-80fb-47b5-86af-e7dde6cff14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_b5353cb7-36cc-4f3a-82f1-c912f0ab14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_b5353cb7-36cc-4f3a-82f1-c912f0ab14d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e277ed7-dbda-411e-941c-e4235582ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e277ed7-dbda-411e-941c-e4235582ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_c9e530dd-8934-4429-a0e4-7460782cc702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_c9e530dd-8934-4429-a0e4-7460782cc702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_7702db19-47cf-461b-971a-88aea146b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_0e25cd34-d324-4756-8482-c1eb889796dd" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_7702db19-47cf-461b-971a-88aea146b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32004d24-2d0e-4dfb-b006-38f644edbef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32004d24-2d0e-4dfb-b006-38f644edbef6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b564f092-795c-40fb-a6be-af28c2d839ee" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_25f855b8-4279-4cfc-bb11-ded68cac246b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_826b8594-391c-4add-86cf-3ed26810fc77" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_25f855b8-4279-4cfc-bb11-ded68cac246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:to="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_51f13832-7303-4fda-b9c2-417324b821e8" xlink:to="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb642c20-9053-4fde-bcf2-7886beb5c0aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_MinimumMember_bb642c20-9053-4fde-bcf2-7886beb5c0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7106f09c-743b-44b2-9c66-0e0f597e58b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_MaximumMember_7106f09c-743b-44b2-9c66-0e0f597e58b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cb036dea-151f-48a8-a929-ef02cb7eaf3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90d623dd-f43d-4e34-9127-a2a3fad28e2e" xlink:to="loc_srt_WeightedAverageMember_cb036dea-151f-48a8-a929-ef02cb7eaf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5e9cbcad-c4ce-43a9-ba4a-77c0d73038db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_76b2e0c8-22e1-48fd-8b90-0648f6ec04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a7683d4e-3895-42bb-8cf2-91d88967e063" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_76b2e0c8-22e1-48fd-8b90-0648f6ec04b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20210930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_66e3a9dc-3fb2-45c6-bf1c-a1b564d22988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3b182494-fb24-4cbe-a719-89a75ccb7e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_66e3a9dc-3fb2-45c6-bf1c-a1b564d22988" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_3b182494-fb24-4cbe-a719-89a75ccb7e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2dc992d5-f6cb-4559-8753-9d7d0fcc3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ba9fefc0-815f-4bc1-806c-9f4e2caeeab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2dc992d5-f6cb-4559-8753-9d7d0fcc3bd8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ba9fefc0-815f-4bc1-806c-9f4e2caeeab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#InventoriesSummaryofInventoriesDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b29e61f1-9bb5-4d2a-b689-d83e03c7fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b1cbd2c9-9527-4d5f-bcb2-674ac01f9f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b29e61f1-9bb5-4d2a-b689-d83e03c7fb69" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b1cbd2c9-9527-4d5f-bcb2-674ac01f9f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e4c63b96-15cb-4c44-9ffb-5460b8362205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b29e61f1-9bb5-4d2a-b689-d83e03c7fb69" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e4c63b96-15cb-4c44-9ffb-5460b8362205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b1a70896-74fd-4927-8a37-ecca2cb60119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b29e61f1-9bb5-4d2a-b689-d83e03c7fb69" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b1a70896-74fd-4927-8a37-ecca2cb60119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e6aa3a00-3546-4cc9-9bf7-f9e3a93b771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b29e61f1-9bb5-4d2a-b689-d83e03c7fb69" xlink:to="loc_us-gaap_InventoryNet_e6aa3a00-3546-4cc9-9bf7-f9e3a93b771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20210930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c744d6e-879a-45f2-88a8-743618250e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock_a79afaa4-0a49-4dd1-ad5f-7163dd15ef75" xlink:href="nbix-20210930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c744d6e-879a-45f2-88a8-743618250e6a" xlink:to="loc_nbix_RestrictedCashTextBlock_a79afaa4-0a49-4dd1-ad5f-7163dd15ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_35296661-8aa2-44c3-8b77-3a5a5212b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_7eae9169-4334-49ac-8aff-10fac520625b" xlink:href="nbix-20210930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_35296661-8aa2-44c3-8b77-3a5a5212b26c" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_7eae9169-4334-49ac-8aff-10fac520625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_afb8cc14-4c0d-4dee-ba30-f7f32cb123b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_558f125f-0a84-490f-9529-dd446129d71e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_afb8cc14-4c0d-4dee-ba30-f7f32cb123b8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_558f125f-0a84-490f-9529-dd446129d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_28d5cd5d-b75c-4edc-a42e-94df55e08948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_afb8cc14-4c0d-4dee-ba30-f7f32cb123b8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_28d5cd5d-b75c-4edc-a42e-94df55e08948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3677dbde-3e25-4aea-a8c3-a8d9f65c3d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_afb8cc14-4c0d-4dee-ba30-f7f32cb123b8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3677dbde-3e25-4aea-a8c3-a8d9f65c3d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_724bd1cf-a5e3-41f7-b15a-ff5f6b77e2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fc02620c-4612-4b0a-87ed-083038d8f9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_724bd1cf-a5e3-41f7-b15a-ff5f6b77e2c4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fc02620c-4612-4b0a-87ed-083038d8f9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e9ced654-bc15-483e-9902-61be2d0f2c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9e5a6276-2c39-4b90-83a6-b2493e6e149f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e9ced654-bc15-483e-9902-61be2d0f2c1f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9e5a6276-2c39-4b90-83a6-b2493e6e149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e977300-ebbb-4039-85a6-da344de990b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e9ced654-bc15-483e-9902-61be2d0f2c1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e977300-ebbb-4039-85a6-da344de990b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesNarrativeInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cfbb1e2c-c626-4f0f-b967-99efaf8e8070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0e24662d-fcb4-4686-9fa7-2dd7e82ef6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfbb1e2c-c626-4f0f-b967-99efaf8e8070" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0e24662d-fcb4-4686-9fa7-2dd7e82ef6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesSupplementalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_082306ea-430d-4fa4-ac52-aec687761f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_82e8f472-4b68-4050-b0a2-9a08f8820cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_082306ea-430d-4fa4-ac52-aec687761f4d" xlink:to="loc_us-gaap_OperatingLeaseCost_82e8f472-4b68-4050-b0a2-9a08f8820cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5402d49c-673c-4265-9d5f-2d70c6f0549a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_082306ea-430d-4fa4-ac52-aec687761f4d" xlink:to="loc_us-gaap_OperatingLeasePayments_5402d49c-673c-4265-9d5f-2d70c6f0549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_636b2b42-44b0-4bfb-a85d-136836cbc913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_082306ea-430d-4fa4-ac52-aec687761f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_636b2b42-44b0-4bfb-a85d-136836cbc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4cdf3d77-a659-4a6f-a22f-a3e91971669a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_082306ea-430d-4fa4-ac52-aec687761f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4cdf3d77-a659-4a6f-a22f-a3e91971669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesLiabilityPaymentDueDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2a3a97ef-29f0-44c3-ac65-4fae269fec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2a3a97ef-29f0-44c3-ac65-4fae269fec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_67394c02-e616-4213-9ce6-c6bcac352cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_67394c02-e616-4213-9ce6-c6bcac352cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce4d7e77-f3c6-428d-a681-65e318efd027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce4d7e77-f3c6-428d-a681-65e318efd027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_05913249-4e87-47b8-97b6-43d136142f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_05913249-4e87-47b8-97b6-43d136142f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1e52759d-f01b-4daa-8116-8f8f19795764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1e52759d-f01b-4daa-8116-8f8f19795764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_6eb6d8c6-490d-4fcf-bd96-b3cc20a9eb0a" xlink:href="nbix-20210930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_6eb6d8c6-490d-4fcf-bd96-b3cc20a9eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48a219f5-0ddc-48a9-b4fe-4218d32c70bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48a219f5-0ddc-48a9-b4fe-4218d32c70bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e1e6de2-2832-41b4-addd-d4399708ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e1e6de2-2832-41b4-addd-d4399708ad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37423fbf-9bb7-4c90-8cbf-532aa75d0983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_OperatingLeaseLiability_37423fbf-9bb7-4c90-8cbf-532aa75d0983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_59895a74-64d7-4856-a199-b7c20eaa11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_59895a74-64d7-4856-a199-b7c20eaa11ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07287a64-8f49-4113-8b42-6ae5ae46964a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b6d239-b7bf-4295-93b3-70bbf00aad01" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07287a64-8f49-4113-8b42-6ae5ae46964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="simple" xlink:href="nbix-20210930.xsd#LeasesLiabilityPaymentDueDetail_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e5388173-9f10-400c-964b-52e0d7698625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a26ab428-56f3-4831-8a2d-40875289a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5388173-9f10-400c-964b-52e0d7698625" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a26ab428-56f3-4831-8a2d-40875289a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d17bb89c-6322-4426-9eba-108232bb0101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7483d04e-c44c-4802-9a0b-c5be5d7d7950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d17bb89c-6322-4426-9eba-108232bb0101" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7483d04e-c44c-4802-9a0b-c5be5d7d7950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_935d0a59-0f0b-4f07-9d10-d155c695cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_935d0a59-0f0b-4f07-9d10-d155c695cd7e" xlink:to="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e7d5561-5791-46e8-ad3d-a2462df1d261" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_ec2a1776-35b2-420a-ae91-f1d296ec46a2" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d278bb31-b0ec-4883-b7bf-1c99e15f0d99" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_ec2a1776-35b2-420a-ae91-f1d296ec46a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef4ac9fc-cd14-4da5-952f-cd4ae061fb3c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b544cba8-1f79-441e-a888-b093c5b55632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b544cba8-1f79-441e-a888-b093c5b55632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_089b54c0-9595-46b7-a6b0-40c2587710c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_089b54c0-9595-46b7-a6b0-40c2587710c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_47c115a2-1f59-452a-8d87-192f4319de78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_RepaymentsOfDebt_47c115a2-1f59-452a-8d87-192f4319de78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f09845d3-d3dd-40d8-bd13-7fc3d2dd6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f09845d3-d3dd-40d8-bd13-7fc3d2dd6c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_5e9892a4-d9bc-476d-aacc-ac91af6d7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_5e9892a4-d9bc-476d-aacc-ac91af6d7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_073c3692-16f3-4b3d-965e-ac97abfdb2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_073c3692-16f3-4b3d-965e-ac97abfdb2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_320740c9-c7b5-49e1-bb14-07dd51960fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_320740c9-c7b5-49e1-bb14-07dd51960fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays_1ac8f0be-e211-468b-9111-24645a1acbb9" xlink:href="nbix-20210930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_NumberOfConsecutiveBusinessDays_1ac8f0be-e211-468b-9111-24645a1acbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_6d65841c-4d06-4cd5-84d5-32f5cde75a59" xlink:href="nbix-20210930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_6d65841c-4d06-4cd5-84d5-32f5cde75a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_a7475d91-529b-4d7b-8853-12b5979dfae9" xlink:href="nbix-20210930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_a7475d91-529b-4d7b-8853-12b5979dfae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_6b32758d-a7bf-447d-9403-c485fa700fb7" xlink:href="nbix-20210930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtConversionObservationPeriod_6b32758d-a7bf-447d-9403-c485fa700fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fac06e2c-c9d2-4733-bada-6a6d055ea88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fac06e2c-c9d2-4733-bada-6a6d055ea88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_04d12f16-0867-4752-8630-26e17e843cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_04d12f16-0867-4752-8630-26e17e843cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc8af418-2fbb-4a7d-89c6-481609498350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc8af418-2fbb-4a7d-89c6-481609498350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_32186271-ac71-46b3-a63e-4b034332ca96" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_32186271-ac71-46b3-a63e-4b034332ca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84d405b3-a216-4b26-a8ab-2b73f51f8940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_SharePrice_84d405b3-a216-4b26-a8ab-2b73f51f8940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4975484a-aec7-4664-bac0-89e9c2bee288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4975484a-aec7-4664-bac0-89e9c2bee288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_a0bc4721-5879-46f4-811c-531f80bd00e1" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_a0bc4721-5879-46f4-811c-531f80bd00e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_2230b408-ad48-42df-8c03-31c345c4f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_2230b408-ad48-42df-8c03-31c345c4f3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0b7c1b0d-3650-4442-900a-09f87a226e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0b7c1b0d-3650-4442-900a-09f87a226e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_30872b2e-3ec9-4469-a347-6e77ea2ccd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentTerm_30872b2e-3ec9-4469-a347-6e77ea2ccd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_dd9db0c4-6eac-46d1-8ce2-060a1a58fc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_dd9db0c4-6eac-46d1-8ce2-060a1a58fc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f4bb2b28-7492-4b43-a7c4-64b3ec448226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f4bb2b28-7492-4b43-a7c4-64b3ec448226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_742001b1-f169-440d-8b9a-17edcfc06011" xlink:href="nbix-20210930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_742001b1-f169-440d-8b9a-17edcfc06011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f80f7303-6d91-46d1-9cca-e24d3673a241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c1cb33ed-de24-4eab-a246-be3c8d927865" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f80f7303-6d91-46d1-9cca-e24d3673a241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6a087667-54d5-4240-9e6f-0fe591c6b641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11fad04a-ab12-48e9-afc4-b3586be0e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a087667-54d5-4240-9e6f-0fe591c6b641" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11fad04a-ab12-48e9-afc4-b3586be0e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e45271bd-25a7-40d3-83ba-9bb57e4dfbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a087667-54d5-4240-9e6f-0fe591c6b641" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e45271bd-25a7-40d3-83ba-9bb57e4dfbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_7234877e-3d68-4fba-a50c-d8055a752507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a087667-54d5-4240-9e6f-0fe591c6b641" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_7234877e-3d68-4fba-a50c-d8055a752507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_d9cf1b57-cec6-46d2-9ccb-510a80fd5a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a087667-54d5-4240-9e6f-0fe591c6b641" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_d9cf1b57-cec6-46d2-9ccb-510a80fd5a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_61e3668c-ac77-4ef7-bfcd-bd71d677d077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_711a1402-caa1-4ee4-9fd0-3d57f8412a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_61e3668c-ac77-4ef7-bfcd-bd71d677d077" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_711a1402-caa1-4ee4-9fd0-3d57f8412a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1e45c508-e57e-4b6f-84c0-98be9b4a0768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_307f9f6d-d788-4cf7-a87f-87848dbc6b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1e45c508-e57e-4b6f-84c0-98be9b4a0768" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_307f9f6d-d788-4cf7-a87f-87848dbc6b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c1f47e6e-5871-48ff-aa84-29b7fb76d322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1f47e6e-5871-48ff-aa84-29b7fb76d322" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3dd6c61e-8519-447f-a4e5-2b0c4e327035" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fba2af2c-d3df-43c3-a903-b3cfcd39334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fba2af2c-d3df-43c3-a903-b3cfcd39334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0fea2688-31e4-489c-9e9f-d888b717c361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d22a958f-85bf-4d32-a42f-521bd22ac2b6" xlink:to="loc_us-gaap_RestrictedStockMember_0fea2688-31e4-489c-9e9f-d888b717c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:to="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_10c51fb7-59d7-48e7-8e8f-db6f4d5b95bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_d3d5d088-21bd-405d-8645-2ab03105cb92" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7bd5077-9f37-4f87-a09f-95f5e4a07021" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_d3d5d088-21bd-405d-8645-2ab03105cb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_81966ed7-2595-4d33-89a7-75c03c936ac8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ae7aafa-e32d-4b06-9a56-41ff7846ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_NetIncomeLoss_1ae7aafa-e32d-4b06-9a56-41ff7846ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f582db46-6af6-4b7c-8486-3f40b33abd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee1d953d-5ee8-4f80-a8a0-a790b549a574" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f582db46-6af6-4b7c-8486-3f40b33abd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86b0cbea-9246-4356-a0a4-9bba8cbc06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86b0cbea-9246-4356-a0a4-9bba8cbc06d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_d580a2fa-271a-4cab-b29f-baed74a19da2" xlink:href="nbix-20210930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_d580a2fa-271a-4cab-b29f-baed74a19da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5445054-8d3b-413b-94af-ca18d89c0c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_9bf0dc96-a881-434c-a804-c4f019574853" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5445054-8d3b-413b-94af-ca18d89c0c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_80c5704a-2edc-4243-a309-a94f2c6b601e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:to="loc_us-gaap_EarningsPerShareBasic_80c5704a-2edc-4243-a309-a94f2c6b601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_460cde6a-b6ae-4fab-9248-fd93b2d880c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7040dc38-0149-4e5b-b349-2602edbd7d23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_460cde6a-b6ae-4fab-9248-fd93b2d880c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0985c33-3ef4-4b30-9200-3ddca4a274f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_814e536a-b270-4409-b21f-9ca65f6fff43" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0985c33-3ef4-4b30-9200-3ddca4a274f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20210930.xsd#NetIncomeLossPerShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_648eedd4-57e8-43ba-ade7-fbe411d69872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_648eedd4-57e8-43ba-ade7-fbe411d69872" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:to="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0f92f6bf-470f-4ecc-968f-5297ee44f609" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_3cfffc1e-1013-4dd2-ac52-30406526f248" xlink:href="nbix-20210930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74afa436-ddfd-4b77-8e11-df7b0684c13d" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_3cfffc1e-1013-4dd2-ac52-30406526f248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_537ab516-068e-4c76-a537-fd6b84b42a6c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3c0b1571-31a8-4094-8c10-09c4a1e2f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc54ecc4-413c-4e6e-95ad-72796851164b" xlink:to="loc_us-gaap_RestrictedStockMember_3c0b1571-31a8-4094-8c10-09c4a1e2f6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0ebb6cf8-7614-4fde-80e4-248fe84904fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2c253654-67d1-4b30-9be3-d8269ec16555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2c253654-67d1-4b30-9be3-d8269ec16555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe93e64a-aba0-4c8c-97c9-c6f45b72a352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe93e64a-aba0-4c8c-97c9-c6f45b72a352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019050f7-4beb-4f24-a1fc-750b50878e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd38bf14-981d-4699-82f8-88d438440959" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019050f7-4beb-4f24-a1fc-750b50878e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LegalProceedings" xlink:type="simple" xlink:href="nbix-20210930.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f85a3a41-bc7f-4ab0-a2c8-9b3c4381ffac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1daeffa5-b5bb-4e52-96f1-17077bee4a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f85a3a41-bc7f-4ab0-a2c8-9b3c4381ffac" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1daeffa5-b5bb-4e52-96f1-17077bee4a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>nbix-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20210930.xsd" xlink:type="simple"/>
    <context id="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib35f220670e34eec87e5afe4a89f609d_I20211027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-10-27</instant>
        </period>
    </context>
    <context id="if1fdb74440ee42898adbdc8492008e0f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc60fd6179844c8db173a8451d9462a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebf2d8484c7e496bae6f2a07d1b08068_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10ee034471ac4db29f78d7b85eb9dc6e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62082aae9f3941b69d20896eba9b0249_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i57aa7170627244b08601ddb3bf8c9dff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9ed90fc09e974862855048eb200b7e28_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9101b3965a264dc9a0dfee26e4674bae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c5ccd37651e4b678f8252d2497c8369_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9049c0b86b004f30bf4a1ce3cc512077_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i577826782de04321b0effe68b8ac13b2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7803f4c249304f20b4bb0eb8494c2e78_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i754e2b2ae83143ee834e836dd3561f1d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i50142418015f4e47be8aea7229195794_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibb552e33928d4ba2b771f17e9907962a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i26f84bfaa23a48129fc63d149d061b27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c540dc7784a4d6f8d16ff59c05b0b06_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ea2954b9ed8422aa402be311593fa3c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90699ef320ca4ebeb28f38adba5ef805_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9279c8400ef148e1866482b1844adf56_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib5888ff562cf4ba088c5483009e844d7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b123f12d63242b189e51114c701eaf5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8ecddd8f9d5f42dc94c8e2a220f3593a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2a4aa44ca0d044e0a8ec596fca98e7e9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie20178cc9ddf43b4a388c72ac34c2134_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84f9ecb01ca24fbbb38c14c687ebaf91_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i851ba2fafa2f450990491164330f743d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e8c778aad0f4e7f8fa77b3cc9856b9b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i302b1afa8146416aab065909274c7758_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a08b99dfb094c0b91dfe34866290261_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i81bb07b5918e4f64bee6b674512d700e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie5d7325982b647798c3a49c812ccaa00_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia15bb181a93e44b49456802a3f4a8de4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9f76fb77b1f542479312b2aff85aaf3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e0c38cd3765417695f32be58389944a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i046db428318141819987db76bcbb0b60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41785e12188b4d7889ba7b5f21da1623_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c9298bbb4994683a1431a64d26acfef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide770c7feabe4bcd8899467eab2993a4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i421486e0786f480d81e599f2028fb590_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2eeef242bbcc4ec59c2143f1f656c851_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96a678a1180e4c3caa98573b5cd8f7a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3497105df4834dc893428a1a5d881960_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i552dcda95f844a11b769f02470f057fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c4ca114f2d34a558af3a50593c0e518_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i206634836d714da8902b9e165f6fd187_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i421dcee8358442bfb35f87eaafbdae1b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i933021bd48984449911c135ddeafa918_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib684ec080b3a48bb93b07be4df5e2401_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffcf257f1217481a8a1fa04d4a631d43_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie3315e9d2376463bb766c7fda4822a57_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3cc897ab39e04a5aaf3979ecf0b1aaf3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8ce6a674873848c2bf34283197bc4a5f_I20210908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="i7496225d981e45bd95c16039fcf4c975_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i22958d29fbc4450c825ab099cc2474a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia3408f9286a74ad69f879196398aa1cf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9430cff5e9084463bd1354a6bbc4c537_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e55bf4fc19f4fdab09c36ac40b354de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if448122914d649afac62b3524714a81a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i189642a059634ad084c64f09713076dc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08986f72f2a14760851809292bbcdfa6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08163ab015c545f98f6b59567476ccf0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1b114e2d031e4c17872a49ed97a20e50_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic89aa56e595949039d1c9644bf3f36ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0120fe55568d4fc3a5928407baa25b60_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie87e020d0a114fa4b7c4e0660e4c28b6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71e54f0d818448efa8b57b22dab1f6ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9c0708e1e4554808a818ec7f02b33d99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cfab6fa72f8484d9159ecc553820eb1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i187553e4d84849859e9761bba613da29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fa625e3b7b743ae8108fe2498a46588_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icfe511c7bc1040d8bc7d4c231d784b01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e78a0ca3aae402794034bc5f1c455d0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5f340ad37bb64e67aa595f0848a1db28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if43744412019486abe9d453fb54846d3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifc95789714e54acfb4a0507993443712_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i02b450fe3b5341978f085deda2bc6161_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1dcd5486d1340bfa8e720e23609396b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3bf2e3d38fff4af1a6188647ded1558b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica52a652db094241b061229da784c22f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i94fb858a78824577ab6b7073295d027f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i157b928b65e741d6b3db895524a44b01_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0d140b31a337457eacc3647d03f3f97f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29c5af590cb04d4092677c5129d1e809_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i671519a4e4e1485fb15ec6c947a07076_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4f2998a4df4a4439a8cc2c83d9e8f7db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i997255409c3c45f39333fc13018a559c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i875a9a2626b44cf18fa53b7b885a6bce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief8a511b63824552bf8d257b1884b5f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9119184273346b2b8dbad7d616102ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81504f29583943ba9978871037be715e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib37e0266d4814246b83de0b9d9c168bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iafbdfb0943f24a65a8f6da1e886aa8f9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia262940bd03b4238a69d63782e9387d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i463c5678112d48c9bc0abef10ada5150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i274f33b722f340dd83f22e59cf90400f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4db6ebba6644f3e9527c7fee2cff544_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice63c8557e304f948f1fafe5ab4e071f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic87fa5828e80490fb8b8d1bd0374f894_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i192729099dcb4d288cb1d45579633c95_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1f2778fd50f940aa86c54d9c1324bcee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96a4d025226f4fe68766605d098d9d0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e972f1fd84e45db85d8fb910086c0f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1703dbc936474604bfd0656c06657637_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f653c1026734aabb17bcf80cee5821b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98cc854c976a48e1bbc3de3b9891bc67_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1f7dba45ab6a493d93352400235e1210_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i927462043ac04752942634b64cea6355_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a0d773bdaad4ae2b17b1d0b1b65fea4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec29fedb91804fec99b78fa71bf7c4d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e99b5f202a4eeca47d4e76e0d243c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifefce9ebfc0840a2bc5e823a2df50751_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9fe8c38d81284f58932debf4c8cb7618_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0d6fe6eba96941e689ad3a457f7112ec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i85eea9c802ea4670afeeaa43139cc8fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7630f29609c149bc8ed65aeacddff04f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2d8b3c059e442a49871d8451515ebce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78b3269f9d1443bfa965fb2dce758c76_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i147d42e72f9341768d5edb4e870a6497_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if013f2d93404456e9e08b22da1ce31cd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5363925363fe4d49a040c9683212cfcf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie66734cfaa1e439ebc58ca3d6feeadb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d4b8082c01e4b57b79756ab536ae7e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b12614a8c724ea3b20972094290e1be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf3819533757414a9572e60d4e871a06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41cc3330f8b146f39c81072617b752b3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i072cce2288a042b489e120bb3ec32f27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i034c6598652d4102850711d648ea0aa8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icce42ab70b0940f9a48758422d138380_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ac443b5cdc54d92bea87fa506638d36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie38c9afdc13440eaae85aaebae77f419_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d6f931f878e4baca21f094c9ee764f2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9fcf70e01d7421cba408015441496c1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic5ae0844fb5746d38ea81deefd1b9bef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e6c3665c37e4724ae7c9e261e7bbc8f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26221cd897194d5fb2af65836642c604_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i195a15919a14436a91e3c65518029bbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5815797b06f4ee6a46cb160090f637b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia7d8ece4878f459d8c0a6ad585eb5fe8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if00a3aa3229f47c9b38aa8b37fe637f5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i076a6551196f4eff9d3016f750447fd1_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="ia4f2ab910308454c8f7155eed697292f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="id661067c1cf345799ba33c3aaeb96515_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i98a1c92268c9462594c709744c9b9d2b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if731862d3ce642ffae334bf7a6733e28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i613b05cc13dc49b4a0c7a305b35ce164_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6646025f6a78471b87f269eb801ee821_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65276afd2e6542f0b217ec8483499b87_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b01bcc9a078432796345ea93821c9a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4af071ef4314dd5b5a613cc233965c6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3ea3d3697cc4bbbbab42a49a59bd0ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d69c9551a434c0fb66e7651162ab9ea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7c660c5054143d681316ee502a02a1e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7ffb61e2639493c9292444fcc81cf0b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54c87e3ad24243c1a4e073d2ef7e8134_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i056102a1b5034e53811a069c914ac932_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i0a1fca71d61f40dc8fbddba62968770a_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>nbix:subsidiary</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN18yLTEtMS0xLTA_114fb0c7-e55a-42b1-afb8-fae10e18921b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN18zLTEtMS0xLTA_b654bc98-e9e2-411a-bdec-422b1ba79695">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN180LTEtMS0xLTA_90519677-247a-4755-bab0-12d11f1a0df1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN181LTEtMS0xLTA_09bd0288-6c29-4802-a06e-6071f9486e8f">0000914475</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180L2ZyYWc6N2FjYzdjNzNhM2UzNDkxMGI3ZDVkMzIzMTI3MjA2YzAvdGFibGU6NGIxMmMwNjIwMzk0NDUyNmFmMWNkMTU5OTVmZTg5ZTcvdGFibGVyYW5nZTo0YjEyYzA2MjAzOTQ0NTI2YWYxY2QxNTk5NWZlODllN182LTEtMS0xLTA_99cdbd48-842b-4fc4-a7e3-4393365955a1">--12-31</dei:CurrentFiscalYearEndDate>
    <nbix:NumberOfConsecutiveBusinessDays
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTgzMA_ef1eef62-b79a-46f3-a25d-922b0620d60a">P5D</nbix:NumberOfConsecutiveBusinessDays>
    <nbix:NumberOfConsecutiveBusinessDays
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTg3NQ_a16f9f76-754b-427d-8388-b5aa3c37a979">P5D</nbix:NumberOfConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181NS9mcmFnOjBiYjIxMmRlYmFmZDQ0YWViYWJkNWIwMWE1MDMzYmEyL3RhYmxlOjYzNzlhYzc2MjNhYTQ0N2M4M2Y1Njk4YjZjZDBhZDNhL3RhYmxlcmFuZ2U6NjM3OWFjNzYyM2FhNDQ3YzgzZjU2OThiNmNkMGFkM2FfMi0xLTEtMS0w_e31437ab-a59c-4889-9efa-298b8ff0b8d0"
      unitRef="number">0.0131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg5_a65ada46-ec08-40ed-b779-0271ebd02871">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ODI2MWZmNDJiYjMwNDVhMGEwYThiMzc5OWU1M2VjZjUvdGFibGVyYW5nZTo4MjYxZmY0MmJiMzA0NWEwYTBhOGIzNzk5ZTUzZWNmNV8wLTAtMS0xLTA_1866f67c-f621-40fe-94b4-ccfbc0a34bd1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8xMzg_7b82e1a8-ac5c-4651-93f2-83a5979d36ff">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6OGVkYmFhMmVjY2Q4NGNhZDk3MTkyN2Q2ZTdkNzZjNzkvdGFibGVyYW5nZTo4ZWRiYWEyZWNjZDg0Y2FkOTcxOTI3ZDZlN2Q3NmM3OV8wLTAtMS0xLTA_317d48f3-699d-455d-96e5-4a38e6d60740">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkx_9682dd15-2cd2-425e-ad05-d634388a4e21">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTky_54aaab02-f1bd-4fb3-a0a2-1e776d89511f">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk2_dff34f0e-ff81-487b-a89f-af4efa0bcbd5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg2_398fb387-ef0b-4afb-83df-09c2363b7ebe">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkz_0460b7c6-0d52-479d-bf2e-3a43fe32ae0f">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg3_8751b6cd-0803-48b0-bfd8-21a3c4870201">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk3_e1a47fb1-7bc3-48a4-818c-c044b437b2ea">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk0_75ba624a-ae73-430a-a4e7-bd27936959dc">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTg4_5b6313a1-435e-4f85-a122-16918becdb85">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk1_15c9824b-3daa-47f9-877c-974c22e9030d">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTAtMS0xLTA_6085f359-c87a-4695-a3cb-50a27107f247">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTItMS0xLTA_12e91bb0-7b4e-4323-8e03-7bd6616f1ff2">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6ZjZjYTVhYTE1NDgzNDMyYTljZjQ5MDQ0MmZkNTM4NWYvdGFibGVyYW5nZTpmNmNhNWFhMTU0ODM0MzJhOWNmNDkwNDQyZmQ1Mzg1Zl8xLTQtMS0xLTA_56503de7-4493-4436-ab04-367aa2f151c7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTkw_927e6c00-6e3d-4c11-8112-8228fa677382">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk4_5feb09cf-90ab-474e-8ee0-31ed0a2a1c3d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18wLTAtMS0xLTA_eeed40b1-101b-431d-93fb-8ba211efdf01">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18xLTQtMS0xLTA_647931eb-3ca2-40aa-8f70-447b05c3feb6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGFibGU6NTM4OGJiZWVkNTAyNDVkNWJhYTE4MDEzNjYyNGM3YmMvdGFibGVyYW5nZTo1Mzg4YmJlZWQ1MDI0NWQ1YmFhMTgwMTM2NjI0YzdiY18yLTEtMS0xLTA_84c27fe7-1a9d-4d94-a68a-5696eb50cd9e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTk5_e97c6ba4-8fd1-4ecb-adb9-60d64bfb5cb4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib35f220670e34eec87e5afe4a89f609d_I20211027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xL2ZyYWc6ZGFhMTJlNDlmZmRkNGRlMjhkMTI2MjcwMzUxMDAwYjgvdGV4dHJlZ2lvbjpkYWExMmU0OWZmZGQ0ZGUyOGQxMjYyNzAzNTEwMDBiOF8yMTcz_d74a83a0-d03a-4f58-9714-a2454e437fcf"
      unitRef="shares">94866693</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMy0xLTEtMS0w_9186e7ae-3f34-4da5-81ba-3947b317ec58"
      unitRef="usd">311100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMy0zLTEtMS0w_894c6557-fa11-4626-89b0-e608fc1d03f7"
      unitRef="usd">187100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0wLTEtMS0wL3RleHRyZWdpb246Y2VhMTQ0M2EyYjRhNDMwOGI5NjA5YjVjNTdlNTQ0Y2VfNzE_c550122c-6146-4c36-baa1-35fe9309c829"
      unitRef="usd">454600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0wLTEtMS0wL3RleHRyZWdpb246Y2VhMTQ0M2EyYjRhNDMwOGI5NjA5YjVjNTdlNTQ0Y2VfODQ_0f80231b-05c7-4f51-82a3-7b64a4cca97c"
      unitRef="usd">612400000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0xLTEtMS0w_23125f44-ade4-4602-aabc-45ebe5279972"
      unitRef="usd">454800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNC0zLTEtMS0w_1f981f34-0bb6-4b80-bd05-80c09744e50d"
      unitRef="usd">613900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNS0xLTEtMS0w_56bbfbc7-b634-411a-a203-91d98dfded04"
      unitRef="usd">163800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNS0zLTEtMS0w_41b0a90b-1249-4f47-8a2f-cbe6648afe88"
      unitRef="usd">157100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNi0xLTEtMS0w_addc1733-3b2d-4f8f-a4d8-b5548a4a2964"
      unitRef="usd">25500000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNi0zLTEtMS0w_4791e0eb-8e2f-4ac8-b03d-49def5c32385"
      unitRef="usd">28000000.0</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNy0xLTEtMS0w_e2d2a0b8-b760-4019-b4d3-0ce9a3d9f765"
      unitRef="usd">50500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfNy0zLTEtMS0w_4e174432-cb2a-4265-9287-e452888772e2"
      unitRef="usd">30100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOC0xLTEtMS0w_3514be28-1271-49b9-bee6-ba3a2433f918"
      unitRef="usd">1005700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOC0zLTEtMS0w_01bbb2d7-6779-4f33-93cc-847f8c574371"
      unitRef="usd">1016200000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOS0xLTEtMS0w_d42083c4-1d7b-4fb7-8341-bfe26bd15180"
      unitRef="usd">310400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfOS0zLTEtMS0w_5fdd3523-7a15-4333-9ee8-5e7775c7b879"
      unitRef="usd">319400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmM3YjcwODMxYjRlNDQ2OWJhZmUwZjI5YjFjNmM1N2FhXzcx_75240047-885d-4fb7-b2af-32961604c0b4"
      unitRef="usd">513800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmM3YjcwODMxYjRlNDQ2OWJhZmUwZjI5YjFjNmM1N2FhXzg0_3338b524-d7a5-41e6-b287-6ee3f56ec6b5"
      unitRef="usd">226700000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMS0xLTEtMA_8f237260-7672-4cc6-80bc-f56c49af917f"
      unitRef="usd">513700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTAtMy0xLTEtMA_95f03291-6c8b-4b53-ab04-22cf6c0a4f19"
      unitRef="usd">227100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTEtMS0xLTEtMA_73de5d00-86fb-4b11-a649-5245d2545f66"
      unitRef="usd">97900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTEtMy0xLTEtMA_ca9806f5-ae93-4abb-a0a7-35b4d7d25e09"
      unitRef="usd">82800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTItMS0xLTEtMA_8af82af2-164d-4b66-9739-bb8c5c42065c"
      unitRef="usd">35300000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTItMy0xLTEtMA_91590e72-6fc3-4cfa-bc0a-8cd701165443"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTMtMS0xLTEtMA_075505e6-6fff-401d-9f07-d2b67ced9930"
      unitRef="usd">51100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTMtMy0xLTEtMA_099a2037-6deb-4e6c-8383-9e2bcf24332c"
      unitRef="usd">44600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTQtMS0xLTEtMA_d5e4172f-a3e2-47cf-afb0-9bb36d862b76"
      unitRef="usd">3200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTQtMy0xLTEtMA_94e65406-c546-44fc-8c48-3c8d0ca33d96"
      unitRef="usd">6400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTUtMS0xLTEtMA_fa6221d6-02cf-4dbc-9425-a20baee0df31"
      unitRef="usd">2017300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTUtMy0xLTEtMA_79b0f64c-9334-4810-a028-b022043bca2b"
      unitRef="usd">1734700000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTktMS0xLTEtMA_b911d74d-3267-4162-9c05-29658cb53cd7"
      unitRef="usd">205900000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMTktMy0xLTEtMA_7b6a86f0-9a3b-4717-914e-3029443121a1"
      unitRef="usd">168700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjEtMS0xLTEtMA_86135dde-4088-42f2-b34e-a13e909b223f"
      unitRef="usd">20000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjEtMy0xLTEtMA_d80c9132-9fb9-491f-a1a1-b385a7dbd9ff"
      unitRef="usd">17800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjItMS0xLTEtMA_60719919-793a-4742-9bef-c96ed1d1f764"
      unitRef="usd">225900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjItMy0xLTEtMA_e0db1041-ca44-493d-a734-955f239acf81"
      unitRef="usd">186500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjMtMS0xLTEtMA_e4070052-93db-45f1-95af-3b24d367a0d6"
      unitRef="usd">330700000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjMtMy0xLTEtMA_0e342565-1e8c-42a2-9eb3-6b0fa79f3bab"
      unitRef="usd">317900000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjQtMS0xLTEtMA_3fe941ed-01e9-416a-826b-a3a6d7a7d7c5"
      unitRef="usd">106400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjQtMy0xLTEtMA_f67d69b6-d37a-411d-baaf-6ea70034a622"
      unitRef="usd">94400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjUtMS0xLTEtMA_cc8b476c-4297-4c30-a05a-0db286f6d52d"
      unitRef="usd">8300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjUtMy0xLTEtMA_005e1721-0648-46d5-84e1-0a3d2bce58dd"
      unitRef="usd">9700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjYtMS0xLTEtMA_4aac04c1-db65-4673-a6ad-067e740d8299"
      unitRef="usd">671300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjYtMy0xLTEtMA_9277fd2d-beb7-4fec-bda0-7b2096c60812"
      unitRef="usd">608500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzIy_6e83b16c-9956-42a4-96ac-b4929d184ae7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzIy_f57b878b-b275-4415-8015-080b88b98f9d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzM2_058838d3-1af4-4470-b33d-bedad751f5ab"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzM2_58885f9c-4988-4fb2-a8b6-403c65daf0e1"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_31a54a53-3db4-403f-8ae0-c6a6cfd93c0a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_5d4d1f8d-404d-4253-8e11-4abcff30a2ec"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_9fc20640-7e80-4cf1-803d-175b9d862c44"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjczZmI0Y2FjOWZjZjQ3ZGM4OTM1ZTQ5MzIwYzU4MzYzXzU4_dced4cda-48f4-4b1e-ba95-5c9cbcad8c83"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMS0xLTEtMA_e1ec04b2-cb7f-445e-871a-f065734ee33b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMjktMy0xLTEtMA_c25169bb-6bdf-46dd-9fdc-44a21fc080ff"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzE5_18be85dc-85eb-46e2-8387-004530c51090"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzE5_fb2e36f6-4536-4d49-8597-e2edbe235191"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzMz_3d714e08-aaac-4b0d-b913-c9a7bcbfd43b"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzMz_84242faf-1a87-4812-9fc7-d9e5ee2009cd"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3Xzkw_38f59345-0021-4734-9e04-561b3a1f95e5"
      unitRef="shares">94800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3Xzkw_8add3c2a-ef80-4a46-bfe3-41f29f7c94eb"
      unitRef="shares">94800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzEwMw_157dacda-5a5f-4b29-93a8-5d07bdf27fee"
      unitRef="shares">93500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzM2NhZjA0M2Y5NjQ4ZjdhZTkyZjdlZTE1MDQxZTk3XzEwMw_edc0a263-00be-4fed-8dd3-c5d59455c9e9"
      unitRef="shares">93500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMS0xLTEtMA_a616f799-ef8a-43cc-a91b-f8bb6f55ca87"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzAtMy0xLTEtMA_05b00d8e-1ff3-48d9-bfef-d54fe59ee475"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzEtMS0xLTEtMA_2a0dac89-9614-4f69-a8b1-6a155cb0f5ad"
      unitRef="usd">1974000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzEtMy0xLTEtMA_cfb19fca-158e-434f-91b0-ab7f94c6c6db"
      unitRef="usd">1849700000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzItMS0xLTEtMA_4e2b73a1-b820-42e8-85e9-b23a835853a3"
      unitRef="usd">400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzItMy0xLTEtMA_f1016f4c-01a8-4657-96d6-c989588c7de0"
      unitRef="usd">1800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzMtMS0xLTEtMA_4f5194d4-dfca-4c22-bd1c-db3f51696520"
      unitRef="usd">-628500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzMtMy0xLTEtMA_2aea6d25-bb9f-4d49-b7bb-194058a295ad"
      unitRef="usd">-725400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzQtMS0xLTEtMA_19b25aaa-d78b-4ba7-8f0a-bbd6203a70a5"
      unitRef="usd">1346000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzQtMy0xLTEtMA_4c810bb7-38f8-45bb-8429-3d36cd7428f8"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzUtMS0xLTEtMA_a71a7c1c-f7be-4ac3-9cd7-fabf1f5969d9"
      unitRef="usd">2017300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xNi9mcmFnOjk3NGUzYTEwNzgxZjRlYzZhZTU0YTg5ZjkwOWQ5YTM5L3RhYmxlOmEzYjFjZTk1MmRiYjQ5ZDBhOTczNmY2YTg3N2I3NjdhL3RhYmxlcmFuZ2U6YTNiMWNlOTUyZGJiNDlkMGE5NzM2ZjZhODc3Yjc2N2FfMzUtMy0xLTEtMA_57ec28b9-e1c1-4596-b5dd-77d54342a600"
      unitRef="usd">1734700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebf2d8484c7e496bae6f2a07d1b08068_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy0xLTEtMS0w_dee05417-07ad-4d50-919a-47e27da217d0"
      unitRef="usd">288800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10ee034471ac4db29f78d7b85eb9dc6e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy0zLTEtMS0w_3509b55f-187f-4bfc-8f55-8afd879cb1a3"
      unitRef="usd">254100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62082aae9f3941b69d20896eba9b0249_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy01LTEtMS0w_86f39cbb-eafe-4e9b-90a5-be7de937c7bf"
      unitRef="usd">786600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57aa7170627244b08601ddb3bf8c9dff_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMy03LTEtMS0w_40b987d6-9044-4f8b-92fb-8bf173606cdc"
      unitRef="usd">752800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ed90fc09e974862855048eb200b7e28_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC0xLTEtMS0w_229e0e5b-2a36-4dd3-9bc1-72f98061e310"
      unitRef="usd">7200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9101b3965a264dc9a0dfee26e4674bae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC0zLTEtMS0w_32f51185-2ca6-48b9-849c-b623bfccb2e4"
      unitRef="usd">4400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5ccd37651e4b678f8252d2497c8369_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC01LTEtMS0w_aa69c47f-db1f-4694-9e76-50a525bcd500"
      unitRef="usd">34900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9049c0b86b004f30bf4a1ce3cc512077_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNC03LTEtMS0w_71401dc0-bd16-4cc7-9799-e1e078e1b6eb"
      unitRef="usd">45200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS0xLTEtMS0w_369d3c9c-5891-438f-91d2-55e6f956cfec"
      unitRef="usd">296000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS0zLTEtMS0w_a4dfc2c7-1d1c-4fa1-ab4e-ad80b17ca2f5"
      unitRef="usd">258500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS01LTEtMS0w_d3d0e3c9-19fb-4166-ae77-de4c9e38c3ad"
      unitRef="usd">821500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNS03LTEtMS0w_bfa29823-8b26-4561-9c58-9d88424a28f1"
      unitRef="usd">798000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy0xLTEtMS0w_e0f83a69-7c72-47c5-b9fa-e18b7e9fb4b4"
      unitRef="usd">4200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy0zLTEtMS0w_1d6813ad-435a-4a60-9149-8d79a1cba023"
      unitRef="usd">2700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy01LTEtMS0w_347f8269-e602-420f-81fc-09a389529565"
      unitRef="usd">10200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfNy03LTEtMS0w_a94d7cba-8a44-4c29-bb4a-f900d2ccc8d1"
      unitRef="usd">7200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC0xLTEtMS0w_b69cb1f7-52f9-4313-8f04-57be0489e200"
      unitRef="usd">92700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC0zLTEtMS0w_9b3e8647-58f8-49cf-a365-14be4b1fe2ff"
      unitRef="usd">69100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC01LTEtMS0w_85d40bdb-7f40-41fb-b027-de6c585c2bde"
      unitRef="usd">240700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOC03LTEtMS0w_2f32b2cc-178a-42cd-832d-f6f44cf3bc9b"
      unitRef="usd">208300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS0xLTEtMS0w_b15e6e84-2630-4c51-b4e8-900b8c3f7353"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS0zLTEtMS0w_1b93eb76-e6c1-4f4c-ac80-4c6f38051dc7"
      unitRef="usd">118500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS01LTEtMS0w_d78e8e27-6543-44e8-9490-e04b954e4621"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfOS03LTEtMS0w_29df1816-5b87-437d-9d7c-495f8fc3832a"
      unitRef="usd">164500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtMS0xLTEtMA_cad9f7ac-e876-466a-a36e-0da5a06fd7be"
      unitRef="usd">154600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtMy0xLTEtMA_8b9920d3-f2e5-4e2f-b02f-686df955151c"
      unitRef="usd">112500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtNS0xLTEtMA_f3c7c497-cf42-4c18-947f-598d77146afa"
      unitRef="usd">426800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTAtNy0xLTEtMA_1a541b50-6724-4c2c-a9db-2ca1d5f12561"
      unitRef="usd">326800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtMS0xLTEtMA_3c5550df-52ca-42da-8d16-575df416dacc"
      unitRef="usd">251500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtMy0xLTEtMA_933a1afc-bf2b-4206-8607-a22134bb84ae"
      unitRef="usd">302800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtNS0xLTEtMA_c3477491-aada-4394-a4cd-a2de7717cfce"
      unitRef="usd">682700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTEtNy0xLTEtMA_822c2410-77ec-4fca-b91d-070424a45c83"
      unitRef="usd">706800000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItMS0xLTEtMA_749a5aea-5fbf-4af1-b96d-1857e2f6d917"
      unitRef="usd">44500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItMy0xLTEtMA_eb5e4d5d-da8a-4f03-bc9a-f03b3ff00b76"
      unitRef="usd">-44300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItNS0xLTEtMA_03e52251-6b99-4fa7-ac1f-40e3bba817c9"
      unitRef="usd">138800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTItNy0xLTEtMA_634f6873-39b2-47fd-8e06-673d378b495b"
      unitRef="usd">91200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtMS0xLTEtMA_878774b3-265b-441d-abc2-8bd8bdad5d0a"
      unitRef="usd">6600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtMy0xLTEtMA_84796afa-3a0f-4c80-9ba4-0fdc39bdaada"
      unitRef="usd">8500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtNS0xLTEtMA_a130202f-47c7-4a74-a140-fddcff51d500"
      unitRef="usd">19200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTQtNy0xLTEtMA_3e187071-c9b8-4acb-9679-7facf06ad6da"
      unitRef="usd">25000000.0</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtMS0xLTEtMA_df57fa07-cc3b-4147-a789-07e5c76c2c99"
      unitRef="usd">-8200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtMy0xLTEtMA_dfdb6019-ecbb-4dc6-99e8-40c42399b3f6"
      unitRef="usd">-7000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtNS0xLTEtMA_97da89dd-9494-4f41-b250-cdb78da2c8af"
      unitRef="usd">-7500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTUtNy0xLTEtMA_c4e6cd49-88cc-4a12-8315-597dc7f8f1dd"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtMS0xLTEtMA_b5e63128-2312-4f7f-9380-d53e3c97c549"
      unitRef="usd">800000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtMy0xLTEtMA_9c86bff7-c281-422f-8134-04344e416074"
      unitRef="usd">2700000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtNS0xLTEtMA_29ce4ec9-bc6c-4ced-a998-f9cff70ae5fc"
      unitRef="usd">3100000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTYtNy0xLTEtMA_58a14277-1b20-47fd-82d1-460e5e86209e"
      unitRef="usd">11000000.0</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctMS0xLTEtMA_2a8eb109-c5ea-4f4a-b085-8d0b84a83e2c"
      unitRef="usd">-14000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctMy0xLTEtMA_105b94d7-ac92-42b6-9317-98b296a570df"
      unitRef="usd">-12800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctNS0xLTEtMA_47ca717c-1ae7-4bfb-a41b-224b39d5abbd"
      unitRef="usd">-23600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTctNy0xLTEtMA_d997f429-ab3d-45bc-bc2c-4c8a397cf373"
      unitRef="usd">-26200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtMS0xLTEtMA_9be0e96d-a7f8-4dee-b033-192db5cf1fe1"
      unitRef="usd">30500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtMy0xLTEtMA_baf0d21d-1ac7-4e63-83d4-8c1661e56db6"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtNS0xLTEtMA_9082cf3b-99ee-4aba-9f2c-fe73bf140bd1"
      unitRef="usd">115200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTgtNy0xLTEtMA_b5e1064f-a0cb-4fc1-a79b-bd9a0ad5eb6c"
      unitRef="usd">65000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktMS0xLTEtMA_03f7877c-dcee-4259-8e66-2c5688442021"
      unitRef="usd">8000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktMy0xLTEtMA_ba0170d3-9a30-4cf1-9186-9ddb9344ccba"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktNS0xLTEtMA_dd761d08-b3d7-4d7f-a18b-882af63c3396"
      unitRef="usd">18300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMTktNy0xLTEtMA_ee560d32-bf62-447e-9750-744ccaca9b76"
      unitRef="usd">5600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtMS0xLTEtMA_5cd9fbaa-f49c-4095-ab96-54259daad0c7"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtMy0xLTEtMA_b1bc2332-1d56-44e0-a1a0-574023a433fd"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtNS0xLTEtMA_2a526523-1830-4b6c-a9d5-c5bd29f44caf"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjAtNy0xLTEtMA_afc2e7ef-c000-4c5e-9c8e-4e837f97c262"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtMS0xLTEtMA_ffe10985-e2a4-44ce-a968-44df9303f356"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtMy0xLTEtMA_d53ce5e7-43d1-41d7-9fad-4f5d95353ba7"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtNS0xLTEtMA_45788085-a8c9-438f-8326-c4e6e503d89c"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjEtNy0xLTEtMA_d0965d59-8484-4754-bb3a-08d24e511878"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItMS0xLTEtMA_467824b8-d837-4bfc-abfa-b6a9a141cb7b"
      unitRef="usd">22200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItMy0xLTEtMA_a05a170a-5fa4-49e8-909f-931ad7477427"
      unitRef="usd">-59000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItNS0xLTEtMA_e5df544d-d349-4134-afdf-723f41534104"
      unitRef="usd">95500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjItNy0xLTEtMA_1d30273d-93e8-4667-8bf2-c26e9b3ae304"
      unitRef="usd">61200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtMS0xLTEtMA_4df478b8-79b6-486a-a14e-468bef0cb3d0"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtMy0xLTEtMA_62af6937-de29-4127-843f-f58397955244"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtNS0xLTEtMA_781f7f4b-d2aa-4e27-ac80-ea4a793320ee"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjMtNy0xLTEtMA_101464bf-491d-49cc-9ce2-fd7273293eab"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtMS0xLTEtMA_6ca1ba00-f07e-4d81-8f41-025523c5f97b"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtMy0xLTEtMA_26321a92-dc6a-41be-b9f5-ec8357d8229e"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtNS0xLTEtMA_64e8ef94-16ec-4664-96cd-88d5fa51754c"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjQtNy0xLTEtMA_a875f182-2272-413a-86d0-7fec4610191c"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtMS0xLTEtMA_5cf5fd54-cca4-4d75-943a-7b6ba18453f5"
      unitRef="shares">94700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtMy0xLTEtMA_c746f30a-31df-4793-ba90-052a1bf977fc"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtNS0xLTEtMA_b8e9ca30-8352-44b6-9996-4cd3a7913d3c"
      unitRef="shares">94500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjUtNy0xLTEtMA_0432d93a-4422-44f9-937a-0c88292211a6"
      unitRef="shares">93000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtMS0xLTEtMA_e015787e-f110-4211-ba4e-ff58943fdcdc"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtMy0xLTEtMA_73a06f9a-94ed-462a-a448-ca7544f56789"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtNS0xLTEtMA_1bcb6e4d-99fc-4ba9-9db8-b39316df6417"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18xOS9mcmFnOmI5YmVjZTM3N2FmMDQxNjFhOGYwYjZlMmVhZTA1OWI5L3RhYmxlOjAwMzkzNjU3MDlkODQwMjA4MGMyZDE0YWQxODIzMTMwL3RhYmxlcmFuZ2U6MDAzOTM2NTcwOWQ4NDAyMDgwYzJkMTRhZDE4MjMxMzBfMjYtNy0xLTEtMA_59b4573a-5dcf-4790-ae04-94e447de6a44"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0xLTEtMS0w_74a52da3-38dc-4f5a-865e-95907d9cb2ed"
      unitRef="shares">94600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i78cf83f2c299452b9591ea0cb1e50dc0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0zLTEtMS0w_7d94b885-8db9-431a-aede-32243952e545"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7803f4c249304f20b4bb0eb8494c2e78_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy01LTEtMS0w_42ca067c-22b4-47f7-851f-585f849a9cc8"
      unitRef="usd">1929400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i754e2b2ae83143ee834e836dd3561f1d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy03LTEtMS0w_3d713e12-7c9c-40f3-9d17-ded880717938"
      unitRef="usd">700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50142418015f4e47be8aea7229195794_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy05LTEtMS0w_cb7719b5-b99e-4e9e-8d7c-176635eae1d0"
      unitRef="usd">-651000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb552e33928d4ba2b771f17e9907962a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMy0xMS0xLTEtMA_6f811c59-f45a-4351-bd33-9c9bc06d8855"
      unitRef="usd">1279200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i26f84bfaa23a48129fc63d149d061b27_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNC05LTEtMS0w_7d556280-dbe7-41d6-996a-5384f8ca56b1"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNC0xMS0xLTEtMA_76828410-56d4-4635-a2dc-b7a8798f9cd9"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c540dc7784a4d6f8d16ff59c05b0b06_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNS03LTEtMS0w_dd893eff-2769-461c-b1fb-1f173e174269"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNS0xMS0xLTEtMA_5627b7fe-5932-4e3d-bb02-41b94d68260e"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNi01LTEtMS0w_9b26d917-447b-4624-9512-47b51560037c"
      unitRef="usd">37100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNi0xMS0xLTEtMA_716ead12-dc62-4a0a-8fe4-53e54d447849"
      unitRef="usd">37100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8ea2954b9ed8422aa402be311593fa3c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy0xLTEtMS0w_46394a7e-8282-4d3a-acee-0ad4a4faad2e"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4c8158bf6d614bf588672436574ede4a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy01LTEtMS0w_ebc59e85-a564-43fd-83ad-9e1fdc47be62"
      unitRef="usd">7500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfNy0xMS0xLTEtMA_6ff32d39-7469-419e-8017-681f63472d3c"
      unitRef="usd">7500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0xLTEtMS0w_b3dc280d-9618-4c5a-bc01-28d8128eaa01"
      unitRef="shares">94800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0zLTEtMS0w_39b5ee49-7ed1-4437-8029-bff2e06670f7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9279c8400ef148e1866482b1844adf56_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC01LTEtMS0w_c0380da5-1066-4d6f-9cf8-af30ec52f4c4"
      unitRef="usd">1974000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5888ff562cf4ba088c5483009e844d7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC03LTEtMS0w_4307f81c-5ce2-4e67-b594-723042b74095"
      unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b123f12d63242b189e51114c701eaf5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC05LTEtMS0w_e2bbdf99-da35-452b-94cf-c647209fe794"
      unitRef="usd">-628500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfOC0xMS0xLTEtMA_e7e26dd1-24e5-4d11-bef7-c17d8867223b"
      unitRef="usd">1346000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMS0xLTEtMA_175d9ab1-74dc-48f9-9d67-e339dd22e555"
      unitRef="shares">93200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i14a75c199ed1499ea1bfc6b2dcbe5113_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMy0xLTEtMA_26ca78fe-9d0c-4206-83fe-fd63437f2ab7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ecddd8f9d5f42dc94c8e2a220f3593a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtNS0xLTEtMA_60904448-413f-47ed-a5ab-df35da488cb8"
      unitRef="usd">1842200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a4aa44ca0d044e0a8ec596fca98e7e9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtNy0xLTEtMA_82a8b8d7-3ba6-4539-8de2-ba9e69fd7848"
      unitRef="usd">4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie20178cc9ddf43b4a388c72ac34c2134_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtOS0xLTEtMA_fde1e178-31ac-4c96-a3bb-47594826bb03"
      unitRef="usd">-1015700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84f9ecb01ca24fbbb38c14c687ebaf91_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTAtMTEtMS0xLTA_6fcbbe8d-7133-4098-bdcb-39f80f171f07"
      unitRef="usd">831200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i851ba2fafa2f450990491164330f743d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTEtOS0xLTEtMA_25ff7d00-3dcf-43cb-8b26-ec4c7198de65"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTEtMTEtMS0xLTA_1fe224a1-5322-4824-bdd3-5aacb7b78f9c"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e8c778aad0f4e7f8fa77b3cc9856b9b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTItNy0xLTEtMA_9d3cc641-1aac-4e72-b7a5-16e793d0392e"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTItMTEtMS0xLTA_90e42f46-a3fc-46c2-b5c3-c7908103671b"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTMtNS0xLTEtMA_50933216-b20f-437a-bb27-41ea6b472cb7"
      unitRef="usd">26700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTMtMTEtMS0xLTA_0f5ec84c-018d-49fd-b207-826dd84eed60"
      unitRef="usd">26700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i302b1afa8146416aab065909274c7758_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtMS0xLTEtMA_ca91ec62-e21e-4347-9a46-2b850d34cb8a"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idba7d872b45147769cda2cdf64d43f0f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtNS0xLTEtMA_620d348a-c81e-4998-9a71-00a308c9bcec"
      unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTQtMTEtMS0xLTA_337fdacf-70e0-4b23-847f-7d7a99f74428"
      unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMS0xLTEtMA_9433254e-44dc-4608-8777-3c76d1167ffb"
      unitRef="shares">93400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMy0xLTEtMA_c0d5192f-0a16-4718-8004-b152c1e538fd"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81bb07b5918e4f64bee6b674512d700e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtNS0xLTEtMA_2c96d2b7-e397-4cfa-8b19-a4394264f154"
      unitRef="usd">1874300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5d7325982b647798c3a49c812ccaa00_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtNy0xLTEtMA_fa2dd6fd-1d68-421f-84a5-b7bb52b62934"
      unitRef="usd">3200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia15bb181a93e44b49456802a3f4a8de4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtOS0xLTEtMA_f341e250-ef15-48fd-be51-6d06447fb93b"
      unitRef="usd">-1073300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTUtMTEtMS0xLTA_3df78b8c-8873-41b1-a8ac-c8f76b7a454c"
      unitRef="usd">804300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9f76fb77b1f542479312b2aff85aaf3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMS0xLTEtMA_07cec1f2-9284-4cb8-83ad-b643caa96f67"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9f76fb77b1f542479312b2aff85aaf3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMy0xLTEtMA_60ce0cd1-b8b8-46cf-a227-8f3e9d40c014"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e0c38cd3765417695f32be58389944a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctNS0xLTEtMA_dece2b4f-92be-4723-bfe3-dcaea1a2dd82"
      unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i046db428318141819987db76bcbb0b60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctNy0xLTEtMA_82f6c6dc-84ea-41ee-88b2-b76967c796d4"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41785e12188b4d7889ba7b5f21da1623_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctOS0xLTEtMA_bcdbb013-24ae-4f70-9ff6-d5eac8f36cb2"
      unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTctMTEtMS0xLTA_992d36a7-0c23-436e-af32-552f558228a4"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5c9298bbb4994683a1431a64d26acfef_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTgtOS0xLTEtMA_d5b72017-615b-449e-a894-fdd4e9847c2a"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTgtMTEtMS0xLTA_c5d128d8-8e2e-4a0d-8d86-250bed2ce038"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ide770c7feabe4bcd8899467eab2993a4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTktNy0xLTEtMA_fe11ab7a-dfce-4d98-b8b1-05381b91be70"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMTktMTEtMS0xLTA_c0b08100-4bb6-4813-9769-99b58c392357"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjAtNS0xLTEtMA_345f32ab-d8ae-45a1-8061-19e5539aecd6"
      unitRef="usd">98600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjAtMTEtMS0xLTA_85088551-5a39-4337-8f2b-3d63ae0908d8"
      unitRef="usd">98600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i421486e0786f480d81e599f2028fb590_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtMS0xLTEtMA_e0de3d77-808a-4cef-bc6d-0823758f73fd"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i179a93c8d8114f529ba95ace9315af99_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtNS0xLTEtMA_e61cde90-9c19-4393-a5cb-c49d26c6039a"
      unitRef="usd">25700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjEtMTEtMS0xLTA_f6c99213-f295-419d-9342-00d30bf73587"
      unitRef="usd">25700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMS0xLTEtMA_f088bca3-cfd0-4378-a7c5-32d17af1eb5b"
      unitRef="shares">94800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i90699ef320ca4ebeb28f38adba5ef805_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMy0xLTEtMA_2d30c232-65a9-4b57-ba63-0e420bcef6f9"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9279c8400ef148e1866482b1844adf56_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItNS0xLTEtMA_2424812f-ee11-48be-8994-1296ddd95948"
      unitRef="usd">1974000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5888ff562cf4ba088c5483009e844d7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItNy0xLTEtMA_8a16a678-b790-463d-a140-7c30c3ad5e11"
      unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b123f12d63242b189e51114c701eaf5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItOS0xLTEtMA_bbed2698-2409-4a1c-a186-7ee79725422f"
      unitRef="usd">-628500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjItMTEtMS0xLTA_0c458d9c-eac6-4a99-9b58-6829440719da"
      unitRef="usd">1346000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i2eeef242bbcc4ec59c2143f1f656c851_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMS0xLTEtMA_2ce01367-e961-46d3-8642-50c4e9ba0ff0"
      unitRef="shares">92300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2eeef242bbcc4ec59c2143f1f656c851_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMy0xLTEtMA_37dfff58-a5c6-44e1-b565-5e5d2e5c4b9b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96a678a1180e4c3caa98573b5cd8f7a8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtNS0xLTEtMA_72819369-8602-4edd-9a6c-8bcbe172ecd2"
      unitRef="usd">1768100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3497105df4834dc893428a1a5d881960_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtNy0xLTEtMA_282d0251-bdb6-484d-a192-154cb10e747e"
      unitRef="usd">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i552dcda95f844a11b769f02470f057fa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtOS0xLTEtMA_21faa143-5cf3-40e1-afd6-7d489884355f"
      unitRef="usd">-1132700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c4ca114f2d34a558af3a50593c0e518_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjQtMTEtMS0xLTA_075768e6-c0ac-4e67-b97f-9580cb1104cb"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i206634836d714da8902b9e165f6fd187_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjUtOS0xLTEtMA_6bfe4db7-098f-41b0-905b-703bb19e6949"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjUtMTEtMS0xLTA_f486939f-8858-415c-bfa4-c9b86d33a3b4"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i421dcee8358442bfb35f87eaafbdae1b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjYtNy0xLTEtMA_dc7fb220-2df6-4270-8b26-86b50db40f60"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjYtMTEtMS0xLTA_4bfc1bfb-122c-47b2-ab46-0c85a1220571"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i933021bd48984449911c135ddeafa918_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjctNS0xLTEtMA_38e19a78-d01e-4897-a7f3-16442b5c860e"
      unitRef="usd">79000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjctMTEtMS0xLTA_a9e6ef04-80d3-48d6-9a6c-70d68523b02a"
      unitRef="usd">79000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib684ec080b3a48bb93b07be4df5e2401_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtMS0xLTEtMA_547c432d-792a-4634-b74e-dd4b1ce7a034"
      unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i933021bd48984449911c135ddeafa918_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtNS0xLTEtMA_05f17d5f-8172-49c1-be08-d5c91e4f7b80"
      unitRef="usd">27200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjgtMTEtMS0xLTA_0a88eec6-bfff-440d-b614-086b8c9d5755"
      unitRef="usd">27200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMS0xLTEtMA_322bd8ce-2d36-4a68-9ee4-1ee60d63330e"
      unitRef="shares">93400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6a08b99dfb094c0b91dfe34866290261_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMy0xLTEtMA_a4e55ce8-8e88-4cc7-8816-2183a26f8bfa"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81bb07b5918e4f64bee6b674512d700e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktNS0xLTEtMA_af19eae1-1929-4385-94bf-315f83f38e3e"
      unitRef="usd">1874300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5d7325982b647798c3a49c812ccaa00_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktNy0xLTEtMA_8a29fffb-9867-4e5c-b795-bf9227d640e7"
      unitRef="usd">3200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia15bb181a93e44b49456802a3f4a8de4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktOS0xLTEtMA_52f22552-2b61-48bc-85d2-beef37a0e766"
      unitRef="usd">-1073300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yMi9mcmFnOmFkNzFhNmY0OGE3NDQxMGY4NGUwODVlZjQyYzU5MTcyL3RhYmxlOmZjMTFlMjQ3ZTNlZTQ3NWZiMWNjYWQ1NmY5MzgzZjIzL3RhYmxlcmFuZ2U6ZmMxMWUyNDdlM2VlNDc1ZmIxY2NhZDU2ZjkzODNmMjNfMjktMTEtMS0xLTA_0be09a04-60e4-407b-bd4e-e2413af634b2"
      unitRef="usd">804300000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMy0xLTEtMS0w_cfc5efbc-4276-46c7-a353-11ce162922b8"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMy0zLTEtMS0w_9d711382-1792-4784-a04d-3cce36ef69ca"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNS0xLTEtMS0w_dac45fc8-5a85-45eb-a10c-2f1a5f1d293d"
      unitRef="usd">98600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNS0zLTEtMS0w_7b3a9ee9-9354-466e-b01e-ee1cdd7bb0ff"
      unitRef="usd">79000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNi0xLTEtMS0w_4ab1589b-11ac-4666-9b6c-c5d6c16081a6"
      unitRef="usd">7900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNi0zLTEtMS0w_53ffe51d-a0bc-45f4-b6b7-fb6a286064c8"
      unitRef="usd">6400000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNy0xLTEtMS0w_89564540-21c1-45ba-9e83-43da3b8bf809"
      unitRef="usd">12100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfNy0zLTEtMS0w_385f4534-970a-4cc5-8de0-d7c59d8fa834"
      unitRef="usd">15200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOC0xLTEtMS0w_62334cd5-6ef7-436a-abac-78c2ece6167d"
      unitRef="usd">800000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOC0zLTEtMS0w_b785f2f7-a35a-468d-b58c-e91d5762f861"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOS0xLTEtMS0w_46b629a4-e5ed-4b53-8056-1bac06c2b5a0"
      unitRef="usd">-7500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfOS0zLTEtMS0w_b6588f73-03d9-4dc7-8782-896d206b8f11"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTAtMS0xLTEtMA_c0764e23-7d4d-4fd4-86e4-7bd608079827"
      unitRef="usd">9000000.0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTAtMy0xLTEtMA_82acdbd8-f02e-4e4c-a5ea-049f222af8fe"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTEtMS0xLTEtMA_3e26dd91-db23-4023-9e16-2fc680b46974"
      unitRef="usd">7700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTEtMy0xLTEtMA_8cc732fe-e13c-48b8-8aee-b150a314e492"
      unitRef="usd">1700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTMtMS0xLTEtMA_9f9fb2b1-ef68-4861-991e-019e243f6e6b"
      unitRef="usd">6700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTMtMy0xLTEtMA_29c7d1bb-14f8-4b8c-a069-961ea9661564"
      unitRef="usd">30300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTQtMS0xLTEtMA_a1cb386a-bdbb-43e6-af26-0afb786d7f31"
      unitRef="usd">-2500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTQtMy0xLTEtMA_3d9bf1fe-6e52-4484-bdbf-a004d48d5f7a"
      unitRef="usd">3400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTUtMS0xLTEtMA_a7d52dc4-6144-4a7d-802f-4ad6dfb7df67"
      unitRef="usd">37700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTUtMy0xLTEtMA_00e4c4bd-8de0-46c2-8ff7-9fc32a6080c5"
      unitRef="usd">28100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTYtMS0xLTEtMA_feec54ff-a953-4ca7-b89a-dd2a7f8cf25a"
      unitRef="usd">21700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTYtMy0xLTEtMA_b0b615b1-c55d-4d84-a93e-0849c9b6d7f8"
      unitRef="usd">35300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTctMS0xLTEtMA_91dc1c60-a86c-4d4b-98fb-984003db3d2d"
      unitRef="usd">252300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMTctMy0xLTEtMA_12039b2b-64bb-4242-a992-ffb4e9012bad"
      unitRef="usd">134000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjAtMS0xLTEtMA_f493323e-0475-4af5-8e68-67642d62a7f9"
      unitRef="usd">658700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjAtMy0xLTEtMA_0de98611-82ba-40ed-96a5-267c770faa55"
      unitRef="usd">399200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjEtMS0xLTEtMA_6d2d8878-2285-4a67-a748-55bee9dd69c7"
      unitRef="usd">523900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjEtMy0xLTEtMA_17899f39-dd4c-4d96-b3f7-da3f306bc549"
      unitRef="usd">557400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjItMS0xLTEtMA_ef62adc7-bc78-4650-b54d-8c199aee3f99"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjItMy0xLTEtMA_16e61457-bcd7-4cdb-934a-7d81094a9b40"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjMtMS0xLTEtMA_fa2b585b-b81b-462a-89c2-e798c5a04bed"
      unitRef="usd">14500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjMtMy0xLTEtMA_30d789d8-f956-45a0-b364-5c019c10b40a"
      unitRef="usd">6400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjQtMS0xLTEtMA_d9f6f157-1554-49a5-beb4-58407f4a7246"
      unitRef="usd">-153900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjQtMy0xLTEtMA_dbb0da06-c1e0-46be-9e0b-9d834c3428a9"
      unitRef="usd">151800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjctMS0xLTEtMA_5c7d6691-92ac-4190-9821-2b9616e9952a"
      unitRef="usd">25700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjctMy0xLTEtMA_a2ce5889-d8e9-4f9b-8684-a3cca51c8fab"
      unitRef="usd">27200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjgtMS0xLTEtMA_4cd1649c-3f02-48a0-8d22-5c64fc2bb2c2"
      unitRef="usd">100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjgtMy0xLTEtMA_5842c78b-ffa2-42a8-9708-a9674bec90e3"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjktMS0xLTEtMA_3a8c12a6-0083-4a82-abda-44bf481097e0"
      unitRef="usd">25600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMjktMy0xLTEtMA_82f2e845-75e7-4f66-ac18-69a6b9436018"
      unitRef="usd">27200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzAtMS0xLTEtMA_7e2c8d6c-7162-4afa-9f23-7d2ff8ec0964"
      unitRef="usd">124000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzAtMy0xLTEtMA_421d2f63-5028-425d-8ec4-68b89f61f875"
      unitRef="usd">313000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzEtMS0xLTEtMA_85b47180-4d0c-489b-95ec-a8aa932e5202"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c4ca114f2d34a558af3a50593c0e518_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzEtMy0xLTEtMA_93e641ea-c774-4a76-bb6e-ceb3f9275d90"
      unitRef="usd">115500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzItMS0xLTEtMA_ba876074-1ba0-42dd-80ce-07a09a4615b5"
      unitRef="usd">314300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzItMy0xLTEtMA_564635d9-844f-418b-9c75-2d8f7c290e6e"
      unitRef="usd">428500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzUtMS0xLTEtMA_440f428c-8cc4-4100-a9e6-7919d32d617c"
      unitRef="usd">300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzUtMy0xLTEtMA_2267cb51-8261-45ca-ae4e-3b73a300c3d5"
      unitRef="usd">1100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzYtMS0xLTEtMA_ddcd0c6c-49a1-4dfb-b10e-96c713e2b96d"
      unitRef="usd">21600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzYtMy0xLTEtMA_28b39ace-7765-4650-b80d-d057a764b243"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzctMS0xLTEtMA_f96d9f3f-6779-4e68-816a-1169fca720aa"
      unitRef="usd">4300000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzctMy0xLTEtMA_a7c7f5d1-3702-428d-a417-095ffadba020"
      unitRef="usd">5800000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzgtMS0xLTEtMA_1ca72620-fdc3-4c3b-ad2e-80103ab3d8c5"
      unitRef="usd">3400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18yNS9mcmFnOjE5MDNmYmFiOThkYjRjNzg5YjNiOWE4ZTM3YzAwNzgxL3RhYmxlOmZiZGJhZGY4OTQzNzQzMWJhMWNjNzZiYWM0NDAxODQwL3RhYmxlcmFuZ2U6ZmJkYmFkZjg5NDM3NDMxYmExY2M3NmJhYzQ0MDE4NDBfMzgtMy0xLTEtMA_c7a0ffdb-0ac5-472b-a48e-eed2f097b3bc"
      unitRef="usd">400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzNg_8f6034db-20bf-48b2-8a3a-0a9620a0fe05">Organization and Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approved treatments for tardive dyskinesia, Parkinson&#x2019;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*in collaboration with AbbVie Inc.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, or the 2020 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2020, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant changes to our significant accounting policies as disclosed in the 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted Accounting Standards Update, or ASU, 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, using the modified retrospective transition method. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. The adoption of ASU 2019-12 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods. The impact of the adoption is expected to be immaterial to our financial position, results of operations, and cash flows on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities will account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of ASU 2020-06 is expected to prospectively reduce reported interest expense and increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per &lt;/span&gt;&lt;/div&gt;share, or EPS, which is expected to result in more dilutive EPS results. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 using the modified retrospective transition method.</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <nbix:BusinessDescriptionPolicyTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzOA_f0c6bc14-5c7a-48aa-99cf-0f2464f19725">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approved treatments for tardive dyskinesia, Parkinson&#x2019;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*in collaboration with AbbVie Inc.)&lt;/span&gt;&lt;/div&gt;</nbix:BusinessDescriptionPolicyTextBlock>
    <nbix:NumberOfIrishSubsidiaries
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfMzcy_5fee5ef9-47fa-4137-9020-db94caddb496"
      unitRef="subsidiary">2</nbix:NumberOfIrishSubsidiaries>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzOQ_79643ce5-1878-4939-a15f-2c882a4d9adc">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, or the 2020 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2020, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant changes to our significant accounting policies as disclosed in the 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zMS9mcmFnOjM3N2E5ZjA3Y2Y5ZjQxYjZhMmMxNzNiNTc5NDhkYzNjL3RleHRyZWdpb246Mzc3YTlmMDdjZjlmNDFiNmEyYzE3M2I1Nzk0OGRjM2NfNDgzNw_e42da4f5-2342-494a-980b-d972168ff772">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted Accounting Standards Update, or ASU, 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, using the modified retrospective transition method. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. The adoption of ASU 2019-12 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods. The impact of the adoption is expected to be immaterial to our financial position, results of operations, and cash flows on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities will account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of ASU 2020-06 is expected to prospectively reduce reported interest expense and increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per &lt;/span&gt;&lt;/div&gt;share, or EPS, which is expected to result in more dilutive EPS results. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 using the modified retrospective transition method.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfNzI2OQ_14138727-f01a-49ac-8a7c-33a6884b481d">Significant Collaboration and Licensing Agreements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited, or Takeda.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#x2019;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to (i) luvadaxistat (NBI-1065844/TAK-831) which we are studying in cognitive impairment associated with schizophrenia, (ii) NBI-1065845 (TAK-653) which we are studying in inadequate response to treatment in major depressive disorder, (iii) NBI-1065846 (TAK-041) which we are studying in anhedonia in depression and (iv) four non-clinical stage assets. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9&#160;billion upon the achievement of certain milestones associated with luvadaxistat and the four non-clinical stage assets, as well as receive royalties on the future net sales of such assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to luvadaxistat, Takeda declined to opt-in to a profit-sharing arrangement and instead will be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to NBI-1065845 and NBI-1065846, Takeda will retain the rights to opt-out of the profit-sharing arrangements pursuant to which Takeda would be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out rights immediately following the completion of the associated second Phase II clinical study or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical study for such asset. We and Takeda will equally share in the operating profits and losses associated with NBI-1065845 and NBI-1065846.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd., or Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals Inc., or Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates. Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we received approval of a clinical trial application, or CTA, submitted in the European Union for NBI-921352 for the treatment of focal-onset seizures in adults. In connection with the approval of the CTA for NBI-921352, we paid Xenon a regulatory milestone of $10.0&#160;million, of which we expensed $4.5&#160;million as research and development in the third quarter of 2021, and purchased 0.3&#160;million shares of Xenon&#x2019;s common stock (at $19.9755 per share) for $5.5&#160;million. The purchased shares were recorded at a fair value of $4.6&#160;million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. Further, we recorded a charge of $0.9&#160;million to research and development to reflect the premium paid on our purchase of the shares on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc., or Voyager.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into a collaboration and license agreement with Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#x2019;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) for Parkinson&#x2019;s disease program, the Friedreich&#x2019;s ataxia program and the rights to two undisclosed programs. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#x2019;s disease program, which became effective August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#x2019;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3&#160;billion upon the achievement of certain milestones, as well as receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A., or BIAL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2017, we entered into an exclusive license agreement with BIAL to acquire the United States, or US, and Canada rights to ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (opicapone). Under the terms of the agreement, BIAL may be entitled to receive potential future payments of up to $75.0&#160;million upon the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We launched ONGENTYS in the US in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation, or MTPC.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In March 2015, we entered into a collaboration and license agreement with MTPC for the development and commercialization of INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product in select territories in Asia and may also be entitled to receive potential future payments of up to $55.0&#160;million upon the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, MTPC submitted a marketing authorization application, or MAA, with the Ministry of Health and Welfare in Japan for valbenazine for the treatment of tardive dyskinesia. The MTPC submission of the MAA for valbenazine triggered a milestone payment of $15.0&#160;million, which we recognized as milestone revenue in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently conducting the KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington disease patients with chorea. In connection with our performance of the study, we recognized non-cash collaboration revenue of $0.9&#160;million and $3.3&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $0.5&#160;million and $1.8&#160;million, respectively, in the three and nine months ended September&#160;30, 2020. As of September&#160;30, 2021, $3.5&#160;million of revenue is being deferred in connection with our continuing performance obligations under the collaboration and will be recognized as non-cash collaboration revenue over the remaining study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc., or AbbVie.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#x2019;s and men&#x2019;s health. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product and may also be entitled to receive potential future payments of up to $366.0&#160;million upon the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie launched ORILISSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix tablets) in the US and Canada in August and November 2018, respectively. In June 2020, AbbVie launched ORIAHNN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the US. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix. We recognized elagolix royalty revenue of $5.9&#160;million and $16.3&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $3.9&#160;million and $13.4&#160;million, respectively, in the three and nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nbix:PotentialMilestonePayments
      contextRef="iffcf257f1217481a8a1fa04d4a631d43_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1ODk3OA_7ed15ce6-9423-4906-b63b-c3d88eca5f0f"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="ie3315e9d2376463bb766c7fda4822a57_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMjQxOA_b9b71c8d-2513-45c8-a063-c3b5da2d0984"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i3cc897ab39e04a5aaf3979ecf0b1aaf3_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1OTQ5Nw_24a15cd2-61c9-4a26-b7c3-8b7e58b7e53f"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:MilestonePayment
      contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc4Mg_90c38cdd-b470-4f84-90ea-877a65ac5512"
      unitRef="usd">10000000</nbix:MilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NjI5NQ_651aea50-457d-4d5d-b114-975343f4238e"
      unitRef="usd">4500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDcxNw_3d127a37-a822-4cab-9f29-73aeda151538"
      unitRef="shares">300000</us-gaap:InvestmentOwnedBalanceShares>
    <nbix:PaymentsToAcquireRestrictedInvestmentsSharePrice
      contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc3MA_6e8b2f6f-49e9-43cd-b4eb-99557436aa70"
      unitRef="usdPerShare">19.9755</nbix:PaymentsToAcquireRestrictedInvestmentsSharePrice>
    <nbix:MilestoneEquityPurchasePayment
      contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc0NQ_a4f0d2a7-554b-4b8d-ad44-6b6d6d1815b6"
      unitRef="usd">5500000</nbix:MilestoneEquityPurchasePayment>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDY4OQ_0f4ef79b-e79e-4a04-b881-d81624377ee0"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <nbix:PremiumPaidForEquityPurchase
      contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2NDc5Ng_c16f1036-bbda-4549-846b-b023bf5ee43b"
      unitRef="usd">900000</nbix:PremiumPaidForEquityPurchase>
    <nbix:PotentialMilestonePayments
      contextRef="i7496225d981e45bd95c16039fcf4c975_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY2MTE0OQ_49957c41-630e-49e4-bdc5-644e43c65cd8"
      unitRef="usd">1300000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i22958d29fbc4450c825ab099cc2474a7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzNzIzNg_2d3718be-839e-4251-b511-42391160f34a"
      unitRef="usd">75000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="ia3408f9286a74ad69f879196398aa1cf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzNzkyMQ_dd8c50ad-b26a-4fc5-b9c8-b69848113de6"
      unitRef="usd">55000000</nbix:PotentialMilestonePaymentReceipts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9430cff5e9084463bd1354a6bbc4c537_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY0NTU4NQ_3e42ccd6-658e-4b2e-9b9d-0f3306d0cbc7"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i5e55bf4fc19f4fdab09c36ac40b354de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg1Mw_085d2dd1-917a-441d-989e-a8fc658fc34f"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if448122914d649afac62b3524714a81a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg2Nw_7711b35f-3db5-477c-9e32-956b0bd98b09"
      unitRef="usd">3300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i189642a059634ad084c64f09713076dc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTg5Ng_c7b65357-9342-4306-bdfd-3517fb4a34db"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i08986f72f2a14760851809292bbcdfa6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTkxMA_61fb0bdc-c74d-4c33-a6e3-462575371df3"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia3408f9286a74ad69f879196398aa1cf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY0NjMwMA_ad00a60f-dccf-4ad7-a973-e185fd3d69c9"
      unitRef="usd">3500000</us-gaap:ContractWithCustomerLiability>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i08163ab015c545f98f6b59567476ccf0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTYzODQzMA_88801a79-3be8-4f95-bb2b-57564951ef86"
      unitRef="usd">366000000</nbix:PotentialMilestonePaymentReceipts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b114e2d031e4c17872a49ed97a20e50_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ3OA_7a5d517d-91fa-45f4-b79c-677dc76f0ba6"
      unitRef="usd">5900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic89aa56e595949039d1c9644bf3f36ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ5MA_9e8d47a9-3a6a-4574-885a-09a7fba3f2c2"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0120fe55568d4fc3a5928407baa25b60_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ0MQ_675cfac3-7089-46ac-9e66-57c35154e4f0"
      unitRef="usd">3900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie87e020d0a114fa4b7c4e0660e4c28b6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNC9mcmFnOmVmYmY4NDZkNTNkZjRhNGZhNDljZTY2ODA2MmQ5M2I3L3RleHRyZWdpb246ZWZiZjg0NmQ1M2RmNGE0ZmE0OWNlNjY4MDYyZDkzYjdfMTA5OTUxMTY1NTQ1NQ_c9b07973-7be8-4499-855b-56fb3f05ef0a"
      unitRef="usd">13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1MA_f4e94fc9-10f9-4490-b039-7e121d486322">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, our security portfolio consisted of 160 securities related to investments in debt securities available-for-sale, of which 82 securities were in an unrealized loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in corporate debt securities in an unrealized loss position as of September&#160;30, 2021 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;their amortized cost basis. We did not recognize an allowance for credit losses as of September&#160;30, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for less than 12 months, aggregated by major security type. There were no debt securities available-for-sale in an unrealized loss position for longer than 12 months as of September&#160;30, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $2.8 million and $3.7 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1MQ_dad10468-5fca-46c0-ab11-a472cf824c2b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0zLTEtMS04MDc3_b0369866-59e5-4ee8-a60a-90c87a381a48"
      unitRef="usd">208600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi01LTEtMS04MDg0_990ed46c-572a-480c-9f34-d5fd27e772f0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi03LTEtMS04MDg0_b734678d-2fc0-4c7a-8862-0ce7b747e025"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d3ca7b6ba924004ad97adc4ac3d5241_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi05LTEtMS04MDkw_176d2459-6217-4dd8-8979-a4b61f7feef5"
      unitRef="usd">208600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xMS0xLTEtODA5Ng_98964ce3-7aca-4f1f-8eca-9959204f7502"
      unitRef="usd">82200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xMy0xLTEtODA5Ng_2265194c-270e-47eb-80de-63cd1ed2740c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xNS0xLTEtODA5Ng_00ddc01a-a3dd-46db-9f2c-ebb74ef70186"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bb4e3749d7a4709b878ebc0ea005dee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMi0xNy0xLTEtODEwMg_e95e4dd5-f64a-4f15-81f6-fa02b136a9a0"
      unitRef="usd">82200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0zLTEtMS04MDc3_49d34223-dc54-4ee1-bbe6-ca1f5fe34fe9"
      unitRef="usd">170600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy01LTEtMS04MDg0_5c7bcb16-a537-4074-8a2d-c24d6dfedbed"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy03LTEtMS04MDg0_2de4227f-106c-4d62-875f-8708e2bcb624"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71e54f0d818448efa8b57b22dab1f6ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy05LTEtMS04MDkw_22ce9fa3-bfe1-4ecc-a4f0-450635498bba"
      unitRef="usd">170800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xMS0xLTEtODA5Ng_9bf76ffa-6590-4015-9e5e-92ea1b1c2b37"
      unitRef="usd">299300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xMy0xLTEtODA5Ng_f0a49047-0dfe-4de4-adc6-c02ac12e5055"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xNS0xLTEtODA5Ng_2dd71c37-32e9-4313-9d64-83406cebd175"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c0708e1e4554808a818ec7f02b33d99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfMy0xNy0xLTEtODEwMg_66fae6bb-2c50-41c3-a9f4-b77f0d4ee54a"
      unitRef="usd">300700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0zLTEtMS04MDc3_f35b2bf0-9eb9-47e0-8e23-bb50d4cd077e"
      unitRef="usd">75400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC01LTEtMS04MDg0_187aa4ff-27fe-47c1-91c9-28748664031d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC03LTEtMS04MDg0_3d07acf2-273e-4464-baf6-683b0b45c8d0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cfab6fa72f8484d9159ecc553820eb1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC05LTEtMS04MDkw_640ebcd3-41b4-4cba-9246-2a576a2611c9"
      unitRef="usd">75400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i187553e4d84849859e9761bba613da29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xMS0xLTEtODA5Ng_bf5e5fa2-c1f4-46c2-aa1a-1499b4c45004"
      unitRef="usd">230900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i187553e4d84849859e9761bba613da29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xMy0xLTEtODA5Ng_299577fa-8c44-4e72-8fb0-7c2f6297fe0c"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i187553e4d84849859e9761bba613da29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xNS0xLTEtODA5Ng_68fe0a5c-9986-4b97-b348-20e829a2b732"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i187553e4d84849859e9761bba613da29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNC0xNy0xLTEtODEwMg_7ee316d3-cce3-4abe-b0dd-29dafc38ddb3"
      unitRef="usd">231000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0zLTEtMS04MDc3_7777764b-5150-47f7-9167-8b327239f2a9"
      unitRef="usd">454600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS01LTEtMS04MDg0_c6739522-ab28-441a-a2e8-83cabf232fe4"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS03LTEtMS04MDg0_fd1fe876-f2fb-44dc-8616-a8a09af9d009"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fa625e3b7b743ae8108fe2498a46588_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS05LTEtMS04MDkw_488c26d5-0141-45be-b907-a7b96745b617"
      unitRef="usd">454800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xMS0xLTEtODA5Ng_79464065-2645-4922-9fed-c9a3a0a7cad8"
      unitRef="usd">612400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xMy0xLTEtODA5Ng_e056197e-eb61-4ed5-9c68-98d1d44bc2b0"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xNS0xLTEtODA5Ng_9f8153f0-7620-494d-843c-3c2ed007b711"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfe511c7bc1040d8bc7d4c231d784b01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNS0xNy0xLTEtODEwMg_be5be8fe-faa6-4c22-8c2f-d19e88ccf2c6"
      unitRef="usd">613900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0zLTEtMS04MDc3_66181558-1410-4330-b0c4-966726a95128"
      unitRef="usd">328600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy01LTEtMS04MDg0_43bf5d70-2219-429c-a6a9-24b1bbb3bbd6"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy03LTEtMS04MDg0_36baaa8a-a5ff-46f0-a2df-a0a04ed639d6"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e78a0ca3aae402794034bc5f1c455d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy05LTEtMS04MDkw_0dbf5c99-cabe-42b6-a1df-f9d5165f0dab"
      unitRef="usd">328500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xMS0xLTEtODA5Ng_8ccf6371-61ee-49cb-b2df-d33f76f2932d"
      unitRef="usd">144800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xMy0xLTEtODA5Ng_b4b75730-05b5-4867-b079-b229851739d4"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xNS0xLTEtODA5Ng_31d0a2a8-8f6a-47f4-95ea-57b603437571"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f340ad37bb64e67aa595f0848a1db28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfNy0xNy0xLTEtODEwMg_87a27649-2214-448c-b1e2-044ddf4cfa82"
      unitRef="usd">145200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if43744412019486abe9d453fb54846d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0zLTEtMS04MDc3_4f3f7622-f264-42ab-b720-9f635126de29"
      unitRef="usd">185200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if43744412019486abe9d453fb54846d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC01LTEtMS04MDg0_5d483850-241d-41b0-b394-07e59ee3fad1"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if43744412019486abe9d453fb54846d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC03LTEtMS04MDg0_6701a96a-98da-4c8c-9726-2ddf55ef2366"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if43744412019486abe9d453fb54846d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC05LTEtMS04MDkw_4228f00b-9f01-45f0-bdc6-8d04d38ddd8b"
      unitRef="usd">185200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc95789714e54acfb4a0507993443712_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xMS0xLTEtODA5Ng_e16e5667-34ee-4f40-9465-48d23f82de87"
      unitRef="usd">81900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc95789714e54acfb4a0507993443712_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xMy0xLTEtODA5Ng_ed98c6ad-4692-4d5e-9955-31c19721b302"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc95789714e54acfb4a0507993443712_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xNS0xLTEtODA5Ng_59cabcca-0455-4aae-a496-c02e16fa7c21"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc95789714e54acfb4a0507993443712_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOC0xNy0xLTEtODEwMg_53a93238-e292-4f21-a319-7b999858ba6e"
      unitRef="usd">81900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0zLTEtMS04MDc3_6d89ad93-8ea0-46c5-a663-71cff50439c8"
      unitRef="usd">513800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS01LTEtMS04MDg0_9fdb5fe8-cc83-4a97-a9b2-fc93304aa139"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS03LTEtMS04MDg0_ef31cfd3-13b3-402f-82b8-cdc47765e241"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ceac967d0bc47f1a2e9ea688c271f18_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS05LTEtMS04MDkw_c68aabd0-69f1-4b6c-8bcd-16e063e6f6da"
      unitRef="usd">513700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xMS0xLTEtODA5Ng_4eb0f2e0-fcad-4741-ad19-f5db4a5d5b31"
      unitRef="usd">226700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xMy0xLTEtODA5Ng_a21e4043-0bdf-475c-b1dc-e652a14b3d6f"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xNS0xLTEtODA5Ng_ba55bd32-835b-4ccd-b2e3-d10df7bba4b1"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02b450fe3b5341978f085deda2bc6161_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOmZkNDQ2MWJhOWE2MjQ1NDdiYmZmODU4YjgwMjUzNTI3L3RhYmxlcmFuZ2U6ZmQ0NDYxYmE5YTYyNDU0N2JiZmY4NThiODAyNTM1MjdfOS0xNy0xLTEtODEwMg_1d3e4092-52be-4c5a-8c6c-3babebbe12a1"
      unitRef="usd">227100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTA5OTUxMTYzNDE1OA_c7518f73-2c5c-4899-b160-67dacd5065b9"
      unitRef="security">160</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTA5OTUxMTYzNDI0NA_6cdbebe7-c7b8-48b5-9316-51351bf752df"
      unitRef="security">82</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMjA1Mg_50170103-056c-40c6-9919-4eaaededd5d7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for less than 12 months, aggregated by major security type. There were no debt securities available-for-sale in an unrealized loss position for longer than 12 months as of September&#160;30, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMy0xLTEtMS0w_27a78913-32aa-4800-a26d-9f7c229da3ff"
      unitRef="usd">298500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMy0zLTEtMS0w_f5c3ff23-5990-4050-83d2-2ce1bc094bb2"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMi0xMi0xLTEtMTA1NzE_7b74d561-80cc-4673-ae77-dcf519adc1e2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfMi0xNC0xLTEtMTA1NzE_354e36fe-fee0-46aa-a194-963fc6c51aa0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ica52a652db094241b061229da784c22f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNC0xLTEtMS0w_4df4ba47-47a6-4f72-b283-d4c446a06854"
      unitRef="usd">107300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ica52a652db094241b061229da784c22f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNC0zLTEtMS0w_c14b5b61-aa7d-4e55-b87f-587eb29b1304"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i94fb858a78824577ab6b7073295d027f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xMi0xLTEtODY1Ng_a1e8d804-dd4b-4f98-9c93-65d4c5c07cd9"
      unitRef="usd">95000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i94fb858a78824577ab6b7073295d027f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xNC0xLTEtODY1Ng_42f373cf-1062-4ccc-b381-9c73bc949077"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xLTEtMS0w_c0c2c0d9-fe56-49b1-b7ac-c69618a35887"
      unitRef="usd">405800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0zLTEtMS0w_b0abc96e-9eb9-4971-81bd-15b0f7749fcc"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xMi0xLTEtODcyMA_e5ae5b4f-97fa-49bb-b6d8-a0e62dffcbd3"
      unitRef="usd">95000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RhYmxlOjBjMjEzNDRlZmNiMTQwODY4MjRkMDVlNTU1MTAzOTUyL3RhYmxlcmFuZ2U6MGMyMTM0NGVmY2IxNDA4NjgyNGQwNWU1NTUxMDM5NTJfNS0xNC0xLTEtODcyMA_e3f78688-0569-4ebc-ab4b-3d9b95a76222"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:InterestReceivableCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTUxOQ_b6c4fe29-a64c-464e-a8a7-42dd837f7ef5"
      unitRef="usd">2800000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTUyNg_427378db-c624-406e-a354-d2558357fad1"
      unitRef="usd">3700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTk2Mw_127eb11a-2b0b-4119-9f2f-9dc8c9598975"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM18zNy9mcmFnOjhkNjM3MzI5OTE0MjQ0OTE5NTZmYjAwMDYyOTYyMjg3L3RleHRyZWdpb246OGQ2MzczMjk5MTQyNDQ5MTk1NmZiMDAwNjI5NjIyODdfMTk2Mw_a4f6f049-4d8d-4e25-955e-279372504015"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1Mw_d3a6784d-89e1-40c6-bf74-7427cb698cd6">Fair Value Measurements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to certain holding period restrictions are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,318.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In September 2021, we purchased 0.3&#160;million shares of Xenon's common stock, valued at $4.6&#160;million on the date of purchase, in connection with the approval of the CTA for NBI-921352.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the discount for lack of marketability used in the valuation analysis of equity security investments ranged from 2.5% to 7.5% (weighted average of 3.9%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity security investments are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1NA_81aa08ae-041f-476e-8d8d-7f47b4310ab7">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to certain holding period restrictions are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1NQ_af90768f-f272-4300-ba5c-2a01f2ab0f4a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,318.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="i157b928b65e741d6b3db895524a44b01_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xLTEtMS0w_26421546-8f70-4396-a2d6-6742291eb5fa"
      unitRef="usd">311100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d140b31a337457eacc3647d03f3f97f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0zLTEtMS0w_8d61ac1c-f98b-4c90-844e-b8b89b6a3821"
      unitRef="usd">311100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i29c5af590cb04d4092677c5129d1e809_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy01LTEtMS0w_6de0aab3-2b61-4536-b560-3273c6f07d3b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i671519a4e4e1485fb15ec6c947a07076_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy03LTEtMS0w_3591555d-3a69-40be-85f4-650d7d498332"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i4f2998a4df4a4439a8cc2c83d9e8f7db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy05LTEtMS00MDY1_91f7f8a3-ecdf-4a0e-9086-f6081dcf3a06"
      unitRef="usd">187100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i997255409c3c45f39333fc13018a559c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xMS0xLTEtNDA2NQ_0b86549a-1029-466a-8ddd-8e69c1725f92"
      unitRef="usd">187100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i875a9a2626b44cf18fa53b7b885a6bce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xMy0xLTEtNDA2NQ_0fb4173e-26c5-480a-b82b-8a15c7126dd7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief8a511b63824552bf8d257b1884b5f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMy0xNS0xLTEtNDA2NQ_efd7d665-80fd-4c7e-8931-413cf5e385aa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic9119184273346b2b8dbad7d616102ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xLTEtMS0w_7d7f8c3b-9490-4328-bc32-161156e4432c"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81504f29583943ba9978871037be715e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0zLTEtMS0w_5a6bd9a0-53be-4121-8a90-a3748303daaf"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib37e0266d4814246b83de0b9d9c168bb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi01LTEtMS0w_068c86b5-2e86-4eb6-a96d-74c4d4ea78ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iafbdfb0943f24a65a8f6da1e886aa8f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi03LTEtMS0w_7631cdc3-777f-4bf9-93eb-669764b4a398"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia262940bd03b4238a69d63782e9387d8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi05LTEtMS00MDY1_b4158d5c-c87d-47d6-84fe-0f403f1d239e"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i463c5678112d48c9bc0abef10ada5150_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xMS0xLTEtNDA2NQ_62aac1a8-4493-4916-bb49-fc7eb7137665"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i274f33b722f340dd83f22e59cf90400f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xMy0xLTEtNDA2NQ_3929c3e4-192b-43f6-9e86-b00518edd3b0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4db6ebba6644f3e9527c7fee2cff544_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfNi0xNS0xLTEtNDA2NQ_7f78bfb6-61fc-4626-9729-65ead30ba4d7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ice63c8557e304f948f1fafe5ab4e071f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xLTEtMS0w_ef4752ad-5e5e-4d1c-9d3b-14d2ff0ce12a"
      unitRef="usd">208600000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic87fa5828e80490fb8b8d1bd0374f894_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0zLTEtMS0w_eb2a7536-5f75-4a05-bbae-079497a0e9ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i192729099dcb4d288cb1d45579633c95_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS01LTEtMS0w_2b53b0c3-00fb-41c5-9bac-605096a3a681"
      unitRef="usd">208600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f2778fd50f940aa86c54d9c1324bcee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS03LTEtMS0w_87be1555-903d-4f5b-b59c-933ccf1ca5c0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i96a4d025226f4fe68766605d098d9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS05LTEtMS00MDY1_ab2c8f1c-c1ec-4ac3-94ec-927e43fd6ab3"
      unitRef="usd">82200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e972f1fd84e45db85d8fb910086c0f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xMS0xLTEtNDA2NQ_539708e1-ce0f-4c0f-96b5-52a60a6811fc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1703dbc936474604bfd0656c06657637_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xMy0xLTEtNDA2NQ_d438ed91-8980-437b-9c9e-1fd8d6c1cc10"
      unitRef="usd">82200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f653c1026734aabb17bcf80cee5821b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfOS0xNS0xLTEtNDA2NQ_6b51d5c2-affb-4a00-a18c-640f7eaecb20"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ib1dcd5486d1340bfa8e720e23609396b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMS0xLTEtMA_003abb91-47d3-433f-aedd-5ebd2d518be9"
      unitRef="usd">499300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i98cc854c976a48e1bbc3de3b9891bc67_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMy0xLTEtMA_73746160-5e25-4ef0-afd6-70ddbe2e92d6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f7dba45ab6a493d93352400235e1210_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtNS0xLTEtMA_0a8eea26-a909-43c5-a447-7cc4c2e79e57"
      unitRef="usd">499300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i927462043ac04752942634b64cea6355_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtNy0xLTEtMA_b58cbc0e-b959-43f8-9f72-c6fae388de5f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i3bf2e3d38fff4af1a6188647ded1558b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtOS0xLTEtNDA2NQ_54094236-51ae-4734-9885-768b582889d6"
      unitRef="usd">445900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a0d773bdaad4ae2b17b1d0b1b65fea4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTEtMS0xLTQwNjU_5e2ffd51-49f9-4e35-ba89-5087f3acbc12"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iec29fedb91804fec99b78fa71bf7c4d8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTMtMS0xLTQwNjU_ecda4c33-c1b2-4d33-9e8e-0d0906de184f"
      unitRef="usd">445900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42e99b5f202a4eeca47d4e76e0d243c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTAtMTUtMS0xLTQwNjU_0ed55109-665f-47df-96a7-3b8e1ea55118"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ica52a652db094241b061229da784c22f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMS0xLTEtMA_bfb244af-3c12-46a3-946f-9c288f4a548d"
      unitRef="usd">260600000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifefce9ebfc0840a2bc5e823a2df50751_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMy0xLTEtMA_d6762a34-599e-4eef-b359-9c7a409ef54b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fe8c38d81284f58932debf4c8cb7618_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtNS0xLTEtMA_426c97b4-bd0e-4662-8bfa-8ae982e996bf"
      unitRef="usd">260600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d6fe6eba96941e689ad3a457f7112ec_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtNy0xLTEtMA_79d29672-6f07-4568-806c-05d1fbac4c01"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i94fb858a78824577ab6b7073295d027f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtOS0xLTEtNDA2NQ_81dc4942-4636-46d7-b3d3-b051b8d65a22"
      unitRef="usd">312900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85eea9c802ea4670afeeaa43139cc8fc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTEtMS0xLTQwNjU_58a937b9-0e09-470e-bc3d-72d7af31f1df"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7630f29609c149bc8ed65aeacddff04f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTMtMS0xLTQwNjU_b8ca782e-a996-40d2-9262-51c9286a6838"
      unitRef="usd">312900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib2d8b3c059e442a49871d8451515ebce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTEtMTUtMS0xLTQwNjU_6f045acb-9435-4ecc-8b3f-be0e409138f7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i78b3269f9d1443bfa965fb2dce758c76_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMS0xLTEtMA_0403def5-5cc6-44f8-be88-9f9cccea9e79"
      unitRef="usd">35300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i147d42e72f9341768d5edb4e870a6497_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMy0xLTEtMA_6a2bd4f7-0bd0-445d-b290-3d6ab792a2ad"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if013f2d93404456e9e08b22da1ce31cd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtNS0xLTEtMA_466bcee6-0c70-4a2d-ac51-00031846e5df"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5363925363fe4d49a040c9683212cfcf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtNy0xLTEtMA_122d698a-252f-4703-9be3-b3afec67865e"
      unitRef="usd">35300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ie66734cfaa1e439ebc58ca3d6feeadb8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtOS0xLTEtNDA2NQ_5aa17a06-7efe-458d-b027-a8fef0d564e3"
      unitRef="usd">38200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d4b8082c01e4b57b79756ab536ae7e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTEtMS0xLTQwNjU_cc4061f2-5e05-40dd-b22c-458bd7e94860"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b12614a8c724ea3b20972094290e1be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTMtMS0xLTQwNjU_b15f4878-e39c-476d-969b-062d5faeacf6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idf3819533757414a9572e60d4e871a06_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTQtMTUtMS0xLTQwNjU_035d85a3-ba64-4240-b1c4-ac4beac5e256"
      unitRef="usd">38200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMS0xLTEtMA_8db833cf-4527-4f31-a7e3-a6181a11e2ad"
      unitRef="usd">1318100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41cc3330f8b146f39c81072617b752b3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMy0xLTEtMA_eb887ec1-0708-48d9-a269-defebfbb88b6"
      unitRef="usd">314300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i072cce2288a042b489e120bb3ec32f27_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtNS0xLTEtMA_4626be1d-f21b-4e1a-9652-7e3e787858ab"
      unitRef="usd">968500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i034c6598652d4102850711d648ea0aa8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtNy0xLTEtMA_bcc0da4b-6caa-4ea4-8809-c727e8a8f7d4"
      unitRef="usd">35300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtOS0xLTEtNDA2NQ_30ed4f9e-5910-423e-95bf-cb94918cbb13"
      unitRef="usd">1069500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icce42ab70b0940f9a48758422d138380_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTEtMS0xLTQwNjU_fa1d5a15-c168-4d8b-ac8a-f2e86eaa529b"
      unitRef="usd">190300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ac443b5cdc54d92bea87fa506638d36_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTMtMS0xLTQwNjU_76d75ede-9a1a-4676-a4f9-1b0da743bc35"
      unitRef="usd">841000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie38c9afdc13440eaae85aaebae77f419_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOmQ2OGI5MzFhYmZiYTQ4NGU4YzM0ZTRiOTU2ODBlNzFlL3RhYmxlcmFuZ2U6ZDY4YjkzMWFiZmJhNDg0ZThjMzRlNGI5NTY4MGU3MWVfMTYtMTUtMS0xLTQwNjU_9a110c34-f1e9-496d-b3b8-54838b24151f"
      unitRef="usd">38200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMzM1Ng_ffd1e858-9c5c-450e-9fa2-a47fa91ceb31">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In September 2021, we purchased 0.3&#160;million shares of Xenon's common stock, valued at $4.6&#160;million on the date of purchase, in connection with the approval of the CTA for NBI-921352.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i0d6f931f878e4baca21f094c9ee764f2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi0xLTEtMS0w_37d99ac7-5508-4cc1-9022-e64eeff57aa7"
      unitRef="usd">38900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ib9fcf70e01d7421cba408015441496c1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi0zLTEtMS0w_0e1209a8-3640-4dd3-b744-926b2b9e4eed"
      unitRef="usd">50700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ic5ae0844fb5746d38ea81deefd1b9bef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi01LTEtMS0w_cd9778af-b3a0-49fd-80ec-357f84bf65c5"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i8e6c3665c37e4724ae7c9e261e7bbc8f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMi03LTEtMS0w_0760f435-67bb-44d0-a365-ac8214dbfa00"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy0xLTEtMS0w_2a9cbd6f-1abb-4af9-86c3-005a410c986b"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i26221cd897194d5fb2af65836642c604_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy0zLTEtMS0w_466f0fd9-66e8-4708-a3cd-31fb81f55599"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy01LTEtMS0w_e49af870-1eaa-49ae-94fc-58185a1347ac"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i195a15919a14436a91e3c65518029bbe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfMy03LTEtMS0w_77e1c7cc-b0cd-4993-850f-ca54481c9464"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3eb800a52e87457e8410df4e3cdfc1ae_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC0xLTEtMS0w_c28834cf-1d32-491e-9ed3-acdf4e4c9743"
      unitRef="usd">-8200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i26221cd897194d5fb2af65836642c604_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC0zLTEtMS0w_d2921aca-c49b-4fe0-9155-c22e4c960831"
      unitRef="usd">-7000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i27cf1626bb5546c8a4caecb9b8a53c52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC01LTEtMS0w_93fa91e2-d72c-4c32-8fd7-576ca66c6857"
      unitRef="usd">-7500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i195a15919a14436a91e3c65518029bbe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNC03LTEtMS0w_b41f6514-f810-4210-a050-cad1c30a4cf2"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ib5815797b06f4ee6a46cb160090f637b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS0xLTEtMS0w_dbbff840-5fa0-479b-9e57-f8d15affa74b"
      unitRef="usd">35300000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS0zLTEtMS0w_2031e5ac-d646-4f14-83c7-0236ea4e4a65"
      unitRef="usd">43700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ib5815797b06f4ee6a46cb160090f637b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS01LTEtMS0w_9693fd57-e7f4-423f-886f-6c5de14e13db"
      unitRef="usd">35300000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i3f3328d2e5bb4e18a12813b73caf1db2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RhYmxlOjY0MTUxYTU3YTI1ZDQ1NjY4ZTMxZThhYWMxODVmMzgyL3RhYmxlcmFuZ2U6NjQxNTFhNTdhMjVkNDU2NjhlMzFlOGFhYzE4NWYzODJfNS03LTEtMS0w_d08f8f85-f054-44cb-a999-1ecee877bf1b"
      unitRef="usd">43700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i8ce6a674873848c2bf34283197bc4a5f_I20210908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfNDk0NzgwMjMzNDIzOA_cc99d8fb-afb0-4a59-afa2-7cd4d94f78f8"
      unitRef="shares">300000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i1fb1b799816b4579bdf8d70f351d4306_D20210908-20210908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfNDk0NzgwMjMzNDI1MQ_5fdb616f-450f-431f-a8fd-90fc9a8b15d1"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk1Ng_68789312-f513-48ad-a714-63127e833a4a"
      unitRef="number">0.025</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="ia7d8ece4878f459d8c0a6ad585eb5fe8_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk2Mg_e8bfbbf6-a49f-4f86-968c-d1a4dc615000"
      unitRef="number">0.075</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="if00a3aa3229f47c9b38aa8b37fe637f5_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180MC9mcmFnOjNhZWJkZjk3YzFhNDQ4NWViN2EyY2ZlYmNkZTk0Mzg4L3RleHRyZWdpb246M2FlYmRmOTdjMWE0NDg1ZWI3YTJjZmViY2RlOTQzODhfMjk4Ng_945d2c6b-3b44-406e-9539-33d960dec6d2"
      unitRef="number">0.039</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RleHRyZWdpb246NzAxMTM1MjA3ZDI0NDNlN2JkYzEyZTc5ODc0YmQ4MGJfNjE_208752c8-f65d-4ebb-91d6-08e52b3f3568">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RleHRyZWdpb246NzAxMTM1MjA3ZDI0NDNlN2JkYzEyZTc5ODc0YmQ4MGJfNjI_d8b98962-ba6e-4794-8a88-044453fb975f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMS0xLTEtMS0w_6c1c9dba-27ab-4f90-9f0a-41e61d8abd8e"
      unitRef="usd">13000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMS0zLTEtMS0w_ecbb1e3a-8e81-455e-bd17-ba3871602c49"
      unitRef="usd">16600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMi0xLTEtMS0w_27bb6805-d1e7-4ca5-83f5-a43ba370a388"
      unitRef="usd">1300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMi0zLTEtMS0w_78022b63-808e-4f3d-9e08-9dcea567e799"
      unitRef="usd">2400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMy0xLTEtMS0w_eca6d57a-15dd-4df2-b75a-496d4579512e"
      unitRef="usd">11200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfMy0zLTEtMS0w_65ee443a-0fd3-4477-b5b2-fdd39484db18"
      unitRef="usd">9000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfNC0xLTEtMS0w_73e9294b-098e-4775-967a-d07a157288b4"
      unitRef="usd">25500000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180My9mcmFnOjcwMTEzNTIwN2QyNDQzZTdiZGMxMmU3OTg3NGJkODBiL3RhYmxlOmE1YWM3NjlhMzg1MDQ2NTRiYTk1YTUzZTAzYTQ3OGE1L3RhYmxlcmFuZ2U6YTVhYzc2OWEzODUwNDY1NGJhOTVhNTNlMDNhNDc4YTVfNC0zLTEtMS0w_d3e86ffd-0b66-43ee-98dc-13b1e1abfc37"
      unitRef="usd">28000000.0</us-gaap:InventoryNet>
    <nbix:RestrictedCashTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RleHRyZWdpb246ODg3MDlhYmEwYTBiNDcyYjgyZjcxMTZjNDRlZTQxYjlfMjE3_25e217a9-8eae-44d6-b980-9104bb5c0d88">Cash, Cash Equivalents and Restricted Cash&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:RestrictedCashTextBlock>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RleHRyZWdpb246ODg3MDlhYmEwYTBiNDcyYjgyZjcxMTZjNDRlZTQxYjlfMjE4_87d1e347-6877-45fc-ab59-2ed97fcd51c2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMS0xLTEtMS0w_3155f481-5424-43a0-8b9a-3a15a330c92b"
      unitRef="usd">311100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMS0zLTEtMS0w_6e9752b7-063a-4a09-a70f-570e4dff4a15"
      unitRef="usd">425300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMi0xLTEtMS0w_eb2d9821-8503-4931-8f7f-596fd0e4984e"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMi0zLTEtMS0w_1d5b37ae-4a91-4d99-8e6b-409ef91c8efe"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMy0xLTEtMS0w_ad7b06cf-2136-45b0-b8de-f0614019dc43"
      unitRef="usd">314300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180Ni9mcmFnOjg4NzA5YWJhMGEwYjQ3MmI4MmY3MTE2YzQ0ZWU0MWI5L3RhYmxlOjJmZDRjN2EzNDdjYzQ4MDhiZDg5Y2E4NDBhZDE1Y2MzL3RhYmxlcmFuZ2U6MmZkNGM3YTM0N2NjNDgwOGJkODljYTg0MGFkMTVjYzNfMy0zLTEtMS0w_f14b7675-248e-41b9-ba1c-5363197c9e4e"
      unitRef="usd">428500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODM5_98718752-a687-4d24-af41-4c93d7d8a057">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2024 through 2031. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities. In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate future minimum lease payments under operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfNjYy_a2b0355c-b128-4ee5-871e-4f7c6f4e0caa"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODQw_fd8a20a7-0b80-410c-aea2-19370bfba76f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMi0xLTEtMS0w_994657f2-9ea1-4df4-b168-09467469de6c"
      unitRef="usd">11200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMi0zLTEtMS0w_8f040711-afb1-4e02-8d83-af83996448d2"
      unitRef="usd">7400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMy0xLTEtMS0w_ead51421-0cf5-4a33-8c21-17b7ba566461"
      unitRef="usd">9100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfMy0zLTEtMS0w_e13a392b-3867-47eb-bca8-c593f61e43e0"
      unitRef="usd">6400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNi0xLTEtMS0w_0c7808d5-7095-4ac3-84a3-dc542ee53ebe">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNi0zLTEtMS0w_29668ee0-aae3-48ed-a903-68718a35d22c">P10Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNy0xLTEtMS0w_b48ee369-a550-4287-9760-02813f4d4bcb"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i15c8cb47d45942eda9d8fb11ff473ecb_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFhZTY0NDdiZjE3ZTQxNTVhMmMxYjYxNzRiMGNjNjFlL3RhYmxlcmFuZ2U6YWFlNjQ0N2JmMTdlNDE1NWEyYzFiNjE3NGIwY2M2MWVfNy0zLTEtMS0w_91b87072-29c9-4e18-90a2-ed6495d87910"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RleHRyZWdpb246ODJlNTIwYzUyZmNmNDM0ZDgwZGVmMDkwNTUwYjc2M2RfODM1_ad28531a-c0a1-402a-b1f5-5095e2beef36">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate future minimum lease payments under operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMS0xLTEtMS0w_bca96969-dd2f-4da1-9ffd-72fa9695bb33"
      unitRef="usd">3500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMi0xLTEtMS0w_50eb7a8f-f9ce-422e-aea1-66577cea2fde"
      unitRef="usd">16800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMy0xLTEtMS0w_bf35187f-81bf-4353-b60d-42eb1ab416d5"
      unitRef="usd">17500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNC0xLTEtMS0w_777c2385-e8e5-4365-85cd-1e4c18dc47bd"
      unitRef="usd">17000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNS0xLTEtMS0w_4d060b5e-33dc-4006-bd33-8d6ca7d45301"
      unitRef="usd">15500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNi0xLTEtMS0w_d669407c-29e6-4e92-9e0f-9a1e6ccb6753"
      unitRef="usd">85400000</nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfNy0xLTEtMS0w_c210440e-b2b2-4527-a13a-a1d70d82c7ef"
      unitRef="usd">155700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfOC0xLTEtMS0w_de1c7381-0370-4004-8bda-529560eb0ff8"
      unitRef="usd">33800000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfOS0xLTEtMS0w_20493900-552d-44ec-a791-712da136ec98"
      unitRef="usd">121900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMTAtMS0xLTEtMA_ae391964-b8bd-4d80-ab5b-ab04ad47c73a"
      unitRef="usd">15500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM180OS9mcmFnOjgyZTUyMGM1MmZjZjQzNGQ4MGRlZjA5MDU1MGI3NjNkL3RhYmxlOmFmOTU0M2UxNTYwNDQwYWRiOWVjZmFlZWQxYTNmOTM4L3RhYmxlcmFuZ2U6YWY5NTQzZTE1NjA0NDBhZGI5ZWNmYWVlZDFhM2Y5MzhfMTEtMS0xLTEtMA_d1987468-2284-4c54-8023-1b681f649e7a"
      unitRef="usd">106400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyNg_2de469b8-0fb5-4f1f-bcea-8072e52cb19c">Convertible Senior Notes&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;the 2024 Notes and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At September&#160;30, 2021, $381.2&#160;million aggregate principal amount of the 2024 Notes remained outstanding. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the 2024 notes, we could not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of September&#160;30, 2021) for at least&#160;20&#160;trading days (whether or not consecutive) during any&#160;30&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of September&#160;30, 2021) on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTgzMA_ef1eef62-b79a-46f3-a25d-922b0620d60a"&gt;five&lt;/span&gt; business-day period immediately after any&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTg3NQ_a16f9f76-754b-427d-8388-b5aa3c37a979"&gt;five&lt;/span&gt;&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#x201c;principal portion&#x201d; and delivery of the &#x201c;share amount&#x201d; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#x201c;principal portion&#x201d; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price, or VWAP, of our common stock. The &#x201c;share amount&#x201d; is the cumulative &#x201c;daily share amount&#x201d; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$381.2&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#x2018;&#x2018;make-whole fundamental change&#x2019;&#x2019; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the 2024 Notes are currently classified as a long-term liability, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would then be considered a current obligation and classified as such.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2021, the remaining period over which the discount on the liability component will be amortized was approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $497.7 million at September&#160;30, 2021 and $514.3 million at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODU_bc746105-15a3-47b6-a027-e27fca766c4d"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia4f2ab910308454c8f7155eed697292f_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDAz_1d3e7b77-6d49-43c4-aa48-ef2a057bcb8e"
      unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="id661067c1cf345799ba33c3aaeb96515_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDg4_f5793e92-7d75-48bd-80c0-bba83a2de415"
      unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTA3_23e47215-0a50-4513-a212-d80c8b29e556"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTQ4_74332fb4-8fb3-49f0-9ce1-8130877bef98"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTAwMA_a06bb8d3-65d3-4bff-8fa0-3edfbac3ca77"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTAyNg_6496bae9-6ab8-4875-84ec-4d081451593f"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTA4Mg_0d19ffd9-7756-403f-a11d-ba2bcfc84e9d"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTU1Mg_70b88d79-2618-462b-9237-86221299a114"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTYxNg_28aa31b4-1fc3-42a0-a63c-bef40296a5ef"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTczNw_d40ec339-123f-40ed-b8f6-ba47114f7a27"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTc3NA_a06bb8d3-65d3-4bff-8fa0-3edfbac3ca77"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjAwMA_d10e92cb-aae5-49d4-a348-93c27b567b55"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjA5OQ_b4c2a2ab-3b7c-4aa8-939e-f6927bc27c01"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMjg0Mw_55fa3c2a-2c65-41bf-910f-7db2241f0457"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzQyNg_fe334ab1-bdfe-4364-9490-329ee154406f"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzUxOQ_1790db08-7cd1-4510-98a9-3ed1805320ad"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:DebtConversionObservationPeriod
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzU1OQ_d8e67b38-6704-408b-a52b-7c5b6c34be03">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:DebtConversionObservationPeriod
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMzc0OA_9c9147dc-b5f4-4b19-a41e-0985e5d11fb1">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDA1OA_5ee55015-ffa8-425f-9811-8cb2e81ad475"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDE0OA_bb90f719-63c9-4165-b8a2-1214411a959c"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDIzNw_84242f5b-e954-4eab-81c0-4fda020cbd55"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDM4MQ_66fe987d-3d05-4b5c-91be-49e43cd32da0"
      unitRef="shares">5000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDYwNQ_dd564e3a-a087-4de6-b078-17cbacf344a8"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNDYzNw_0108f464-05c8-4375-9762-0d26156821f9"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTE3Mg_e68190f1-49dc-45dc-b7b6-d66180e66d94"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNTUyMw_675c501c-7f8a-4f16-8586-f500297cfd1c"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzIzNA_368b8b6c-9c8b-49d2-8063-9bc5e9437318"
      unitRef="usd">368300000</nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzI2MA_0c322a3e-1b31-4edb-a682-d1eba2632c19"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzMxMQ_cd0137fd-1dfa-4a77-8014-80e792abad88"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyOA_67e5e267-28cb-4d3c-9e30-2a8711baf812">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfNzk4NA_508fd2e0-7607-48f6-a494-296fd327bf13">P2Y7M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i076a6551196f4eff9d3016f750447fd1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODA0Ng_ec8f45fd-6590-4508-bf8e-815e0bbbaa36"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMyOQ_62619082-487c-4e52-8a85-2bcb797af306">P7Y</us-gaap:DebtInstrumentTerm>
    <nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfODc3MQ_5875e29c-6c09-4621-a0b8-7be9e661d81f"
      unitRef="number">1</nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMzMA_26321428-f419-4782-9138-8a731d2144ec">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMS0xLTEtMS0w_a967ceec-9982-4efb-bc97-c369a5640ea0"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMS0zLTEtMS0w_cbfba291-622d-4955-9d35-296223e4e04d"
      unitRef="usd">381300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMi0xLTEtMS0w_d4931d06-cdd1-452b-8f72-9b6295af7040"
      unitRef="usd">3200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMi0zLTEtMS0w_8cb2c14f-b817-4b0c-b429-3caf50d157c5"
      unitRef="usd">4000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMy0xLTEtMS0w_e958b788-3ae5-4984-a99e-8ba74b28ac2a"
      unitRef="usd">47300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfMy0zLTEtMS0w_14596c8e-7b52-44c9-8ae0-26b9c3532628"
      unitRef="usd">59400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="if1fdb74440ee42898adbdc8492008e0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfNC0xLTEtMS0w_5f9a1334-283e-466f-87bd-600814d98777"
      unitRef="usd">330700000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ibc60fd6179844c8db173a8451d9462a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RhYmxlOmM5YTExMDk1OTA0OTQwNzhhMGVkZjI5NTkxMGFjMjc5L3RhYmxlcmFuZ2U6YzlhMTEwOTU5MDQ5NDA3OGEwZWRmMjk1OTEwYWMyNzlfNC0zLTEtMS0w_cc87b16c-f13a-4338-9c78-19ecd0af6d03"
      unitRef="usd">317900000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4ac19d8bdc704cff9d2b15cb27cfaf08_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMzMQ_5165b0f7-7f3b-4d3b-8adc-b28c52bfc4e0">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i98a1c92268c9462594c709744c9b9d2b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMwNA_0f445d72-fc41-4b9c-8489-e2e588a8d1ba"
      unitRef="usd">497700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if731862d3ce642ffae334bf7a6733e28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfOTMxNw_7ce692e4-60d3-441f-96b9-425755f352e5"
      unitRef="usd">514300000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNzc2_492e8593-87b2-483f-9561-2ffe69097d74">Net Income (Loss) Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2021, our board of directors approved an equity grant in the form of restricted stock units, or RSUs, to our full-time employees other than our executive officers, consisting of approximately 0.5&#160;million RSUs, which will vest over a period of two years.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.&lt;/span&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNzc3_25275e92-b1e0-4b42-af1b-2bb166ff10de">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2021, our board of directors approved an equity grant in the form of restricted stock units, or RSUs, to our full-time employees other than our executive officers, consisting of approximately 0.5&#160;million RSUs, which will vest over a period of two years.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.&lt;/span&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi0xLTEtMS0w_e70400ae-f8d0-4f31-9bd0-7543f8f35959"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi0zLTEtMS0w_7763776b-e918-4821-a181-abf18e439710"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi01LTEtMS0w_661b6a6d-67d6-4629-9f84-246b4b8a14de"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMi03LTEtMS0w_dd35df30-94c1-41f6-8179-1c7b2af1e342"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC0xLTEtMS0w_49f15db5-a855-43ec-b5c3-c777b07cbc56"
      unitRef="shares">94700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC0zLTEtMS0w_f41a48a9-aa32-4d91-ae4b-4b783895c3b5"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC01LTEtMS0w_704204b3-b6c4-4756-82fd-35165375ed52"
      unitRef="shares">94500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNC03LTEtMS0w_10c8eefc-b90b-4ecd-abcb-3b98f5a2b507"
      unitRef="shares">93000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i613b05cc13dc49b4a0c7a305b35ce164_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi0xLTEtMS0w_8421ee9d-2901-4436-90ca-c7e08b2182e5"
      unitRef="shares">1800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6646025f6a78471b87f269eb801ee821_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi0zLTEtMS0w_dda383b9-78b9-4c9d-afd3-92b6913f8749"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i65276afd2e6542f0b217ec8483499b87_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi01LTEtMS0w_5017831a-9cec-4e03-a931-ba4d7dd404ae"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8b01bcc9a078432796345ea93821c9a0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNi03LTEtMS0w_e066d239-0808-44e5-9de7-cc5b9bda33a7"
      unitRef="shares">2500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic4af071ef4314dd5b5a613cc233965c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy0xLTEtMS0w_690b0c43-55f1-4a19-b687-610d39aafce8"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id3ea3d3697cc4bbbbab42a49a59bd0ee_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy0zLTEtMS0w_a7be6479-d4ff-497f-95b8-a154c6484d14"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0d69c9551a434c0fb66e7651162ab9ea_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy01LTEtMS0w_9c4d2d61-deb4-4bdf-85aa-4281f14022e5"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia7c660c5054143d681316ee502a02a1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfNy03LTEtMS0w_b59297dc-0ef8-47e7-b380-a7ce0f57e59a"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i73039f27b8bc48928d0cb7f4492ccd5a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC0xLTEtMS0w_9e30a29b-cc1a-415c-b83c-85a3adcdef9a"
      unitRef="shares">1000000.0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ia7ffb61e2639493c9292444fcc81cf0b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC0zLTEtMS0w_6936f7c8-4698-4326-9aca-e9f075c45a2a"
      unitRef="shares">0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC01LTEtMS0w_087a177a-89c7-414b-bc36-439d5e7642a2"
      unitRef="shares">1100000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i54c87e3ad24243c1a4e073d2ef7e8134_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOC03LTEtMS0w_f0815825-7a55-4a98-b1d2-42e7f609c8d1"
      unitRef="shares">2000000.0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS0xLTEtMS0w_3c8be11f-9576-4dde-84cd-7e52f9a02f8b"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS0zLTEtMS0w_96f0ed5f-e2ed-44f7-9b42-b1e00dc311cb"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS01LTEtMS0w_641a3d98-faf8-4895-8110-1596b8d8036b"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfOS03LTEtMS0w_5a67c1b3-e1bb-43bb-9149-e35ec61fa9fd"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtMS0xLTEtMA_0943ccd0-510d-461c-8f05-ef0359524050"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtMy0xLTEtMA_de2ebad8-3768-4e23-a3d4-569d8276a8de"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtNS0xLTEtMA_a4e53a36-e18d-433d-834c-f9d9e1c43414"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTEtNy0xLTEtMA_9a8a6d0b-6d32-4ff0-b712-cc69a762e26f"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItMS0xLTEtMA_63f63da6-1435-4eb9-83d8-00db0958fe2f"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItMy0xLTEtMA_462a5b41-f3b5-4063-b117-e48764f2136e"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItNS0xLTEtMA_85b2b477-8000-4c81-a83d-fedf5279c576"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTItNy0xLTEtMA_38421654-42db-4840-9445-225239a60678"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtMS0xLTEtMA_fd37bf43-b685-494a-a714-fb41de5d8d9b"
      unitRef="shares">4500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i577826782de04321b0effe68b8ac13b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtMy0xLTEtMA_d827d210-81c1-490e-a725-8d4ae11c0b5c"
      unitRef="shares">10900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtNS0xLTEtMA_5c6ab879-9618-418e-9c72-b5cb74fe2e84"
      unitRef="shares">4000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic290267ee4f5403ca721163c2857bc6c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RhYmxlOjdlNjgxMzUxMDBmZTQzNzQ5MjcxZWVjYjExNzUwNWU3L3RhYmxlcmFuZ2U6N2U2ODEzNTEwMGZlNDM3NDkyNzFlZWNiMTE3NTA1ZTdfMTQtNy0xLTEtMA_1237101c-37e5-4397-958d-c9625aa5ec0b"
      unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i056102a1b5034e53811a069c914ac932_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfMTA5OTUxMTYzMTcxMw_7f00b533-7f71-46e7-bc49-0639775fe0f3"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0a1fca71d61f40dc8fbddba62968770a_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfMTA5OTUxMTYzMTMwNA_7f70aa49-503b-4ae0-98c7-904e820f7730">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i59928dbc3a794c87817b87dd10abbec1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181OC9mcmFnOjQ5YzM1ZWM3OWI0ZjRkNDhhMmE4NzAzYjA5ZGE1YzRlL3RleHRyZWdpb246NDljMzVlYzc5YjRmNGQ0OGEyYTg3MDNiMDlkYTVjNGVfNjIx_2f5e6f7e-f5ad-4750-9d63-729d365ade49"
      unitRef="shares">5000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM182MS9mcmFnOmE5ZTQzOTI3OWI5MDQ0MmRhNDI5ZDMyMjcxNDg1YjkyL3RleHRyZWdpb246YTllNDM5Mjc5YjkwNDQyZGE0MjlkMzIyNzE0ODViOTJfMjA0Mg_bc0691d7-bdba-444a-9c84-7b6c4af8edba">Legal ProceedingsIn the second quarter of 2021, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. (each an &#x201c;ANDA Filer&#x201d;) that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. The ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer&#x2019;s manufacture, use or sale of the medicine for which the ANDA was submitted. We filed suit in the U.S. District Court for the District of Delaware in July 2021 against (i) Teva Pharmaceuticals, Inc. and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., (ii) Lupin Limited and its affiliates Lupin Pharmaceuticals, Inc., and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., and its affiliate Crystal Pharmatech Co., Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC. We also filed suit in the U.S. District Court for the District of New Jersey in July 2021 against Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC seeking to prevent any ANDA Filer from selling a generic version of INGREZZA.</us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946999789560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,866,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139947084993048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 311.1<span></span>
</td>
<td class="nump">$ 187.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale, at fair value (amortized cost $454.6 million at September&#160;30, 2021 and $612.4 million at December&#160;31, 2020)</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">613.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">163.8<span></span>
</td>
<td class="nump">157.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,005.7<span></span>
</td>
<td class="nump">1,016.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">310.4<span></span>
</td>
<td class="nump">319.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities available-for-sale, at fair value (amortized cost $513.8 million at September&#160;30, 2021 and $226.7 million at December&#160;31, 2020)</a></td>
<td class="nump">513.7<span></span>
</td>
<td class="nump">227.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">82.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">51.1<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,017.3<span></span>
</td>
<td class="nump">1,734.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">205.9<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">225.9<span></span>
</td>
<td class="nump">186.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">330.7<span></span>
</td>
<td class="nump">317.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">94.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">671.3<span></span>
</td>
<td class="nump">608.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 94.8 at September&#160;30, 2021 and 93.5 at December&#160;31, 2020</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,974.0<span></span>
</td>
<td class="nump">1,849.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(628.5)<span></span>
</td>
<td class="num">(725.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,346.0<span></span>
</td>
<td class="nump">1,126.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,017.3<span></span>
</td>
<td class="nump">$ 1,734.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994983464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">$ 454.6<span></span>
</td>
<td class="nump">$ 612.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">$ 513.8<span></span>
</td>
<td class="nump">$ 226.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996033784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 296.0<span></span>
</td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="nump">$ 821.5<span></span>
</td>
<td class="nump">$ 798.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
<td class="nump">240.7<span></span>
</td>
<td class="nump">208.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">118.5<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">154.6<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">426.8<span></span>
</td>
<td class="nump">326.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">251.5<span></span>
</td>
<td class="nump">302.8<span></span>
</td>
<td class="nump">682.7<span></span>
</td>
<td class="nump">706.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="num">(44.3)<span></span>
</td>
<td class="nump">138.8<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity securities</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
<td class="num">(26.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="num">(57.6)<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on debt securities available-for-sale, net of tax</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="num">$ (59.0)<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="nump">$ 61.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in USD per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in USD per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">94.7<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 288.8<span></span>
</td>
<td class="nump">$ 254.1<span></span>
</td>
<td class="nump">$ 786.6<span></span>
</td>
<td class="nump">$ 752.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995102984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 636.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,768.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="num">$ (1,132.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">59.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">79.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">804.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,874.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(1,073.3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">831.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,842.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(1,015.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(57.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">804.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,874.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(1,073.3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">1,126.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,849.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(725.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">1,346.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,974.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(628.5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2021</a></td>
<td class="nump">1,279.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,929.4<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(651.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 1,346.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,974.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="num">$ (628.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946999579976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="nump">$ 59.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity security investments</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(30.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(21.7)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">252.3<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(658.7)<span></span>
</td>
<td class="num">(399.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">523.9<span></span>
</td>
<td class="nump">557.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14.5)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(153.9)<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Partial repurchase of convertible senior notes</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">124.0<span></span>
</td>
<td class="nump">313.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">314.3<span></span>
</td>
<td class="nump">428.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946992896296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">Organization and Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, or the 2020 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2020, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2020 Form 10-K.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted Accounting Standards Update, or ASU, 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective transition method. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. The adoption of ASU 2019-12 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods. The impact of the adoption is expected to be immaterial to our financial position, results of operations, and cash flows on an ongoing basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities will account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of ASU 2020-06 is expected to prospectively reduce reported interest expense and increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per </span></div>share, or EPS, which is expected to result in more dilutive EPS results. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 using the modified retrospective transition method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946993028776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Collaboration and Licensing Agreements</a></td>
<td class="text">Significant Collaboration and Licensing Agreements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to (i) luvadaxistat (NBI-1065844/TAK-831) which we are studying in cognitive impairment associated with schizophrenia, (ii) NBI-1065845 (TAK-653) which we are studying in inadequate response to treatment in major depressive disorder, (iii) NBI-1065846 (TAK-041) which we are studying in anhedonia in depression and (iv) four non-clinical stage assets. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9&#160;billion upon the achievement of certain milestones associated with luvadaxistat and the four non-clinical stage assets, as well as receive royalties on the future net sales of such assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to luvadaxistat, Takeda declined to opt-in to a profit-sharing arrangement and instead will be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, Takeda will retain the rights to opt-out of the profit-sharing arrangements pursuant to which Takeda would be entitled to receive royalties on the future net sales of such asset (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out rights immediately following the completion of the associated second Phase II clinical study or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical study for such asset. We and Takeda will equally share in the operating profits and losses associated with NBI-1065845 and NBI-1065846.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates. Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7&#160;billion upon the achievement of certain milestones as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we received approval of a clinical trial application, or CTA, submitted in the European Union for NBI-921352 for the treatment of focal-onset seizures in adults. In connection with the approval of the CTA for NBI-921352, we paid Xenon a regulatory milestone of $10.0&#160;million, of which we expensed $4.5&#160;million as research and development in the third quarter of 2021, and purchased 0.3&#160;million shares of Xenon&#8217;s common stock (at $19.9755 per share) for $5.5&#160;million. The purchased shares were recorded at a fair value of $4.6&#160;million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. Further, we recorded a charge of $0.9&#160;million to research and development to reflect the premium paid on our purchase of the shares on the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) for Parkinson&#8217;s disease program, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3&#160;billion upon the achievement of certain milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2017, we entered into an exclusive license agreement with BIAL to acquire the United States, or US, and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone). Under the terms of the agreement, BIAL may be entitled to receive potential future payments of up to $75.0&#160;million upon the achievement of certain milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched ONGENTYS in the US in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2015, we entered into a collaboration and license agreement with MTPC for the development and commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product in select territories in Asia and may also be entitled to receive potential future payments of up to $55.0&#160;million upon the achievement of certain milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, MTPC submitted a marketing authorization application, or MAA, with the Ministry of Health and Welfare in Japan for valbenazine for the treatment of tardive dyskinesia. The MTPC submission of the MAA for valbenazine triggered a milestone payment of $15.0&#160;million, which we recognized as milestone revenue in the second quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting the KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington disease patients with chorea. In connection with our performance of the study, we recognized non-cash collaboration revenue of $0.9&#160;million and $3.3&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $0.5&#160;million and $1.8&#160;million, respectively, in the three and nine months ended September&#160;30, 2020. As of September&#160;30, 2021, $3.5&#160;million of revenue is being deferred in connection with our continuing performance obligations under the collaboration and will be recognized as non-cash collaboration revenue over the remaining study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#8217;s and men&#8217;s health. Under the terms of the agreement, we are entitled to receive royalties on the future worldwide net sales of any collaboration product and may also be entitled to receive potential future payments of up to $366.0&#160;million upon the achievement of certain milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the US and Canada in August and November 2018, respectively. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the US. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix. We recognized elagolix royalty revenue of $5.9&#160;million and $16.3&#160;million, respectively, in the three and nine months ended September&#160;30, 2021, and $3.9&#160;million and $13.4&#160;million, respectively, in the three and nine months ended September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994551176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our security portfolio consisted of 160 securities related to investments in debt securities available-for-sale, of which 82 securities were in an unrealized loss position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position as of September&#160;30, 2021 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their amortized cost basis. We did not recognize an allowance for credit losses as of September&#160;30, 2021 or December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for less than 12 months, aggregated by major security type. There were no debt securities available-for-sale in an unrealized loss position for longer than 12 months as of September&#160;30, 2021 or December&#160;31, 2020.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $2.8 million and $3.7 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946993028776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to certain holding period restrictions are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,318.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,069.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2021, we purchased 0.3&#160;million shares of Xenon's common stock, valued at $4.6&#160;million on the date of purchase, in connection with the approval of the CTA for NBI-921352.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the discount for lack of marketability used in the valuation analysis of equity security investments ranged from 2.5% to 7.5% (weighted average of 3.9%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity security investments are included in other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994551176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994364808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_RestrictedCashTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946992799496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2024 through 2031. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities. In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future minimum lease payments under operating leases.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946993040360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;the 2024 Notes and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At September&#160;30, 2021, $381.2&#160;million aggregate principal amount of the 2024 Notes remained outstanding. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2024 notes, we could not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of September&#160;30, 2021) for at least&#160;20&#160;trading days (whether or not consecutive) during any&#160;30&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of September&#160;30, 2021) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTgzMA_ef1eef62-b79a-46f3-a25d-922b0620d60a">five</span> business-day period immediately after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjIzMmUzZDczNDA5YjQ2NDM4NWEwMTgwZjViNWJhNmUzL3NlYzoyMzJlM2Q3MzQwOWI0NjQzODVhMDE4MGY1YjViYTZlM181Mi9mcmFnOjIwN2Q1OTFkOWI1NzRjYzViMjA5MmRiNWI3MmJlNGU1L3RleHRyZWdpb246MjA3ZDU5MWQ5YjU3NGNjNWIyMDkyZGI1YjcyYmU0ZTVfMTg3NQ_a16f9f76-754b-427d-8388-b5aa3c37a979">five</span>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$381.2&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the 2024 Notes are currently classified as a long-term liability, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would then be considered a current obligation and classified as such.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2021, the remaining period over which the discount on the liability component will be amortized was approximately 2.6 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $497.7 million at September&#160;30, 2021 and $514.3 million at December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994250872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">Net Income (Loss) Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2021, our board of directors approved an equity grant in the form of restricted stock units, or RSUs, to our full-time employees other than our executive officers, consisting of approximately 0.5&#160;million RSUs, which will vest over a period of two years.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994498680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal ProceedingsIn the second quarter of 2021, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. (each an &#8220;ANDA Filer&#8221;) that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. The ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer&#8217;s manufacture, use or sale of the medicine for which the ANDA was submitted. We filed suit in the U.S. District Court for the District of Delaware in July 2021 against (i) Teva Pharmaceuticals, Inc. and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., (ii) Lupin Limited and its affiliates Lupin Pharmaceuticals, Inc., and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., and its affiliate Crystal Pharmatech Co., Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC. We also filed suit in the U.S. District Court for the District of New Jersey in July 2021 against Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC seeking to prevent any ANDA Filer from selling a generic version of INGREZZA.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946999623736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_BusinessDescriptionPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, or the 2020 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2020, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted Accounting Standards Update, or ASU, 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective transition method. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. The adoption of ASU 2019-12 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods. The impact of the adoption is expected to be immaterial to our financial position, results of operations, and cash flows on an ongoing basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities will account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of ASU 2020-06 is expected to prospectively reduce reported interest expense and increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per </span></div>share, or EPS, which is expected to result in more dilutive EPS results. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 using the modified retrospective transition method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to certain holding period restrictions are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessDescriptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessDescriptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946993022632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for less than 12 months, aggregated by major security type. There were no debt securities available-for-sale in an unrealized loss position for longer than 12 months as of September&#160;30, 2021 or December&#160;31, 2020.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994302952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,318.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,069.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2021, we purchased 0.3&#160;million shares of Xenon's common stock, valued at $4.6&#160;million on the date of purchase, in connection with the approval of the CTA for NBI-921352.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946992972376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946992871784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994470328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Description of Operating Lease</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future minimum lease payments under operating leases.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996903192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Notes Net of Discount and Deferred Financing Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994294984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2021, our board of directors approved an equity grant in the form of restricted stock units, or RSUs, to our full-time employees other than our executive officers, consisting of approximately 0.5&#160;million RSUs, which will vest over a period of two years.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946992962744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfIrishSubsidiaries', window );">Number of wholly owned Irish subsidiaries</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfIrishSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Irish Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfIrishSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995655016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="nump">821.5<span></span>
</td>
<td class="nump">798.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice', window );">Common stock per share (in USD per share)</a></td>
<td class="nump">$ 19.9755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MilestoneEquityPurchasePayment', window );">Milestone purchase payment</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases to acquire equity securities</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PremiumPaidForEquityPurchase', window );">Premium paid for equity purchase</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | BIAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | License | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Royalty | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestoneEquityPurchasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Equity Purchase Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestoneEquityPurchasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Restricted Investments, Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payment receipts under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PremiumPaidForEquityPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium paid for equity purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PremiumPaidForEquityPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_AbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_AbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995750920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 454.6<span></span>
</td>
<td class="nump">$ 612.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">613.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">170.6<span></span>
</td>
<td class="nump">299.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">170.8<span></span>
</td>
<td class="nump">300.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">230.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">231.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">208.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">208.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">513.8<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">513.7<span></span>
</td>
<td class="nump">227.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">328.6<span></span>
</td>
<td class="nump">144.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">328.5<span></span>
</td>
<td class="nump">145.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">185.2<span></span>
</td>
<td class="nump">81.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 185.2<span></span>
</td>
<td class="nump">$ 81.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995530440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Number of debt securities available for sale | security</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available for sale in unrealized loss position | security</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables | $</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139947000070488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 405.8<span></span>
</td>
<td class="nump">$ 95.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">298.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946997415832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">$ 1,318.1<span></span>
</td>
<td class="nump">$ 1,069.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">314.3<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">968.5<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">499.3<span></span>
</td>
<td class="nump">445.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">499.3<span></span>
</td>
<td class="nump">445.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">260.6<span></span>
</td>
<td class="nump">312.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">260.6<span></span>
</td>
<td class="nump">312.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">311.1<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">311.1<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">208.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">208.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996888680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.2)<span></span>
</td>
<td class="num">$ (7.0)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember', window );">Xenon | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases to acquire equity securities</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 43.7<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 43.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139947077229512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Discount for Lack of Marketability<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995544104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996191144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 311.1<span></span>
</td>
<td class="nump">$ 187.1<span></span>
</td>
<td class="nump">$ 425.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 314.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994355800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946994591240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996658648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Liability, Payment, Due (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year ending December 31, 2021 (3 months remaining)</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2022</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2023</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2024</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2025</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">85.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">155.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">121.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities included in other current liabilities</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">$ 106.4<span></span>
</td>
<td class="nump">$ 94.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946997359768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Detail)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
<td class="nump">$ 381,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Common stock price trigger (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfConsecutiveBusinessDays', window );">Number of consecutive business days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtConversionObservationPeriod', window );">Conversion observation period</a></td>
<td class="text">25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes convertible in to shares</a></td>
<td class="nump">0.0131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Convertible senior note premium</a></td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Convertible senior notes redemption rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent', window );">Convertible senior note carrying value of the liability component</a></td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Convertible senior note assumed borrowing rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Convertible senior note carrying value of the equity component</a></td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible senior notes term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Discount on liability component, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior notes</a></td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault', window );">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,700,000<span></span>
</td>
<td class="nump">$ 497,700,000<span></span>
</td>
<td class="nump">$ 514,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtConversionObservationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtConversionObservationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component of a convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Consecutive Business Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946995811688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 381.2<span></span>
</td>
<td class="nump">$ 381.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net</a></td>
<td class="num">(47.3)<span></span>
</td>
<td class="num">(59.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net carrying amount</a></td>
<td class="nump">$ 330.7<span></span>
</td>
<td class="nump">$ 317.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946997334312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) - basic and diluted</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="nump">$ 59.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">94.7<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities', window );">2024 Notes (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139946996086360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Additional Information (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of RSUs (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MAT]-';;T#B=:[O)=L9746L;YX5;P0"CS -Q?2ZE/)^8%Q<;J^#]02P,$%
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MW3VN&07QQ@"^7PDH@_H7<_.\_T_#]3]02P,$%     @ I(!A4X\24W$I P
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MWV;_)LD*7?U3_BA[M9\DQR3+D\><3U5>3/7FJ:X,>B>EL@,+&8-*9^J:<[K
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M"+8IWBBX9T*PI#A<4R)K+3>0OZ\8$]].\I<4#N_)3/X'4$L#!!0    ( *2
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M:X1OT$83]D[]4XH!$=,\05!"MU!'WZJ%8<L>X3!]W,1VH2IHR6+&'^DV]1;
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MCUZ]&"B?/H^G%_"1?)*>NQA=)8\%H$^>-V"=Q['NA15L_H_B_-]02P,$%
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M"264_@R%&*/+%&.R8Z'1/(HXDW,\L0%;PM(UY+G!CI4#7$ZC&U$&U+1")S$
M]8VA:?^3?J_;HUM9T&ZRA*OJNJ083\63G>ZP7A)\$@*X';\U1F8=9]JF NW
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M;ZZ<W0A'TM!&#WQ47@UPNB"CW >'MQKKPLV/4COQJS2E$N^5]*538#SXJWZ
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M71.E@(LF_=X*%]A!:JU"15C6GD(E O%=HQQ3Z6P=8S[#6V?;587--,_HBEU
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M,(D]<+7),,3&&\TC^79#W=5 *W&=3;L6DC?NQ0Q9E(IDCC&3_QI[=%G^VOK
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M1[2[\[$CHY5]5KX_ .MHTVS:-WG/&&7!CGPX3P-W-@:4.Y)B8,^$<A1PJ>'
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MHO^NE81DB O@^Z4%V\8/>$#WT\G7_P-02P,$%     @ I(!A4ZB]/MWR!
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MILGI\8A<]]KJ)L$V\86SL@'OI3@L\4!E)P+8+RS8Z2=B8'CR7OT#4$L#!!0
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M_8FH];/I;(Z._\&(?TJ4%Z:#F"XS)EGRKAST75."'H)PMC$=$$((FV1I/)V
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M^II&W-V48HZ4"F6[/3"[6D[3UO!7;'ND6"'K@O _SB #J-Z7?Q!8ZKH+HX9
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M<FMS:&5E=',O<VAE970Q."YX;6RM5FUOVS80_BL'+1AB(-&K'=N9;<!QVJ[
M"@1-VWT8]H&6S[)62E1)RJ[WZW>D7BPGCML ^R+JCO?RW/'NR,E.R*]J@ZCA
M>\9S-74V6A>WGJ?B#69,N:+ G';60F9,$RD33Q42V<HJ9=P+??_&RUB:.[.)
MY3W(V424FJ<Y/DA0998QN;]#+G93)W :QL<TV6C#\&:3@B7XB/IS\2")\EHK
MJS3#7*4B!XGKJ3,/;N\&1MX*?$EQISK_8")9"O'5$.]74\<W@)!CK(T%1LL6
M%\BY,40POM4VG=:E4>S^-];?VM@IEB53N!#\SW2E-U-GY, *UZSD^J/8_8YU
M/!9@++BR7]C5LKX#<:FTR&IE0I"E>;6R[W4>?D8AK!5"B[MR9%'>,\UF$REV
M((TT63,_-E2K3>#2W!S*HY:TFY*>GMWC4L,CQJ5,=8H*+C^Q)4?5FWB:K!L9
M+ZXMW566PA<LC>&#R/5&P9M\A:MC?8]0M=#"!MI=>-;@(Q8N1/X5A'X8G+$7
MM:%&UE[T@KWW^1:5IH+2Z@ILW"Q?P9MO9:KWW13\-5\J+:E<_C[CM-\Z[5NG
M_1><SC,A=?HOKF AE+Z"=U(H!9]S:B!NV>^H<91%\@?M($&;<^H4EL<(U'.P
MD+A*=;UIY=ZR5,(7QDL$L8:G!SC?LI2;,[RFJKU^9!Q/'>59T&80W*J"Q3AU
MJ-,5RBTZLT\; \A@2_,$M'%1MS+%H4#3-FN#C6VPY2',A,*TZ+F)7V(LDMQN
M&'8<EUG)F292D!U)ZADYWIC>WR*)$(UP:51[5];*VN1@V^1@97*@#CE@;0XH
M@]>*<D!:22(QL3Z6>^J@?RBWM<H>]+Y :S>F$C9'7S).,MKNNI3>0F.V)&"F
M'.\QKHG@"BX)?Y9R3A-&]>B,#^J'DW]RVEW:'&MUH*\47X@L0QFGY*A@!8'Q
M00L(8(],*KB@GAFY-[3^^LLH#,+?COZ:O5'HAB^(V*V%D(60E+)G"3YR%@Q]
M,N>30J-O.",(QV,W@L#MM_S(]]UAMUCI[!*Q19F;KKQ6!2514+T#42<<#0<=
M6\UJF6'DNV."$+3L, I<GP+I#_HV5O])J(8_HO4F"$G_@F .CO9O@H@LOIR!
MP  +VW1'X:CCYM)WHU[--6:#?N7,MZX.3H+^@.1?DX\CM\'(J)NHR6'0J^E1
M4*>B8EKR @843P4AJ@#V>S5W:"HBO+&K;^%6BH8[)#-GAN"@'8*#LT/PV= [
M/<V>CR[HS&PXT0H/0J7F<C\UXLY#^L$T^_%$L8,K[XXX.]F*&I&=W721FL%(
M8D$(F;T=?V(0N4#@),+.?'+Q?V$1>4)CXA@-,%MSQ_/-7+= &D=SCIC^*P:A
M/=7.:3VE#XWU]/ZBLAN/FC*T7?1\/KVJ8_PAE7Q5TN,!S82FNOO^P'9$TPMV
MLR[^4S7O=1Y9-'H3^Y14=&.4N:[>6RVW?:W.JT?:0;QZZGY@,C&W/L<UJ=),
MI%J5U?.Q(K0H[)-M*30] .WOAE[<*(T [:^%T UA'+1O^-E_4$L#!!0    (
M *2 85-GV@#/S 0  /$+   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;*56"V\B-Q#^*Q:-VD0BL ](@ .DD-SI(C77*(]KI:JJS.[ 6O':>[87+OWU
MG?$N9,D%&JD167OL\<PWGH=GO-;FR68 CGW/I;*35N9<,>IV;9)!SFU'%Z!P
M9Z%-SAV29MFUA0&>^D.Y[$9!<-;-N5"MZ=BOW9KI6)=."@6WAMDRS[EYGH'4
MZTDK;&T6[L0R<[30G8X+OH1[<(_%K4&JNY62BAR4%5HQ XM)ZR(<S?K$[QF^
M"EC;QIR1)7.MGXBX3B>M@ "!A,21!([#"BY!2A*$,+[5,EM;E72P.=](_^1M
M1UOFW,*EEK^+U&63UJ#%4ECP4KH[O?X,M3T>8**E]5^VKGF#%DM*ZW1>'T8$
MN5#5R+_7]_"> U%](/*X*T4>Y15W?#HV>LT,<:,TFGA3_6D$)Q0YY=X9W!5X
MSDT_<6'85RY+8#? ;6D ;]Q9=OS YQ+LR;CK4 OQ=I-:XJR2&.V1.&0W6KG,
MLH\JA73W?!?1;2%&&XBSZ*# >R@Z+ [:+ JB\("\>&MR[.7%_VWRE;")U&2U
M97]>S*TS&"5_'=#1V^KH>1V]/3JNU0JLJZZROM>4<<<:NC$D[R IC1%JR6;<
M"OO671]40QD[L@5/8-+"E+1@5M!JZFZS=2:2C*W! ,L;.!:$8[7!P3&]-DCF
MA*3-$HUY9QURZP5S&;"%EIC R#%BZ! '^1R,]\H5)#41MBO[]L74HR4%[V Y
M%@IC74I,6WO"?H452!;68U2/\=[U2VXSQE7*$IK MU*@H21]]+*5:P7/F$?F
M">O>HE2I94=H0-@)&^///PVB,/JP,PL'YWYO,_[(<X>7;T1"5T< 4"D8)Q8B
MX0ZC#&\SA4);X5C<B?S_YN!FW+=^!7/'+#E*.(&B^(H+25EZBK7YU**-J$OG
M.9A$<,D*7J!3HF#0.=N*V*4&44/+#G&I3:$- D:PNTI[PV$GWO*]HGK]SG /
M=?\B J]@J5=@%+G\U!;H9$UAB53%$)T%3<P[5!Q&#:F[U$=TM7MNH!W]N.1Y
MPP]SH1TDF=)2+Y^94"E66O/,XG[#G*T26HP';WF*%C$6VG$XJ".GA[Q';'@V
MZ/2)[GLR; =G0[\0#@._,NB%G8 82,*!>M/?UIO^P7J#E42K1$C!_5N'5_Q;
M:=A+)4 3FX%97TO#*>\N4G6*WHNE\D&-LA^5GE/MH5A$G45)[T>=C6\^((=M
M>6A6&^:\5%_=J$#X4O7*5-AQ,KGS?Q= 5GHK;</*LFFE>&7EB#UD!F#GZ6-?
MT+#=E=W"1N\9?8+&;,8E5PD0Q#DLA5($ VW$7!8ZK2)FB$,_Z)QOX@<I2K7;
MTB09-B@(*SQAO4;2-.>/"GLW*?Y!-/CR6;0DD25A0VC #>E# 2CVA!V?=P+_
M[>,7,PV7&O! I;O JECOQ16P!O7WOC\/]%HU'A2Z"/09.KPV)F64,/6=,9MQ
M4U60/T!I]8O%=RK/:</IY*E=.=3[]XALWAS#'SUA*14T@ES+;I/-&$RJ[A#7
MPF6>D1>%T2AK\_9=/EQ@1!KV979].HS"N!]UWLK9;J,-PRJ\],TF02R5JSJR
M[>JVG[VHVK@7]JH9ON$&G6^9A 4>15]CRIBJP:P(IPO?U,VUPQ;13S/LR<$0
M ^XO-!:XFB %VRY_^B]02P,$%     @ I(!A4]KW#;1I @  ' 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C N>&ULA51-3^,P$/TKHX@#2"B?+0M56XG"
MHN6 5 &['%9[<)-)8N'86=LE\.]W[*2A2-"]Q!Y[WILWDQG/.Z6?38UHX;41
MTBR"VMIV%D4FK[%A)E0M2KHIE6Z8)5-7D6DULL*#&A&E<7P6-8S+8#GW9VN]
MG*NM%5SB6H/9-@W3;RL4JEL$2; [N.=5;=U!M)RWK,('M#_;M28K&ED*WJ T
M7$G06"Z"RV2VFCA_[_"+8V?V]N RV2CU[(S;8A'$3A *S*UC8+2\X!4*X8A(
MQM^!,QA#.N#^?L=^XW.G7#;,X)423[RP]2(X#Z# DFV%O5?=#QSRF3J^7 GC
MO]#UOED:0+XU5C4#F!0T7/8K>QWJL <XC[\ I ,@];K[0%[E-;-L.=>J ^V\
MB<UM?*H>3>*X=#_EP6JZY82SRUOY@M(JS=' \2/;"#0G\\@2L[N/\H%EU;.D
M7[!<P)V2MC;P7198?,1'I&B4E>YDK=*#A _8AI#%IY#&:7* +QO3S#Q?]I\T
MW^":FUPHL]4(OR\WQFKJBS\'(DS&"!,?8?*5XKZK096P5]//2GF0QPWAS+0L
MQT5 4V90OV#PX2_EBB;"6"Q<*%LCE$K0:'%9S>"82VH2(:C?S0E0$2TV&]2^
MDM>8#T9R"O>LHRZRJ#D3!HX@R<+8+6?A&3S1& $1M5KE: PD809I.($;+CDU
M6@&54@4=)V$*%P1[5)8) KQ+/()T&D[=<D[WGQ4WVNO8!G7EY]+EMI6V;][Q
M=!S]R[[CW]W[=^..Z8I+ P)+@L;AMVD NI_%WK"J]?V_49:FR6]K>KY0.P>Z
M+Y6R.\,%&!_$Y3]02P,$%     @ I(!A4VMI $FN @  *P8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&ULE57=3]LP$/]73M$>0$))FK2#H38294S;
M Q("MCU,>W"32V/AV,%V"/SW.SMI*-!6VD/CC_OX_>Y\=YUW2C^8"M'"<RVD
M6025M<UY%)F\PIJ94#4H25(J73-+1[V.3*.1%=ZH%E$2QY^CFG$99'-_=Z.S
MN6JMX!)O-)BVKIE^6:)0W2*8!)N+6[ZNK+N(LGG#UGB']F=SH^D4C5X*7J,T
M7$G06"Z"B\GY<NKTO<(OCIW9VH.+9*74@SO\*!9![ BAP-PZ#XR6)[Q$(9PC
MHO$X^ Q&2&>XO=]X_^9CIUA6S."E$K]Y8:M%<!9 @25KA;U5W7<<XIDY?[D2
MQG^AZW5/TP#RUEA5#\;$H.:R7]GSD(<M@[-XCT$R&"2>=P_D67YEEF5SK3K0
M3IN\N8T/U5L3.2[=H]Q935).=C:[9*8Z ?>%J\>6/S&!TAI@LH!;-%;SW&+1
MRX_NV4J@.9Y'EH"=>90/(,L>)-D#\@6NE;25@2M98/'6/B+"(^MDPWJ9''1X
MATT(:7P"29Q,#OA+QRRDWE^ZQ]_[4%WX'W+RYV)%6E1&?P\@3D?$J4><[HN@
M;P)0)>4Y5S+G@C-?IW2S^U%.=KW*KL<XB.RZ_-PT+,=%0&UL4#]AD-U7"*42
MU*)<KL&ZAP8O]<5 W?>>8NXINB_@N[K1KPR]W"I@M6J=V%2JD\ E6,(CEP5U
MMU-3TBC!"^9LC*6E]MX&'"B)EPGAB QK+@11,,= -4!Z*]2^$-Z>QD?\0/ 3
MI)-).*%UFLS"=#N=7I?+7+14I(ZD(I8:F#%(AFF8^-^]LDS\3_@.<4I(#O$L
MG,&NXHFV&KA&O?9CRE!>*&M]+X^WXR2\Z ? JWH_1J^97G-I0&!)IG%X.@M
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MI\#59ARET7;CEBV6UFW$15[3!=R!_5W?:%S%@:5B J1A2A(-\W$T2<^F:>(
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M3Y?X6()V 7@^5\IN%ZY_A^>W^ =02P,$%     @ I(!A4_T% N=K @  .@8
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M<H/#':0!X/E*"/UAF/G1_RZR=U!+ P04    " "D@&%3]<P[J(<"  #E!@
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M?C ^ /U;K=W1\/,U_$[R?U!+ P04    " "D@&%34V1GWLD"  "5!P  &0
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M3.C=1&4#:'\EI=E-[ 'U2SS] U!+ P04    " "D@&%3+9+ ;0X#    "@
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M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R-E4U/XS 0AO^*%7$
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M<VAE971S+W-H965T-#$N>&ULS59=;]HP%/TK5J1)K;21$*"4"I#XZ+1*;85
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MWB<\ ;D#;=F:NV.23&GRJ"P>5%J LU>W8:?K>J?K_\D+@UK6H+$ J^IB,Z9
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ I(!A4R86.9?1 P  KQL
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MG[>_+Q^;O8=PQ]G!+XW5+U!+ P04    " "D@&%3B(RI-Z4!   O&0  $P
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M5HE"5HE"5HE"UC$*6<?_2=9WK5=__0F_79-:E<W1GW7_2>:?4$L! A0#%
M  @ I(!A4P=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "D@&%3"C%;INX    K @  $0
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M=#(N>&UL4$L! A0#%     @ I(!A4X\24W$I P  "PL  !@
M ("!QQ,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *2
M85.- CH1N08  +<=   8              " @287  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "D@&%3/S.J-CD&   S(P  &
M        @($5'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ I(!A4[P_Q+6$!@  91H  !@              ("!A"0  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *2 85.OZZMI]0D  *\8   8
M              " @3XK  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "D@&%3]Z1V7FD,  #\)   &               @(%I-0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ I(!A4Y%:6!'3!0
MY0\  !@              ("!"$(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( *2 85/9KE4D6 @  $P6   9              " @1%(
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ I(!A4[.O
MAM=< @  % 4  !D              ("!H%   'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "D@&%3\O\A=YD"   O!@  &0
M    @($S4P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M *2 85/IL>:!CP0  )\*   9              " @0-6  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ I(!A4W.</0K;#0  1BD  !D
M             ("!R5H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "D@&%3J+T^W?($  #^"@  &0              @(';:   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *2 85-A''BB2@0
M )$*   9              " @01N  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ I(!A4\,\;)ES#0  G",  !D              ("!
MA7(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "D@&%3
MS(L#.'4$  #/"P  &0              @($O@   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( *2 85-GV@#/S 0  /$+   9
M      " @=N$  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ I(!A4]KW#;1I @  ' 4  !D              ("!WHD  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "D@&%3:VD 2:X"   K!@
M&0              @(%^C   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( *2 85,/:%HTC0,  ,P(   9              " @6./  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ I(!A4^Z@X+2E
M @  E@4  !D              ("!)Y,  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "D@&%3#Q!N^  %  #W"@  &0
M@($#E@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *2
M85/[GS)$*0(  )0$   9              " @3J;  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ I(!A4RPGIFA9!0  [AH  !D
M         ("!FIT  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "D@&%3U%-D]3X%  "/&P  &0              @($JHP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *2 85.?H^:JW (  ,4'
M   9              " @9^H  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ I(!A4\AU= 4  P  _PD  !D              ("!LJL
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "D@&%3=#S@
M9)0&   9-0  &0              @('IK@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( *2 85-@AG3/.P0  !T0   9
M  " @;2U  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MI(!A4Z)50/6! @  B@<  !D              ("!)KH  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "D@&%3_04"YVL"   Z!@  &0
M            @('>O   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( *2 85/US#NHAP(  .4&   9              " @8"_  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ I(!A4Q&%7.[T 0
M6@0  !D              ("!/L(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "D@&%34V1GWLD"  "5!P  &0              @(%I
MQ   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *2 85,M
MDL!M#@,    *   9              " @6G'  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ I(!A4[@='Q78!0  *A@  !D
M     ("!KLH  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M   X%0  #0              @ &HVP  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( *2 85.7BKL<P    !,"   +              "  1W?  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( *2 85,F%CF7T0,  *\;   /              "
M 0;@  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "D@&%3*5V(H),!  #B
M&   &@              @ $$Y   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "D@&%3B(RI-Z4!   O&0  $P              @ '/
LY0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,0 Q $X-  "EYP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Significant Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements</Role>
      <ShortName>Significant Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Inventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail</Role>
      <ShortName>Significant Collaboration and Licensing Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Debt Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Debt Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Leases - Narrative Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesNarrativeInformationDetail</Role>
      <ShortName>Leases - Narrative Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Leases - Supplemental Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSupplementalInformationDetail</Role>
      <ShortName>Leases - Supplemental Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail</Role>
      <ShortName>Leases - Liability, Payment, Due (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail</Role>
      <ShortName>Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Income (Loss) Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nbix-20210930.htm">nbix-20210930.htm</File>
    <File>nbix-20210930.xsd</File>
    <File>nbix-20210930_cal.xml</File>
    <File>nbix-20210930_def.xml</File>
    <File>nbix-20210930_lab.xml</File>
    <File>nbix-20210930_pre.xml</File>
    <File>nbix-20210930exhibit311.htm</File>
    <File>nbix-20210930exhibit312.htm</File>
    <File>nbix-20210930exhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 328,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://www.neurocrine.com/20210930": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 21,
   "keyStandard": 261,
   "memberCustom": 11,
   "memberStandard": 24,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Fair Value Measurements",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Inventories",
     "role": "http://www.neurocrine.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Leases",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Convertible Senior Notes",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.neurocrine.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Legal Proceedings",
     "role": "http://www.neurocrine.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Debt Securities (Tables)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Inventories (Tables)",
     "role": "http://www.neurocrine.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Leases (Tables)",
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.neurocrine.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireRestrictedInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail",
     "shortName": "Significant Collaboration and Licensing Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i8ce6a674873848c2bf34283197bc4a5f_I20210908",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i9fa625e3b7b743ae8108fe2498a46588_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i9fa625e3b7b743ae8108fe2498a46588_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Debt Securities - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail",
     "shortName": "Debt Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "ibc60fd6179844c8db173a8451d9462a3_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
     "shortName": "Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i0d6f931f878e4baca21f094c9ee764f2_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i62fae1fc9abc4bd493e29d2a774eb7ca_I20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "role": "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i15c8cb47d45942eda9d8fb11ff473ecb_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Leases - Narrative Information (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesNarrativeInformationDetail",
     "shortName": "Leases - Narrative Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Leases - Supplemental Information (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesSupplementalInformationDetail",
     "shortName": "Leases - Supplemental Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail",
     "shortName": "Leases - Liability, Payment, Due (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
     "shortName": "Convertible Senior Notes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i076a6551196f4eff9d3016f750447fd1_I20170502",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail",
     "shortName": "Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "if1fdb74440ee42898adbdc8492008e0f_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail)",
     "role": "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail",
     "shortName": "Net Income (Loss) Per Share - Schedule of Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i1e25126c5e4f4d1fb3b21316f4881570_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i056102a1b5034e53811a069c914ac932_I20210831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
     "shortName": "Net Income (Loss) Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i056102a1b5034e53811a069c914ac932_I20210831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i2eeef242bbcc4ec59c2143f1f656c851_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "i2eeef242bbcc4ec59c2143f1f656c851_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Significant Collaboration and Licensing Agreements",
     "role": "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements",
     "shortName": "Significant Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Debt Securities",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210930.htm",
      "contextRef": "icfc2723d94044f91aa5b5a2fa4e1718b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_A225ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Convertible Senior Notes.",
        "label": "2.25% Convertible Senior Notes [Member]",
        "terseLabel": "2.25% Convertible Senior Notes due 2024",
        "verboseLabel": "2.25% Convertible Senior Notes due 2024"
       }
      }
     },
     "localname": "A225ConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AbbVieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Inc.",
        "label": "AbbVie Inc. [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieIncMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BIALPortelaCaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIAL \u2013 Portela &amp; Ca, S.A.",
        "label": "BIAL \u2013 Portela &amp; Ca, S.A. [Member]",
        "terseLabel": "BIAL"
       }
      }
     },
     "localname": "BIALPortelaCaSAMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BusinessDescriptionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Description",
        "label": "Business Description [Policy Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionPolicyTextBlock",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenues"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtConversionObservationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.",
        "label": "Debt Conversion Observation Period",
        "terseLabel": "Conversion observation period"
       }
      }
     },
     "localname": "DebtConversionObservationPeriod",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Convertible senior note premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability component of a convertible note.",
        "label": "Debt Instrument Convertible Initial Carrying Amount Of Liability Component",
        "terseLabel": "Convertible senior note carrying value of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.",
        "label": "Debt Instrument Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default",
        "terseLabel": "Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default"
       }
      }
     },
     "localname": "DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Number of debt securities available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd.",
        "label": "Idorsia Pharmaceuticals Ltd. [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities",
        "terseLabel": "2024 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_MilestoneEquityPurchasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Equity Purchase Payment",
        "label": "Milestone Equity Purchase Payment",
        "terseLabel": "Milestone purchase payment"
       }
      }
     },
     "localname": "MilestoneEquityPurchasePayment",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "MTPC"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NumberOfConsecutiveBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Consecutive Business Days",
        "label": "Number of Consecutive Business Days",
        "terseLabel": "Number of consecutive business days"
       }
      }
     },
     "localname": "NumberOfConsecutiveBusinessDays",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_NumberOfIrishSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Irish Subsidiaries",
        "label": "Number Of Irish Subsidiaries",
        "terseLabel": "Number of wholly owned Irish subsidiaries"
       }
      }
     },
     "localname": "NumberOfIrishSubsidiaries",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_PaymentsToAcquireRestrictedInvestmentsSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Restricted Investments, Share Price",
        "label": "Payments To Acquire Restricted Investments, Share Price",
        "terseLabel": "Common stock per share (in USD per share)"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestmentsSharePrice",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payment receipts under a collaborative arrangement.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments under a collaborative arrangement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PremiumPaidForEquityPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium paid for equity purchase",
        "label": "Premium paid for equity purchase",
        "terseLabel": "Premium paid for equity purchase"
       }
      }
     },
     "localname": "PremiumPaidForEquityPurchase",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_RestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashTextBlock",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_VoyagerTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voyager Therapeutics, Inc.",
        "label": "Voyager Therapeutics, Inc. [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsIncMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc.",
        "label": "Xenon Pharmaceuticals Inc. [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20210930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r102",
      "r103",
      "r219",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r252",
      "r278",
      "r279",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r388",
      "r428",
      "r430",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r252",
      "r278",
      "r279",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r388",
      "r428",
      "r430",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r152",
      "r265",
      "r268",
      "r390",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r152",
      "r265",
      "r268",
      "r390",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r218",
      "r252",
      "r269",
      "r278",
      "r279",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r388",
      "r428",
      "r430",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r218",
      "r252",
      "r269",
      "r278",
      "r279",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r388",
      "r428",
      "r430",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r102",
      "r103",
      "r219",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r363",
      "r365",
      "r368",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r55",
      "r56",
      "r57",
      "r416",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r63",
      "r64",
      "r65",
      "r106",
      "r107",
      "r108",
      "r307",
      "r431",
      "r432",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r287",
      "r288",
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r280",
      "r281",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r76",
      "r90",
      "r238",
      "r336"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r90",
      "r238",
      "r338"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r141",
      "r144",
      "r150",
      "r180",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r305",
      "r308",
      "r327",
      "r354",
      "r356",
      "r394",
      "r414"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r48",
      "r100",
      "r180",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r305",
      "r308",
      "r327",
      "r354",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r188"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r158",
      "r162",
      "r188",
      "r398"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r160",
      "r188"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Debt securities available-for-sale, at fair value (amortized cost $454.6 million at September\u00a030, 2021 and $612.4 million at December\u00a031, 2020)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r160",
      "r188"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Debt securities available-for-sale, at fair value (amortized cost $513.8 million at September\u00a030, 2021 and $226.7 million at December\u00a031, 2020)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r35",
      "r92"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r92",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r328"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Significant Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 94.8 at September\u00a030, 2021 and 93.5 at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r69",
      "r401",
      "r422"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r262",
      "r263",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue, balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r270",
      "r277",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r390"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued to settle notes at initial conversion rate (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r239",
      "r240",
      "r242",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r99",
      "r104",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r340",
      "r395",
      "r396",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Convertible senior note carrying value of the equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r217",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible senior notes conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r42",
      "r217",
      "r256",
      "r257",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible senior notes convertible in to shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Discount on liability component, remaining amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Common stock price trigger (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "verboseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r215",
      "r246",
      "r247",
      "r337",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Convertible senior notes fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r235",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Convertible senior note assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r99",
      "r104",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Convertible senior notes redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r99",
      "r104",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r246",
      "r247",
      "r248",
      "r249",
      "r256",
      "r258",
      "r259",
      "r260",
      "r336",
      "r337",
      "r340",
      "r341",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Convertible senior notes term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r228",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedLabel": "Debt discount, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r161",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "terseLabel": "Amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r161",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r172",
      "r193",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r172",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r190",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r169",
      "r192",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r170",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available for sale in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior notes"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r36",
      "r228",
      "r338"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r200"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r121",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r312",
      "r313",
      "r402",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share, basic (in USD per share)",
        "verboseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r121",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r312",
      "r313",
      "r402",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share, diluted (in USD per share)",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r135",
      "r181",
      "r255",
      "r261",
      "r287",
      "r288",
      "r289",
      "r297",
      "r298",
      "r311",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r431",
      "r432",
      "r433",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Equity securities measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRestricted": {
     "auth_ref": [
      "r371",
      "r456",
      "r458"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Restricted",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRestricted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r179",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity security investments",
        "terseLabel": "Unrealized loss on equity securities",
        "verboseLabel": "Unrealized loss included in earnings"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r12",
      "r17",
      "r175",
      "r413",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r315",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r318",
      "r319",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r230",
      "r270",
      "r271",
      "r276",
      "r277",
      "r315",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r270",
      "r271",
      "r276",
      "r277",
      "r315",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r315",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r176",
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r192",
      "r194",
      "r195",
      "r196",
      "r241",
      "r254",
      "r310",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r141",
      "r143",
      "r146",
      "r149",
      "r151",
      "r391",
      "r399",
      "r404",
      "r425"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r117",
      "r118",
      "r140",
      "r296",
      "r299",
      "r300",
      "r426"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r87",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r128"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r139",
      "r335",
      "r338",
      "r403"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r84",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r197"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r46",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r197"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r197"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r438",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r392",
      "r408",
      "r455",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Description of Operating Lease"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Year ending December 31, 2021 (3 months remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r100",
      "r145",
      "r180",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r306",
      "r308",
      "r309",
      "r327",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r100",
      "r180",
      "r327",
      "r356",
      "r397",
      "r418"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r100",
      "r180",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r306",
      "r308",
      "r309",
      "r327",
      "r354",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "terseLabel": "Discount for Lack of Marketability"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r60",
      "r65",
      "r68",
      "r91",
      "r100",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r125",
      "r141",
      "r143",
      "r146",
      "r149",
      "r151",
      "r180",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r313",
      "r327",
      "r400",
      "r421"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss) - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r141",
      "r143",
      "r146",
      "r149",
      "r151"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r345",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less current operating lease liabilities included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r348",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r47",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r52",
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r39",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r77",
      "r79",
      "r159"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedTerseLabel": "Purchases of equity securities",
        "terseLabel": "Purchases to acquire equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r77",
      "r78",
      "r159"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r201",
      "r356",
      "r409",
      "r419"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Partial repurchase of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Aggregate repurchase price paid in cash"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r293",
      "r389",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r92",
      "r97",
      "r393",
      "r415"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r92",
      "r97",
      "r457"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r261",
      "r290",
      "r356",
      "r417",
      "r434",
      "r436"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r181",
      "r287",
      "r288",
      "r289",
      "r297",
      "r298",
      "r311",
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r142",
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r264",
      "r265",
      "r390"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r347",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r165",
      "r166",
      "r171",
      "r172",
      "r173",
      "r174",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r104",
      "r246",
      "r248",
      "r256",
      "r258",
      "r259",
      "r260",
      "r336",
      "r337",
      "r341",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Notes Net of Discount and Deferred Financing Costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of RSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r63",
      "r64",
      "r65",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r135",
      "r181",
      "r255",
      "r261",
      "r287",
      "r288",
      "r289",
      "r297",
      "r298",
      "r311",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r431",
      "r432",
      "r433",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r135",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r255",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r261",
      "r282",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r100",
      "r157",
      "r180",
      "r327",
      "r356"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r176",
      "r177",
      "r178",
      "r241",
      "r254",
      "r310",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r270",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r128"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r128"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.neurocrine.com/role/NetIncomeLossPerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r462": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r464": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r465": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r466": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r469": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r472": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r473": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r475": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0000914475-21-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-21-000058-xbrl.zip
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M6% '!$U:)]P4D&,F[%0J%Q6-!/I/,TZLYAH'@YS%@2/OT"B2*<H'M&-G8WL
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M#SRIP"QWREDF/>.:D>"-]BI:C&-DDH)S_'+RF58/I-HVT8*#A"-GA$E-<4J
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M42&@<N!=XQG/2:]PMWQ\;H+Y^LHYQ=,^[$#L5,#6.NH#M5II;)TH\3[<SUQ
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M#]J?ISCT['.5]U\.=]IP7?O+P0[YQ!KO&_N[:X>TWCP\;Y!/9+?I#QL7NP?
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M:[V:.G6$F*\/(MDW'H-%VL5,(V,S)L$Q4"&@C.+@P3<VV%%?0>0,0^1, "%
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M*8])<3\<[RTQ,:-$"\ *YI!E"\L<WY9U^!I6FE4Z.F4=W4/?8(A3%O0T\]+
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M*E103B90F>EDS?1:6 !SC8(DF8@.J("+)K,.F4PY+Q'&@C-&P4S5Q/+"JJC
MO8SL8Z\+[!?(0)KK2G7AC](N5&]JG3"HH@//3 K&??^Q93J#E8Y?'W=_E6+R
M4*RI7Z<$2'*.>!" -3&FM6D^TQ')S!,KI M>)\DL\[DLHEX9Z80I066DDS32
M*T* M$X5HF0F?+ 9"\)EBJJ4#D:LBVEM" '>SFXK$ES%!IY]9?K3UZ?--;@\
MPXKT:O;QD:CRZ?K0[WE@6)*8&1I(QJ2#OZ)%F;:6"J\$L5* FU$J+Z,*!I1S
MY*^,<R+&>2T& *,\9TADCJ>- 5B$(=\QE5$0$G*&4J_!.,734[^K$,##5Z;?
M/N+_ZC7O7'WW"G9KNN>[SPNLON"R^PID'P2RGZ\SH&@$(=B+#!$@/\Q;EVE&
M>"K':TT(R$<8]Y;)&X3ETZ=$'F0))=]>KH*R5P-E+UA3H(*RAT+9%5^4VJ(H
M&  8347%%4:90205,R0$,6J=(3:5$Y"4/3T1_$6@;,0FQZT8ZR\I@&H*.R-?
M>UL*K^2[Q[85)K-/]W1;.5>T_?9-VC_DQN:MT=++CJ]M#[KN<+_;@J[J_V]M
M.)/]E"W<R[)+^VO?B+UU)>=J-_;YJ/YZN>_+D3E/"U,*^S7.]8Z#OR[O:G/V
M5[%#\J2WMODXU*J5CE\9ZM2UH:*J<?486GIXW<.V&F,OF<\H$3)C6)!,.\0S
MH@57SG+JO 0/&_%Y7'Q00=!<0M"D=^ZI(.@9(.B:9VR%42*B3!MJ,R:QS#1F
M(:.(:,8H)MBD0GM"3<PO?H&Y%)_WCUKF/#4V_!RU7NK,U[7WT,T]"7Y"0ZN9
MYN=( ZD0\FD(>7!C@:@2F'+O0\:04ADCD626 D(:3(-&VA)"8R)II=H#I<H$
M*2>KJ>QS0O9YQ6"\0DYC"JY3M#IC&D<P38/!2!4W$F!41[!/+$NUJ?A<197O
MLTW!4TG KR95[C6[.LL(-"F&4('/$\'GQII1@236&NM,:FK ?6( 0S;$S&D1
M//8XRF+/0C*Y"$YI]B28X/*1UVO5D^(5E54_W:JO*$5 ( C$<.8,8T IJ,^,
MI"S3G$="M7%1I:"($A/;DZQ\>P_,X#1GMU.T)DV#]4,G[_9JG>Z@"CH\.Z6X
MUO&I#EZ5XOY(#+JQ]#0P)!'BP">HMQGC$0/\I(K$EC!/A33(I_4G%%65*^?8
M1"?%#RH3G9B)7EMX&B@C7/ ,!^4R1@P8:[ T$Q9%(W6DUMBT!<$$:L=5H8<'
MS3^,R[#56JD.VZ2"#W.--,]3J'+LEYQ7B/-(Q+FQ*)7&H!D./D,XZ)0P8C)%
MA,T,-<)+([UT'!P3-(&5;^5+&*E,]5FK55:F.@%3O2('44@OM!69I]* J6*?
M60/\700#O)ZRM+AJ85FS4EGJ*X@2#',36MW.7C8(O7:5G3#%[(0*:1Z)-#?6
M:3JG+),B>2!:9LS1M+B)FPQY2Y2(PG/B%Y955;9RCBWTN?(3*@M]O(5>"Q0@
M'K D.$."J8R!16:*!?AHJ"?6!:X\6*@N523O%80)AAD*569"2=C!-=BIP.9!
M8+-SG0XP8QQB#F?>"@Y@(VEFA/& /3)(AKPB6B\L"XF?OVA#E9(P@^;\#"D)
ME3D_U)ROE;HB4D9/?&:#!78?@\NL-RB3EB M0%8*$S!GI&8N%Z$TM0M*?8]7
MP,.NUQOXGW\H@N4?10'QP?GCEJE790=F=2/PC[T0 [B;":1 )][\?,_DCZ&W
MO6]Z82)\=*/Q[L>"S:/6% KZT?0V>]L#,PC^2]J#_.KIH\$-58/;/0:WP[LW
M1#YP%[OM#;1#WAUL?H4K#S[1W?=UMMFLX]WF)UZ_V#C=N?C,ZA<[%_^^V#C_
M)H*B%@N7:<U%FG]GF18&QD<0M?98,1/DSZG/'1KT. I4:=#,:5#DTBJI;&:)
M!%^)89XI!#^00E8IJU74?F$9+2+T8X'_'_?8/C*]VDD2[!^U.Y6NGP3>?[9M
M(*ZK6Z%;_97CP7ZWE_9QKUCX5-2L3KXAKA15GF;81 9J)E%F*4V4WALO.8X\
M)0H]3&<FMRM!I3-EU!E0&<6C=AG3:=EIM"0SRL(PAZ@3W)N( EY8YK>L.OT1
MF(8*5#.78GTH0$VFS&',SX+/+D*O>Q\EW.CWCRL%G)("?F;?*#:<&4XSZBU+
M:A<S90+*G##"1:^I0^:AH#69RK^5'LV2'G'//([*@PJE;14):)0*&*=-7%V,
M%!D2W"SHT>;QH#\PG>0Z5\HT+672T1$D&,ID4"AM_H>!L .3PI);G7;E<(R]
M').JE&FFE<F[X)GS)F,JT7*+0V:-YAEWVEEGO'**+BQWNK]F6/?G8'DQ&A5E
M&KM7.E S@]IV.!J$M@V]8=2>HC>U!&+%J6O!73^$BT/H,CCJ\Y,J)^:9MAFX
MKUT7$9W*EA]JR]<6O.'@$ ,WQUD9P4GF(5,2FRPBP25E(5 *3G(Q/T#^*%&B
M3)7*5I;YY\IL7\QLK^:G'>%8:&LS87U,N6UIBU3OP( -P=$AA5+YG?*9[4O/
MJ\[&!-QJM]WN=IXR^S:QN9-A4ZJ)DXG9[<7*3ZCS9[BBL;][L(+J9(?#N[)=
M>!ZTZ1Q^MW:;Z[B^]ND,/M-_7ZSS;UC9H#B8N>)ISU412-IS568(,4Z1XT"K
MT*.FWB8V>5NI3XG5)UH2J(@B VV!'YYI4"0MLT""MX%0CC5^@7FWR:VNO]2U
M:@*E%#I6O_A&O<0L()498X".6.0SJS'-G#;2.AL]HP^>=)M<Q91*84JG,(H1
M1J*)&38PDC&%4TE))S.O P\!)*R=3[7<;JOT>J\YMSMB/Z,S3T,O3"EOX =U
MK.9,IJB*AZ??J(I<4\:!3Q&<L:+V6$ LXP);:G#4//#28%<5RRZ!QH T/77$
M9"&FB1'#1&9CH!G#D>@HG6;!%LO-?ZR"^R-V_2(:71*258'4-$G\:?WT&^;2
MFS2!P@V/0+&(SC3(-N,>2>LCD3&$:>4U53!53IT)WB%#!(6AS8:TGL5G"J K
M<]QSS3AW.F@ *GK+<I9;@6KB4V.OH8+,,W"!*I#^*,.ZFO\R HLHM4XCN,D8
M=2XS&MLL*FM%!,, KR3%1'Z,B%25G>;%+I]A\*OL\E%V>:UX [<(>14R'"/P
M:>5U8M8Q\QP&+ZX!0"4OFUV^KNVF5J#1J<--JW9D<I_EG9HS1_G M*J*3L^:
M&_.K?>LOY?(1Q++161T*Y1HX5;CT(%RZL2\5,0B<+P4NE\ ,B+30:8$ SH3!
M0!8LBMSXM*>]EJS:FFJ.37DR^3*5*;^X*5_+H8D6Z^A,ACGP#$99S(#YH\Q8
M&35SP@EODRD#/L]CC:A9H1G.';>/6RF-H-8=[G#9;1_UPG[H]/.34,L[\#E4
M!::??V_RL1B*:G6KUX6P4<C@0[??;X3!9FR:LPJ7'H1+-W:W8H%8&$QP9A5!
M&2-!I7P?\'\(C#"4*TX-3:Y/F4K85B&)LM"+RFQ?U&ROE9[&"(O(7(:P2>4F
MN00?P8O,::6Y4D[Z@(!./'U#S"IB,0$JX4/,73YX7:&*WUZ$./3A->&O[Z%H
M*PP,M,BOFUX'NJU_31IK0V%4Z/,@]+FQ<16+'&OF6>:31\,<(9GUV&7>TIB6
M"@A. 'T$N:U@W>]50&(.#/;QE*$RV!<SV/-K@<1@A"<\LU;'83*VE=9F8,6(
M*T-T$4B4A-_"\Z=BL*^@).*P-'7_SL*(5:7JTLYZ7*]FN5X(JP*G!X'3C1VO
ML+:$&V,RG\JT,6MDIB(R@%5>$$2-1";M>/6&,O'T68ZJGO4<&OV+S(]41O]T
MH[]B)" FC*R5&55198P#&5&,Z(QZ*IR7 -U1):/'1"R263'Z5["WU@\;:A3I
MXO=G,;_JBI&,AJ^X1$$0OGN<MOL>O]G34*YLW?G?4^R?>4'_%Z%\U[8Z6.GX
M:BQXXEAP8W<S([&1#KLLRI0O;AS--(P!H%<69,NUT%XO+),W",N)[7 V.3N:
M<DRJ M0*4&>13E> .FE O2+77 9'E-59P X#N=8BL]S[3$K/&67$")1F!]](
MRB:6;#1]0"W8]]N!@8>.5P5=J\AS[5XN@++W)FV&&/W*#DFQ$TH(->-26I'I
MG*>UX9WN .X^Z-8&^R'9H0^=?DAC0Z?HHF(",>8=TW%Y$2^$+]KP OW%FPN@
MKKWJZ'F<08..NOTBJV^I%UIFD)^$/TYS/]@?@\*UJT:20U>7& LM.![<?<E=
M?;K\I^V]7;ZS?641!?UN"=FUGZFU!>H02@+U8"A(6R885=P@K%#DEELC OV&
M]<+XHOW+_8Z.S%[(;"^8P\Q$>,$ETSHUY_V%MS?ZH9UWQ@V2!%K\?3??W9D_
M=&G;]/;@;B,9BIMC] MULKRUDQOKG[<V5[<V&NNUOS8VMU<WUANKZ]MO:AN-
MU;LUN"R-7]ULK*TWMM?7:O#7]N:'C;65)GS8;L*O^GJCN5W;?)?>9+.^7OOM
MP^;V]N^E?Z651GJ9^L>M]7_!FVU\6;]G^V]J6-K)JS0J]MMQQQS['(#ROLV7
M<-_1-VD\XL-MR=+(<86&Q6@%K] R1_VP-/[C#Y_WCUKF?"GO% TI+OKCYMW_
M'WMOW]36L:R/?A45]U>W]C[E8<]+SUMRBBIBXVSV+X;$."?7_B<UKT8.2!Q)
M^.W3WYXE0 L;'&1)L(2F*L& Q-*LU?,\\W1/3W?)3/EBI6H>U?3E&<RWZ13J
M%Q&CBT^^>'F[>>F+U7?ZFA3;G,E;7Z;;[-;7OG59NZV5^*ZK?OLU"5#'ND9C
MO=M5_R;6^;<;&O:KM][@74YIY7[<*/-W7#.-?QZ/4,"]P/<=CWM[*-9BLSQ?
MU=+H"?KD#AWM'NOC.<#?S/-T[CB+'C3P<'7GS05_*(=B^N$.S^(?_4$//^<$
MI?3X22]]#/@4>F?X$)JB&#U4]NZKW(J;(D*W^4W?VC;HWLPH,=BEW.U=^C0^
MFD=&E\$EC_'!U+FTX%S:@ RKE^E]&IRG\4(M9N\4MGKH_K/K/<AU'>%F'6@X
M2*A>1L-X'O#)N),T7B0O]''N)3W*W:#D,X\&# 2=P"KODLK<41V9IX8J\^>S
M9GM=4T;N=KKS@I:?CX:G3_&#RA#^Z$^.GYZ/\7&DT=['<')>'N/N>)SPO]BE
MHV*'1Q>;0:?[\O7I_[Q[\^J%..#/3TL%M(-WSX\/?W[]X?4[?._I_QR_>;7+
M\'JSS:!WNQ]>?/[K\\&[W\6+9R=_'3[[[<.+=[OX&2\^O7FV1U__\=O'PV<X
M_E<O/GRY&?3BV>[GPU<O^,&K4#:9 ._MTXMG;S^\_OR?OUZ\>GG\IHSUW8N/
M+S[_E*\V@H[HAS]C2E0"TX1J%PE$28EEUA'0B>OH.-.1HCHP9O&C8MT[KU$9
MZ5$R$J,XJ06 9BY ]*7XJ8G:ESX%-@:5&D:BEXQ$*R-U@)$^7S&2D-1Z*3-A
MIC2!\CD0DZ4DQN5HM V>E1/G7,+BY;8J(U5&NA=&4IP:[ERR65A@7MF(O[ J
M>6<]Y6 O-!*K&JD[C,2N&,DH-%OPGB27$X%D/;'42>*3CLD*';3/6SO:J&U5
M&:DRTEHPDM3.:::IXIH#H*>F*(O1"Y]-L#'G"XW$JD;J#B.)*T8"ZJW142$/
M02G\9Y"1>/;$^,RT4%2%&)"1).^4U[99M<*>EHP0/QRY!HJCBUASK0UV"R'9
M%"W-@=ID-1C%C9043/+(/5XG7L-(72.D@Z>M,!+G-M$D/>&NZ>86!;$^,*)Y
MMH8JE@2C2$A+.ZJWID=P'S>"42QX895T7$$,UM&84^(J@=+@70V[=!#!K; +
MSY(Q(PD/#A%<3@<8L(%XQ5$4AN!Y@JT=J(7^'C&"39 A1*&59 F\TB8;+GGD
M8'4P0M4P10<1/ M3.*=L )U)]*RTX;:E8YQ61%(GN?0ARG*J1\"VK1!^M!!&
MA] &ZHWRE$(6U&=P+"01@F2<:EW]^NY!>.;7:P:4Q4!+N3Q<A$/0Q#;]@%BB
MVB3F56GA![)3.GICJEHLY,-?/P:Y@45X6.)(02K(!!DBRUYXSD2I4FL,DYI6
M![]KS'34<O!1_441T!^0QC("PI3^!)$3*9/*5JJ04]C:X78));CF1<H:%?W<
M7/1+K0U'CX+'1$%PYBDN/TD9;UQ@R 0U.- ]],^" PYB#AS5""ME?"$[1IR'
M1%PTU#,=',^RY&3<5-"WHK^B/^#LT5Q$"Q0@6^:<]!(GC8/$-#.^!A:ZA_Y9
M8"&*2-&#M(39[ DPI8A+6I.8(-@D3!"E.K#AK**_HO\F]'-+<>U/*/PE4!&<
MYHPI$;B1V@<5:DRB>^B?Q21\=MP:+HCQ7!&0BA$;I"$V&@,<'#>9;>UH:]9'
M^6_ V;;#LU0R#P9O>^GC6:D8M-@IMZZ<P*K7N,,U-NO<V=/A>-(;YIO/G,VS
M0#_J-7CIT;?RV _SS\-A;.KSI='[?DCCH^%)K$OM/$MM^S!6HMD(IRS107,"
M.DCB;78DH8ND$XIO\,T>_,+1_^ZE&5>@KBI05H&Z+*#.XF$L*L-$.3 II"/@
M5#DU"9:8J*UCP3O*RQFE3G7JK4#M>$RK G590)V%K@3HC'1J25(45U1.,S$L
M!T*M$\9*;J4JO6-H75(?,U*7'7^J2%T64F=A)F<A:EPYB7'E2 O:C'@/CF1+
M:>0A!!/94C+(ZX&6[RZ7-$YN%(Z;CBXQO4\GP[-2:;H>:;F_C)>I!9!TGLV>
M_]XTP#>+>H?_/>^/4MP?_#H:(B^-"UU58IJ#F [;1UN\*C4'LB:29XN"GXG2
M?@X(KAWHH1F;>$FKM4L0^S6MMK-07D'Z2H7R/4%YYK9;+Y)1@%!NFLK9D(D3
M2A(&/@%B//&<MW:47;RR2(5R9Z&\@ER4"N5[@G*K)H>,0'WT1&>@!%!<$4]Y
MR4E!O65DX#ZFK1T.M"[+CQG+R\\LJ5B^)RS/7'^>!??HXA.FC2/ 0R1&\$@R
M>DH0LO#!^E*AV"S>W:][QU[6Q/F_G/*]_H"<32=];[3,@, F!"*7$!!H=]#+
M_8\IDL]I-+P;C95TN,FE(0\GQVGTZM@-7AVC'=X>_W0^QELK5';J^X.F:,D?
MH_YDD@:'*(HKM\W!;>US,Y[)I)(!PI5 G1(D(QZ2(992;X+(6DBQM=/T1.8_
M=BBT6?<@UC* 4"%^7Q!O)0-X*Y+7BJ#KP0@R>R NF )VE86ADL6@MW886][A
MF KP[@'\GL(*%>#W!?#6^1=MDDE<$R5!$&B6;["4()-[*R&!XFQK1RXM_[W"
MNX/POI](0X7W?<&[%7ZP,3/#%)'>: )"1V*C#@2LS"8'801WN'XKZ-3ZO5FY
M!T?I!'_Y]DGO;1JDD3MI0@XNGO8'_?%DU#2NKFD(]Y6&<&&,GZ>F0 +;O6:(
MBVAI):1YJON^VBUD-(T;[/X97+19NT"20;\"E')EHS(1&IUT5.6H?4)*DK!X
MQ?&ZN]%9X"X]9E"!NQK@?KH"KO'6<AH%R3Q) HGGLBV9B3(J9BLEDRR46 !?
M7$M4X'86N$N/!53@K@2X![,5-XN@ UA-0@9.(+#BX^M,I#51:P;*970"@*O%
M*^I7X'87N,OV\BMP5P/<V8K+G 3F)25*\^;<0"#.1E_*6+,H,^-2L:T=T3'@
M;DS-S.%7=2AJ]<Q../$E9:F<7KJ@H''EH+DX:*_MKHL@I:01U0*R#@$>'3&E
M@*_4,F9@*KI0BF/*6B"K@OO>SOQ7<"\"[IG L$(XYG(@/G-?CA K8A35Q'$D
M8/#>@$LH,.CR>FU5<#\F<*^D3D %]P+@;KG]08#68!EQ#A=M$!:(@Q 1W#&A
MVZ_1> AN9997RJ."^U&!>Q6E!2JX%P%W*QC/>># *-$ZE:K5J,V]99&@D"J%
M*T$&([9V-%U":."^P+U1E2O[@S \3;U_G S'XW\NLKV_N?RT]+#!E77V&^/\
M@J:I%#471>VW(P>H/9QTR1&9?2;@,D.*4I$P7#\2SRI:IK=V8 FI1_-"88VV
M)!X9O/]QOY&#,=XO?E>!O@*@S[1(\DC!448273GCF*D@/EA'\!LO<BY-CE4#
M]*^/.'ZU]%6,KSW&'S)^4)&].+);(00JDN2HLHCRUI;>.)H@]^)B3I/PWAFF
M@]W:8<(L;0.RXOM1X7O9(82*[R7@>[9R*P%9&2V(L+X4Y<Z1F$0545I$H8T'
M*_W6CF5+Z\G9O2#"^B4?-$=G>O^XR#GXYT4HX?M:8-PU4%JOT9UK;-;IF'U<
M3D9I/+G,L=FLHS#S^,M+CX==/OJ:R?<]"^UO[5B8T49K\()P)3T!8)$X'S@Q
M/N)_#IUGZK9VU U'7N;VD-=4)#]N;"X]"Z9B<T%LMK;20-N2 D^$H^C:EO(6
MUCL@-,> NCB6[?.MG9LJ7%1L/@9L+CT(5;&Y&#9; 2C'!-(ASZ5AE";@-!#'
M@)(<8\A9LBA+@6IF;W!0*S@?!3B7'4&JX%P0G+.%4R1F--6,!.L-@C-X8I6V
M1&<7,E4NJK)P\IN*QSP(.#>KJN7O@U'"47Q.L5>23'J(L_2_Y_W)I]XXA?-1
M?]+?M):2]^Q,W[+YO-<8X>C*!L_?'_1GMOK9]0<UJCTW+_W>=K9CEDA!5),0
M1.GI#IHX;2RA.LF@5>#!VB+H%]$,M9Q5=[&[NL21BMW58/=3"[O1*\HL2<$C
M=F-0Q-J$ZH(&X,):+[(JK;(6D105N]W%[A*<\8K=^\1NRUFW.CIC8RP5)*$4
MBV7$<TE)B%Z;Z'@P+A?L+A)(J]CM,'87]]4K=N\5N[-U-T!2(98VSR8$].49
M)T8P222".NAL,HMQ:X?QKHCF3=L$?Y_&DU)$]?+@2*D1.2R)($]Z@U3;5*Y\
M3WS@\4-G9IBFG^T.IG5L#U+MD#,?][QN^^M>)B48-X3C5]0-.A,K#"51BB2"
MU4$"^NNT4T5N:J"_HV4B*E"7#=16N8A@E,]9$Y1TC #GI>.\ ((6 TB 6-2P
MM5.[Q3YFH"YMM[P"=<E ;7GBW(8$*5A2W"X"(47BK#4DVX#PI2[)'+9V1.T%
M^YB!NJR=\PK490-UMJ)*XQAPK0GSG%X<P. 1UU9%DTQ&<6I+,72V>/^5[NVC
M=]GAOBCPV)RTN$@\_WY'^W%6DNG&;OK!<#"\?B:L)O9\#RN%MD/.G4D>K4#0
M8.5 -SCBJ9'$1%I*PAF1>*GT#LO8A>O,@<]:,ZK;>^\5Z4M#>JO"-)7>0BS'
MNBU'C]XK8@73Q!K/K7)(S3$W8?^O8V\5Z9N-]-7MU%>D+POIK9  :/0 F0Z$
MN:0)^.R) ^8)Y^"%C=)Y'[=VN%CH"%I%^J-$^LKV]2O2EX;T5@J=M3H#M\1Y
M$0E('X@OK2,@&">L#EEH@4A7R]C*[UX]A_4K"KG?+@79\RD/1ZEW-AJ^[X\+
M,/''RTW_B?OXG3G[&U^)9@6'XR\+T#P?#4^?XF?U!^?X^"XJU P'XY\:2T[?
M]ZI8;N_C9.30 OV!&WW:GZ33,?)?&>5HV'32N3R:5,EO+O)[VPY=6)]H*E4F
MG<Z&0$R)>"H$899'+T-F.966.;06G=P<FNA&_*(21H<(8Z:6O,LT<A;1+RHG
MC),2Q(@(Q 2F%$M21:^V=J2^8:^T%J]\?%SQL'4#*D-TA2':QQJHX>@T^7(0
M*1%PWA&;T9_*20N?&5 ?6=FCE>M3):_RQ#HF8E2>Z"!/?&JG,3.J(!-'@R\M
M.1@Z(=83'ZVC+LKD5=C:43>50^@H36Q HL>ORXVSK.TYKX</I2!/701_?TJ#
ME/N5B^;CHK_:81 J<JDX&$@,1;-P:8E)2A$>I#(&H!BFE$!8F(KJ><S.XG0%
M-0<K3I>"TW;T@3)-HR#6"4H@9$8L,XK8&+T5 "%X5XX^+:NW;L5I]W"ZHCA"
MQ>FB.&W% &+4BD5JB!=1$X@:53Z:AAC#749?3@BKMG:8N:'%307JHP'J:ASY
M"M2%@=KJ196DPO64$Y\5)P Z$:LE);JLI2XXV_2BDC=D.3T<3C<@Q^$@36K+
MRPZZWFB7VDGG^WCGW6[;X98AVNR=(QEL($"M),Y;163QO4L)<1KTU@[G->]@
M<X#=C;R#"O&%(-[RU9D/7*"T8%$JE!:)H@_@*)$:*!<.A,BQR1180A./BN[.
MH_LA/?R*Z44PW2Z4X"17D@O"3(F_>16(LU&2('WD-J/34$H66K5MZ[)=@;WZ
MB$ %]D+ GBW6#BDWZ91)P+E" #TF8H-)!)(1.EL=N.*X6-MM6!=@;\!F?*ME
MP<5IB+>N/RB="V+RDU;?@IY[[_HGSI\DDH<C,D:4-.49>L-<-N\W:^N^&X48
MFFHP3X>G9Z-TG ;C_OLT([+=2VL]'XZ.T%:S0JZ[\=WYM*P,,M]A?N4^5M*;
MB_3VVD$(]!C19$:2Q!V@AQ(2JAEE\+N8T9(B"ZG*;N+7FQ2U /-C0/?J@@@5
MW0^%[M:Y3BE"DN7PMB@5HEC4Q&87"6K/:*60PCN]M<-N4#05W8\!W:LKN%#1
M_4#H;M=GD-J84F3)F6 1XB83([@BI3![DE1$8T-%]WJA^R$C"173#X7IUHI-
MK9*QY-Z"03VN)1#OA2/41 Y),F:T*9A>N+!Y34:8!Y;74/'MM(35ACZ[]F#^
MS^IN_['P]-(S,&Z@Z$J]WT6]^^U0"!0W&+PAT8BFW%4@SF='O'+6,6#!:]_D
M8VS:F<W*:)O :-V(&E5N6R*WM?:VJ'1,4T=D+F'>TA[34EN:YC 7-6@-7#=[
M6TOHNUUIK=):=^[[(7-N*IDMC\Q:<:\D8Y8 D40!ED!I)^1RS 1MEX%) 8S"
MUHZ5&Y<X6QFM,MIJ0X25T9;(:*V:ZE%0KD5$/58:ERNEB?&9D\!5LEZX) JC
M*;8^KN<&I!Y]=4"I=Y9&O?&Q&Z4G/>_&_;! :5R!SST.S_U)V@2"GO_^UY:A
M?TVCHS)%EALDY%^UOW:C 3ZL\>7'_53FXQ5%TTK1=Z#H%]>B@S&#-MX0;;TB
M8)0CCD%"LC8^91J\B+0D2O&%LT/G!L,#;\A65ML,5OMF@/ 66ELP4,AOC1-6
M?EL*O\TDJ"I5*:S0)"9>G&J.$A1$)ED:8;65D@,4?E/+;0%0J:U#"-]8:OL.
M9ELP6%@%VTH(K14EU(9EG<&3R)TCD'CI6&8H20Z<MD)PFDJ?U&VZK/H[E=4J
MJW7JQK^'U18+&%966PVKM;LO,E#@,P'+(GX)@=B0.,E1<RVX%<GY1J:MCQNZ
M >F#WPP5QO[)^23%1=IR/S(>OND.'QO3KCK@]VPZJRK7SL6UO[5#?BHXYAVE
M)%.="$3#B,G ".7H#8L@L]4-U_*%%>3-C-;EK>3*/MVYM4X'YBH/?2</S30?
M5V@@9SF)0:$GRWPBWF9)4C!"ZF@XMVGAT%REH$I!CRJ 5HGG^XBG%4)3D$S*
M%@A3*92T%"!6A4B,B3([R;2$4(C'+JO4566?RCZ/(]!5V><[V:=U9L%HF9GA
MA.,Z4=)\'3$J4J)S"J#0,I8U[*.^;K/Y<.RS 7EO?S0_I-AS."CW-N%]GIXB
MZIIPUK@W/)^,)VY0[N:6-+@E/9?UH:'IDUGUL=!+N^Q.S7)P?NK3Z# W=#0^
MG%GE>@R^9NO>A9A^OUZX.\L<)9 0RF&JJ"6Q@.RDO?*.&9 BRZT="]OZ*V):
M!A1N+8BQT7!:>NNJ"J>5PFFVS@<-*@OJB& Q$]!6$.\L)51RQWRV6F=<YZVX
MH09=A=.JX+3TLW 53JN$4\MI]R;94%K#&2%+.QNOB+56$0A1.&V9B"(TJ]/7
MI^,JG%8&IV4?Q*IP6BF<9JM3$1/1HKH#X 5.V1(KM",T&,,M1S,ZU:Q.7Y^<
MOP:G#<ARF,<QO"7I84E/9LW9XKY<PXL@U5>D4?EB+KYXW78.$T4+&9U(9HP2
M0'Y -0OX8Y8&O<0<0RS+KUZ6<WC7I@P;#:C[<@XKH)8%J-D"K(6C*EM'+*1(
M0'%''( AJ*$D+L<2S6J7Z1Y60'7(/:R 6A*@6@XB\\&K!!'=PAP(>(>*-OK2
MI]BBQHA9 =/-"O7UKFX%U+H[B!50RP+4;(62UH/$98K(&)H )B4.=499L !T
M3,J5HY/6W,E%_->D5%G&?V/__<Y_XY?+:=N:ZR'AS!DM>UHS^G?SFI=Y?912
MSP5T[?"S/^',Z0V&$[SZ9-B;'!>7;Q!+7^J"ZT%35L05CS#W!VX0^NX$1XN_
M*-6BQ]M7-__EK9ZZT=O^@$S1VXSKXEYW_MN/_K5SZ]]=C%,"WLC9<-POC_B'
M43IQD_[[]..'?IP<7X*S]5<7'T-G?^(\CAQA<NN?W&:+OQE?5TP(UT?8_EI&
MV^"?"YY$U (HSFX%PDA'F:$9UWGO5!)_<KYU^4?'H\L[.$.J(7Z4W%_$9;S!
M']S)!_=IO/6OZ_9%XUX,2',<\9>/^?:'^3=315U?$^[I(>L;'_+!WN\O#Y^^
MW#_8Z_VT?WCT='_OX.G>T9/>_L'3VV=^5P;_]/#@V=[!T=ZS'GYW=/C+_K/=
M5_C#T2O\Y\7>P:NCWN%S_.GPZ?_]]^$OS_9>'OV__X_A3/_8V_OM]_U7K^^*
M;-XA>_WC?.#.8Q_9ZI]W'+Z^9?0-@\_8I3D_A7=QXL[&Z8?+;WZ,_?'9B?OT
M0W_0C*7YHQ^O?X \^TK1-)\W?7D&FVTZA<Y%>/'BDR]>WFY>^B('9OJ:H-O2
MJEM?IMOLUM>^=5F[#4I^UU6__1JZ>W6L:S)61K>57)?!KM.#+6.U=[KJQ8[#
M%^*(3;VOFQVO.7RT#7[K:/CAMC^[P3&=+@OWXYGJOUOIFG5B-X3ST_.31I@W
M/5]ZU]M;[%^<5/WEIO86G;+$M]ZZBNEOU]/@3Z?[<$>38?AK2?:\P@!?ST>R
MBV,MOAYZI+^Z?B3[@]Y3=]:?N)/[G_!K_RQ;?/(LY7[H3^[A(2Z [P?=2[_;
M,_U'?]##JY[@%+T3!]]:T/5;,=/N3:5I7'(I]WN7.//C>&A?G>Q9FS5Z;IAV
M[^&_&GZY9MQWIL]5P.R>-SA^<B=N$$IG]4GO/^>#-#UT(^B37MGR^R)N]Z6U
MO]6\\>]J5#^FMHXW;@9I$[(1F0=N+4CNK;0L.1H\2Y+&0/_<;S95U=_M 75V
ME^?3B_[E+L_SOPX^/\?KO*:'/^^)@V>_?<3WPL'/OW_ OSUY\^ZW3Z\__RY?
MO J?KG9Y3M^\>_'J^<F+=[^)-Z\.3MZ\^DT<_/&F_^*/@W>O__B-X;7DB\]O
M/[_!>_ARE^?-Z8N/+_[X_=/!LXAC_9^3@V>!O3G=__B:'QR_>?8[?_/N+QSS
MP>F+=P?Y*@?AB'[X4X.3/#I!A(FA]$\NA]%D(F@:JJ,-GJ?89-6J55=H7Z=#
ML@M N&O)C<OK-O%(#M:NBK.*DWH\/,%G-][[W_/^Y%,EK?E(Z_.,M*(%;XPD
M)OK2()HYXE),1' .PDJ>),AR@G99!V@K9U7.>O";GHNSJ,@0.%A!(7/JP7N:
MO &+OTS:W,Y9>3@Z=1.\Q,?)#X/S4Q*'$W+QCDIHRR8T=D5HP(.C2@?"N2_=
ML;,F1K),I)$9K>9L"*4[]A/+[0U=[RNI55+; %*3D+CG+AG!0"3\!_!_%:.0
MBF46JQ"[+]X25[PEHF8B,4YTL.@]TBR(C:ST6HC&4,VT%:8(L:_/A%3.JIRU
MIIPU5T-IRH #,Y3)# FT3\8EISFWS$IMX7;2NJ4,966O1=E+7K%7\%HSZR7Q
MUB8"";^8B"*,::6$3"ZQTOI*2;;2[M&5NBIU=5!N>2\E3T)8;B)XQPM6,M/)
M6JJMXJ[ZD)U@LX_MNM[9,!:D)1FD(R D(SX*E&3!^D 52C(IBQ?)M5U]P]5:
M=6[>%@JW[G9_:T_QAAM>CYW#)K&>__A]S3LZU'2H6JE:J5JI6JE:Z7%8:0Z)
MS%%P@<_.<>' ,&YS4"(RL)$JYKF>NYP-:H%ICGK)4*]*> XE?/"TY=?K**7B
MAI+HDR; 8JD4IQR1PD VP4GEV=8.YS=4BJO@?"S@7'JMJ0K.!<#9=E.U,MP
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MZ@QY9[2B2-C,.U1@/);NK2$1JAVU#DH3I\9AA,7%UYH=RJM<5[GN&M<Q&4Q
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MG/BNF\MK%N!WZ3'@N3B_9OQ7!?KM5L11>\6OC/2KHFHF10?K&.WF^1/<@\L
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M<^!C;FU$EAN)/*8@OI-5GE[BWBKF\+HR\QKP<C&'5\6N\U$$@EG#*-,HTBR
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M R!\5,@KIX&LG$"&$8D$88*XI 0-:6-;G\_:GZ65T]B/F89LIH3Q%K0ZL <
M0_6B;TT$1(6TYY&UD00 KK^L!=;N Y@NL(B_K%'N-7-OV:MPNV5A\>#R$;R\
MY?LQM(>M_QW!<P#$7_4K;MUI]?K5]=C_::OU<?XUN>)AMS4\BH,X-^!J4T[Z
MP$M]6)U6&,7,]?[(=@_K$;>!0?MP>RN_9+#5^@OFU6MU>\/J2K<"B4'L="YX
MMH6K,,SVH+K]&&S75J?]+<)KAO#\ZD/X90AC:)VVX0DN O+\[ZC=CU<]U556
M,-SI<_G&LTI<S5%-IL&,*^WNR%9$.$M'S>X)#ML[7OF?*[QK_QU_.6V'X=%8
MD9WY5D-V>/H5ZT#7& TO_\J,FN%C7L.&0K?_V_7_L7TIG5_VM8<F;+.PIC,_
MC_KCP9S8PX@<T-DW9!.,]6?;.;5G@XU_S+,N<&GS;$7AY8LK=OFZU#\7MK,&
M8\P,#4*+1&TNN2I=DD0IBC4!&1>)WG@*Z '$W>ZW[/A0$J #^,SE8\F:ST"7
MS4R22?VP"W=D^+"=3N_4=GW,-<O'2-!P^-4( K>_B7[V"JFNX 74G5-OYR6T
M3YXJRH+AL.C)$&N%$Y8FRR-11+LO;RH)#?^@J:B^NVS^S;;[_[&=43S(MQ[
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M4,' 3+0#( 'O@,'_T*"0DPZ6)1_F160O7HX,5]0OYSW>&6'%\9L+F5L9[UW
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M),57;;7Y3VVE%9E9';, IJ1^.H3_XCB1NBAQST%!<$Q_L&*.L9#88F&_/%'
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M]^UJS5H]9^_MSC1/#1^\>>JA%@-,O>^D6%-Z2W*+:7/<I/KXLN5\I">G[W_
M/;1U]>G[V=4_21/9M/L)WG'L-KM_=EH?OM#YW&*XQOUV^,5K?OT(X_OBMC#'
M_NOQJ'GX8P3L!^^3H[/N%_O;Z3\QL.VH=7'N*,W\2(3$CH5'&(A((J3FP'.!
MHSU'"AK)^;ZI0NA *1GQ2 8,/5>N$X<1D)YR6,B%GL]&?I?V#/DC3WW6O23-
MK%8ZN%,GU=M?/3M4:GLQ]2B3<6PS(6(NE*MMV_7C,'"DMSA5^LD[KY[TK"8?
M%=+,P>@D&NQCFU*9=OL=XPKG5C]+?F+"=+_#Q_U&BSO6:99I!S[W/8\";HX9
M",-(N3;UX\ #[@IB15$ETL#V;&=:)1ZWWJ_5+1,Y[KB7 S7@0-_#@+?+9?SX
MS'?XY5P !?M GX1ZW"4L$#[AMA,0[02QY('O2Z;VWGH+ YVKU.5BP\&>YQ<7
MF;XP])"!G9_TL=.M6>,Q66 =?=--U_">Z=IK\I.+@Y44/K P8;!G\N_'S71-
M?]GQK<?5!673WDSG?2T'V"-W]O&FSVPK_5F$V&&I%$/ ,R_,=9]C[:K]BI8[
M(ZNG+])!T2QWD $'%?/-B[=5'7G;:4>5767G)@5/S71_F,DV6A?K, )GL<-%
M1&W7#IG'9!@'U/.T5GX4.)%38$.;TGMUC9WE@T_CD:J:)6*8P]4Y!>D<B" @
MOF(18:YDA',6$@V;8V.9;1%B>I+KW]8P]F:&F"<;TWIB^IXI(H+;I<9[UJ$F
MY0-G^X&D,G:9%T21X*XK7<ZUB'R/>D6M<%K5"K\G60$AE2$")S&2V NFH0MV
M'L-ZNQAU%*@ $ WZ@D);VD0('KH<\0[%_)'07^K%KF@(.XCSO-VP#@;6N')"
M<8EK%_4 ]M<B"[ XJ8P<QP\E8!;'BP#"V!%8I#(2D7+$1EI3U\IVGBI.#]QS
MQ]4L<*A';(XEY3SJ$NY0ARB@C5 XD?8\?^^M&R[O:W8GR5(4B0!ME@X'^8";
MT'/4C44@ W9#G[LAR2TUQ&[HW83P'F#?#FC%U.!!BWI&:X_5*OP-;]1<MDU)
MS.ME<+8-U_X]S/(A[XWQ A:.GE7C/5R$$NL..PK_AC54@$7F%PH6'Y%).D'*
MU"MXLF$!?D:)CO&<U[\V3^_"<I;/1>%OVMO#4N-M $H6[612?-+A.8ZHGV:(
M47+>J33$*PX[IV.SV4EO 63ZS70N&F:(XKLIKCT8G1;H&$MH#60U,#[1@;5>
MG3K&)8T4"#F0)&CEH!BAGA1.(&,>VR%JF@+ DZ5(_B;Y,66[8<I0CMBKK%7'
M+_1)_!EG\3>NP&F67%SH2>#L4U>P>P*+^B,[#Y@+)JE@)(P%H/HHMDDD-24A
MJ/@P"(2.S1FJ>STOZ-\5T4FSY#GN?4%:\*%11F"?(=A^I?\+8@%)_T;= [OT
MN<TS/4<P7A0YH1( 1@)0/V$0TD"$8%-3FX-Q+>DMG9.<E<EE.678+XPPFJ<'
MEW@^9?M"A,HEO@<_F(AC(!)N$U>K6'")'66"O;=1V BN$X?%C9Q<@D)^*Q!L
M*4%*+^@RTI@')4\A04XSCIKPD(_RETP5Z(#S6>0+KB/B<Q$"7 7,&F+D!5-V
M2 &G8/,:["J]!)4,BI6T%"RE]>JRK<W!/E #:D[8YUS+X2#Y"=I'#3.\D/=&
M.T @[R8CGZ(5^I*)A34OSFU%L>Q01(+ \PFSW9AP2A41W!$RED XD0(4NXQ8
MINC!*@F' .%8?8!SJ:HR(]/>OL&91;P(?+)?@+4)I5E)MZM54KAL0*6EF5%2
M\!6@XLMV H#T$G%1^C-1&BFQ-*$1<77[.*#MQZK_6>ID0NQ8Z.C!_%<@@H&_
MK $,9 )0C4[OI+E9 C',X55Y7D'_\=_SR]K/M-1FP><1+-N'F^&*HACF8*:R
MIDPR.>RBI2%U_GK%179A0682=&GX9,O^*AF7TWO\U\^N0MCP ER'B>"T4/CT
M%,\L0& 96A>OD%',;I17Y4,@_OG+?MN_U7Q89!O42GT'Y?07"G(ZL$48JB B
MCD]!J?N.()'C!B3T'8<Z401"FVU4J5<BO'+V;S6AU,I]GFC.?N%1;,BY2\%T
MI+$$^\ !TX#[KB2@8)GM1#[W,$5I'>5>$-!8K4\DT+0N+Q7<8MUS3> EN761
M:3XPFH?W;J&VVF6Q[90'\[@\5\S6TG4C0AU E/ '(,HP]@%6L@ D51QP)UCB
MM"@(8)GGHG95[!Y!N*V'=57 WAN7->_W.XDT9=JGQ-&;N3(L"\.>\IENJ1Y#
M_)KF"5[P.M,=CC)P4IG]W[-!'B7HM2>W<)&GG>%@^2W7:GJ7X/BM*:&]%&4O
MN^VQ,36=KV<Z];,][CW;!^%(!,CV'\1XSE_SSB5"N=]G+0<P&\J'!QC0-;]D
MRQ?FAJB>6Z-TYJ)ZE. (I(2'1_5A3$/M\C!B 2@/X0D5W!35LUW&SO98.UXC
MG#)V0)J7JGUZ7-@OCR2_2#M12O=>OR"I>''5/#C7,=4Z]ATB@H@#JH_Q#-%3
M .T=8?N.K7R;[[V-0?B4FSJV[J>]+-- JSBBFKCDZL4VB^VV/IYSZL=1'/@D
M\)@ -!PH$KIA2(0'*%FZ 8^":&:Q5W)QO4*8T@6#>I@507/%Y[_A\4KAN)IV
M=:U\LM>OU-SVQ-Z9TC=_5R?410C 2>_=&*%ATZF7"W.^FQ,90)(Z<J3 'I0>
M89%BA+LL))$KG4!X/OR'H2+[((67&%TK!A<9P+/ Z+I.B=8E4%L''8)/;UX9
M$FH6G7BF#:C2:"\ <_H7&)2?2H_69Z F\_$+-JG@>2<?SP63#G>X(*X()&&<
M(U5%FL1^!*0%Y"6Q^%IT/:-_UJ+J9ZD:RC%9K>4^1-?DG%6&X99C &Y<E<NA
M]ZX@J.V!4&[#=G$EAOW2UY+*(B&HV" ,E4WB1&.B7P9;B'NA?V+8WO[DK,7B
M(!2RB\+=QXLMAGO+V)1\*-"W/TA,6)#YL-AXGN=ZD+^!:U8_6-FB3?RY17M8
M./V3V 0AX1(OD.>3@ZQ]D,:#I'/O0QZ\;/)4<Y*V_6=DTW%6?W(PZ;)K)U4K
MK$XNVUH-.T7(]\(CQAO/PJIH\+ECN21;<C"W_<OZ!>7'1&I/IGB9 #GB6AAT
MVUX:@3@W=] #.'EMBO5,JX.?O#/4^TCE<M@Q0?<"H]&KC0%$8N7HE[-^IIUA
M5Y>CGNI!72B?,<(IWEZ?0.P@:+FPFY?GGA>#;>5PXD@?\##6WX^H'9- "<=A
M-+:9%]SE!&+B5+!2 4SQL_#]5#89(-XNAA#$0]1J2N<R2\128ZMAO0=Z R9M
MS[, 9K0LH_%I*5%Q$$9][A<4GB]$4$8%PR<BZ14CAHN*4%%XU?+[]E'<X(?I
MCL0Z' _P7 ='C"76>@,SOW[:2>3(,HDZ@T%G&D>B<9*EPXOVS.(4EQ5)0X4M
MC67$*K"2]$"(_#0AT66V@L$UO2G)999V?&* F_N__K_0<::M+$2^)N\)/J=O
MS#B5[L!F9F.;JKRG$%S%PZO+,8:R() QO)Y[,%XRV=AY8BBR 8Y[UH7N@0#L
M[$]$7VWX[X:@N_J(07>Q=EW&!25"Q1K+]S,2L<@FKA-I33W&;#]>9O@CB8SI
M9G\E,JUHVQ@&$S8QP?ZE8XGGA8&'+).MFVY4$]03$M277V#NTR"RE;!#$DA%
M,;W$)E'((SPPHZ'MN8[-U3*"VE]DJ1NU-:TX;TJ*OQ.$FMIY=#6_AG>!LI[9
M= 12DWT^F:CNOXWF?GE;36&K5:C]0+@A\6&Q";-#0;CG"-AY3_C294+;[MY;
MQYO/;C=NZ 7PQWB7;X0\#>MT$7$DA<C(A]U*G2D.V.#ZA84R+B^?\R@5.04&
M#<VYB0"G)%@M3(QJVML"VI/VR<%Y)"/* B6)\&*@/4$CPAG5Q(Y"3WN*TEC0
M1;17P/!*S!1D4MATUF*;SJ1]__/UX._]10"W(,B;@%9!:W+8'1:G\=7%Q:L7
MW7*CC; _H>%I8W54$&EU7_%P''618&X^2X# "Q><T(-+S+2Z@5->)0W=V+_&
M"K^F'OV;6<9:.^\$V\ <*+"-I[7GV=0C<<Q#PAP/[-J04A*"F-(AQ>)P2\]Y
M&M;6FV_(C G0'QA:UT@WGB[?4*68EBXTMT$#2HL_EA@]]<'FKA'\$>H)(2([
M#D [^*Z,"*.^1T3('4(=RABE//(BN=[!YI0$!@L]^8EQH2:/UY0-N49[U:E4
M\3#>!]3Q"S;1>'/O$@IX-Y):/0)P0C[F^/+E>@);A\<8$1HRASFQ)XB./  :
MF@L24FD3%BMN.[84"D_& Z\1+4N7GSB/%P*(@R)W9HG8VI^VDA<?J=_@MKLT
MJ>-31+<\I[IXRARQ!:[M1K$3B%!(%F(,*DPXB!F+'"F5Q\NXTV!)W.D=ZC5,
MR*^D2:TF9&KX(3_.\R$8DR^WB@.,O?GQW/=C'86!(JZR/4# GB01%9JP2#-7
M*M<!^MQ[ZRWHNUC53"HIYYI19=2E.6$1:%2)[V5A(ZZ^#_-!X:^!F]-N=6IK
MB>&@N '3,N"FXDH ID4]F9'I7#%$: V(<=CK\V32PZ)X_0V2\WHEB3[<AV&D
M1?4OW4T*PV]&N-XE8.1NLM6]9JW=*EC-D%]N9$CK\.RR]?%<*<]G&EO/V&%
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M[MG*:N93-?'#<H8'Q>BG<@[H"V.3UM4/!C#5L\-8.=HF@6\'A&%A2,XB1AR
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MH%IR(X6S8=]\4(Z58*(/_MW5N)U);D:!FJORSIJ[0)[TM DT <W31N!5&<:
MKW^B0L$73'8M!^M*=V'(#WPNM29@>/4_1O!W.ERDQ=875'H@Q#^)-H;-;[O
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M\>?/.RNM'EJ;W:R[8+P7@'!^629N>)!/1-9GHWW?@6FA.'Y8QICBART03*6
MH>$^&H)]-&4!UXV,!/ISV-.E\"FW;WJW#O[3:M6;=9_- BR(*%,E::>T(\&
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M!G1 -Y$F)E5EO,L-<NF,+.-#*T-(C5L%B&O,Q>ANFWAN.-9@06%BD$//)/
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M" &B6O=!A%E3O +IPD<0R&T)$@X?U[/F;W9*F9IH?T82CK</1G]J(^&8;_^
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MLM^,^ >PUHJ<H'77%>G1SX$,FB>/? 0K#3H</+R)Q7IX-,9&Q1\8G02?#/[
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M:D5EHR$Y)MP"?2X:_*Z6A8V_^2 6]Z9L7G]U7(([ F/;@>;,&UN8D5G?!YX
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MS$4[$<@E)\7GV'RK7 16_!T1_:EL[6X[A&9"O&+O,+WAC8J<D.!WN VCQDI
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MKQJU0@OQ#EPLJ?J8K[*B<.4Y5S86> (U$<4IE:3.-KF&D[4F.8Z6]R+:&JJ
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MAXRH_'.+)!BNL'"+'>L&M[.262WH%;#B[:K",?<O,KYW,13--_<"KG*TU(A
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MDI_=OU1TZ-%$J)G( '9LRT@,N JJKL$X8<EFFT?4T-,]/W1$'1VSW%(?!\/
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MP]@=L;D/0E!O:"'^S>Y&:)&3!F*)WIFUY!/7K)>/3G.J'#H@-Y)6S!#5@B3
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M;\R R'P")X4A (9AAGEQA2!-C/NAY8UGDB&>*XJ$*WOB4IE*.%."[:^%U9)
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M$^8;H?SV[>WK9_)&+SQ&^T)S09<MY7-7PJ"HU$E W=5>.GOTK<)SE>4"2/1
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M=>RS:4F3TKU2T>0*$X - :N*/#._!6^(DWHVA&&'N_7U(?2:1VO$N 8 DV+
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MG/G1^X33]KK^V9@+1?_45:94OPHNY0,3!$?ZTJ^8,KV2I-=LH&4$I:!>]X/
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MRN#\ _3CV\$K^-(?P?EDA2Z]'R?]RG#TL^ 5#3SLC](L-)Z.ZV,*S>F4^'_
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M>,[221$%K2.>^W'M/J*H2NN=H*$S3CK,BUK:3A>B%%*!(3J4KIQ),V)9T+B
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M::H%S\?T999*<E7S- _Q\GZ4%4!V[OFM#&_WGN#V3#:[HJ'CR65UL-H'J[3
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MU([ZN8^_5K9/7Z<OY6S]<L!,:)$E$.=I2;,VGEBPF0"HR'2,)IHZL<$]H)Z
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MC.>2J=(071&I)</H(3@2''4Q!BH4KU.TN0*X'[%9E^S=%9BLX2Y? 9R]6ZM
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M626XCUMP!TKK N5VG"A\U9BAAV%EGE1MZW*T/YE=70A T(A1:"/0AKL(Y:X
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M9VA+7M75AM+$M3T9Q!G>*Y,8*M$DPJ(<I"/H\."[(? KKBE/T4<3>1UO<46
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M*W]T[?NG@Z_G.E_K27-^9O#J)W[B"VV8O2SASC@:0_8B0):+BSZ\:IBTB'\
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MK=Z?M:*_3[(P#"/",\B1'@VDZ1_2D*0P9"EG#--$$Y7->N!;L+$M&[5J8*'
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MIN7[DQL%[2(7\92B()4PEBB%**(!I-JP@U&L9( "E;"(N/!\=^0&X/$M<I=
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M^>V_;M;Q,)E*, DBF B*(8JIT*028YA%G">A4D3PU(54'/L?&\V4%TC%1DI
MU^I M<AAH16Z G0)E#DU^EJ>&OU GQ?Y<OK?QJ%R42S!/Z$$_9B"Y^EL9IPQ
M]<-?]'<DGYG,__F/81K\)0ZNJDP 9M_R3VD8_8B:3]]*WGPX+!\.'+?7KE^!
M'?WU.+9#W MN!;P"UT?&]<9W"$E'O+QRI:L,@[)G1X#V^;1K,]T8]EX/C]0-
MB2_+!?_]RY/>5A=WJZ5)<&'<-R<R35#& Z[W:?H/%!(,F93ZGPG)B(ABA2+I
MPJAG^AL;@V[$!861]PH4I<1@L149_#"=US]VY+5SV-OQF$=$>^:M+9A?*C K
M84%#6G]T90F+5WHZU^>@=&0)P#[]V+[F?C!TH_>9U[FD-PLA)R1-%(]9!BD6
MVE)C'$&:I0)2I&VT(-:T@ZTBE_<;'AN!&-F $0X8Z>R/>G; .G^VTQ6"GF>\
MI?9.AS?'5.UT6K/3T&#',\?$;Y[''/U]M[6]G+SW^93+B=)S2X]6!@.! N-?
M*""AD8*81"ECD5[6L7"[8-DV/K[;E5]H_KM<@A<C71E MGA^UON1<@DOE^M?
MO]P"O6VMEFW'5;N!JMT"W0VIGF=F*10HI?*89N1 4[^91+;-#YLLY$"M@WP@
MAT^X3=DB7TX^Z_&1OY3;Y8D*HRA F8!8D!@BGL20I0)!%,<D1DD:ARRP61[W
MVAW;ZOC%Q)46RRDW@4];#P>[";F/6?MLO ")OJ?B<1 \^NN<T+UM<NI7&A-3
M_VM_4NZW.<B,/*'(>CJ>^G6WY?.S7&KXI7A'\[F)9+SF?/6\FAFOV%NIIGRZ
MG"@9)]S,T(R$&40D"R$+]%SE49#2($FH(DZN'N>['-L,;D@(1"6BVW)J@;+=
M,NL7NY[G_%I8L)86_-!$LA;XM&7BO#3;H^-UR;;H=M"EW!Z&_27>X<VN/A/7
M0NAOK*C_\U'W%DY0*EF28@(C'&I#0 0!Q%D601&&DN$L91ER])@XTLO82*7V
M :A%O%K_!1AAP=W<81M]&MCS>VHO</7,(YV1ZN OT8+$!=X2QUH=V%>B1;%#
M3XFVAR^,(BAO3$WH^,=M*K7:(!1W\\_FY#_7U*,?^+28Y^M__DR+:6'>+[-C
M/$C^-)_^8R6+,@/&1#$L:*8XY#PF$)GH(LKTQM]<AT9<!2R43C>B?0H[-AIJ
M>-,W[?(/\Y=5G7]FHPG8JE)G%[),*33(1V!G0(UE:'NFS)Y&M7OP1(]P]Q-K
MT8? ;Q.:T2/T)R,Y^NRSXSGQ4ENQ9A+<J?+2YVDQTR\7)KV27N_6*9EQ2FB4
MH! J;'(+!A&"F,421HRD">8"A<3J2,JIU[$M"1NAS;%R4^Q_ 97@-NF;+Q@$
MRQ-GW] .< )V,:KNI]4N*/D]R+;J>=@S;A<P#HZ_G5[ND"/UE^E\^KQZOI?Z
M@YLOZ:.\4P\Y-??1Y:'[P^(C+9:?Y<LBU]MQXS13W<\$J39^&1,PXD&DC5_C
MQA*$D39^LU3R@) HL+IDOD"&L1%8K86Y_:K5.+@@JZ[-EOGT\5'F#HDQ.PY2
M.Z4-!'W/!+=&?:N!25A:ZU#=PH&'!3!J@+4>P"ARYH;.VR X)"+M?S &RCGZ
M\"3!\]'IL-2_><D78L67ZW_NS)!E/7#53'E>S9;3E]E4#QE[K1^>UR6X0*Z9
M$8B5,>'*7STWMAPO9:$90 O3^@LUCE'+1=WY.LO0?*'?KU(-Z=_0Y7I>ZIU*
MLYO%2Y4L=5Z^;EXJKL!4@:GQ[IW-"J#'</%-_W):-'3UE2_ULD^B-35JQZ:'
MRX)ZF>X["4\O;,I'AJ^;\I-:3O6FXF;S=97=A)/(9! /5 QCH@*(>$ AQ;&Y
MHF:8J"@)0Y9U3_G5TO/8UM"&J*"0\^DBKV9<<T)6U'"IKXG]X-AM#'J!O.>U
M\R +5D/L]3]*R#T[LSACU6.BK+;>WS!SE@4H[:FT;!KHFEO+A#)O-B:;#;1,
MJ53F*%PR1"%B*8$4B10JBL.,!0@3MVI>)_H9&V75P?3;C7;78XI3N-KQCP>T
M>F:;+D!UR,;5"H/GK%S'^QHX.U>KPH=9NMH?=[]@O];MB#)YWXP^3A17(<=I
M"E-*$$2"QI %+(,9DBJ),4:IL@IJ.6AY;--^(QPPTME?F^_"=?ZJO#,(/<]F
M2_V=+L./ZMKI GRWI<$NO8\JT+SH/OY QPA>(:9F:TIG]W0J/LQOZ,O4%,TK
MM]/E8>&$R(QCEH4PPJEQ<<$4L@03J&<I)4Q& 9=.(6;GNQS=--U(#%ZTR%#O
M&G@EM&.@['FP[=9IOQ#V/<FWZ!EI@4:OEM=L#\ICFU)DCZ&PUO#XC7X]W^VP
M :_6,!S$N-J_V=69[OUT)O,;;4$\+O+7"5%A2#(JH II %$0"$A#@2$-DH 1
M1EF<68>;'6E_;(12NX65,H*UD*Y><[L(GC<"+L2E9Y9P@Z2#>]Q1Q2]PC-MM
M;V"7N*/*'#K#'7_,1[J@OTN32$2*ZZ_ZIX_RLS2A$.M?/LC\.9R8-(&*< HY
M(QE$823U5CYB4!+])U=I$J2B>P:A\P*,;=*O)0:T$AGD:YGK"JU:B.=+T@Q9
MC(F=>=$GTCW3R$$RH@WJM?A@(W_U!'AH0_W"_$3VT/68LLA"B#?,8F0/47MB
M(X=VNIY8?M5;+LVCM]."SQ;FEG!SNB9D)C%3"&:"*8@XPQ#'*(.*B!3I/1)%
MR"E96DM?8V.UC:A@*^L%IY>G,;8]P?2"7.^GF-U ZW"2>18.SZ>9I_L;^$3S
MK.*'IYKG7^G@&V6:+9;FN*8Z-KV>B[OED\P_R>5$D82'U%042C,!D=(['H)#
M!".2A"J.,Q%(J]N.<QV-D30J4==9EHU?]\)(>P7F+?D"W>!MIPR?H W %S5>
M]06(*9M<"@H^>8/+P<G($VP#>1*U?&[F:_/E9F,!2JLO3=O[PSG,6&BQXQ5C
M\WS'':=IIG+'_Z0%K[,'(L1)$*<8)K&((4K2!+(T2B&+)29$X3025A&7K;V,
MC3"KJ=XI$^U1$"WW@9="T_=FKT2E$O *;$7TN)UK0\#OGNUH3\-NS-J4/=A]
MM3[LV==MLYLSIIGQM;RNTJ"6Z\9]Z:893A3'C&0RAC1CQG5$<P(EG,- Q 0A
M$2626ITA>Y%F; 2R%M6XH,[JP*;7TJ]U,2^]MK:'4;2A3>T#Z\DKSFH8[:AI
ML,'IF<+:O>>V9U6;\6NJ ^[;1\>?3YT+JL/XV5E)- [?.Q?PK/WQG!KM1L<W
MM'@R_S-Q0E_I3/=??-:F7C[E2RG,+[2IM_N#QI.5"-HDS,T!W*VL_JO_/5L9
MC^EWW_F3R03TF2[E.Z4D7TZ(#&6DF1H&09!I_HXC2$48PU1&*8E$EF1!ZE+1
M:ECQG0A_@))9-Z5\H'15*)ZNRC^!W"I8;H'RC?KE[]UH?N#/PVY=&.^@][R0
MW)2C;/X$#8W,$K(9XO*79MCW?[;S0@4"6*, ?ECC\*<KL($"K+$ !@Q0H>%O
M'7J;4?2Z< VLPJ KW=L,S_[2^$927.+O_D"_UY5M?Y9SJ:;+"::*)FF&(<],
M,<(TBR&+0VJ"=AA*@S1!$77W=S_H9VS;D?M\\75:1H6H1;X^E%O2[]+Q=.,4
MK+:711>#U?O!;XF,%G%=<QK\4$OI,?G<&1QZ\'<_[.L-_-U/*GS<W_WTXUU=
M;_]K51V<%@^+$QYW9>):IIE)F)I?NN_2O/]L[+ABNI1?9/YURF5%9I\E7SS.
MRU;*1":3,!!9* 6&(5),<XO^&\N0@"3,1!IQ2A1.W!QW^Q5X;"15Z@)+9<J3
MDK4V0)XI__XVPVW'>6,:Q)[)\_K^PTU=Q*(>Q7OZ6MX"7>>Y6=VK$Y>-I6N6
MHIM%&>*_T<FG4_(PP'MV:>Y9Z($=HH<9@D-WZH'Z[;@0\?( 25O/7&K[F,WD
M)[E<%^OB,0G3*-$?!Z/:0(TC4PA$!#!F+$VXBAC)G (RVSH;VP*PEA7D&V$=
M.;\-64N^]H17WUR[AFHKYQ6@:FGNYV:SQ3>J)VA%L+G4WS\P18S[*()F@99?
M@FSK<%ARLU#]@)ALWKDP:5V59>IF?=-47'^?%I, :5Y1<09#S#-MFBH"*94,
M"DI)S&(>!(G3)7YK;V.CE3IGVE;(CIGHCB)KQRK>\.J95@Z@ K\9"?O(,M>&
M1#_9Y8[V^#99Y=J4/YE-KO6ECE=.YG9+3?6@R>).W<J7A39^ZOHA 4TC&HI4
MDX2IM)+Q"&(J(HB$C'$81#A)G5(EM_0U-L9HBFHR7HE*6,?[FA9L+2]7_"#6
M]TW('EBUG."W2E*/W&&!A]\[A9;^AKT .*_XP6F]Q2L7YF??^FT7FZB!%"44
M!RJ#$9$$(JE-#HH8@3&5098J+"+$.^57/]+9V%BCD4F[(6WGX(Q6G.T(Q!=Z
M/3-(=^"Z9QEO0:2?+.''.GR;+-\MJI_,TMWV3J<@#5XE?=P$N9>%5:^7RWS*
M5DNS,WI8W$YGJ^7T:WTA>*>V*;$,H35K/T\$B?1^)L00AR:Z@VC:(9AQ2$.I
MDBP)HE19Y>+K0[BQT93^4!'X5";H<R[5W,O@M7/96P])_S>.:\TVV3FJ,M!-
MY4PVW+5ZM?>'R9C;R/9W9PPOM@1;)=]P1)TB6]YL9 >*AFGD8ZFKI4]+MP=9
MIF8I\^/2&3>EL\J4M7JW8;0UM=#NOYADN-2XC:UFF]2[+WKJSI=3.IN]5H^:
M;T)6WT29NWJ;C5.8+Z+8@ -6Q3KO[C(O$^^^UAE\G^7R:2'\!>;T,J9G@GG\
M]CED % O:.T%#?731\<+$/WYKK_<;:/OOE>SXKV&QQQRK*J)>:?6)>;N95Z*
M_?/K\0:JDTZ9R4 R!+F( XBB!&LC(,M@(#EF4F&DN%-H>(^RCLTP:$KJO(X,
M,;:6-SCC&+&^+X".#Y;W\]H!T/1[0=2CO,/>+_4/_,'UU !==D\&4MWH/^@&
M2C)081)E1' 8) A#A%4*2991J +!J/X+1=C1DW._B['Q<R.LVHCHGNIC#T$[
M.KT,E]YW3SN0>&>_T\I[3^.QU\W@V3N.JWDL:<>))SO:@F5(Z]I' S,>H\B<
MWI!40J1(# G6UEN69'&<$452PEQBDG9:=YK/ X0,/9@^0!W*VRG8?!<\2_.H
M*R1]&S1U6+E_'Y5C"ONU.79Z&-9*.*;<P;I^]"'W3**W]8')^VG!Z>P_)<W?
MZY\4$YF@,(MX &664HA"12$360P5%R1)8R1XB&RSB9[H8VQK\5I,4,D)C*"@
ME-0^K>@I.-OGL2>0>I[-'?!QRC%Z!H%.>49/M3E8KM$S2C7SC9Y[M-MB_%%J
MII"[B?[695E?:V?NXG8E)RJ.8X8D@S%-B)[Q1,]X'"D8*(YY&M( 2^RR3MMV
M/,XE?+%)@EDE%GVI!79;S*W!MUOG^X"T9]*H1+X"!TE%-W)?F8IP3):)S?U9
M"*Y0>34>K#L?U*YPA63?Y'!^_\(DH2:?6B($$@BE,"4FH0%*4N.P%FK@$Z)"
M1((X=HJ_:C8^-OMC+9OS^>P.8DC2F)M*+YACO=V2*((LUC2>A#1-(D7"Q%R;
MV]-X9\0&H^JI%]SL3TZZH#' F4DIUE5K+L/NN4\/\N_Y3G8Z6(*^-M5.IC/M
MGHBOO*J[6<STWQ=Y'8^D&UW)VFL4I4RS6L8@Y11!%$BE"2Y1D(=!S#DAB!![
M+Y?3_8R-ZW8D!7DEJHM[0PND[3/9(U ]3^I=C&HIS[O@.F'EX-7A![.!'#2.
M?E^^?"'.(]'JUM#R^G >"N=UV'$VL'C\DBHVGU;EUYAD21JI*( TB[FV]O3?
M6! '4" E"*;E-9!["9NJ\;$QX+MML1902=BE>$T-W/GCI4O@Z)GG')#H6+-F
M5^4+"];4C;U!M9I=-8Z7JME[YL)P@.J4^7HNUOL\;6/_4I5W%W>:!\Q%A]X*
MZ@<^+>;Y^I\_TV):?)S.Y8>E?"XF$2&IX(C"4 0Q1!%+()$$027"E.-4H"!T
M*JKM5;JQT<+6;_ZJSLI;IAMK: C6*H+2*JBU*I]JJ@E*/<%O1E-0JMHU5L'+
M1V"WO7JSH>V9XMYD5+L'4OA$OY_("R\2ODVHAD]P3\9V>.WDPNCU._5^.J=S
M/J6S>Q.QIBW(;=4?@E6(8P2E#!E$L200BXQ 262841(F$76*+;/I=&R4ORW$
MO5!@(S58B]TYV,QJ .QXV3>L/=.M!T2[!\%;0-1/+'Q;QV\3$F\!Q<G(>)MW
MW\15_?K9Y/N89#$6FJ44I%R/"4IB"7'"! S#%(4H$$'&G*Q:+U*-CMJJX!A9
M:P',M[*)A7F1>14]8]+EEXEOF.1T9:HX/DEM+]7Q+]\6JYD 3_2KU+^7<VT2
M+:=PXR;M'.[F]RNPH\_!Q[9G?CWEJ/YN9YP;.AD>7FMELB-7\7!7H-)L-)[M
MNT"/R8>]ENQ_DK?Z+IB>_=+W&N^A'.^Z)H!)7ZQ[Y<8;,^,D"[&BFN2E@"AD
M,22A3&#$*&9*I*FTNZSI*L#8Z/V@'*]8E]C0:CDZLSL/AAWU]@EQSRQ[O@[O
MIJ*)4:!,.\^]NMEV!6^X2KS'A!A/)=X6B)PJ\;:UTW%SSI^D6,WDG=K<<=>^
MQ ]EX*C\OOQ9J_G[)$YI&B@],!F6L2FOF9C<QPQ*&F093L(H(TXA.;8=CXWJ
MOJR>GVG^:@R9SGXZUJ!;;LI[@++OC7DM<A/&UTU\ /CMH4J,H"4'I>@^]^>.
M:/G=H]MV/NP^W1&2@[VZZ_L=$]HMYN6V_^_3Y=/-JE@NGF6^\3NL[Z+K=+[_
M+<4DYA'*$B1ABA&%*-#F&E&!@#(3898)R21R8BRW[L?&6[=2R=Q<*]0^$"8/
M;RVJ8^H[MU&PH[#^L.V9R-:"@V]:<K 6?<>K>>VP\_D\X.Y9\SKAYC>1GIL(
MP^;6ZP3/0;J];JVXD5R1+R?W^4*L^/(NKS.4EY&\%(N F*(344R8WFLF$:01
M)A"3)*,)B^. 8AL:.]7!V(BJEK&\\:S%M".HDPBV4Y /7'HFF2.0>(N&/J=^
M&U?H=QL\H?^USQ$G&Q^$!<ZIMI[G9Y_KZM%F:MWD+[6S7'FA<6-V;]HZ6@@Y
M42F7,58*QEDF(8K#&)(@%%!P$E)SY!TKJRM/R_[&-L]K;Z\=F:] *34HBX>4
MD@,CNJM#7#ON[730 YH]LX,/(#OXTUG!<X&+77O[ WO=62E[Z(AG]UI7>OGR
M3&>SGTW>-UEH.R'E1&KM8,AB;2>84QI"LQ!RC#..(H8XM3J3/M'^2.FCE!&L
MA70EBET$;8FA,R[#$($E)!VF_%'%+YCBN^T-/*6/*G,XA8\_UNT XSZO-^%?
M3&+&>YIK<\.0@BA=M=976I-4F_12BA2J(",0)81"*A2'$0XBA C/1"Q=#B[L
MNAW;!-](7:6QO (O- =?RT32YJ[_UR^W6\<!QRM_RW&P.[KPCV[ONXDUL%\J
M8+7,QE"HI*YS=6_NYOV=5;@!Y?6,PK+K0<\FW.#8/Y-P?+L;7^T5);E=/-/I
M?!*F$1)8Q9"EH3E7129,)\L@"](PS9004>Q4.^1H+V-CH_WB.6Z$<QQ(.WZY
M&)Z^K8X]9,!OE8@>KVQ:(?!*%,=[&I076I7=IX'VASM$**\MG5M9\'SZ8O8M
M]XO9E+]N+R43H6=ZEJ:08:0@0I)#PHB".!(,*<H%#ZSFOV5_8V."AJ3F]M)M
MZV&+<3LU](!<SR2Q%A8TT?NMDM?JFK<3B@Y!S7[1'"BX^1BJGD*;[?%H#7&V
M:&:X4&=[G79"GAU>ZQH@H]OX4!0K*6Y7)ORFJDQ;^4Q7V7?W:]E.J(PBG 0(
M$JJI%V5"[Q%C%4&NTA2C,*$!=]HC=I!A;,1LI#>E48NJ4D)9;J.J@+":"[-3
M+/_^HM_I4!SEDK&RL_-Z'H&>";YV\*_DKPN%%Q8%PZNRMN\7N9+3Y<KG=O,"
M/#V'Y;C+,7"43F>@#H-VNC?5T75[^21STUXNGW23TZ_2G+D_RU_GN:0S<Q__
M'XN9T)+\51O&IE#RW;R1O#R?FJ(I35$_R>6=>J#?)R8#>:!("FD8FEK=(8,D
M4QQRF: 4)UF %7-R\>Y)T+&Q\%8?\*@U 3_,M"Y_,L',^P5KZ%<ZG1G_,*@6
M.2RHJ7(]EU4I'/K=T6F\K\_ CKO',+@]$_S=S8>K_2I45^!Z9PR_E&/8^ )J
MK<%?RR_!*/ZG*\"D?E:":_%?JRK;^'H5>&@9=7>7]9Z'Q*]K>U_"#NL"WS/D
M!Z[R???7;4DRDV1;7JGZVU**#_-BF9>[PFHYK);)<))&)-:VO/XL$ TADMJ<
M)ZF,H8I"1<-8(&J7ZZA;]V-;/FH[<EI*9Q+"%G*YG$DP+VL:TB68SJ>F/EI=
M"JTLCV=BC+I;]([#9;<@]#<(/=-\R?!;R:_ 1G:P%7YMW]?FOC_2[@:;5RIV
M%&%0@NT&SSYM=FREWZSCG^3WY<,W.?LJ?UG,ET_%)(H33D)3]550"5&0!9 J
ME4 <2\ZT.1Z(R,G^[BK(V BR3+8OYZ59=2MYF7H/Q.$5T-]SU$]2\H.QL>/
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M:TP[9#S?7)[I=.#+2CL(#N\G+=_K?OM1VP.E/U9QO5H^+7*3*F<2\2A%21I
M+J)8[Q^R$#*24<@3F05,_[\43A486OH:&ZG<-#8+5Z HI05T(R[X83JO?_HG
MQXC(%KSM[Y8\H#C 3=)Z1W!5.7T68"NIWUNC,W!XOR,ZU=_@-T)G%#]V_W/N
ME6XT<M2M<V+4(H13F$1)J/<&*H(L01B&4F89#RCG2+H0R-%>QD8=QL5\NE,<
M\$7F%5E< 5:Z/1OV^/7+[?87CB1R'.T@$)*R,(4HTD"C**"0J)1"A@+!,REH
M0*6;7]S%> _C__9SCZ#:<?+%0/5]]'O* ]\?#[="X)6!C_<T*/>V*KO/NNT/
M=XS,E,4RG_*E%#>T>#*7^?H_YM+I*YV5U_MK?Y5,*!%DDD+%< 91@ 7$08AA
M%M,XRF(4J]@I):MMQV-CY:W<P$A<>;>8OS1DM_%JN6PT[-BD#XQ[)AA?\+I'
M3#IBY3<\TK;S86,A'2$Y"'QT?;]K=K J^9A)F:%MIHD0F6:J4.H]9LH@HAQ!
M2D@&2:H0$B*5/'-BJKWVQT9(Y>PH<P%6I:+/U ZV@M".7BX IF<6V>3/-*)=
MU87MC%-]G7JEW'JO'[IJ!&1?F[O5,O&OSPQ?1V'RG,QKMX^!\W8=5? P1=?Q
MQ[K-^H^R**0\$3==^\D4MROYGY+FQ@-?3D22,DXYAHJJS&QK,,18;R)CQ4*E
M<(P0H2Z\X"S!V)C#" 9,"B(3;2)Y6;H5Q.$5T!\9<B,0]]&PHYA>,>Z9A"K9
MK_;3/5QM\SU<@>4",%FS5#D<I1+^N*<S?E[9R5V*0?FK,TC[#->]H0ZNT57,
MPIWZD$^+ITV-.[UR3;@2L<HR!!.62(A2/29$( ECS-,@H)S%*;/VBC[9S=C8
MK!+4.)%\>UK,9J]@\<TD7RGE!D5#< ='W],8M].7/^1ZYJ@:M#M5X_3%-TX.
MOM!>\!K(#;H3;FX>T&?A:'5^/OWV<'[/9S78<7D^_W0'DKR.HJ01BOE%SJ>+
M_--B*8NJ4OV$$XZR-&10QJGFRAAGD"(L3:J;+ S2*.&26W/EN=[&1IG1CU'R
M_S;CD$$E,BAE+E/*VYN"EG@+_9EF(H9(,@J1!AP2QA D%">4\E@R8AES[QWQ
M8>X8W@!SB[7*)XX]+UEG /RM$MCRX-4.0(=%S">0 ZUE[8#ZJAUA"TSKJG:V
MD>$6-UM]=M8XZY<Z7^;HG04W1ZVW\JN<+5[*F@XFSW A)P&EDO&(PHPDFG^%
MTJR+DP1&B"K%% Y$;+746?4VMJ5N+6QYH2"VXCK?S[0 ;'TIXP>V_F]BMH@U
M) 6UJ%ZO7LXCXON^I:7'H2]9SBM_Y&;%XB4W$BGRI7'U%RM>!G5_D?G7*9?%
M[>*93N<3(A6C(9>0*Y89XRV .(T"&(8T44(1E$EE0QZMO8R--&I!RQE02VK'
M%^U8MO.$-X1ZYH<CX(#?*BD]7,M:H=#&";J!!A_H?^US07L/@W" E9+KN6_W
M<#?#X1=)3<8&0R(?YB^KI4GB8-)^OU_D'RG__4[]0O/?Y;(^R:RM8A*$+"9!
M#$,L0N,KIBF!Z3^(4(*D2IL6=FD0+Q%B;(RQEKF\BS52F_/(';G=#(Y. V-G
MA_0-=\_TTQ ?E/)?@?/@G]\=.ALOE\#HU:;I),B@ILXE4.U;0!>UY9XVX;;>
MBC_H5R<BPBJ*(PY-25U-?#2#-*5(LQ_7)E$6))Q9I<?>;WAT9%;+!HQP]DD0
M=K!JYZ)+$.B97^R4=TII<$S33BD,=AH:+&7!,?&;*0J._KYKAI(ZM<%G^6+J
M;<\?ORSI<E5,HAA')#"EU63"3'VU#.)8[T6,2SJ/>(HIM@H$.-?1V*9BG7*C
M%A9LI 65N*X92DZ@>WZR^L*LY\G;%:X.&4K:L;@@0\F)A@?.4-*NWF&&DC//
M=]N>O*?3_&]TMI(_OS;6_?>Y_,=*SOGK]?>I9@:$!0^Y@JE(,$0H8Q!+%,.,
MA"@3 I.86!U0./0Y-I)HFL0;0=WV&S9(VVTO/.,WX&YB(R/XS4CI<:_@@(G7
MK8%-OX/N!!R V#?\75[MQC:?Y-+X5-_GBZ]3(<7/K[\6)FIZX]:U]1&>$"HS
MA@B%% EMCB1I!"E3 @8F4B:(LT )ZI*SQ+YK)^X9(*^)"58L:[V^U+(#]MHH
M/4;/^U5?.A9VM-0/PCVSDP&W=/._;X#[@Y$<3.=_ZME]W1TQK]SET/V@%.8.
MRSZ3=6CAD@RZZ^RD#"FEA"8IS5S:4,(IA21@$J8(L3 )TC"..N3,'7^6W.Y9
M7KNDPQUS MP+$MY>DN+V?T)2VYZ2V'9*6_N&B6JM4M->EHQV>Y5=S\S"Y)3;
MN,:8:AH3B7FF_X]"@3"%*! !),:;/2,IBEA(9)IIH<KBS>+!Q7'E9)=6'R>I
M/LZ#CGN\:Z5:1#IK%*2N$E%N7;:*RF5K;GR)7'U:3@^ G4UU*9Y#^;.LI:P2
M36ZQ,X+Z]&8YBX9G7Y;3_0WLR7)6\4,_EO.O7'AD5.7.NYZ+=2#.U#C;E1M'
M<3?_+/DJSXVQ-1>?%O-\_4^36J$H:PA.6&!J3 <(DM"<.Q,3-DBE@E%"@TR9
MTVB[\CK>)1N;K644 Z5FINY[+6[I'M*4OR[/Z9@8P=]P.IY>#3E(/1.@I_'I
M?NKE"\M^SL8NENYM3M!\@7KRG,U;!SY*.E9S6'_J 6:4PB!)!4094WH+JQC$
M092D2(99&#K5IS[2Q]C(M5D&^>-B_@AUI\]@KZ9@T8U<CT%L1Y,7 M<SX7G"
M[,):B_U1U[%^WK!N8BN=M#W:-0&$W@;=+(KE7F%TQFC"&0YA*E0*49IDD&3Z
M;R'#@>01QH%P3/-PM)\Q$\2M+'@^?3&')N:?>PD(7#,['(?9CB \@-<S2=0Y
M&8R,O5:./X.$YWP+Q_L:.*M"J\*'N1/:'^^>E5CF?$IG]U3/@MI!-F.)"(0F
M!AY2!)'*$DC#,(5)2#*J2)90Y10)=;27L1'$5DCP8J1T3S=\"*0="5P,3\\4
MT$"F%+ '+^%6"+RG%3[L:?"$PB>5/99*^/3#7=T''^CW#T(;&E,UY>7E05WR
M5R*9A8P*;1*@$*(DRR"C&,,X81D+2"R$O>MN:T]CF_VU1YQ)RK\KKG,9Y7:
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M.H>&YR.BD]T-?$!T3NW#XZ&S;W0CB,_RJYROFD8#35F2A12F3)CHOX!!2HF
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M"A'Z6%=V>3M?BZK(J9UQN_W9+[NXY3?^<<L.X^'&9&%1CLQ@6V4MJ/M,YZ,
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MVY)>J&OE&6.[&U2>NWAX)<"Z -)7\X W;*.^V52+ZK2Z^>1BS%$A2 &$A Q
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M[48D4BSG&8$O%(_9;7IW3&7//<-XQ!9-^:1;1[]5(E<)-<0TQ: HA2&0DDK
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M#$FY@-')44XW#_07V>XZ58%];9NS_G*__&-?+"HK$,X9T@ 5*C?,I I I61
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MFK,5F59<_^80&O\_YV%!GWCZ[3U^GB]6$Z=$DK*0X73<@\ID0B-S#"0+LLC
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M]-4LX]?_%[]-A%8L,\/ H*5#SGA'X9--D(1E0CJ>R4,>PI>XN^QVB.@_BWF
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MIM<%!5IA">)-8+(MA>.&_LV+1)HHJ@,K=(NO^SFWJ%U0A@?@08=:WE_3;3Z
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MH%RB_*8WIO7.!.8YF*0-*&_(;^><[)\77FH6C7=M"MOO4]*)J[JG9A^\B3A
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MV=7T"U[*>B*+L"FH -;7(\>Q5 <U1F#%)"Y#*5PT>LZ]%7WCUKNW068#S72
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MY)?SU9OYZC]Q5;MW3Q!%UJIX**884"Y:",D:X$I*)H,M,K:Y>=J6PI&;R+6
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M PGZA-EH!3%Q,O-.DD/AF0##(XK,BDB\_!#F@C[M^7QYOT[-HPY&6 ,B24]
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M.5V"973TVJT0]9V%1GYN,3ATAI1KS^'?'1L[G?-)"8F9=4]MGP7%M5)"##G
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MAS(K%!D101!P5! O0@Y1."%DKA.MO452BX@\5?,O]Y)&44,#>/H57<AJ'LJ
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MFCH=SD,I;26"'QUQ5576@/GJRU]WL#W+RO+HI28:<AE.90*QTFHBLJ1>",
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MY.[KK/(&XR0R$POOO ZY-+J+I2\M._2:G7Z+[!<Q;4;&]0V"LRI'7PR^%D&
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M!)YWB)<D ;@W_IPD,XK'4ARS+%,NXT>-#/ ,@SD5%!W=+WQ^BZ[5X7=ZS1+
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M2\>-:_$V5?Y>U\G?4$L! A0#%     @ I(!A4X4GEH18[P$ T?$3 !$
M         ( !     &YB:7@M,C R,3 Y,S N:'1M4$L! A0#%     @ I(!A
M4W(!PY&N#   L'4  !$              ( !A^\! &YB:7@M,C R,3 Y,S N
M>'-D4$L! A0#%     @ I(!A4_%IOOS/&   B.H  !4              ( !
M9/P! &YB:7@M,C R,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( *2 85/R-A70
M1#,  .8S @ 5              "  685 @!N8FEX+3(P,C$P.3,P7V1E9BYX
M;6Q02P$"% ,4    " "D@&%3<,=7 V69   8)P8 %0              @ '=
M2 ( ;F)I>"TR,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ I(!A4Y*!-UMB
M6@  B ,$ !4              ( !=>(" &YB:7@M,C R,3 Y,S!?<')E+GAM
M;%!+ 0(4 Q0    ( *2 85,W-CV'&P@  ,8G   ;              "  0H]
M P!N8FEX+3(P,C$P.3,P97AH:6)I=#,Q,2YH=&U02P$"% ,4    " "D@&%3
MKR&YHQT(  #5)P  &P              @ %>10, ;F)I>"TR,#(Q,#DS,&5X
M:&EB:70S,3(N:'1M4$L! A0#%     @ I(!A4YH&&05"!0  ,B8  !H
M         ( !M$T# &YB:7@M,C R,3 Y,S!E>&AI8FET,S(N:'1M4$L%!@
0   )  D 9 (  "Y3 P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
